{"ac176aee62546a955278ac424f3f257d4361e710": [["IntroductionThe outbreak of the SARS-CoV-2 virus in late 2019 and subsequent evolution of the COVID-19 disease has affected the world on an enormous scale.", [["SARS", "DISEASE", 32, 36], ["SARS-CoV-2 virus", "ORGANISM", 32, 48], ["CoV-2 virus", "SPECIES", 37, 48], ["SARS-CoV-2 virus", "SPECIES", 32, 48], ["the SARS", "TEST", 28, 36], ["the COVID-19 disease", "PROBLEM", 90, 110], ["an enormous scale", "TREATMENT", 137, 154], ["disease", "OBSERVATION", 103, 110]]], ["While hospitals are at the forefront of trying to mitigate the life-threatening consequences of the disease, practically all societal levels are dealing directly or indirectly with an unprecedented situation.", [["the disease", "PROBLEM", 96, 107], ["disease", "OBSERVATION", 100, 107]]], ["Schools and universities are closed or operate online-only, and merely essential shops are kept open.IntroductionAt the same time, lockdown measures such as social distancing (e.g., keeping a distance of at least 1.5 meters from one another and only socializing with two people at most) might have a direct impact on people's mental health.", [["people", "ORGANISM", 317, 323], ["people", "SPECIES", 271, 277], ["people", "SPECIES", 317, 323], ["IntroductionAt", "TREATMENT", 101, 115], ["lockdown measures", "TREATMENT", 131, 148]]], ["With an uncertain outlook on the development of the COVID-19 situation and its preventative measures, it is of vital importance to understand how governments, NGOs, and social organizations can help those who are most affected by the situation.", [["the COVID", "TEST", 48, 57]]], ["That implies, at the first stage, understanding the emotions, worries, and concerns that people have and possible coping strategies they use.", [["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95]]], ["Since a majority of online communication is recorded in the form of text data, measuring the emotions and worries around COVID-19 will be a central part of understanding and addressing the impacts of the COVID-19 situation on people.", [["people", "ORGANISM", 226, 232], ["people", "SPECIES", 226, 232], ["text data", "TEST", 68, 77], ["the COVID", "TREATMENT", 200, 209]]], ["This is where computational linguistics can play a crucial role.IntroductionIn this paper, we present and make publicly available a high quality, ground truth text dataset of emotions and worries around COVID-19.", [["COVID", "TEST", 203, 208]]], ["We report initial findings on linguistic correlates of emotions, topic models, and prediction experiments.Ground truth emotions datasetsTasks like emotion detection (Seyeditabari et al., 2018) and sentiment analysis (Liu, 2015) typically rely on labeled data in one of two forms.", [["sentiment analysis", "TEST", 197, 215], ["labeled data", "TEST", 246, 258], ["truth emotions", "OBSERVATION", 113, 127]]], ["Either a corpus is annotated on a document-level (i.e., judging a document as positive, neutral, or negative) or individual n-grams are judged on their polarity (i.e., assigning a score to each n-gram on a word list).", [["corpus", "ANATOMY", 9, 15], ["n-gram", "DNA", 194, 200], ["corpus", "OBSERVATION", 9, 15]]], ["These annotations are done (semi) automatically (e.g., exploiting hashtags such as #happy) (Mohammad and Kiritchenko, 2015) or manually through third persons (Mohammad and Turney, 2010) .", [["persons", "SPECIES", 150, 157], ["These annotations", "TEST", 0, 17]]], ["While these approaches are common practice and have accelerated the progress that was made in the field, they are limited in that they propagate a pseudo ground truth.", [["pseudo", "OBSERVATION", 147, 153], ["ground truth", "OBSERVATION", 154, 166]]], ["For example, rather than wanting to know whether a Tweet is written in a pessimistic tone, we are interested in learning whether the author of the text actually felt pessimistic.Ground truth emotions datasetsThe limitation inherent to third-person annotation, then, is that they might not be adequate measurements of the emotional state of interest.", [["truth emotions", "OBSERVATION", 185, 199]]], ["The solution, albeit a costly one, lies in ground truth datasets.", [["The solution", "TREATMENT", 0, 12]]], ["Whereas real ground truth would requirein its strictest sense -a random assignment of people to experimental conditions (e.g., a group that is given a positive product experience vs. the opposite), variations that rely on self-reported emotions can also mitigate the problem.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92]]], ["Datasets that rely on self-reports are the International Survey on Emotion Antecedents and Reactions (ISEAR) 1 , which asked participants to recall from memory situations that evoked a set of emotions.", [["participants", "SPECIES", 125, 137]]], ["The COVID-19 situation is unique and calls for datasets that capture peoples affective responses to it while it is happening.Current COVID-19 datasetsSeveral datasets mapping how the public responds to the pandemic have been made available.", [["COVID-19 datasets", "DNA", 133, 150], ["Current COVID", "TREATMENT", 125, 138], ["Several datasets mapping", "TREATMENT", 150, 174]]], ["For example, tweets relating to the Coronavirus have been collected since March 11, 2020, yielding about 4.4 million tweets a day (Banda et al., 2020) .", [["Coronavirus", "CANCER", 36, 47], ["the Coronavirus", "PROBLEM", 32, 47], ["Coronavirus", "ANATOMY", 36, 47]]], ["Tweets were collected through the Twitter stream API, using keywords such as 'coronavirus' and 'COVID-19'.", [["'coronavirus'", "TREATMENT", 77, 90]]], ["Another Twitter dataset of Coronavirus tweets has been collected since January 22, 2020, in several languages, including English, Spanish, and Indonesian (Chen et al., 2020) .", [["Coronavirus tweets", "OBSERVATION", 27, 45]]], ["Further efforts include the ongoing Pandemic Project 2 which has people write about the effect of the coronavirus outbreak on their everyday lives.The COVID-19 Real World Worry DatasetThis paper reports initial findings for the Real World Worry Dataset (RWWD) that captured the emotions and worries of UK residents at a point in time where the impact of the COVID-19 situation affected the lives of all individuals in the UK.", [["coronavirus", "DISEASE", 102, 113], ["people", "ORGANISM", 65, 71], ["coronavirus", "ORGANISM", 102, 113], ["UK", "GENE_OR_GENE_PRODUCT", 422, 424], ["people", "SPECIES", 65, 71], ["The COVID", "TEST", 147, 156], ["the COVID", "TREATMENT", 354, 363]]], ["The data were collected on the 6th and 7thThe COVID-19 Real World Worry Datasetof April 2020, a time at which the UK was under lockdown (news, 2020), and death tolls were increasing.", [["death", "DISEASE", 154, 159], ["The data", "TEST", 0, 8], ["increasing", "OBSERVATION_MODIFIER", 171, 181]]], ["On April 6, 5,373 people in the UK had died of the virus, and 51,608 tested positive (Walker , now) .", [["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24], ["the virus", "PROBLEM", 47, 56]]], ["Furthermore, it was also announced that Prime Minister Boris Johnson was admitted to intensive care in a hospital for COVID-19 symptoms (Lyons, 2020) .", [["symptoms", "PROBLEM", 127, 135]]], ["The RWWD is a ground truth dataset that used a direct survey method and obtained written accounts of people alongside data of their emotions and worries.", [["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107]]], ["We present two versions of RWWD, each consisting of 2,500 English texts representing the participants' genuine worries about the Corona situation in the UK: the Long RWWD consists of texts that were open-ended in length and asked the participants to express their feelings as they wish.", [["participants", "SPECIES", 89, 101], ["participants", "SPECIES", 234, 246]]], ["The Short RWWD asked the same people also to express their feelings in Tweet-sized texts.", [["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36]]], ["The latter was chosen to facilitate the use of this dataset for Twitter data research.The COVID-19 Real World Worry DatasetThe dataset is publicly available.", [["this dataset", "TREATMENT", 47, 59], ["The COVID", "TEST", 86, 95]]], ["3 .DataWe collected the data of n = 2500 participants (94.46% native English speakers) via the crowdsourcing platform Prolific 4 .", [["participants", "SPECIES", 41, 53]]], ["Every participant provided consent in line with the local IRB.", [["participant", "SPECIES", 6, 17]]], ["The sample requirements were that the participants were resident in the UK and a Twitter user.", [["participants", "ORGANISM", 38, 50], ["participants", "SPECIES", 38, 50]]], ["In the task, all participants were asked to indicate how they felt about the current COVID-19 situation using 9-point scales (1 = not at all, 5 = moderately, 9 = very much).", [["participants", "SPECIES", 17, 29]]], ["Specifically, each participant rated how worried they were about the Corona/COVID-19 situation and how much anger, anxiety, desire, disgust, fear, happiness, relaxation, and sadness (Harmon-Jones et al., 2016) they felt about their situation at this moment.", [["anxiety", "DISEASE", 115, 122], ["participant", "SPECIES", 19, 30], ["anxiety", "PROBLEM", 115, 122], ["happiness", "PROBLEM", 147, 156]]], ["All participants were then asked to write two texts.", [["participants", "SPECIES", 4, 16]]], ["Finally, the participants indicated how well they felt they could express their feelings (in general/in the long text/in the Tweet-length text) and how often they used Twitter and whether English was their native language.", [["participants", "SPECIES", 13, 25]]], ["The overall corpus size of the dataset was 2500 long texts (320,372 tokens) and 2500 short texts (69,171 tokens).ExcerptsBelow are two excerpts from the dataset:ExcerptsLong text: I am 6 months pregnant, so I feel worried about the impact that getting the virus would have on me and the baby.", [["corpus", "ANATOMY", 12, 18], ["corpus", "ORGAN", 12, 18], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["corpus", "OBSERVATION_MODIFIER", 12, 18], ["size", "OBSERVATION_MODIFIER", 19, 23]]], ["My husband also has asthma so that is a concern too.", [["asthma", "DISEASE", 20, 26], ["asthma", "PROBLEM", 20, 26], ["asthma", "OBSERVATION", 20, 26]]], ["There is just so much uncertainty about the future and what the coming weeks and months will hold for me and the people I care about.ExcerptsTweet-sized text: Proud of our NHS and keyworkers who are working on the frontline at the moment.", [["people", "SPECIES", 113, 119], ["sized", "OBSERVATION_MODIFIER", 147, 152]]], ["We need to unite as a country, by social distancing and stay in.Descriptive statisticsWe excluded nine participants who padded the long text with punctuation or excessive letter repetitions.", [["participants", "SPECIES", 103, 115], ["punctuation", "TREATMENT", 146, 157], ["excessive letter repetitions", "PROBLEM", 161, 189]]], ["The dominant feelings of participants were anxiety/worry, sadness, and fear (see Table 1 ).", [["anxiety/worry, sadness, and fear", "DISEASE", 43, 75], ["participants", "SPECIES", 25, 37], ["anxiety", "PROBLEM", 43, 50], ["sadness", "PROBLEM", 58, 65], ["dominant", "OBSERVATION_MODIFIER", 4, 12]]], ["For all emotions, the participants' self-rating ranged across the whole spectrum (from \"not at all\" to \"very much\").", [["participants", "SPECIES", 22, 34]]], ["The participants' self-reported ability to express their feelings in the long text (M = 7.12, SD = 1.78) was larger than that for short texts (M = 5.91, SD = 2.12), Bayes factor > 1e + 96.Correlations of emotions with LIWC categoriesWe correlated the self-reported emotions to matching categories of the LIWC2015 lexicon (Pen- , 2015) .", [["Bayes factor", "PROTEIN", 165, 177], ["participants", "SPECIES", 4, 16], ["SD", "TEST", 94, 96], ["SD", "TEST", 153, 155], ["Bayes factor", "TEST", 165, 177]]], ["The overall matching rate was high (92.36% and 90.11% for short and long texts, respectively).", [["The overall matching rate", "TEST", 0, 25]]], ["Across all correlations, we see that the extent to which the linguistic variables explain variance in the emotion ratings (indicated by the R 2 ) is larger in long texts than in Tweetsized short texts (see Table 2 ).", [["larger", "OBSERVATION_MODIFIER", 149, 155]]], ["There are significant positive correlations for all affective LIWC variables with their corresponding self-reported emotions (i.e., higher LIWC scores accompanied higher emotion scores, and vice versa).", [["all affective LIWC variables", "PROBLEM", 48, 76], ["higher LIWC scores", "PROBLEM", 132, 150], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["positive", "OBSERVATION", 22, 30]]], ["These correlations imply that the linguistic variables explain up to 10% and 3% of the variance in the emotion ratings for long and short texts, respectively.", [["the linguistic variables", "PROBLEM", 30, 54]]], ["The LIWC also contains categories intended to capture people's concerns, which we correlated to the self-reported worry.", [["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60]]], ["Positive (negative) correlations would suggest that the higher (lower) the worry score of the participants, the larger their score on the respective LIWC category.", [["participants", "SPECIES", 94, 106], ["higher", "OBSERVATION_MODIFIER", 56, 62], ["larger", "OBSERVATION_MODIFIER", 112, 118]]], ["We found no correlation between the categories \"work\", \"money\" and \"death\" suggesting that worry was not associated with these categories.", [["death", "DISEASE", 68, 73]]], ["Significant positive correlations emerged for long texts for \"family\" and \"friend\": the more people were worried, the more they spoke about family and -to a lesser degree -friends.Topic models of peoples worriesWe constructed topic models for both the long and short texts separately using the stm package in R (Roberts et al., 2014a) .", [["people", "ORGANISM", 93, 99], ["people", "SPECIES", 93, 99]]], ["The text data were lowercased, punctuation, stopwords and numbers were removed, and all words were stemmed.", [["The text data", "TEST", 0, 13]]], ["The most prevalent topic seems to relate to following the rules related to the lockdown.", [["most prevalent", "OBSERVATION_MODIFIER", 4, 18]]], ["The second most prevalent topic seems to relate to calls for others to adhere to social distancing rules.Predicting emotions about COVID-19We used linear regression models to predict the reported emotional values (i.e., anxiety, fear, sadness, worry) based on text properties.", [["anxiety", "DISEASE", 220, 227], ["COVID", "DNA", 131, 136], ["COVID", "TEST", 131, 136], ["anxiety", "PROBLEM", 220, 227], ["sadness", "PROBLEM", 235, 242]]], ["Specifically, we applied regularised ridge regression models using TFIDF and part-of-speech (POS) features extracted from long and short texts separately.", [["regularised ridge regression models", "TREATMENT", 25, 60], ["TFIDF", "TREATMENT", 67, 72]]], ["TFIDF features were computed based on the 1000 most frequent words in the vocabularies of each corpus; POS features were extracted using a predefined scheme of 53 POS tags in spaCy 5 .Predicting emotions about COVID-19We process the resulting feature representations using principal component analysis and assess the performances using the mean absolute error (MAE) and the coefficient of determination R 2 .", [["corpus", "ANATOMY", 95, 101], ["corpus", "CANCER", 95, 101], ["COVID", "DNA", 210, 215], ["principal component analysis", "TEST", 273, 301]]], ["Each experiment is conducted using five-fold crossvalidation, and the arithmetic means of all five folds are reported as the final performance results.", [["five-fold crossvalidation", "TREATMENT", 35, 60]]], ["We observe MAEs ranging between 1.26 (worry with TFIDF) and 1.88 (sadness with POS) for the long texts, and between 1.37 (worry with POS) and 1.91 (sadness with POS) for the short texts.", [["MAEs", "TEST", 11, 15]]], ["The models explain up to 16% of the variance for the emotional response variables on the long texts, but only up to 1% on Tweet-sized texts.DiscussionThis paper introduced the RWWD as a ground truth dataset as a resource to measure emotional responses to the Corona pandemic.", [["the emotional response variables", "PROBLEM", 49, 81]]], ["We reported initial findings on the linguistic correlates of emotional states, used topic modeling to understand what people in the UK are concerned about, and ran prediction experiments to infer emotional states from text using machine learning.", [["people", "ORGANISM", 118, 124], ["people", "SPECIES", 118, 124]]], ["These analyses provided several core findings.", [["These analyses", "TEST", 0, 14]]], ["(1) Some emotional states correlated with word lists made to measure these constructs, (2) longer texts were more useful to identify patterns in language that relate to emotions than shorter texts, (3) Tweet-sized texts served as a means to call for solidarity during lockdown measures while longer texts revealed peoples worries, and (4) preliminary regression experiments indicate that we can infer from the texts the emotional responses with an absolute error of 1.26 on a 9-point scale (14%).Linguistic correlates of emotions and worriesAffective reactions to the Coronavirus were obtained through self-reported scores.", [["Some emotional states", "PROBLEM", 4, 25], ["solidarity during lockdown measures", "TREATMENT", 250, 285], ["Affective reactions", "PROBLEM", 541, 560], ["the Coronavirus", "PROBLEM", 564, 579]]], ["The lexicon-approach was best at measuring anger, anxiety, and worry and did so better for longer texts than for Tweet-sized texts.", [["anxiety", "DISEASE", 50, 57], ["anxiety", "PROBLEM", 50, 57]]], ["In behavioral and cognitive research, small effects (here: a maximum of 10.63% of explained variance) are the rule rather than the exception (Gelman, 2017; Yarkoni and Westfall, 2017) .", [["small", "OBSERVATION_MODIFIER", 38, 43]]], ["If 10% of the variance in the anxiety score is explained through a linguistic measurement, 90% are not.", [["anxiety", "DISEASE", 30, 37], ["the anxiety score", "PROBLEM", 26, 43], ["a linguistic measurement", "TEST", 65, 89]]], ["An explanation for the imperfect correlations -aside from random measurement error -might lie in the inadequate expression of someone's felt emotion in the form of written text.", [["the imperfect correlations", "TEST", 19, 45], ["random measurement error", "TEST", 58, 82]]], ["The latter is partly corroborated by even smaller effects for shorter texts, which may have been too short to allow for the expression of one's emotion.Docs TermsLong texts 9.52 people, take, think, rule, stay, serious, follow, virus, mani, will 8.35Docs Termswill, worri, job, long, also, economy, concern, impact, famili, situat 7.59 feel, time, situat, relax, quit, moment, sad, thing, like, also 6.87 feel, will, anxious, know, also, famili, worri, friend, like, sad 5.69 work, home, worri, famili, friend, abl, time, miss, school, children 10.70 stay, home, safe, live, pleas, insid, save, protect, nhs, everyone 8.27 people, need, rule, dont, stop, selfish, social, die, distance, spread 7.96 get, can, just, back, wish, normal, listen, lockdown, follow, sooner 7.34 famili, anxious, worri, scare, friend, see, want, miss, concern, covid 6.81 feel, situat, current, anxious, frustrat, help, also, away, may, extremTopics of peoples worriesPrevalent topics in our corpus showed that people worry about their jobs and the economy, as well as their friends and family -the latter of which is also corroborated by the LIWC analysis.", [["corpus", "CANCER", 969, 975], ["people", "ORGANISM", 988, 994], ["people", "SPECIES", 178, 184], ["children", "SPECIES", 536, 544], ["people", "SPECIES", 623, 629], ["people", "SPECIES", 988, 994], ["the LIWC analysis", "TEST", 1116, 1133], ["smaller", "OBSERVATION_MODIFIER", 42, 49]]], ["For example, people discussed the potential impact of the situation on their family, as well as their children missing school.", [["people", "ORGANISM", 13, 19], ["children", "ORGANISM", 102, 110], ["people", "SPECIES", 13, 19], ["children", "SPECIES", 102, 110]]], ["Participants also discussed the lockdown and social distancing measures.", [["Participants", "SPECIES", 0, 12], ["social distancing measures", "TREATMENT", 45, 71]]], ["In the Tweet-sized texts, in particular, people encouraged others to stay at home and adhere to lockdown rules in order to slow the spread, save lives and/or protect the NHS.", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["sized", "OBSERVATION_MODIFIER", 13, 18], ["texts", "OBSERVATION", 19, 24]]], ["Thus, people used the shorter texts as a means to call for solidarity, while longer texts offered insights into their actual worries.Topics of peoples worriesWhile there are various ways to select the ideal number of topics, we have relied on assessing semantic coherence of topics and exclusivity of topic words.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12]]], ["Since there does not seem to be a consensus as to the best practice for selecting topic numbers, we encourage others to examine other approaches or models with varying numbers of topics.Predicting emotional responsesPrediction experiments reveal that ridge regression models can be used to approximate emotional responses to COVID-19 based on encodings of the textual features extracted from the participants' statements.", [["COVID-19", "DNA", 325, 333], ["participants", "SPECIES", 396, 408], ["ridge regression models", "PROBLEM", 251, 274], ["COVID", "TEST", 325, 330]]], ["Similar to the correlational and topic modeling findings, there is a stark difference between the long and short texts: the regression models are more accurate and explain more variance for longer than for shorter texts.", [["a stark difference", "PROBLEM", 67, 85]]], ["Additional experiments are required to investigate further the expressiveness of the collected textual statements for the prediction of emotional values.Suggestions for future researchThe current analysis leaves several research questions untouched.", [["The current analysis", "TEST", 184, 204]]], ["With much of today's stream of text data coming in the form of (very) short messages, it is important to understand the limitations of using that data and worthwhile examining how we can better use that information.Suggestions for future researchSecond, with a lot of research attention paid to readily available Twitter data, we hope that future studies also focus on non-Twitter data to capture emotional responses of those who are underrepresented (or non-represented) on social media but are at heightened risk.Suggestions for future researchThird, future research may focus on manually annotating topics to precisely map out what people worry about with regards to COVID-19.", [["COVID-19", "CHEMICAL", 670, 678], ["people", "ORGANISM", 635, 641], ["people", "SPECIES", 635, 641], ["future studies", "TEST", 340, 354], ["future researchThird", "TREATMENT", 531, 551], ["COVID", "TEST", 670, 675]]], ["Then through discussion or majority votes, final topic labels can be assigned to obtain a model of COVID-19 real-world worries.ConclusionsThis paper introduced the first ground truth dataset of textual emotional responses to COVID-19.", [["COVID-19", "DNA", 225, 233], ["COVID", "TEST", 99, 104], ["COVID", "TEST", 225, 230]]], ["Our findings highlight the potential of inferring concerns and worries from text data but also show some of the pitfalls, in particular, when using concise texts as data.", [["text data", "TEST", 76, 85]]], ["We encourage the research community to use the dataset so we can better understand the impact of the pandemic on people's lives.", [["people", "ORGANISM", 113, 119], ["people", "SPECIES", 113, 119]]]], "PMC7094507": [["IntroductionRestrictive cardiomyopathy (RCM) in man is characterized by restrictive filling and reduced diastolic volume of either or both ventricles, with normal or near-normal systolic function and wall thickness (Richardson et al., 1996).", [["ventricles", "ANATOMY", 139, 149], ["wall", "ANATOMY", 200, 204], ["IntroductionRestrictive cardiomyopathy", "DISEASE", 0, 38], ["RCM", "DISEASE", 40, 43], ["man", "ORGANISM", 48, 51], ["ventricles", "MULTI-TISSUE_STRUCTURE", 139, 149], ["wall", "TISSUE", 200, 204], ["man", "SPECIES", 48, 51], ["IntroductionRestrictive cardiomyopathy", "PROBLEM", 0, 38], ["restrictive filling", "PROBLEM", 72, 91], ["reduced diastolic volume", "PROBLEM", 96, 120], ["cardiomyopathy", "OBSERVATION", 24, 38], ["restrictive filling", "OBSERVATION", 72, 91], ["reduced", "OBSERVATION_MODIFIER", 96, 103], ["diastolic volume", "OBSERVATION", 104, 120], ["both ventricles", "ANATOMY", 134, 149], ["normal", "OBSERVATION", 156, 162], ["normal", "OBSERVATION", 171, 177], ["systolic function", "OBSERVATION", 178, 195], ["wall", "ANATOMY_MODIFIER", 200, 204], ["thickness", "OBSERVATION_MODIFIER", 205, 214]]], ["A variety of specific pathological processes can cause RCM, including endomyocardial scarring, myocardial fibrosis or infiltrative disorders (Gallo and d'Amati, 2001).", [["endomyocardial", "ANATOMY", 70, 84], ["myocardial", "ANATOMY", 95, 105], ["RCM", "DISEASE", 55, 58], ["endomyocardial scarring", "DISEASE", 70, 93], ["myocardial fibrosis", "DISEASE", 95, 114], ["endomyocardial", "MULTI-TISSUE_STRUCTURE", 70, 84], ["myocardial", "MULTI-TISSUE_STRUCTURE", 95, 105], ["specific pathological processes", "PROBLEM", 13, 44], ["RCM", "PROBLEM", 55, 58], ["endomyocardial scarring", "PROBLEM", 70, 93], ["myocardial fibrosis", "PROBLEM", 95, 114], ["infiltrative disorders", "PROBLEM", 118, 140], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["endomyocardial", "ANATOMY", 70, 84], ["scarring", "OBSERVATION", 85, 93], ["myocardial", "ANATOMY", 95, 105], ["fibrosis", "OBSERVATION", 106, 114], ["infiltrative", "OBSERVATION_MODIFIER", 118, 130]]], ["These conditions are divided into two distinct groups in man: those with predominant endocardial involvement (endomyocardial form) and others with predominant myocardial involvement (myocardial form) (Gallo and d'Amati, 2001).", [["endocardial", "ANATOMY", 85, 96], ["endomyocardial", "ANATOMY", 110, 124], ["myocardial", "ANATOMY", 159, 169], ["myocardial", "ANATOMY", 183, 193], ["man", "ORGANISM", 57, 60], ["endocardial", "MULTI-TISSUE_STRUCTURE", 85, 96], ["endomyocardial", "ORGAN", 110, 124], ["myocardial", "MULTI-TISSUE_STRUCTURE", 159, 169], ["myocardial", "MULTI-TISSUE_STRUCTURE", 183, 193], ["man", "SPECIES", 57, 60], ["predominant myocardial involvement", "PROBLEM", 147, 181], ["endocardial", "ANATOMY", 85, 96], ["involvement", "OBSERVATION", 97, 108], ["predominant", "OBSERVATION_MODIFIER", 147, 158], ["myocardial", "ANATOMY", 159, 169], ["involvement", "OBSERVATION", 170, 181]]], ["This classification of RCM also appears to be applicable to cats (Ferasin et al., 2003, Fox, 2004) and the endomyocardial type, also known as endomyocardial fibrosis, is the most prevalent form of feline RCM (Bond and Fox, 1984, Kimura et al., 2016).IntroductionA prominent pathological feature of the endomyocardial form of feline RCM is severe and extensive fibrous thickening of the endocardium and chamber deformity (Fox, 2004).", [["endomyocardial", "ANATOMY", 107, 121], ["endomyocardial", "ANATOMY", 142, 156], ["endomyocardial", "ANATOMY", 302, 316], ["fibrous", "ANATOMY", 360, 367], ["endocardium", "ANATOMY", 386, 397], ["RCM", "DISEASE", 23, 26], ["endomyocardial type", "DISEASE", 107, 126], ["endomyocardial fibrosis", "DISEASE", 142, 165], ["RCM", "DISEASE", 204, 207], ["RCM", "DISEASE", 332, 335], ["cats", "ORGANISM", 60, 64], ["endomyocardial", "ORGAN", 142, 156], ["feline", "ORGANISM", 197, 203], ["endomyocardial", "ORGAN", 302, 316], ["feline", "ORGANISM", 325, 331], ["fibrous", "TISSUE", 360, 367], ["endocardium", "MULTI-TISSUE_STRUCTURE", 386, 397], ["endomyocardial fibrosis", "PROBLEM", 142, 165], ["extensive fibrous thickening of the endocardium and chamber deformity", "PROBLEM", 350, 419], ["RCM", "OBSERVATION", 23, 26], ["appears to be", "UNCERTAINTY", 32, 45], ["endomyocardial", "ANATOMY", 107, 121], ["endomyocardial", "ANATOMY", 142, 156], ["fibrosis", "OBSERVATION", 157, 165], ["feline RCM", "OBSERVATION", 197, 207], ["prominent", "OBSERVATION_MODIFIER", 264, 273], ["pathological", "OBSERVATION", 274, 286], ["endomyocardial", "ANATOMY", 302, 316], ["feline RCM", "OBSERVATION", 325, 335], ["severe", "OBSERVATION_MODIFIER", 339, 345], ["extensive", "OBSERVATION_MODIFIER", 350, 359], ["fibrous", "OBSERVATION_MODIFIER", 360, 367], ["thickening", "OBSERVATION", 368, 378], ["endocardium", "ANATOMY", 386, 397], ["chamber deformity", "OBSERVATION", 402, 419]]], ["This process primarily affects the left ventricle (LV) or, rarely, both ventricles.", [["left ventricle", "ANATOMY", 35, 49], ["LV", "ANATOMY", 51, 53], ["ventricles", "ANATOMY", 72, 82], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 35, 49], ["LV", "MULTI-TISSUE_STRUCTURE", 51, 53], ["ventricles", "MULTI-TISSUE_STRUCTURE", 72, 82], ["left ventricle", "ANATOMY", 35, 49], ["LV", "ANATOMY", 51, 53], ["both", "ANATOMY_MODIFIER", 67, 71], ["ventricles", "ANATOMY", 72, 82]]], ["There are two basic morphological patterns of endocardial fibrosis, although a degree of overlap in features may occur (Fox, 2004).", [["endocardial", "ANATOMY", 46, 57], ["fibrosis", "DISEASE", 58, 66], ["endocardial", "MULTI-TISSUE_STRUCTURE", 46, 57], ["endocardial fibrosis", "PROBLEM", 46, 66], ["two", "OBSERVATION_MODIFIER", 10, 13], ["basic", "OBSERVATION_MODIFIER", 14, 19], ["morphological", "OBSERVATION_MODIFIER", 20, 33], ["patterns", "OBSERVATION_MODIFIER", 34, 42], ["endocardial", "ANATOMY", 46, 57], ["fibrosis", "OBSERVATION", 58, 66], ["degree", "OBSERVATION_MODIFIER", 79, 85]]], ["In the first pattern, the LV shows diffuse, marked fibrosis, which appears as an opaque, white\u2013grey, firm covering involving substantial portions of the left ventricular cavity.", [["LV", "ANATOMY", 26, 28], ["left ventricular cavity", "ANATOMY", 153, 176], ["fibrosis", "DISEASE", 51, 59], ["LV", "MULTI-TISSUE_STRUCTURE", 26, 28], ["ventricular cavity", "MULTI-TISSUE_STRUCTURE", 158, 176], ["diffuse, marked fibrosis", "PROBLEM", 35, 59], ["LV", "ANATOMY", 26, 28], ["diffuse", "OBSERVATION_MODIFIER", 35, 42], ["marked", "OBSERVATION_MODIFIER", 44, 50], ["fibrosis", "OBSERVATION", 51, 59], ["opaque", "OBSERVATION_MODIFIER", 81, 87], ["white\u2013grey", "OBSERVATION_MODIFIER", 89, 99], ["firm", "OBSERVATION_MODIFIER", 101, 105], ["substantial", "OBSERVATION_MODIFIER", 125, 136], ["portions", "ANATOMY_MODIFIER", 137, 145], ["left ventricular cavity", "ANATOMY", 153, 176]]], ["In the second pattern, large trabecular or irregular broad bands are observed bridging the left ventricular free wall and ventricular septum (VS) and often causing fixed stenosis or a fibrotic tube in the mid to apical left ventricular chamber.", [["trabecular", "ANATOMY", 29, 39], ["left ventricular free wall", "ANATOMY", 91, 117], ["ventricular septum", "ANATOMY", 122, 140], ["VS", "ANATOMY", 142, 144], ["fibrotic tube", "ANATOMY", 184, 197], ["left ventricular", "ANATOMY", 219, 235], ["stenosis", "DISEASE", 170, 178], ["trabecular", "MULTI-TISSUE_STRUCTURE", 29, 39], ["ventricular free wall", "TISSUE", 96, 117], ["ventricular septum", "MULTI-TISSUE_STRUCTURE", 122, 140], ["fibrotic tube", "TISSUE", 184, 197], ["ventricular chamber", "MULTI-TISSUE_STRUCTURE", 224, 243], ["large trabecular or irregular broad bands", "PROBLEM", 23, 64], ["fixed stenosis", "PROBLEM", 164, 178], ["a fibrotic tube", "TREATMENT", 182, 197], ["large", "OBSERVATION_MODIFIER", 23, 28], ["trabecular", "OBSERVATION", 29, 39], ["irregular", "OBSERVATION_MODIFIER", 43, 52], ["broad bands", "OBSERVATION", 53, 64], ["left ventricular", "ANATOMY", 91, 107], ["free", "ANATOMY_MODIFIER", 108, 112], ["wall", "ANATOMY_MODIFIER", 113, 117], ["ventricular septum", "ANATOMY", 122, 140], ["fixed", "OBSERVATION_MODIFIER", 164, 169], ["stenosis", "OBSERVATION", 170, 178], ["fibrotic", "OBSERVATION_MODIFIER", 184, 192], ["tube", "OBSERVATION", 193, 197], ["mid", "ANATOMY_MODIFIER", 205, 208], ["apical", "ANATOMY_MODIFIER", 212, 218], ["left ventricular", "ANATOMY", 219, 235], ["chamber", "ANATOMY_MODIFIER", 236, 243]]], ["This is the most common form reported in cats with endomyocardial RCM (Fox, 2004).IntroductionThe aetiology of endomyocardial RCM in cats is unknown, but is thought to be multifactorial, as there is a wide spectrum of clinical manifestations and pathological phenotypes (Fox, 2004).", [["endomyocardial", "ANATOMY", 51, 65], ["endomyocardial", "ANATOMY", 111, 125], ["endomyocardial RCM", "DISEASE", 51, 69], ["endomyocardial RCM", "DISEASE", 111, 129], ["cats", "ORGANISM", 41, 45], ["endomyocardial", "ORGAN", 51, 65], ["endomyocardial", "MULTI-TISSUE_STRUCTURE", 111, 125], ["cats", "ORGANISM", 133, 137], ["cats", "SPECIES", 133, 137], ["endomyocardial RCM in cats", "PROBLEM", 111, 137], ["clinical manifestations", "PROBLEM", 218, 241], ["pathological phenotypes", "PROBLEM", 246, 269], ["most common", "OBSERVATION_MODIFIER", 12, 23], ["endomyocardial", "ANATOMY", 51, 65], ["endomyocardial", "ANATOMY", 111, 125], ["RCM", "OBSERVATION", 126, 129], ["thought to be", "UNCERTAINTY", 157, 170], ["wide", "OBSERVATION_MODIFIER", 201, 205]]], ["Possible hypotheses include viral or immune-mediated endomyocarditis followed by reparative fibrosis, or a consequence of the end stage of myocardial failure and infarction from hypertrophic cardiomyopathy (Fox, 1999, Fox, 2004).IntroductionThe present report provides a fuller description of the range of pathological features in the endomyocardial form of RCM and presents a hypothesis to explain the pathogenesis of this disease in the cat.Animals ::: Materials and MethodsAs described in our previous report (Kimura et al., 2016), the materials for the present study were obtained from consecutive feline necropsy examinations conducted at the Laboratory of Veterinary Clinical Oncology, Tokyo University of Agriculture and Technology, Tokyo, Japan, during the period 2005\u20132014.", [["myocardial", "ANATOMY", 139, 149], ["endomyocardial", "ANATOMY", 335, 349], ["endomyocarditis", "DISEASE", 53, 68], ["fibrosis", "DISEASE", 92, 100], ["myocardial failure", "DISEASE", 139, 157], ["infarction", "DISEASE", 162, 172], ["hypertrophic cardiomyopathy", "DISEASE", 178, 205], ["RCM", "DISEASE", 358, 361], ["myocardial", "MULTI-TISSUE_STRUCTURE", 139, 149], ["endomyocardial", "ORGAN", 335, 349], ["cat", "ORGANISM", 439, 442], ["feline", "ORGANISM", 602, 608], ["cat", "SPECIES", 439, 442], ["viral", "PROBLEM", 28, 33], ["immune-mediated endomyocarditis", "PROBLEM", 37, 68], ["reparative fibrosis", "PROBLEM", 81, 100], ["myocardial failure", "PROBLEM", 139, 157], ["infarction", "PROBLEM", 162, 172], ["hypertrophic cardiomyopathy", "PROBLEM", 178, 205], ["a hypothesis", "PROBLEM", 375, 387], ["this disease in the cat", "PROBLEM", 419, 442], ["the present study", "TEST", 553, 570], ["consecutive feline necropsy examinations", "TEST", 590, 630], ["viral", "OBSERVATION", 28, 33], ["reparative", "OBSERVATION_MODIFIER", 81, 91], ["fibrosis", "OBSERVATION", 92, 100], ["myocardial", "ANATOMY", 139, 149], ["failure", "OBSERVATION", 150, 157], ["infarction", "OBSERVATION", 162, 172], ["hypertrophic", "OBSERVATION_MODIFIER", 178, 190], ["cardiomyopathy", "OBSERVATION", 191, 205], ["endomyocardial", "ANATOMY", 335, 349], ["RCM", "OBSERVATION", 358, 361]]], ["A total of 327 necropsy examinations were performed on cats with heart disease, and 41 cats were diagnosed as having the endomyocardial form of RCM.", [["heart", "ANATOMY", 65, 70], ["endomyocardial", "ANATOMY", 121, 135], ["heart disease", "DISEASE", 65, 78], ["RCM", "DISEASE", 144, 147], ["cats", "ORGANISM", 55, 59], ["heart", "ORGAN", 65, 70], ["cats", "ORGANISM", 87, 91], ["endomyocardial", "ORGAN", 121, 135], ["cats", "SPECIES", 55, 59], ["cats", "SPECIES", 87, 91], ["necropsy examinations", "TEST", 15, 36], ["heart disease", "PROBLEM", 65, 78], ["heart", "ANATOMY", 65, 70], ["disease", "OBSERVATION", 71, 78], ["endomyocardial", "ANATOMY", 121, 135], ["RCM", "OBSERVATION", 144, 147]]], ["In these cases, the diagnosis was based on characteristic gross features of marked fibrosis focally or diffusely involving the endocardium of the LV.", [["endocardium", "ANATOMY", 127, 138], ["LV", "ANATOMY", 146, 148], ["fibrosis", "DISEASE", 83, 91], ["endocardium", "MULTI-TISSUE_STRUCTURE", 127, 138], ["LV", "MULTI-TISSUE_STRUCTURE", 146, 148], ["marked fibrosis", "PROBLEM", 76, 91], ["marked", "OBSERVATION_MODIFIER", 76, 82], ["fibrosis", "OBSERVATION", 83, 91], ["diffusely", "OBSERVATION_MODIFIER", 103, 112], ["endocardium", "ANATOMY_MODIFIER", 127, 138], ["LV", "ANATOMY", 146, 148]]], ["The hallmark gross findings included an enlarged heart with marked left atrial and often right atrial dilation and hypertrophy; severe and extensive endocardial fibrosis, frequently bridging the left ventricular free wall and VS; left ventricular hypertrophy commonly associated with wall and chamber deformity; and mural thrombi in the left atrium (LA) or LV (Fox, 1999, Fox, 2004).Pathological Studies ::: Materials and MethodsA complete necropsy examination was performed on all 41 cats within 12 h of death.", [["heart", "ANATOMY", 49, 54], ["left atrial", "ANATOMY", 67, 78], ["right atrial", "ANATOMY", 89, 101], ["endocardial", "ANATOMY", 149, 160], ["left ventricular free wall", "ANATOMY", 195, 221], ["left ventricular", "ANATOMY", 230, 246], ["wall", "ANATOMY", 284, 288], ["mural thrombi", "ANATOMY", 316, 329], ["left atrium", "ANATOMY", 337, 348], ["LV", "ANATOMY", 357, 359], ["hypertrophy", "DISEASE", 115, 126], ["fibrosis", "DISEASE", 161, 169], ["left ventricular hypertrophy", "DISEASE", 230, 258], ["wall and chamber deformity", "DISEASE", 284, 310], ["thrombi", "DISEASE", 322, 329], ["death", "DISEASE", 505, 510], ["heart", "ORGAN", 49, 54], ["atrial", "MULTI-TISSUE_STRUCTURE", 72, 78], ["atrial", "MULTI-TISSUE_STRUCTURE", 95, 101], ["endocardial", "MULTI-TISSUE_STRUCTURE", 149, 160], ["ventricular", "MULTI-TISSUE_STRUCTURE", 200, 211], ["wall", "MULTI-TISSUE_STRUCTURE", 217, 221], ["ventricular", "MULTI-TISSUE_STRUCTURE", 235, 246], ["wall", "MULTI-TISSUE_STRUCTURE", 284, 288], ["atrium", "MULTI-TISSUE_STRUCTURE", 342, 348], ["LA", "MULTI-TISSUE_STRUCTURE", 350, 352], ["cats", "ORGANISM", 485, 489], ["an enlarged heart", "PROBLEM", 37, 54], ["marked left atrial and often right atrial dilation", "PROBLEM", 60, 110], ["hypertrophy", "PROBLEM", 115, 126], ["severe and extensive endocardial fibrosis", "PROBLEM", 128, 169], ["left ventricular hypertrophy", "PROBLEM", 230, 258], ["wall and chamber deformity", "PROBLEM", 284, 310], ["mural thrombi in the left atrium", "PROBLEM", 316, 348], ["Pathological Studies", "TEST", 383, 403], ["MethodsA complete necropsy examination", "TEST", 422, 460], ["death", "PROBLEM", 505, 510], ["hallmark", "OBSERVATION_MODIFIER", 4, 12], ["gross", "OBSERVATION_MODIFIER", 13, 18], ["enlarged", "OBSERVATION", 40, 48], ["heart", "ANATOMY", 49, 54], ["marked", "OBSERVATION_MODIFIER", 60, 66], ["left atrial", "ANATOMY", 67, 78], ["right atrial", "ANATOMY", 89, 101], ["dilation", "OBSERVATION", 102, 110], ["hypertrophy", "OBSERVATION", 115, 126], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["extensive", "OBSERVATION_MODIFIER", 139, 148], ["endocardial", "ANATOMY_MODIFIER", 149, 160], ["fibrosis", "OBSERVATION", 161, 169], ["left ventricular", "ANATOMY", 195, 211], ["free", "ANATOMY_MODIFIER", 212, 216], ["wall", "ANATOMY_MODIFIER", 217, 221], ["left ventricular", "ANATOMY", 230, 246], ["hypertrophy", "OBSERVATION", 247, 258], ["wall", "ANATOMY_MODIFIER", 284, 288], ["chamber deformity", "OBSERVATION", 293, 310], ["mural", "OBSERVATION_MODIFIER", 316, 321], ["thrombi", "OBSERVATION", 322, 329], ["left atrium", "ANATOMY", 337, 348], ["LA", "ANATOMY_MODIFIER", 350, 352], ["LV", "ANATOMY", 357, 359]]], ["The hearts were examined and weighed, and the heart weight to body weight (HW/BW) was calculated (i.e. HW in g/BW in kg).", [["hearts", "ANATOMY", 4, 10], ["heart", "ANATOMY", 46, 51], ["body", "ANATOMY", 62, 66], ["hearts", "ORGAN", 4, 10], ["heart", "ORGAN", 46, 51], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["the heart weight", "TEST", 42, 58], ["body weight", "TEST", 62, 73], ["HW/BW", "TEST", 75, 80], ["hearts", "ANATOMY", 4, 10], ["heart", "ANATOMY", 46, 51]]], ["The hearts were then placed in 10% neutral buffered formalin for a minimum of 5 days.", [["hearts", "ANATOMY", 4, 10], ["formalin", "CHEMICAL", 52, 60], ["formalin", "CHEMICAL", 52, 60], ["hearts", "ORGAN", 4, 10], ["formalin", "SIMPLE_CHEMICAL", 52, 60], ["10% neutral buffered formalin", "TREATMENT", 31, 60], ["hearts", "ANATOMY", 4, 10]]], ["After fixation, the ventricles were sliced transversely into serial sections approximately 5 mm thick, from the mitral valve to the cardiac apex.", [["ventricles", "ANATOMY", 20, 30], ["sections", "ANATOMY", 68, 76], ["mitral valve", "ANATOMY", 112, 124], ["cardiac apex", "ANATOMY", 132, 144], ["ventricles", "MULTI-TISSUE_STRUCTURE", 20, 30], ["mitral valve", "MULTI-TISSUE_STRUCTURE", 112, 124], ["cardiac apex", "MULTI-TISSUE_STRUCTURE", 132, 144], ["fixation", "TREATMENT", 6, 14], ["fixation", "OBSERVATION", 6, 14], ["ventricles", "ANATOMY", 20, 30], ["5 mm", "OBSERVATION_MODIFIER", 91, 95], ["mitral valve", "ANATOMY", 112, 124], ["cardiac", "ANATOMY", 132, 139], ["apex", "ANATOMY_MODIFIER", 140, 144]]], ["Each transverse ventricular slice was embedded in paraffin wax, sectioned (5 \u03bcm) and stained with haematoxylin and eosin (HE).", [["transverse ventricular slice", "ANATOMY", 5, 33], ["paraffin", "CHEMICAL", 50, 58], ["haematoxylin", "CHEMICAL", 98, 110], ["eosin", "CHEMICAL", 115, 120], ["transverse ventricular slice", "MULTI-TISSUE_STRUCTURE", 5, 33], ["haematoxylin", "SIMPLE_CHEMICAL", 98, 110], ["eosin", "SIMPLE_CHEMICAL", 115, 120], ["haematoxylin", "TREATMENT", 98, 110], ["transverse ventricular", "ANATOMY", 5, 27]]], ["Selected sections were also stained with Masson's trichrome for collagen fibres, elastic van Gieson for elastic fibres and alcian blue (pH 2.5) and toluidine blue for acidic glycosaminoglycans.", [["sections", "ANATOMY", 9, 17], ["elastic fibres", "ANATOMY", 104, 118], ["alcian blue", "CHEMICAL", 123, 134], ["toluidine blue", "CHEMICAL", 148, 162], ["alcian blue", "CHEMICAL", 123, 134], ["toluidine blue", "CHEMICAL", 148, 162], ["sections", "MULTI-TISSUE_STRUCTURE", 9, 17], ["collagen", "GENE_OR_GENE_PRODUCT", 64, 72], ["alcian blue", "SIMPLE_CHEMICAL", 123, 134], ["toluidine blue", "SIMPLE_CHEMICAL", 148, 162], ["acidic glycosaminoglycans", "SIMPLE_CHEMICAL", 167, 192], ["Selected sections", "TEST", 0, 17], ["alcian blue", "TEST", 123, 134], ["pH", "TEST", 136, 138], ["toluidine blue", "TEST", 148, 162], ["acidic glycosaminoglycans", "TREATMENT", 167, 192]]], ["The microscopical examination focused on any morphological changes in the endocardium of the LV.Pathological Studies ::: Materials and MethodsImmunohistochemistry (IHC) was performed for identification of the endothelial marker CD34 (mouse monoclonal anti-human CD34 class II, Clone QBEnd-10; 1 in 100 dilution; Dako, Glostrup, Denmark), vimentin (mouse monoclonal antibody against vimentin, clone Vim 3B4; 1 in 100 dilution; Dako), \u03b1-smooth muscle actin (\u03b1-SMA; mouse monoclonal antibody against human smooth muscle actin, clone 1A4; 1 in 100 dilution; Dako), caldesmon (mouse monoclonal antibody against human caldesmon, clone h-CD; 1 in 100 dilution; Dako), platelet-derived growth factor (PDGF; rabbit polyclonal antibody against PDGF BB; 1 in 50 dilution; Abcam, Cambridge, UK) and transforming growth factor-\u03b2 (TGF-\u03b2; rabbit polyclonal antibody against TGF-\u03b2; 1 in 100 dilution; Abcam) in the endocardium of the LV.", [["endocardium", "ANATOMY", 74, 85], ["LV", "ANATOMY", 93, 95], ["endothelial", "ANATOMY", 209, 220], ["smooth muscle", "ANATOMY", 503, 516], ["endocardium", "ANATOMY", 899, 910], ["LV", "ANATOMY", 918, 920], ["endocardium", "MULTI-TISSUE_STRUCTURE", 74, 85], ["LV", "MULTI-TISSUE_STRUCTURE", 93, 95], ["endothelial", "CELL", 209, 220], ["CD34", "GENE_OR_GENE_PRODUCT", 228, 232], ["mouse", "ORGANISM", 234, 239], ["CD34", "GENE_OR_GENE_PRODUCT", 262, 266], ["Glostrup", "GENE_OR_GENE_PRODUCT", 318, 326], ["vimentin", "GENE_OR_GENE_PRODUCT", 338, 346], ["mouse", "ORGANISM", 348, 353], ["vimentin", "GENE_OR_GENE_PRODUCT", 382, 390], ["Dako", "GENE_OR_GENE_PRODUCT", 426, 430], ["\u03b1-smooth muscle actin", "GENE_OR_GENE_PRODUCT", 433, 454], ["\u03b1-SMA", "GENE_OR_GENE_PRODUCT", 456, 461], ["mouse", "ORGANISM", 463, 468], ["human", "ORGANISM", 497, 502], ["smooth muscle actin", "GENE_OR_GENE_PRODUCT", 503, 522], ["Dako", "GENE_OR_GENE_PRODUCT", 554, 558], ["caldesmon", "GENE_OR_GENE_PRODUCT", 561, 570], ["mouse", "ORGANISM", 572, 577], ["human", "ORGANISM", 606, 611], ["caldesmon", "GENE_OR_GENE_PRODUCT", 612, 621], ["platelet-derived growth factor", "GENE_OR_GENE_PRODUCT", 661, 691], ["PDGF", "GENE_OR_GENE_PRODUCT", 693, 697], ["rabbit", "ORGANISM", 699, 705], ["PDGF BB", "GENE_OR_GENE_PRODUCT", 734, 741], ["Abcam", "GENE_OR_GENE_PRODUCT", 761, 766], ["UK", "GENE_OR_GENE_PRODUCT", 779, 781], ["transforming growth factor-\u03b2", "GENE_OR_GENE_PRODUCT", 787, 815], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 817, 822], ["rabbit", "ORGANISM", 824, 830], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 859, 864], ["Abcam", "GENE_OR_GENE_PRODUCT", 885, 890], ["endocardium", "MULTI-TISSUE_STRUCTURE", 899, 910], ["LV", "MULTI-TISSUE_STRUCTURE", 918, 920], ["endothelial marker CD34", "PROTEIN", 209, 232], ["mouse monoclonal anti-human CD34 class II", "PROTEIN", 234, 275], ["Clone QBEnd-10; 1", "PROTEIN", 277, 294], ["Dako, Glostrup, Denmark", "PROTEIN", 312, 335], ["vimentin", "PROTEIN", 338, 346], ["mouse monoclonal antibody", "PROTEIN", 348, 373], ["vimentin", "PROTEIN", 382, 390], ["clone Vim 3B4", "PROTEIN", 392, 405], ["Dako", "PROTEIN", 426, 430], ["\u03b1-smooth muscle actin", "PROTEIN", 433, 454], ["\u03b1", "PROTEIN", 456, 457], ["SMA", "PROTEIN", 458, 461], ["mouse monoclonal antibody", "PROTEIN", 463, 488], ["human smooth muscle actin", "PROTEIN", 497, 522], ["clone 1A4", "PROTEIN", 524, 533], ["Dako", "PROTEIN", 554, 558], ["caldesmon", "PROTEIN", 561, 570], ["mouse monoclonal antibody", "PROTEIN", 572, 597], ["human caldesmon", "PROTEIN", 606, 621], ["platelet-derived growth factor", "PROTEIN", 661, 691], ["PDGF", "PROTEIN", 693, 697], ["rabbit polyclonal antibody", "PROTEIN", 699, 725], ["PDGF BB", "PROTEIN", 734, 741], ["Abcam, Cambridge, UK) and transforming growth factor-\u03b2", "PROTEIN", 761, 815], ["TGF-\u03b2; rabbit polyclonal antibody", "PROTEIN", 817, 850], ["TGF", "PROTEIN", 859, 862], ["Abcam", "PROTEIN", 885, 890], ["mouse", "SPECIES", 234, 239], ["mouse", "SPECIES", 348, 353], ["mouse", "SPECIES", 463, 468], ["human", "SPECIES", 497, 502], ["mouse", "SPECIES", 572, 577], ["human", "SPECIES", 606, 611], ["rabbit", "SPECIES", 699, 705], ["rabbit", "SPECIES", 824, 830], ["mouse", "SPECIES", 234, 239], ["mouse", "SPECIES", 348, 353], ["mouse", "SPECIES", 463, 468], ["human", "SPECIES", 497, 502], ["mouse", "SPECIES", 572, 577], ["human", "SPECIES", 606, 611], ["rabbit", "SPECIES", 699, 705], ["rabbit", "SPECIES", 824, 830], ["The microscopical examination", "TEST", 0, 29], ["mouse monoclonal anti-human CD34 class II", "TREATMENT", 234, 275], ["Clone QBEnd", "TREATMENT", 277, 288], ["vimentin (mouse monoclonal antibody", "TREATMENT", 338, 373], ["vimentin", "TEST", 382, 390], ["Dako", "TEST", 426, 430], ["mouse monoclonal antibody", "TREATMENT", 463, 488], ["caldesmon (mouse monoclonal antibody", "TREATMENT", 561, 597], ["human caldesmon", "TREATMENT", 606, 621], ["Dako", "TEST", 654, 658], ["platelet", "TEST", 661, 669], ["growth factor", "TEST", 678, 691], ["PDGF", "TEST", 693, 697], ["rabbit polyclonal antibody", "TEST", 699, 725], ["PDGF BB", "TEST", 734, 741], ["Abcam", "TEST", 761, 766], ["transforming growth factor", "TEST", 787, 813], ["TGF", "TEST", 817, 820], ["\u03b2", "TEST", 821, 822], ["rabbit polyclonal antibody", "TEST", 824, 850], ["TGF", "TEST", 859, 862], ["\u03b2", "TEST", 863, 864], ["Abcam", "TEST", 885, 890], ["endocardium", "ANATOMY", 74, 85], ["LV", "ANATOMY", 93, 95], ["endothelial", "ANATOMY", 209, 220], ["muscle", "ANATOMY", 442, 448], ["SMA", "ANATOMY", 458, 461], ["endocardium", "ANATOMY", 899, 910], ["LV", "ANATOMY", 918, 920]]], ["The avidin\u2013biotin\u2013peroxidase method (Vectastain, Vector Laboratories, Burlingame, California, USA) was employed in order to identify the reaction product, with haematoxylin as a counterstain.Molecular Biological Studies ::: Materials and MethodsReal-time polymerase chain reaction (PCR) was used to determine whether viral nucleic acids were detectable in cardiac tissues including the endocardium, myocardium and epicardium.", [["cardiac tissues", "ANATOMY", 356, 371], ["endocardium", "ANATOMY", 386, 397], ["myocardium", "ANATOMY", 399, 409], ["epicardium", "ANATOMY", 414, 424], ["nucleic acids", "CHEMICAL", 323, 336], ["haematoxylin", "CHEMICAL", 160, 172], ["haematoxylin", "SIMPLE_CHEMICAL", 160, 172], ["cardiac tissues", "TISSUE", 356, 371], ["endocardium", "MULTI-TISSUE_STRUCTURE", 386, 397], ["myocardium", "MULTI-TISSUE_STRUCTURE", 399, 409], ["epicardium", "MULTI-TISSUE_STRUCTURE", 414, 424], ["The avidin\u2013biotin\u2013peroxidase method", "TREATMENT", 0, 35], ["haematoxylin", "TREATMENT", 160, 172], ["Methods", "TEST", 238, 245], ["PCR", "TEST", 282, 285], ["viral nucleic acids", "TEST", 317, 336], ["cardiac tissues", "ANATOMY", 356, 371], ["endocardium", "ANATOMY", 386, 397], ["myocardium", "ANATOMY", 399, 409], ["epicardium", "ANATOMY", 414, 424]]], ["DNA and RNA samples were extracted from wax-embedded tissue blocks of 14 cat hearts with endomyocardial RCM collected between 2012 and 2014 using the RecoverAll\u2122 Total Nucleic Acid Isolation Kit for FFPE (Life Technologies, Carlsbad, California, USA).", [["samples", "ANATOMY", 12, 19], ["tissue", "ANATOMY", 53, 59], ["hearts", "ANATOMY", 77, 83], ["endomyocardial", "ANATOMY", 89, 103], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["tissue", "TISSUE", 53, 59], ["cat", "ORGANISM", 73, 76], ["hearts", "ORGAN", 77, 83], ["DNA", "PROBLEM", 0, 3], ["RNA samples", "TEST", 8, 19], ["endomyocardial RCM", "TEST", 89, 107], ["the RecoverAll\u2122 Total Nucleic Acid Isolation", "TREATMENT", 146, 190], ["endomyocardial", "ANATOMY", 89, 103]]], ["Screening for a total of six viruses, including feline herpesvirus (FHV), feline panleukopenia virus (FPLV), feline calicivirus (FCV), feline coronavirus (FCoV), feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV), was carried out according to their prevalence, and the feline \u03b2-actin gene (ACTB) was selected as a positive control.", [["feline herpesvirus", "DISEASE", 48, 66], ["feline panleukopenia", "DISEASE", 74, 94], ["feline calicivirus", "DISEASE", 109, 127], ["feline coronavirus", "DISEASE", 135, 153], ["feline immunodeficiency virus (FIV)", "DISEASE", 162, 197], ["feline leukemia virus", "DISEASE", 202, 223], ["feline herpesvirus", "ORGANISM", 48, 66], ["FHV", "ORGANISM", 68, 71], ["feline panleukopenia virus", "ORGANISM", 74, 100], ["FPLV", "ORGANISM", 102, 106], ["feline calicivirus", "ORGANISM", 109, 127], ["FCV", "ORGANISM", 129, 132], ["feline coronavirus", "ORGANISM", 135, 153], ["FCoV", "ORGANISM", 155, 159], ["feline immunodeficiency virus", "ORGANISM", 162, 191], ["FIV", "ORGANISM", 193, 196], ["feline leukemia virus", "ORGANISM", 202, 223], ["FeLV", "ORGANISM", 225, 229], ["feline", "ORGANISM", 287, 293], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 294, 301], ["ACTB", "GENE_OR_GENE_PRODUCT", 308, 312], ["feline \u03b2-actin gene", "DNA", 287, 306], ["ACTB", "DNA", 308, 312], ["feline herpesvirus", "SPECIES", 48, 66], ["feline panleukopenia virus", "SPECIES", 74, 100], ["feline calicivirus", "SPECIES", 109, 127], ["FCV", "SPECIES", 129, 132], ["feline coronavirus", "SPECIES", 135, 153], ["feline immunodeficiency virus", "SPECIES", 162, 191], ["feline leukemia virus", "SPECIES", 202, 223], ["feline", "SPECIES", 287, 293], ["feline herpesvirus", "SPECIES", 48, 66], ["FHV", "SPECIES", 68, 71], ["feline panleukopenia virus", "SPECIES", 74, 100], ["FPLV", "SPECIES", 102, 106], ["feline calicivirus", "SPECIES", 109, 127], ["FCV", "SPECIES", 129, 132], ["feline coronavirus", "SPECIES", 135, 153], ["FCoV", "SPECIES", 155, 159], ["feline immunodeficiency virus", "SPECIES", 162, 191], ["FIV", "SPECIES", 193, 196], ["feline leukemia virus", "SPECIES", 202, 223], ["FeLV", "SPECIES", 225, 229], ["Screening", "TEST", 0, 9], ["six viruses", "PROBLEM", 25, 36], ["feline herpesvirus", "PROBLEM", 48, 66], ["feline panleukopenia virus (FPLV)", "PROBLEM", 74, 107], ["feline calicivirus (FCV", "PROBLEM", 109, 132], ["feline coronavirus (FCoV", "PROBLEM", 135, 159], ["feline immunodeficiency virus", "PROBLEM", 162, 191], ["feline leukemia virus", "PROBLEM", 202, 223], ["the feline \u03b2-actin gene (ACTB", "TREATMENT", 283, 312], ["a positive control", "TREATMENT", 330, 348], ["feline leukemia virus", "OBSERVATION", 202, 223]]], ["Primer pairs and TaqMan probes labelled with the reporter dye FAM at the 5\u2032 end and fluorescent dye TAMRA at the 3\u2032 end for FHV, FPLV, FIV and FeLV were designed on the basis of the published sequences (Dieter et al., 1999, V\u00f6gtlin et al., 2002, Ravi et al., 2005, Andr\u00e9 et al., 2013).", [["FAM", "CHEMICAL", 62, 65], ["TAMRA", "CHEMICAL", 100, 105], ["FAM", "SIMPLE_CHEMICAL", 62, 65], ["FIV", "ORGANISM", 135, 138], ["FeLV", "ORGANISM", 143, 147], ["Primer pairs", "DNA", 0, 12], ["TaqMan probes", "DNA", 17, 30], ["5\u2032 end", "DNA", 73, 79], ["3\u2032 end", "DNA", 113, 119], ["FHV", "SPECIES", 124, 127], ["FIV", "SPECIES", 135, 138], ["TaqMan probes", "TEST", 17, 30], ["the reporter dye FAM", "TREATMENT", 45, 65], ["fluorescent dye TAMRA", "TEST", 84, 105], ["FHV", "PROBLEM", 124, 127]]], ["New primer\u2013probe sets for FCV, FCoV and ACTB were designed to amplify the conserved region of each genome using PrimeQuest\u2122 software (Integrated DNA Technologies, Coralville, Iowa, USA).", [["FCV", "ORGANISM", 26, 29], ["ACTB", "GENE_OR_GENE_PRODUCT", 40, 44], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["primer\u2013probe sets", "DNA", 4, 21], ["FCoV", "DNA", 31, 35], ["ACTB", "DNA", 40, 44], ["FCV", "SPECIES", 26, 29], ["FCV", "PROBLEM", 26, 29], ["ACTB", "TREATMENT", 40, 44]]], ["All primer sequences, target gene names and Genbank accession numbers are listed in Table 1.", [["primer sequences", "DNA", 4, 20], ["target gene names", "DNA", 22, 39], ["All primer sequences", "TEST", 0, 20]]], ["Nuclease-free water was used for negative controls in each run.", [["Nuclease", "GENE_OR_GENE_PRODUCT", 0, 8], ["Nuclease", "TEST", 0, 8], ["free water", "TREATMENT", 9, 19]]], ["The thermal cycling conditions were the same as those described previously (Tsuchiaka et al., 2016).Necropsy Examination ::: ResultsMacroscopically, although some overlap was evident between them, two types of fibrotic lesion were observed in the endocardium of the LV.", [["fibrotic lesion", "ANATOMY", 210, 225], ["endocardium", "ANATOMY", 247, 258], ["LV", "ANATOMY", 266, 268], ["fibrotic lesion", "CANCER", 210, 225], ["endocardium", "MULTI-TISSUE_STRUCTURE", 247, 258], ["LV", "MULTI-TISSUE_STRUCTURE", 266, 268], ["The thermal cycling conditions", "PROBLEM", 0, 30], ["Necropsy Examination", "TEST", 100, 120], ["fibrotic lesion", "PROBLEM", 210, 225], ["two", "OBSERVATION_MODIFIER", 197, 200], ["types", "OBSERVATION_MODIFIER", 201, 206], ["fibrotic", "OBSERVATION_MODIFIER", 210, 218], ["lesion", "OBSERVATION", 219, 225], ["endocardium", "ANATOMY_MODIFIER", 247, 258], ["LV", "ANATOMY", 266, 268]]], ["Most commonly, patchy endocardial lesions occurred as single or multiple large trabecular bands or irregular broad bands of fibrous tissue bridging the left ventricular lumen from the free wall to the septum (\u2018patchy\u2019 pattern; n = 34) (Fig. 1A).", [["endocardial lesions", "ANATOMY", 22, 41], ["trabecular", "ANATOMY", 79, 89], ["fibrous tissue", "ANATOMY", 124, 138], ["left ventricular lumen", "ANATOMY", 152, 174], ["free wall", "ANATOMY", 184, 193], ["septum", "ANATOMY", 201, 207], ["patchy endocardial lesions", "PATHOLOGICAL_FORMATION", 15, 41], ["fibrous tissue", "TISSUE", 124, 138], ["ventricular lumen", "MULTI-TISSUE_STRUCTURE", 157, 174], ["wall", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 193], ["septum", "PATHOLOGICAL_FORMATION", 201, 207], ["patchy endocardial lesions", "PROBLEM", 15, 41], ["multiple large trabecular bands", "PROBLEM", 64, 95], ["irregular broad bands of fibrous tissue", "PROBLEM", 99, 138], ["patchy\u2019 pattern", "PROBLEM", 210, 225], ["patchy", "OBSERVATION_MODIFIER", 15, 21], ["endocardial", "ANATOMY", 22, 33], ["lesions", "OBSERVATION", 34, 41], ["multiple", "OBSERVATION_MODIFIER", 64, 72], ["large", "OBSERVATION_MODIFIER", 73, 78], ["trabecular bands", "OBSERVATION", 79, 95], ["irregular", "OBSERVATION_MODIFIER", 99, 108], ["broad", "OBSERVATION_MODIFIER", 109, 114], ["bands", "OBSERVATION_MODIFIER", 115, 120], ["fibrous tissue", "OBSERVATION", 124, 138], ["left ventricular", "ANATOMY", 152, 168], ["lumen", "ANATOMY_MODIFIER", 169, 174], ["free wall", "ANATOMY", 184, 193], ["septum", "ANATOMY_MODIFIER", 201, 207], ["patchy", "OBSERVATION_MODIFIER", 210, 216]]], ["The fibrous bands were usually located between the anterior and/or posterior papillary muscles (PMs) and the VS, frequently causing intraventricular partial obstruction and/or chamber deformity at different levels.", [["fibrous bands", "ANATOMY", 4, 17], ["anterior", "ANATOMY", 51, 59], ["posterior papillary muscles", "ANATOMY", 67, 94], ["PMs", "ANATOMY", 96, 99], ["intraventricular partial obstruction", "DISEASE", 132, 168], ["deformity", "DISEASE", 184, 193], ["fibrous bands", "CANCER", 4, 17], ["anterior", "MULTI-TISSUE_STRUCTURE", 51, 59], ["posterior papillary muscles", "TISSUE", 67, 94], ["PMs", "MULTI-TISSUE_STRUCTURE", 96, 99], ["The fibrous bands", "PROBLEM", 0, 17], ["the VS", "TEST", 105, 111], ["intraventricular partial obstruction", "PROBLEM", 132, 168], ["chamber deformity at different levels", "PROBLEM", 176, 213], ["fibrous bands", "OBSERVATION", 4, 17], ["anterior", "ANATOMY_MODIFIER", 51, 59], ["posterior", "ANATOMY_MODIFIER", 67, 76], ["papillary muscles", "ANATOMY", 77, 94], ["intraventricular", "ANATOMY_MODIFIER", 132, 148], ["partial", "OBSERVATION_MODIFIER", 149, 156], ["obstruction", "OBSERVATION", 157, 168], ["chamber deformity", "OBSERVATION", 176, 193], ["different", "OBSERVATION_MODIFIER", 197, 206], ["levels", "OBSERVATION_MODIFIER", 207, 213]]], ["Less commonly, the left ventricular endocardium showed diffuse and marked fibrosis, which appeared as a white\u2013grey, smooth, firm and uniform covering over the inflow and outflow tracts, PMs, mitral valve apparatus and, occasionally, the aortic valves and trunk (\u2018diffuse\u2019 pattern; n = 7) (Fig. 1B).", [["left ventricular endocardium", "ANATOMY", 19, 47], ["outflow tracts", "ANATOMY", 170, 184], ["PMs", "ANATOMY", 186, 189], ["mitral valve", "ANATOMY", 191, 203], ["aortic valves", "ANATOMY", 237, 250], ["trunk", "ANATOMY", 255, 260], ["fibrosis", "DISEASE", 74, 82], ["ventricular endocardium", "MULTI-TISSUE_STRUCTURE", 24, 47], ["PMs", "MULTI-TISSUE_STRUCTURE", 186, 189], ["aortic valves", "TISSUE", 237, 250], ["trunk", "ORGANISM_SUBDIVISION", 255, 260], ["diffuse and marked fibrosis", "PROBLEM", 55, 82], ["mitral valve apparatus", "TEST", 191, 213], ["trunk (\u2018diffuse\u2019 pattern", "PROBLEM", 255, 279], ["left ventricular endocardium", "ANATOMY", 19, 47], ["diffuse", "OBSERVATION_MODIFIER", 55, 62], ["marked", "OBSERVATION_MODIFIER", 67, 73], ["fibrosis", "OBSERVATION", 74, 82], ["smooth", "OBSERVATION_MODIFIER", 116, 122], ["firm", "OBSERVATION_MODIFIER", 124, 128], ["uniform", "OBSERVATION_MODIFIER", 133, 140], ["inflow", "ANATOMY_MODIFIER", 159, 165], ["outflow tracts", "ANATOMY", 170, 184], ["mitral valve", "ANATOMY", 191, 203], ["apparatus", "ANATOMY_MODIFIER", 204, 213], ["aortic valves", "ANATOMY", 237, 250], ["trunk", "ANATOMY", 255, 260], ["diffuse", "OBSERVATION_MODIFIER", 263, 270]]], ["In this type, extensive fibrosis caused a moderate to marked reduction of left ventricular chamber size.", [["left ventricular", "ANATOMY", 74, 90], ["fibrosis", "DISEASE", 24, 32], ["ventricular chamber", "MULTI-TISSUE_STRUCTURE", 79, 98], ["extensive fibrosis", "PROBLEM", 14, 32], ["a moderate to marked reduction of left ventricular chamber size", "PROBLEM", 40, 103], ["extensive", "OBSERVATION_MODIFIER", 14, 23], ["fibrosis", "OBSERVATION", 24, 32], ["moderate", "OBSERVATION_MODIFIER", 42, 50], ["marked", "OBSERVATION_MODIFIER", 54, 60], ["reduction", "OBSERVATION_MODIFIER", 61, 70], ["left ventricular", "ANATOMY", 74, 90], ["chamber", "ANATOMY_MODIFIER", 91, 98], ["size", "OBSERVATION_MODIFIER", 99, 103]]], ["The mitral valve apparatus and PMs were distorted and fused to surrounding structures.Necropsy Examination ::: ResultsHeart weights in the cats with endomyocardial RCM (HW/BW 6.0 \u00b1 1.1 g/kg [mean \u00b1 SD]) were greater than those in cats with normal hearts (4.0 \u00b1 0.3 g/kg; Liu and Tilley, 1980).", [["mitral valve", "ANATOMY", 4, 16], ["Heart", "ANATOMY", 118, 123], ["endomyocardial", "ANATOMY", 149, 163], ["hearts", "ANATOMY", 247, 253], ["mitral valve", "MULTI-TISSUE_STRUCTURE", 4, 16], ["PMs", "MULTI-TISSUE_STRUCTURE", 31, 34], ["Heart", "ORGAN", 118, 123], ["cats", "ORGANISM", 139, 143], ["endomyocardial", "MULTI-TISSUE_STRUCTURE", 149, 163], ["cats", "ORGANISM", 230, 234], ["hearts", "ORGAN", 247, 253], ["cats", "SPECIES", 139, 143], ["cats", "SPECIES", 230, 234], ["Necropsy Examination", "TEST", 86, 106], ["Heart weights", "TEST", 118, 131], ["endomyocardial RCM", "TEST", 149, 167], ["HW", "TEST", 169, 171], ["BW", "TEST", 172, 174], ["mean", "TEST", 191, 195], ["mitral valve", "ANATOMY", 4, 16], ["Heart", "ANATOMY", 118, 123], ["normal", "OBSERVATION", 240, 246], ["hearts", "ANATOMY", 247, 253]]], ["The LA and its auricular appendage were markedly enlarged, often with apparent wall thickening.", [["auricular appendage", "ANATOMY", 15, 34], ["wall", "ANATOMY", 79, 83], ["LA", "CHEMICAL", 4, 6], ["LA", "MULTI-TISSUE_STRUCTURE", 4, 6], ["auricular appendage", "MULTI-TISSUE_STRUCTURE", 15, 34], ["wall", "TISSUE", 79, 83], ["markedly enlarged", "PROBLEM", 40, 57], ["apparent wall thickening", "PROBLEM", 70, 94], ["LA", "ANATOMY_MODIFIER", 4, 6], ["auricular appendage", "ANATOMY", 15, 34], ["markedly", "OBSERVATION_MODIFIER", 40, 48], ["enlarged", "OBSERVATION", 49, 57], ["wall", "ANATOMY_MODIFIER", 79, 83], ["thickening", "OBSERVATION", 84, 94]]], ["Mural thrombi occurred in the LA, left auricle or LV and were found in 29.3% of the affected cats.", [["Mural thrombi", "ANATOMY", 0, 13], ["LA", "ANATOMY", 30, 32], ["left auricle", "ANATOMY", 34, 46], ["LV", "ANATOMY", 50, 52], ["thrombi", "DISEASE", 6, 13], ["LA", "CHEMICAL", 30, 32], ["Mural thrombi", "PATHOLOGICAL_FORMATION", 0, 13], ["LA", "CANCER", 30, 32], ["auricle", "ORGAN", 39, 46], ["LV", "MULTI-TISSUE_STRUCTURE", 50, 52], ["cats", "ORGANISM", 93, 97], ["cats", "SPECIES", 93, 97], ["Mural thrombi", "PROBLEM", 0, 13], ["the affected cats", "PROBLEM", 80, 97], ["thrombi", "OBSERVATION", 6, 13], ["LA", "ANATOMY_MODIFIER", 30, 32], ["left auricle", "ANATOMY", 34, 46], ["LV", "ANATOMY", 50, 52]]], ["In addition, distal aortic thromboembolism was observed in 43.9% of cases.Histopathology ::: ResultsHistologically, the endocardium of the LV was thickened by proliferation of hyaline and/or fibrous tissue in all 41 cases, regardless of the macroscopic pattern of endocardial thickening.", [["aortic", "ANATOMY", 20, 26], ["endocardium", "ANATOMY", 120, 131], ["LV", "ANATOMY", 139, 141], ["hyaline", "ANATOMY", 176, 183], ["fibrous tissue", "ANATOMY", 191, 205], ["endocardial", "ANATOMY", 264, 275], ["aortic thromboembolism", "DISEASE", 20, 42], ["aortic", "MULTI-TISSUE_STRUCTURE", 20, 26], ["endocardium", "MULTI-TISSUE_STRUCTURE", 120, 131], ["LV", "MULTI-TISSUE_STRUCTURE", 139, 141], ["hyaline", "TISSUE", 176, 183], ["fibrous tissue", "TISSUE", 191, 205], ["endocardial", "TISSUE", 264, 275], ["distal aortic thromboembolism", "PROBLEM", 13, 42], ["thickened", "PROBLEM", 146, 155], ["proliferation of hyaline", "PROBLEM", 159, 183], ["fibrous tissue", "PROBLEM", 191, 205], ["endocardial thickening", "PROBLEM", 264, 286], ["distal", "ANATOMY_MODIFIER", 13, 19], ["aortic", "ANATOMY", 20, 26], ["thromboembolism", "OBSERVATION", 27, 42], ["endocardium", "ANATOMY", 120, 131], ["LV", "ANATOMY", 139, 141], ["thickened", "OBSERVATION", 146, 155], ["proliferation", "OBSERVATION_MODIFIER", 159, 172], ["hyaline", "OBSERVATION_MODIFIER", 176, 183], ["fibrous tissue", "OBSERVATION", 191, 205], ["endocardial", "ANATOMY", 264, 275], ["thickening", "OBSERVATION", 276, 286]]], ["The endocardial lesions were divided into three main histological types, although some cases with intermediate features were observed.Histopathology ::: ResultsIn three of the 41 cases, the thickened endocardium was covered by intact endothelial cells and contained a large number of stellate, spindle-shaped or elongated mesenchymal cells surrounded by various amounts of alcian blue-positive ground substance with delicate collagen fibrils (type 1) (Fig. 2A).", [["endocardial lesions", "ANATOMY", 4, 23], ["endocardium", "ANATOMY", 200, 211], ["endothelial cells", "ANATOMY", 234, 251], ["stellate", "ANATOMY", 284, 292], ["spindle", "ANATOMY", 294, 301], ["mesenchymal cells", "ANATOMY", 322, 339], ["endocardial lesions", "CANCER", 4, 23], ["thickened endocardium", "TISSUE", 190, 211], ["endothelial cells", "CELL", 234, 251], ["stellate", "CELL", 284, 292], ["mesenchymal cells", "CELL", 322, 339], ["alcian", "SIMPLE_CHEMICAL", 373, 379], ["collagen fibrils", "GENE_OR_GENE_PRODUCT", 425, 441], ["endothelial cells", "CELL_TYPE", 234, 251], ["stellate, spindle-shaped or elongated mesenchymal cells", "CELL_TYPE", 284, 339], ["collagen fibrils", "PROTEIN", 425, 441], ["The endocardial lesions", "PROBLEM", 0, 23], ["intermediate features", "PROBLEM", 98, 119], ["the thickened endocardium", "PROBLEM", 186, 211], ["intact endothelial cells", "PROBLEM", 227, 251], ["a large number of stellate, spindle-shaped or elongated mesenchymal cells", "PROBLEM", 266, 339], ["alcian blue-positive ground substance", "PROBLEM", 373, 410], ["delicate collagen fibrils", "PROBLEM", 416, 441], ["endocardial", "ANATOMY", 4, 15], ["lesions", "OBSERVATION", 16, 23], ["three", "OBSERVATION_MODIFIER", 42, 47], ["main", "OBSERVATION_MODIFIER", 48, 52], ["histological types", "OBSERVATION", 53, 71], ["intermediate", "OBSERVATION_MODIFIER", 98, 110], ["thickened", "OBSERVATION", 190, 199], ["endocardium", "ANATOMY", 200, 211], ["intact endothelial cells", "OBSERVATION", 227, 251], ["large", "OBSERVATION_MODIFIER", 268, 273], ["number", "OBSERVATION_MODIFIER", 274, 280], ["stellate", "OBSERVATION_MODIFIER", 284, 292], ["spindle", "OBSERVATION_MODIFIER", 294, 301], ["-shaped", "OBSERVATION_MODIFIER", 301, 308], ["elongated", "OBSERVATION_MODIFIER", 312, 321], ["mesenchymal cells", "OBSERVATION", 322, 339], ["various", "OBSERVATION_MODIFIER", 354, 361], ["amounts", "OBSERVATION_MODIFIER", 362, 369], ["alcian blue-positive", "OBSERVATION", 373, 393], ["ground substance", "OBSERVATION", 394, 410], ["collagen fibrils", "OBSERVATION", 425, 441]]], ["These mesenchymal cells had large oval nuclei, prominent nucleoli, faintly eosinophilic cytoplasm and poorly defined cell margins, and were randomly arranged.Histopathology ::: ResultsIn the second type (type 2), which accounted for 19 of the 41 cases, the endocardial thickening revealed a two-layer structure (i.e. superficial and deep layers; Fig. 2B).", [["mesenchymal cells", "ANATOMY", 6, 23], ["oval nuclei", "ANATOMY", 34, 45], ["nucleoli", "ANATOMY", 57, 65], ["eosinophilic cytoplasm", "ANATOMY", 75, 97], ["cell margins", "ANATOMY", 117, 129], ["endocardial", "ANATOMY", 257, 268], ["superficial", "ANATOMY", 317, 328], ["mesenchymal cells", "CELL", 6, 23], ["nuclei", "CELLULAR_COMPONENT", 39, 45], ["nucleoli", "CELLULAR_COMPONENT", 57, 65], ["cytoplasm", "ORGANISM_SUBSTANCE", 88, 97], ["cell margins", "TISSUE", 117, 129], ["endocardial", "MULTI-TISSUE_STRUCTURE", 257, 268], ["superficial", "TISSUE", 317, 328], ["mesenchymal cells", "CELL_TYPE", 6, 23], ["large oval nuclei", "PROBLEM", 28, 45], ["prominent nucleoli", "PROBLEM", 47, 65], ["faintly eosinophilic cytoplasm", "PROBLEM", 67, 97], ["poorly defined cell margins", "PROBLEM", 102, 129], ["the endocardial thickening", "PROBLEM", 253, 279], ["a two-layer structure", "PROBLEM", 289, 310], ["superficial and deep layers", "PROBLEM", 317, 344], ["mesenchymal cells", "OBSERVATION", 6, 23], ["large", "OBSERVATION_MODIFIER", 28, 33], ["oval nuclei", "OBSERVATION", 34, 45], ["prominent", "OBSERVATION_MODIFIER", 47, 56], ["nucleoli", "OBSERVATION", 57, 65], ["faintly", "OBSERVATION_MODIFIER", 67, 74], ["eosinophilic cytoplasm", "OBSERVATION", 75, 97], ["poorly defined", "OBSERVATION_MODIFIER", 102, 116], ["cell margins", "OBSERVATION", 117, 129], ["endocardial", "ANATOMY", 257, 268], ["thickening", "OBSERVATION", 269, 279], ["two", "OBSERVATION_MODIFIER", 291, 294], ["-layer", "OBSERVATION_MODIFIER", 294, 300], ["structure", "OBSERVATION_MODIFIER", 301, 310], ["superficial", "OBSERVATION_MODIFIER", 317, 328], ["deep", "ANATOMY_MODIFIER", 333, 337], ["layers", "ANATOMY_MODIFIER", 338, 344]]], ["These two layers were sometimes ill-defined, and there was some variation, even within the same chamber.", [["two", "OBSERVATION_MODIFIER", 6, 9], ["layers", "OBSERVATION_MODIFIER", 10, 16], ["ill", "OBSERVATION_MODIFIER", 32, 35], ["some", "OBSERVATION_MODIFIER", 59, 63], ["variation", "OBSERVATION_MODIFIER", 64, 73], ["chamber", "OBSERVATION_MODIFIER", 96, 103]]], ["The superficial layer consisted of polymorphic mesenchymal cells and a large amount of alcian blue-positive ground substance intermixed with delicate collagen fibrils.", [["superficial layer", "ANATOMY", 4, 21], ["mesenchymal cells", "ANATOMY", 47, 64], ["alcian blue", "CHEMICAL", 87, 98], ["alcian blue", "CHEMICAL", 87, 98], ["superficial layer", "TISSUE", 4, 21], ["mesenchymal cells", "CELL", 47, 64], ["alcian blue", "SIMPLE_CHEMICAL", 87, 98], ["collagen", "GENE_OR_GENE_PRODUCT", 150, 158], ["polymorphic mesenchymal cells", "CELL_TYPE", 35, 64], ["collagen fibrils", "PROTEIN", 150, 166], ["polymorphic mesenchymal cells", "PROBLEM", 35, 64], ["alcian blue", "TEST", 87, 98], ["delicate collagen fibrils", "PROBLEM", 141, 166], ["superficial", "OBSERVATION_MODIFIER", 4, 15], ["layer", "OBSERVATION_MODIFIER", 16, 21], ["polymorphic mesenchymal cells", "OBSERVATION", 35, 64], ["large", "OBSERVATION_MODIFIER", 71, 76], ["amount", "OBSERVATION_MODIFIER", 77, 83], ["alcian blue", "OBSERVATION", 87, 98], ["positive", "OBSERVATION_MODIFIER", 99, 107], ["ground substance", "OBSERVATION", 108, 124], ["delicate", "OBSERVATION_MODIFIER", 141, 149], ["collagen fibrils", "OBSERVATION", 150, 166]]], ["Some cells in this area were round to polygonal, had a metachromatic capsule when stained with toluidine blue, and sometimes were located within lacunae, showing chondrogenic differentiation.", [["cells", "ANATOMY", 5, 10], ["area", "ANATOMY", 19, 23], ["metachromatic capsule", "ANATOMY", 55, 76], ["lacunae", "ANATOMY", 145, 152], ["toluidine blue", "CHEMICAL", 95, 109], ["toluidine blue", "CHEMICAL", 95, 109], ["cells", "CELL", 5, 10], ["capsule", "CANCER", 69, 76], ["toluidine blue", "SIMPLE_CHEMICAL", 95, 109], ["lacunae", "PATHOLOGICAL_FORMATION", 145, 152], ["Some cells", "PROBLEM", 0, 10], ["a metachromatic capsule", "PROBLEM", 53, 76], ["toluidine blue", "TEST", 95, 109], ["chondrogenic differentiation", "PROBLEM", 162, 190], ["cells", "OBSERVATION", 5, 10], ["round", "OBSERVATION_MODIFIER", 29, 34], ["polygonal", "OBSERVATION_MODIFIER", 38, 47], ["metachromatic capsule", "OBSERVATION", 55, 76], ["lacunae", "OBSERVATION", 145, 152], ["chondrogenic differentiation", "OBSERVATION", 162, 190]]], ["The deep layer was composed of densely arranged collagen fibres with frequently elongated mesenchymal cells.", [["deep layer", "ANATOMY", 4, 14], ["collagen fibres", "ANATOMY", 48, 63], ["mesenchymal cells", "ANATOMY", 90, 107], ["collagen", "GENE_OR_GENE_PRODUCT", 48, 56], ["fibres", "CELLULAR_COMPONENT", 57, 63], ["mesenchymal cells", "CELL", 90, 107], ["elongated mesenchymal cells", "CELL_TYPE", 80, 107], ["frequently elongated mesenchymal cells", "PROBLEM", 69, 107], ["deep", "ANATOMY_MODIFIER", 4, 8], ["layer", "ANATOMY_MODIFIER", 9, 14], ["densely", "OBSERVATION_MODIFIER", 31, 38], ["collagen fibres", "OBSERVATION", 48, 63], ["frequently", "OBSERVATION_MODIFIER", 69, 79], ["elongated", "OBSERVATION_MODIFIER", 80, 89], ["mesenchymal cells", "OBSERVATION", 90, 107]]], ["These cells had fusiform nuclei arranged in a uniform wavy pattern.Histopathology ::: ResultsThe third type (type 3) accounted for the other 19 cases.", [["cells", "ANATOMY", 6, 11], ["fusiform nuclei", "ANATOMY", 16, 31], ["cells", "CELL", 6, 11], ["fusiform nuclei", "PROBLEM", 16, 31], ["fusiform", "OBSERVATION_MODIFIER", 16, 24], ["nuclei", "OBSERVATION", 25, 31], ["uniform", "OBSERVATION_MODIFIER", 46, 53], ["wavy", "OBSERVATION_MODIFIER", 54, 58], ["pattern", "OBSERVATION_MODIFIER", 59, 66]]], ["This type of lesion consisted of thick collagen fibres with sparse elastic fibres, occasionally containing foci of chondroid metaplasia (Fig. 2C).", [["lesion", "ANATOMY", 13, 19], ["collagen fibres", "ANATOMY", 39, 54], ["elastic fibres", "ANATOMY", 67, 81], ["foci", "ANATOMY", 107, 111], ["chondroid metaplasia", "ANATOMY", 115, 135], ["collagen", "GENE_OR_GENE_PRODUCT", 39, 47], ["elastic fibres", "TISSUE", 67, 81], ["chondroid metaplasia", "CANCER", 115, 135], ["lesion", "PROBLEM", 13, 19], ["thick collagen fibres", "PROBLEM", 33, 54], ["sparse elastic fibres", "PROBLEM", 60, 81], ["chondroid metaplasia", "PROBLEM", 115, 135], ["lesion", "OBSERVATION", 13, 19], ["thick collagen fibres", "OBSERVATION", 33, 54], ["sparse", "OBSERVATION_MODIFIER", 60, 66], ["elastic fibres", "OBSERVATION", 67, 81], ["foci", "OBSERVATION_MODIFIER", 107, 111], ["chondroid metaplasia", "OBSERVATION", 115, 135]]], ["The mesenchymal cells interspersed among bundles of mature collagen fibres were oriented predominantly with their long axis parallel to the endocardial surface.", [["mesenchymal cells", "ANATOMY", 4, 21], ["bundles", "ANATOMY", 41, 48], ["collagen fibres", "ANATOMY", 59, 74], ["endocardial surface", "ANATOMY", 140, 159], ["mesenchymal cells", "CELL", 4, 21], ["collagen", "GENE_OR_GENE_PRODUCT", 59, 67], ["fibres", "CELLULAR_COMPONENT", 68, 74], ["endocardial surface", "CELLULAR_COMPONENT", 140, 159], ["mesenchymal cells", "CELL_TYPE", 4, 21], ["The mesenchymal cells", "PROBLEM", 0, 21], ["mesenchymal cells", "OBSERVATION", 4, 21], ["bundles", "OBSERVATION_MODIFIER", 41, 48], ["mature", "OBSERVATION_MODIFIER", 52, 58], ["collagen fibres", "OBSERVATION", 59, 74], ["long axis", "OBSERVATION_MODIFIER", 114, 123], ["endocardial", "ANATOMY", 140, 151], ["surface", "ANATOMY_MODIFIER", 152, 159]]], ["These cells were similar in appearance to those seen in the deep layer of type 2 lesions, but were slightly less numerous.Histopathology ::: ResultsCats with type 1 lesions were young, with a mean age at death of 1.8 years (range = 0.3\u20133.0 years; SD = 1.4), while cats with type 2 and 3 lesions were usually older, with mean ages at death of 5.5 years (range = 2\u201311 years; SD = 2.6) and 10.2 years (range = 3\u201319 years; SD = 5.2), respectively.", [["cells", "ANATOMY", 6, 11], ["deep layer", "ANATOMY", 60, 70], ["type 2 lesions", "ANATOMY", 74, 88], ["lesions", "ANATOMY", 165, 172], ["lesions", "ANATOMY", 287, 294], ["type 1 lesions", "DISEASE", 158, 172], ["death", "DISEASE", 204, 209], ["death", "DISEASE", 333, 338], ["cells", "CELL", 6, 11], ["type 2 lesions", "CANCER", 74, 88], ["lesions", "PATHOLOGICAL_FORMATION", 165, 172], ["cats", "ORGANISM", 264, 268], ["lesions", "CANCER", 287, 294], ["cats", "SPECIES", 264, 268], ["type 2 lesions", "PROBLEM", 74, 88], ["type 1 lesions", "PROBLEM", 158, 172], ["SD", "TEST", 247, 249], ["type 2 and 3 lesions", "PROBLEM", 274, 294], ["mean ages at death", "PROBLEM", 320, 338], ["SD", "TEST", 373, 375], ["SD", "TEST", 419, 421], ["similar", "OBSERVATION_MODIFIER", 17, 24], ["deep", "ANATOMY_MODIFIER", 60, 64], ["layer", "OBSERVATION_MODIFIER", 65, 70], ["type 2", "OBSERVATION_MODIFIER", 74, 80], ["lesions", "OBSERVATION", 81, 88], ["slightly", "OBSERVATION_MODIFIER", 99, 107], ["less", "OBSERVATION_MODIFIER", 108, 112], ["numerous", "OBSERVATION_MODIFIER", 113, 121], ["lesions", "OBSERVATION", 165, 172], ["lesions", "OBSERVATION", 287, 294]]], ["There were significant differences in the age at death among the three types (one-way analysis of variance; P <0.001).Histopathology ::: ResultsIn the endocardial lesions showing a diffuse pattern, the line between the thickened endocardium and the underlying myocardium was usually well defined.", [["endocardial lesions", "ANATOMY", 151, 170], ["thickened endocardium", "ANATOMY", 219, 240], ["myocardium", "ANATOMY", 260, 270], ["death", "DISEASE", 49, 54], ["endocardial lesions", "CANCER", 151, 170], ["thickened endocardium", "TISSUE", 219, 240], ["myocardium", "ORGAN", 260, 270], ["the endocardial lesions", "PROBLEM", 147, 170], ["a diffuse pattern", "PROBLEM", 179, 196], ["the thickened endocardium", "PROBLEM", 215, 240], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["differences", "OBSERVATION_MODIFIER", 23, 34], ["endocardial", "ANATOMY", 151, 162], ["lesions", "OBSERVATION", 163, 170], ["diffuse", "OBSERVATION_MODIFIER", 181, 188], ["pattern", "OBSERVATION_MODIFIER", 189, 196], ["line", "OBSERVATION_MODIFIER", 202, 206], ["thickened", "OBSERVATION", 219, 228], ["endocardium", "ANATOMY_MODIFIER", 229, 240], ["underlying myocardium", "ANATOMY", 249, 270]]], ["There were no inflammatory cells in the endocardium or the myocardium, and there was no evidence of myocardial degeneration, necrosis or fibrosis (Fig. 2).", [["inflammatory cells", "ANATOMY", 14, 32], ["endocardium", "ANATOMY", 40, 51], ["myocardium", "ANATOMY", 59, 69], ["myocardial", "ANATOMY", 100, 110], ["myocardial degeneration", "DISEASE", 100, 123], ["necrosis", "DISEASE", 125, 133], ["fibrosis", "DISEASE", 137, 145], ["inflammatory cells", "CELL", 14, 32], ["endocardium", "MULTI-TISSUE_STRUCTURE", 40, 51], ["myocardium", "ORGAN", 59, 69], ["myocardial", "MULTI-TISSUE_STRUCTURE", 100, 110], ["inflammatory cells", "CELL_TYPE", 14, 32], ["inflammatory cells in the endocardium or the myocardium", "PROBLEM", 14, 69], ["myocardial degeneration", "PROBLEM", 100, 123], ["necrosis", "PROBLEM", 125, 133], ["fibrosis", "PROBLEM", 137, 145], ["no", "UNCERTAINTY", 11, 13], ["inflammatory cells", "OBSERVATION", 14, 32], ["endocardium", "ANATOMY", 40, 51], ["myocardium", "ANATOMY", 59, 69], ["no evidence of", "UNCERTAINTY", 85, 99], ["myocardial", "ANATOMY", 100, 110], ["degeneration", "OBSERVATION", 111, 123], ["necrosis", "OBSERVATION", 125, 133], ["fibrosis", "OBSERVATION", 137, 145]]], ["In some cases, however, fibrous tissue of the endocardium extended for various distances into the myocardium, accompanying mild to moderate atrophy of myocardial fibres.Histopathology ::: ResultsIn the endocardial lesions showing a patchy pattern, trabecular or broad bands of fibrous tissue always included multiple left ventricular false tendons (LVFTs), which were composed of central Purkinje fibres and surrounding collagen fibres.", [["fibrous tissue", "ANATOMY", 24, 38], ["endocardium", "ANATOMY", 46, 57], ["myocardium", "ANATOMY", 98, 108], ["myocardial fibres", "ANATOMY", 151, 168], ["endocardial lesions", "ANATOMY", 202, 221], ["trabecular", "ANATOMY", 248, 258], ["fibrous tissue", "ANATOMY", 277, 291], ["left ventricular false tendons", "ANATOMY", 317, 347], ["LVFTs", "ANATOMY", 349, 354], ["Purkinje fibres", "ANATOMY", 388, 403], ["collagen fibres", "ANATOMY", 420, 435], ["atrophy", "DISEASE", 140, 147], ["fibrous tissue", "TISSUE", 24, 38], ["endocardium", "MULTI-TISSUE_STRUCTURE", 46, 57], ["myocardium", "ORGAN", 98, 108], ["myocardial fibres", "TISSUE", 151, 168], ["endocardial lesions", "CANCER", 202, 221], ["trabecular", "TISSUE", 248, 258], ["fibrous tissue", "TISSUE", 277, 291], ["ventricular false tendons", "MULTI-TISSUE_STRUCTURE", 322, 347], ["LVFTs", "CANCER", 349, 354], ["Purkinje fibres", "TISSUE", 388, 403], ["collagen", "GENE_OR_GENE_PRODUCT", 420, 428], ["fibres", "CELLULAR_COMPONENT", 429, 435], ["central Purkinje fibres", "CELL_TYPE", 380, 403], ["fibrous tissue of the endocardium", "PROBLEM", 24, 57], ["mild to moderate atrophy of myocardial fibres", "PROBLEM", 123, 168], ["the endocardial lesions", "PROBLEM", 198, 221], ["a patchy pattern", "PROBLEM", 230, 246], ["trabecular or broad bands of fibrous tissue", "PROBLEM", 248, 291], ["multiple left ventricular false tendons", "PROBLEM", 308, 347], ["central Purkinje fibres", "PROBLEM", 380, 403], ["fibrous tissue", "OBSERVATION", 24, 38], ["endocardium", "ANATOMY", 46, 57], ["myocardium", "ANATOMY", 98, 108], ["mild", "OBSERVATION_MODIFIER", 123, 127], ["moderate", "OBSERVATION_MODIFIER", 131, 139], ["atrophy", "OBSERVATION", 140, 147], ["myocardial fibres", "OBSERVATION", 151, 168], ["endocardial", "ANATOMY", 202, 213], ["lesions", "OBSERVATION", 214, 221], ["patchy", "OBSERVATION_MODIFIER", 232, 238], ["pattern", "OBSERVATION_MODIFIER", 239, 246], ["trabecular", "OBSERVATION_MODIFIER", 248, 258], ["broad", "OBSERVATION_MODIFIER", 262, 267], ["bands", "OBSERVATION_MODIFIER", 268, 273], ["fibrous tissue", "OBSERVATION", 277, 291], ["multiple", "OBSERVATION_MODIFIER", 308, 316], ["left ventricular", "ANATOMY", 317, 333], ["false tendons", "OBSERVATION", 334, 347], ["central Purkinje fibres", "OBSERVATION", 380, 403], ["collagen fibres", "OBSERVATION", 420, 435]]], ["In lesions showing this pattern, mesenchymal cells derived from pre-existing LVFTs had proliferated vigorously, showing a characteristic concentric circular pattern centering on the LVFTs.", [["lesions", "ANATOMY", 3, 10], ["mesenchymal cells", "ANATOMY", 33, 50], ["LVFTs", "ANATOMY", 77, 82], ["LVFTs", "ANATOMY", 182, 187], ["lesions", "PATHOLOGICAL_FORMATION", 3, 10], ["mesenchymal cells", "CELL", 33, 50], ["LVFTs", "CELL", 77, 82], ["LVFTs", "CANCER", 182, 187], ["mesenchymal cells", "CELL_TYPE", 33, 50], ["LVFTs", "CELL_TYPE", 77, 82], ["mesenchymal cells", "PROBLEM", 33, 50], ["pre-existing LVFTs", "TEST", 64, 82], ["a characteristic concentric circular pattern", "PROBLEM", 120, 164], ["lesions", "OBSERVATION", 3, 10], ["mesenchymal cells", "OBSERVATION", 33, 50], ["characteristic", "OBSERVATION_MODIFIER", 122, 136], ["concentric", "OBSERVATION_MODIFIER", 137, 147], ["circular pattern", "OBSERVATION", 148, 164]]], ["These cells produced a large amount of alcian blue-positive ground substance and delicate collagen fibrils (type 1), resulting in fusion of the markedly thickened LVFTs (Fig. 3A).", [["cells", "ANATOMY", 6, 11], ["alcian blue-", "CHEMICAL", 39, 51], ["cells", "CELL", 6, 11], ["alcian", "SIMPLE_CHEMICAL", 39, 45], ["collagen fibrils", "GENE_OR_GENE_PRODUCT", 90, 106], ["collagen fibrils", "PROTEIN", 90, 106], ["alcian blue-positive ground substance", "PROBLEM", 39, 76], ["delicate collagen fibrils", "PROBLEM", 81, 106], ["the markedly thickened LVFTs", "PROBLEM", 140, 168], ["large", "OBSERVATION_MODIFIER", 23, 28], ["amount", "OBSERVATION_MODIFIER", 29, 35], ["alcian blue-positive", "OBSERVATION", 39, 59], ["ground substance", "OBSERVATION", 60, 76], ["collagen fibrils", "OBSERVATION", 90, 106], ["fusion", "OBSERVATION", 130, 136], ["markedly", "OBSERVATION_MODIFIER", 144, 152], ["thickened", "OBSERVATION", 153, 162]]], ["The cellular fibrous tissue then matured into densely arranged collagenous connective tissue (type 2) (Fig. 3B), and eventually comprised a large mass of fibrous scar tissue (type 3) (Fig. 3C).", [["cellular fibrous tissue", "ANATOMY", 4, 27], ["collagenous connective tissue", "ANATOMY", 63, 92], ["fibrous scar tissue", "ANATOMY", 154, 173], ["fibrous scar", "DISEASE", 154, 166], ["cellular fibrous tissue", "TISSUE", 4, 27], ["collagenous connective tissue", "TISSUE", 63, 92], ["fibrous scar tissue", "TISSUE", 154, 173], ["The cellular fibrous tissue", "PROBLEM", 0, 27], ["a large mass of fibrous scar tissue", "PROBLEM", 138, 173], ["cellular", "OBSERVATION_MODIFIER", 4, 12], ["fibrous tissue", "OBSERVATION", 13, 27], ["densely", "OBSERVATION_MODIFIER", 46, 53], ["collagenous", "OBSERVATION_MODIFIER", 63, 74], ["connective tissue", "OBSERVATION", 75, 92], ["large", "OBSERVATION_MODIFIER", 140, 145], ["mass", "OBSERVATION", 146, 150], ["fibrous", "OBSERVATION_MODIFIER", 154, 161], ["scar tissue", "OBSERVATION", 162, 173]]], ["Also in this lesion pattern, no distinct inflammatory changes were evident.Immunohistochemistry ::: ResultsIn all 41 cases, positive labelling for CD34 was limited to the surface cells of the thickened endocardium and the capillary-like channel-lining cells.", [["lesion", "ANATOMY", 13, 19], ["surface cells", "ANATOMY", 171, 184], ["endocardium", "ANATOMY", 202, 213], ["capillary-like channel-lining cells", "ANATOMY", 222, 257], ["CD34", "GENE_OR_GENE_PRODUCT", 147, 151], ["surface cells", "CELL", 171, 184], ["thickened endocardium", "TISSUE", 192, 213], ["capillary-like channel-lining cells", "CELL", 222, 257], ["CD34", "PROTEIN", 147, 151], ["surface cells", "CELL_TYPE", 171, 184], ["capillary-like channel-lining cells", "CELL_TYPE", 222, 257], ["distinct inflammatory changes", "PROBLEM", 32, 61], ["CD34", "TEST", 147, 151], ["lesion", "OBSERVATION", 13, 19], ["no", "UNCERTAINTY", 29, 31], ["distinct", "OBSERVATION_MODIFIER", 32, 40], ["inflammatory", "OBSERVATION", 41, 53], ["thickened endocardium", "ANATOMY", 192, 213], ["capillary", "ANATOMY_MODIFIER", 222, 231], ["like channel", "ANATOMY_MODIFIER", 232, 244], ["lining cells", "OBSERVATION", 245, 257]]], ["The stellate, spindle-shaped or elongated mesenchymal cells embedded within the fibrous connective tissue were diffusely positive for vimentin, as well as \u03b1-smooth muscle actin and caldesmon, although a small proportion of the cells were not labelled for either of the latter markers (Fig. 4A, B).", [["stellate", "ANATOMY", 4, 12], ["spindle", "ANATOMY", 14, 21], ["mesenchymal cells", "ANATOMY", 42, 59], ["fibrous connective tissue", "ANATOMY", 80, 105], ["\u03b1-smooth muscle", "ANATOMY", 155, 170], ["cells", "ANATOMY", 227, 232], ["stellate", "CELL", 4, 12], ["mesenchymal cells", "CELL", 42, 59], ["fibrous connective tissue", "TISSUE", 80, 105], ["vimentin", "GENE_OR_GENE_PRODUCT", 134, 142], ["\u03b1-smooth muscle actin", "GENE_OR_GENE_PRODUCT", 155, 176], ["caldesmon", "GENE_OR_GENE_PRODUCT", 181, 190], ["cells", "CELL", 227, 232], ["B", "GENE_OR_GENE_PRODUCT", 294, 295], ["stellate, spindle-shaped or elongated mesenchymal cells", "CELL_TYPE", 4, 59], ["vimentin", "PROTEIN", 134, 142], ["\u03b1-smooth muscle actin", "PROTEIN", 155, 176], ["caldesmon", "PROTEIN", 181, 190], ["Fig. 4A, B", "PROTEIN", 285, 295], ["elongated mesenchymal cells", "PROBLEM", 32, 59], ["vimentin", "PROBLEM", 134, 142], ["stellate", "OBSERVATION_MODIFIER", 4, 12], ["spindle", "OBSERVATION_MODIFIER", 14, 21], ["shaped", "OBSERVATION_MODIFIER", 22, 28], ["elongated", "OBSERVATION_MODIFIER", 32, 41], ["mesenchymal cells", "OBSERVATION", 42, 59], ["fibrous", "ANATOMY_MODIFIER", 80, 87], ["connective tissue", "ANATOMY", 88, 105], ["diffusely", "OBSERVATION_MODIFIER", 111, 120], ["muscle", "ANATOMY", 164, 170], ["small", "OBSERVATION_MODIFIER", 203, 208]]], ["PDGF and TGF-\u03b2 were present frequently on the cell surface and in the surrounding fibrous connective tissue, especially in type 1 and 2 lesions (Figs.", [["cell surface", "ANATOMY", 46, 58], ["fibrous connective tissue", "ANATOMY", 82, 107], ["lesions", "ANATOMY", 136, 143], ["PDGF", "GENE_OR_GENE_PRODUCT", 0, 4], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 9, 14], ["cell surface", "CELLULAR_COMPONENT", 46, 58], ["fibrous connective tissue", "TISSUE", 82, 107], ["lesions", "PATHOLOGICAL_FORMATION", 136, 143], ["PDGF", "PROTEIN", 0, 4], ["TGF-\u03b2", "PROTEIN", 9, 14], ["PDGF", "TEST", 0, 4], ["TGF", "TEST", 9, 12], ["type 1 and 2 lesions", "PROBLEM", 123, 143], ["cell surface", "OBSERVATION_MODIFIER", 46, 58], ["fibrous", "OBSERVATION_MODIFIER", 82, 89], ["connective tissue", "OBSERVATION", 90, 107], ["lesions", "OBSERVATION", 136, 143]]], ["4C, D).Real-time Polymerase Chain Reaction ::: ResultsNone of the viral genomes tested were detected in any of the DNA or RNA samples obtained from 14 cat hearts with this abnormality, while the ACTB genome was detected in all samples.DiscussionThe endomyocardial form of RCM in cats was first described in 1970 by Liu, who reported a retrospective series of 68 cases of focal endocardial and myocardial fibrosis in the LV as \u2018acquired cardiac lesions leading to congestive heart failure\u2019.", [["samples", "ANATOMY", 126, 133], ["hearts", "ANATOMY", 155, 161], ["samples", "ANATOMY", 227, 234], ["endomyocardial", "ANATOMY", 249, 263], ["endocardial", "ANATOMY", 377, 388], ["myocardial", "ANATOMY", 393, 403], ["LV", "ANATOMY", 420, 422], ["cardiac lesions", "ANATOMY", 436, 451], ["heart", "ANATOMY", 474, 479], ["RCM", "DISEASE", 272, 275], ["fibrosis", "DISEASE", 404, 412], ["cardiac lesions", "DISEASE", 436, 451], ["congestive heart failure", "DISEASE", 463, 487], ["D", "SIMPLE_CHEMICAL", 4, 5], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["cat", "ORGANISM", 151, 154], ["hearts", "ORGAN", 155, 161], ["ACTB", "GENE_OR_GENE_PRODUCT", 195, 199], ["endomyocardial", "ORGAN", 249, 263], ["cats", "ORGANISM", 279, 283], ["endocardial", "MULTI-TISSUE_STRUCTURE", 377, 388], ["myocardial", "MULTI-TISSUE_STRUCTURE", 393, 403], ["LV", "MULTI-TISSUE_STRUCTURE", 420, 422], ["cardiac lesions", "PATHOLOGICAL_FORMATION", 436, 451], ["heart", "ORGAN", 474, 479], ["viral genomes", "DNA", 66, 79], ["ACTB genome", "DNA", 195, 206], ["the viral genomes", "TEST", 62, 79], ["the DNA", "TEST", 111, 118], ["RNA samples", "TEST", 122, 133], ["this abnormality", "PROBLEM", 167, 183], ["the ACTB genome", "TEST", 191, 206], ["a retrospective series", "TEST", 333, 355], ["focal endocardial and myocardial fibrosis in the LV", "PROBLEM", 371, 422], ["acquired cardiac lesions", "PROBLEM", 427, 451], ["congestive heart failure", "PROBLEM", 463, 487], ["ACTB genome", "OBSERVATION", 195, 206], ["endomyocardial", "ANATOMY", 249, 263], ["RCM", "OBSERVATION", 272, 275], ["focal", "OBSERVATION_MODIFIER", 371, 376], ["endocardial", "ANATOMY", 377, 388], ["myocardial", "ANATOMY", 393, 403], ["fibrosis", "OBSERVATION", 404, 412], ["LV", "ANATOMY", 420, 422], ["cardiac", "ANATOMY", 436, 443], ["lesions", "OBSERVATION", 444, 451], ["congestive", "OBSERVATION_MODIFIER", 463, 473], ["heart", "ANATOMY", 474, 479], ["failure", "OBSERVATION", 480, 487]]], ["Thereafter, the clinical and morphological features of the abnormality were assessed systematically and reported as a distinct disease entity in 1980 by Liu and Tilley.", [["the abnormality", "PROBLEM", 55, 70], ["a distinct disease entity", "PROBLEM", 116, 141], ["distinct", "OBSERVATION_MODIFIER", 118, 126], ["disease", "OBSERVATION", 127, 134]]], ["In 2004, Fox reported the first comprehensive description of the disease.", [["the disease", "PROBLEM", 61, 72], ["disease", "OBSERVATION", 65, 72]]], ["Since then, no additional pathological studies of the aetiology of feline endomyocardial RCM have been reported.DiscussionIn the present study, the endocardial lesions were classified into three types according to their histological composition and structure.", [["endomyocardial", "ANATOMY", 74, 88], ["endocardial lesions", "ANATOMY", 148, 167], ["feline endomyocardial RCM", "DISEASE", 67, 92], ["feline", "ORGANISM", 67, 73], ["endomyocardial RCM", "CANCER", 74, 92], ["endocardial lesions", "CANCER", 148, 167], ["additional pathological studies", "TEST", 15, 46], ["the present study", "TEST", 125, 142], ["the endocardial lesions", "PROBLEM", 144, 167], ["endocardial", "ANATOMY", 148, 159], ["lesions", "OBSERVATION", 160, 167]]], ["Type 1 lesions were found only in young cats aged between 4 months and 3 years, while type 2 and 3 lesions were observed predominantly in middle-aged and older cats, respectively.", [["Type 1 lesions", "ANATOMY", 0, 14], ["lesions", "ANATOMY", 99, 106], ["Type 1 lesions", "CANCER", 0, 14], ["cats", "ORGANISM", 40, 44], ["lesions", "PATHOLOGICAL_FORMATION", 99, 106], ["cats", "ORGANISM", 160, 164], ["cats", "SPECIES", 40, 44], ["cats", "SPECIES", 160, 164], ["Type 1 lesions", "PROBLEM", 0, 14], ["type 2 and 3 lesions", "PROBLEM", 86, 106], ["lesions", "OBSERVATION", 7, 14], ["lesions", "OBSERVATION", 99, 106], ["predominantly", "OBSERVATION_MODIFIER", 121, 134], ["middle", "ANATOMY_MODIFIER", 138, 144]]], ["In addition, the number of cat hearts with type 1 lesions was much lower than the number with type 2 and 3 lesions.", [["hearts", "ANATOMY", 31, 37], ["type 1 lesions", "ANATOMY", 43, 57], ["lesions", "ANATOMY", 107, 114], ["cat", "ORGANISM", 27, 30], ["hearts", "ORGAN", 31, 37], ["type 1 lesions", "CANCER", 43, 57], ["lesions", "PATHOLOGICAL_FORMATION", 107, 114], ["type 1 lesions", "PROBLEM", 43, 57], ["type 2 and 3 lesions", "PROBLEM", 94, 114], ["cat hearts", "ANATOMY", 27, 37], ["lesions", "OBSERVATION", 50, 57], ["lower", "OBSERVATION_MODIFIER", 67, 72], ["lesions", "OBSERVATION", 107, 114]]], ["Considering the degree of fibrous tissue maturation in each lesion type, it is very likely that the type 1 lesion is an early form of this abnormality, which usually progresses to the more mature type 2 and 3 forms with age.", [["fibrous tissue", "ANATOMY", 26, 40], ["lesion", "ANATOMY", 60, 66], ["type 1 lesion", "ANATOMY", 100, 113], ["fibrous tissue", "TISSUE", 26, 40], ["fibrous tissue maturation", "PROBLEM", 26, 51], ["the type 1 lesion", "PROBLEM", 96, 113], ["this abnormality", "PROBLEM", 134, 150], ["fibrous tissue maturation", "OBSERVATION", 26, 51], ["each", "OBSERVATION_MODIFIER", 55, 59], ["lesion", "OBSERVATION", 60, 66], ["very likely", "UNCERTAINTY", 79, 90], ["lesion", "OBSERVATION", 107, 113], ["early", "OBSERVATION_MODIFIER", 120, 125], ["abnormality", "OBSERVATION", 139, 150], ["more mature", "OBSERVATION_MODIFIER", 184, 195]]], ["The gradations of the endocardial lesions, the presence of intermediate cases, and the age relationship appear to indicate that the endomyocardial form of feline RCM develops after birth and progresses gradually with age.", [["endocardial lesions", "ANATOMY", 22, 41], ["endomyocardial", "ANATOMY", 132, 146], ["RCM", "DISEASE", 162, 165], ["endocardial lesions", "PATHOLOGICAL_FORMATION", 22, 41], ["endomyocardial", "ORGAN", 132, 146], ["feline", "ORGANISM", 155, 161], ["the endocardial lesions", "PROBLEM", 18, 41], ["endocardial", "ANATOMY", 22, 33], ["lesions", "OBSERVATION", 34, 41], ["intermediate", "OBSERVATION_MODIFIER", 59, 71], ["cases", "OBSERVATION", 72, 77], ["endomyocardial", "OBSERVATION", 132, 146], ["feline RCM", "OBSERVATION", 155, 165]]], ["The fact that no reports appear to have documented the disease in newborn kittens lends further support to this idea.DiscussionIn the immunohistochemical study, the mesenchymal cells embedded within fibrous connective tissue showed a positive reaction with antibodies against \u03b1-smooth muscle actin and caldesmon, indicating a tendency for smooth muscle differentiation; however, undifferentiated cells best classified as primitive mesenchymal cells were also present.", [["mesenchymal cells", "ANATOMY", 165, 182], ["fibrous connective tissue", "ANATOMY", 199, 224], ["muscle", "ANATOMY", 285, 291], ["smooth muscle", "ANATOMY", 339, 352], ["cells", "ANATOMY", 396, 401], ["mesenchymal cells", "ANATOMY", 431, 448], ["mesenchymal cells", "CELL", 165, 182], ["fibrous connective tissue", "TISSUE", 199, 224], ["antibodies against \u03b1-smooth muscle actin", "GENE_OR_GENE_PRODUCT", 257, 297], ["caldesmon", "GENE_OR_GENE_PRODUCT", 302, 311], ["smooth muscle", "TISSUE", 339, 352], ["undifferentiated cells", "CELL", 379, 401], ["mesenchymal cells", "CELL", 431, 448], ["mesenchymal cells", "CELL_TYPE", 165, 182], ["antibodies", "PROTEIN", 257, 267], ["\u03b1-smooth muscle actin", "PROTEIN", 276, 297], ["caldesmon", "PROTEIN", 302, 311], ["undifferentiated cells", "CELL_TYPE", 379, 401], ["primitive mesenchymal cells", "CELL_TYPE", 421, 448], ["the disease in newborn kittens", "PROBLEM", 51, 81], ["the immunohistochemical study", "TEST", 130, 159], ["the mesenchymal cells", "PROBLEM", 161, 182], ["a positive reaction", "PROBLEM", 232, 251], ["antibodies", "TREATMENT", 257, 267], ["\u03b1-smooth muscle actin and caldesmon", "PROBLEM", 276, 311], ["a tendency for smooth muscle differentiation", "PROBLEM", 324, 368], ["undifferentiated cells", "PROBLEM", 379, 401], ["primitive mesenchymal cells", "PROBLEM", 421, 448], ["disease", "OBSERVATION", 55, 62], ["mesenchymal cells", "OBSERVATION", 165, 182], ["fibrous connective tissue", "OBSERVATION", 199, 224], ["positive reaction", "OBSERVATION", 234, 251], ["muscle", "ANATOMY", 346, 352], ["undifferentiated cells", "OBSERVATION", 379, 401], ["primitive mesenchymal cells", "OBSERVATION", 421, 448]]], ["In this connection, it is of interest that the subendocardial layer originally contains smooth muscle cells and undifferentiated mesenchymal cells, especially in the left ventricular septal region and the LA (John et al., 2001).", [["subendocardial layer", "ANATOMY", 47, 67], ["smooth muscle cells", "ANATOMY", 88, 107], ["mesenchymal cells", "ANATOMY", 129, 146], ["left ventricular septal region", "ANATOMY", 166, 196], ["LA", "CHEMICAL", 205, 207], ["subendocardial layer", "TISSUE", 47, 67], ["smooth muscle cells", "CELL", 88, 107], ["undifferentiated mesenchymal cells", "CELL", 112, 146], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 171, 189], ["smooth muscle cells", "CELL_TYPE", 88, 107], ["undifferentiated mesenchymal cells", "CELL_TYPE", 112, 146], ["smooth muscle cells", "PROBLEM", 88, 107], ["undifferentiated mesenchymal cells", "PROBLEM", 112, 146], ["subendocardial", "ANATOMY", 47, 61], ["layer", "ANATOMY_MODIFIER", 62, 67], ["smooth muscle cells", "OBSERVATION", 88, 107], ["undifferentiated", "OBSERVATION_MODIFIER", 112, 128], ["mesenchymal cells", "OBSERVATION", 129, 146], ["left ventricular", "ANATOMY", 166, 182], ["septal", "ANATOMY_MODIFIER", 183, 189], ["region", "ANATOMY_MODIFIER", 190, 196], ["LA", "ANATOMY_MODIFIER", 205, 207]]], ["Furthermore, the presence of PDGF and TGF-\u03b2 was confirmed immunohistochemically.", [["PDGF", "GENE_OR_GENE_PRODUCT", 29, 33], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 38, 43], ["PDGF", "PROTEIN", 29, 33], ["TGF-\u03b2", "PROTEIN", 38, 43], ["PDGF", "TEST", 29, 33], ["TGF", "TEST", 38, 41], ["PDGF", "OBSERVATION", 29, 33]]], ["It is well known that these growth factors regulate the proliferation of smooth muscle cells and their synthesis of extracellular matrix, leading to the development of arteriosclerotic intimal lesions (Gotlieb and Silver, 2001).", [["smooth muscle cells", "ANATOMY", 73, 92], ["extracellular matrix", "ANATOMY", 116, 136], ["arteriosclerotic intimal lesions", "ANATOMY", 168, 200], ["arteriosclerotic intimal lesions", "DISEASE", 168, 200], ["smooth muscle cells", "CELL", 73, 92], ["extracellular matrix", "CELLULAR_COMPONENT", 116, 136], ["arteriosclerotic", "PATHOLOGICAL_FORMATION", 168, 184], ["intimal lesions", "PATHOLOGICAL_FORMATION", 185, 200], ["growth factors", "PROTEIN", 28, 42], ["smooth muscle cells", "CELL_TYPE", 73, 92], ["these growth factors", "PROBLEM", 22, 42], ["smooth muscle cells", "PROBLEM", 73, 92], ["their synthesis of extracellular matrix", "PROBLEM", 97, 136], ["arteriosclerotic intimal lesions", "PROBLEM", 168, 200], ["proliferation", "OBSERVATION_MODIFIER", 56, 69], ["smooth muscle cells", "OBSERVATION", 73, 92], ["extracellular matrix", "OBSERVATION", 116, 136], ["arteriosclerotic", "OBSERVATION_MODIFIER", 168, 184], ["intimal", "OBSERVATION_MODIFIER", 185, 192], ["lesions", "OBSERVATION", 193, 200]]], ["Therefore, it is considered that the proliferation of pre-existing mesenchymal cells, which are capable of undergoing smooth muscle differentiation, cause or contribute to the formation of endocardial lesions in the endomyocardial form of feline RCM.DiscussionMacroscopically, patchy endocardial thickening was the most common pattern of endomyocardial RCM in cats, as reported previously (Fox, 2004).", [["mesenchymal cells", "ANATOMY", 67, 84], ["smooth muscle", "ANATOMY", 118, 131], ["endocardial lesions", "ANATOMY", 189, 208], ["endomyocardial", "ANATOMY", 216, 230], ["endocardial", "ANATOMY", 284, 295], ["endomyocardial", "ANATOMY", 338, 352], ["endocardial lesions", "DISEASE", 189, 208], ["RCM", "DISEASE", 246, 249], ["endomyocardial RCM", "DISEASE", 338, 356], ["mesenchymal cells", "CELL", 67, 84], ["smooth muscle", "TISSUE", 118, 131], ["endocardial lesions", "PATHOLOGICAL_FORMATION", 189, 208], ["endomyocardial", "ORGAN", 216, 230], ["feline", "ORGANISM", 239, 245], ["endocardial", "MULTI-TISSUE_STRUCTURE", 284, 295], ["endomyocardial", "ORGAN", 338, 352], ["cats", "ORGANISM", 360, 364], ["pre-existing mesenchymal cells", "CELL_TYPE", 54, 84], ["cats", "SPECIES", 360, 364], ["pre-existing mesenchymal cells", "PROBLEM", 54, 84], ["endocardial lesions", "PROBLEM", 189, 208], ["patchy endocardial thickening", "PROBLEM", 277, 306], ["proliferation", "OBSERVATION_MODIFIER", 37, 50], ["mesenchymal cells", "OBSERVATION", 67, 84], ["smooth muscle differentiation", "OBSERVATION", 118, 147], ["endocardial", "ANATOMY", 189, 200], ["lesions", "OBSERVATION", 201, 208], ["endomyocardial", "ANATOMY", 216, 230], ["feline RCM", "OBSERVATION", 239, 249], ["patchy", "OBSERVATION_MODIFIER", 277, 283], ["endocardial", "ANATOMY", 284, 295], ["thickening", "OBSERVATION", 296, 306], ["most common", "OBSERVATION_MODIFIER", 315, 326], ["endomyocardial RCM", "OBSERVATION", 338, 356]]], ["The patchy lesions appeared as single or multiple large trabecular bands or irregular broad bands of fibrous tissue bridging the left ventricular lumen, usually from the anterior and/or posterior PMs to the VS.", [["patchy lesions", "ANATOMY", 4, 18], ["trabecular", "ANATOMY", 56, 66], ["fibrous tissue", "ANATOMY", 101, 115], ["left ventricular lumen", "ANATOMY", 129, 151], ["anterior", "ANATOMY", 170, 178], ["patchy lesions", "CANCER", 4, 18], ["fibrous tissue", "TISSUE", 101, 115], ["ventricular lumen", "MULTI-TISSUE_STRUCTURE", 134, 151], ["anterior", "MULTI-TISSUE_STRUCTURE", 170, 178], ["PMs", "MULTI-TISSUE_STRUCTURE", 196, 199], ["The patchy lesions", "PROBLEM", 0, 18], ["multiple large trabecular bands", "PROBLEM", 41, 72], ["irregular broad bands of fibrous tissue", "PROBLEM", 76, 115], ["patchy", "OBSERVATION_MODIFIER", 4, 10], ["lesions", "OBSERVATION", 11, 18], ["multiple", "OBSERVATION_MODIFIER", 41, 49], ["large", "OBSERVATION_MODIFIER", 50, 55], ["trabecular bands", "OBSERVATION", 56, 72], ["irregular", "OBSERVATION_MODIFIER", 76, 85], ["broad", "OBSERVATION_MODIFIER", 86, 91], ["bands", "OBSERVATION_MODIFIER", 92, 97], ["fibrous tissue", "OBSERVATION", 101, 115], ["left ventricular", "ANATOMY", 129, 145], ["lumen", "ANATOMY_MODIFIER", 146, 151], ["anterior", "ANATOMY_MODIFIER", 170, 178], ["posterior", "ANATOMY_MODIFIER", 186, 195]]], ["Histologically, the fibrous bands invariably included multiple LVFTs around which mesenchymal cells proliferated vigorously and produced alcian blue-positive ground substance and delicate collagen fibrils.", [["fibrous bands", "ANATOMY", 20, 33], ["LVFTs", "ANATOMY", 63, 68], ["mesenchymal cells", "ANATOMY", 82, 99], ["alcian blue", "CHEMICAL", 137, 148], ["alcian blue", "CHEMICAL", 137, 148], ["fibrous bands", "PATHOLOGICAL_FORMATION", 20, 33], ["LVFTs", "PATHOLOGICAL_FORMATION", 63, 68], ["mesenchymal cells", "CELL", 82, 99], ["alcian blue", "SIMPLE_CHEMICAL", 137, 148], ["collagen fibrils", "GENE_OR_GENE_PRODUCT", 188, 204], ["mesenchymal cells", "CELL_TYPE", 82, 99], ["collagen fibrils", "PROTEIN", 188, 204], ["the fibrous bands", "PROBLEM", 16, 33], ["multiple LVFTs", "PROBLEM", 54, 68], ["mesenchymal cells", "PROBLEM", 82, 99], ["alcian blue", "TEST", 137, 148], ["delicate collagen fibrils", "PROBLEM", 179, 204], ["fibrous bands", "OBSERVATION", 20, 33], ["mesenchymal cells", "OBSERVATION", 82, 99], ["alcian blue", "OBSERVATION", 137, 148], ["positive ground substance", "OBSERVATION_MODIFIER", 149, 174], ["collagen fibrils", "OBSERVATION", 188, 204]]], ["These observations suggest that LVFTs provide a framework for the formation of fibrous bands, and it is noteworthy that a pathological condition associated with abnormal diffuse networks of LVFTs (referred to as \u2018excessive moderator bands\u2019) has been reported in 21 cats with heart failure (Liu et al., 1982).", [["fibrous bands", "ANATOMY", 79, 92], ["LVFTs", "ANATOMY", 190, 195], ["heart", "ANATOMY", 275, 280], ["LVFTs", "DISEASE", 190, 195], ["heart failure", "DISEASE", 275, 288], ["LVFTs", "SIMPLE_CHEMICAL", 32, 37], ["LVFTs", "CANCER", 190, 195], ["cats", "ORGANISM", 265, 269], ["heart", "ORGAN", 275, 280], ["fibrous bands", "PROBLEM", 79, 92], ["a pathological condition", "PROBLEM", 120, 144], ["abnormal diffuse networks of LVFTs", "PROBLEM", 161, 195], ["excessive moderator bands", "PROBLEM", 213, 238], ["heart failure", "PROBLEM", 275, 288], ["fibrous bands", "OBSERVATION", 79, 92], ["diffuse", "OBSERVATION_MODIFIER", 170, 177], ["heart", "ANATOMY", 275, 280], ["failure", "OBSERVATION", 281, 288]]], ["The increased numbers of LVFTs most commonly connected the posterior PM or the anterior PM to the VS, showing arrangement patterns similar to those of the trabecular or broad bands observed in the present study.", [["LVFTs", "ANATOMY", 25, 30], ["posterior PM", "ANATOMY", 59, 71], ["anterior PM", "ANATOMY", 79, 90], ["trabecular", "ANATOMY", 155, 165], ["LVFTs", "DISEASE", 25, 30], ["LVFTs", "CANCER", 25, 30], ["posterior PM", "MULTI-TISSUE_STRUCTURE", 59, 71], ["anterior PM", "MULTI-TISSUE_STRUCTURE", 79, 90], ["trabecular", "TISSUE", 155, 165], ["The increased numbers of LVFTs", "PROBLEM", 0, 30], ["the VS", "TEST", 94, 100], ["the trabecular or broad bands", "PROBLEM", 151, 180], ["the present study", "TEST", 193, 210], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["numbers", "OBSERVATION_MODIFIER", 14, 21], ["posterior", "ANATOMY_MODIFIER", 59, 68], ["anterior", "ANATOMY_MODIFIER", 79, 87], ["trabecular", "OBSERVATION", 155, 165], ["broad bands", "OBSERVATION", 169, 180]]], ["Considering that multiple LVFTs were embedded within the fibrous bands, it is possible that excessive LVFTs are closely related to the occurrence of this type of RCM.", [["fibrous bands", "ANATOMY", 57, 70], ["LVFTs", "DISEASE", 102, 107], ["RCM", "DISEASE", 162, 165], ["LVFTs", "CANCER", 26, 31], ["fibrous bands", "TISSUE", 57, 70], ["LVFTs", "GENE_OR_GENE_PRODUCT", 102, 107], ["multiple LVFTs", "PROBLEM", 17, 31], ["the fibrous bands", "PROBLEM", 53, 70], ["excessive LVFTs", "PROBLEM", 92, 107], ["multiple", "OBSERVATION_MODIFIER", 17, 25], ["LVFTs", "OBSERVATION", 26, 31], ["fibrous bands", "OBSERVATION", 57, 70], ["is possible", "UNCERTAINTY", 75, 86], ["excessive", "OBSERVATION_MODIFIER", 92, 101], ["RCM", "OBSERVATION", 162, 165]]], ["Ferasin (2009) believes that \u2018excessive moderator bands\u2019 or \u2018moderator band cardiomyopathy\u2019 are simply lesions associated with endomyocardial RCM.DiscussionThe aetiology of the endomyocardial form of feline RCM remains unresolved; however, it has been suggested that endomyocardial damage followed by reparative fibrosis might be associated with viral or immune-mediated endomyocarditis (Fox, 2004).", [["lesions", "ANATOMY", 103, 110], ["endomyocardial", "ANATOMY", 127, 141], ["endomyocardial", "ANATOMY", 177, 191], ["endomyocardial", "ANATOMY", 267, 281], ["Ferasin", "CHEMICAL", 0, 7], ["cardiomyopathy", "DISEASE", 76, 90], ["endomyocardial RCM", "DISEASE", 127, 145], ["RCM", "DISEASE", 207, 210], ["endomyocardial damage", "DISEASE", 267, 288], ["fibrosis", "DISEASE", 312, 320], ["endomyocarditis", "DISEASE", 371, 386], ["Ferasin", "CHEMICAL", 0, 7], ["lesions", "PATHOLOGICAL_FORMATION", 103, 110], ["endomyocardial", "ORGAN", 127, 141], ["endomyocardial", "ORGAN", 177, 191], ["feline", "ORGANISM", 200, 206], ["endomyocardial", "MULTI-TISSUE_STRUCTURE", 267, 281], ["excessive moderator bands\u2019", "PROBLEM", 30, 56], ["moderator band cardiomyopathy", "PROBLEM", 61, 90], ["simply lesions", "PROBLEM", 96, 110], ["endomyocardial RCM", "PROBLEM", 127, 145], ["feline RCM", "PROBLEM", 200, 210], ["endomyocardial damage", "PROBLEM", 267, 288], ["reparative fibrosis", "PROBLEM", 301, 320], ["viral or immune-mediated endomyocarditis", "PROBLEM", 346, 386], ["band cardiomyopathy", "OBSERVATION", 71, 90], ["lesions", "OBSERVATION", 103, 110], ["endomyocardial RCM", "OBSERVATION", 127, 145], ["endomyocardial", "ANATOMY", 177, 191], ["feline RCM", "OBSERVATION", 200, 210], ["reparative", "OBSERVATION_MODIFIER", 301, 311], ["fibrosis", "OBSERVATION", 312, 320]]], ["Endomyocarditis of undetermined origin has been described as an important disease of cats since the early 1970s (Liu, 1970, Stalis et al., 1995).", [["Endomyocarditis", "DISEASE", 0, 15], ["cats", "ORGANISM", 85, 89], ["cats", "SPECIES", 85, 89], ["Endomyocarditis", "PROBLEM", 0, 15], ["undetermined origin", "OBSERVATION_MODIFIER", 19, 38], ["important", "OBSERVATION_MODIFIER", 64, 73], ["disease", "OBSERVATION", 74, 81]]], ["In addition, parvoviral genomic material has been isolated from a small number of feline hearts with cardiomyopathy (including RCM) and myocarditis, although cause and effect has not been established (Meurs et al., 2000).", [["hearts", "ANATOMY", 89, 95], ["cardiomyopathy", "DISEASE", 101, 115], ["RCM", "DISEASE", 127, 130], ["myocarditis", "DISEASE", 136, 147], ["feline", "ORGANISM", 82, 88], ["hearts", "ORGAN", 89, 95], ["parvoviral genomic material", "PROBLEM", 13, 40], ["cardiomyopathy", "PROBLEM", 101, 115], ["myocarditis", "PROBLEM", 136, 147], ["parvoviral genomic material", "OBSERVATION", 13, 40], ["small", "OBSERVATION_MODIFIER", 66, 71], ["number", "OBSERVATION_MODIFIER", 72, 78], ["feline hearts", "ANATOMY", 82, 95], ["cardiomyopathy", "OBSERVATION", 101, 115], ["myocarditis", "OBSERVATION", 136, 147]]], ["In the present study, histological evidence of endocarditis or endomyocarditis was lacking in all 41 cases.", [["endocarditis", "DISEASE", 47, 59], ["endomyocarditis", "DISEASE", 63, 78], ["the present study", "TEST", 3, 20], ["endocarditis", "PROBLEM", 47, 59], ["endomyocarditis", "PROBLEM", 63, 78], ["evidence of", "UNCERTAINTY", 35, 46], ["endocarditis", "OBSERVATION", 47, 59]]], ["Furthermore, our molecular biological observations using real-time PCR detected no viral genomes in any of the DNA or RNA samples obtained from 14 cat hearts with this abnormality.", [["samples", "ANATOMY", 122, 129], ["hearts", "ANATOMY", 151, 157], ["DNA", "CELLULAR_COMPONENT", 111, 114], ["cat", "ORGANISM", 147, 150], ["hearts", "ORGAN", 151, 157], ["viral genomes", "DNA", 83, 96], ["real-time PCR", "TEST", 57, 70], ["viral genomes", "PROBLEM", 83, 96], ["the DNA", "TEST", 107, 114], ["RNA samples", "TEST", 118, 129], ["this abnormality", "PROBLEM", 163, 179], ["no", "UNCERTAINTY", 80, 82], ["viral genomes", "OBSERVATION", 83, 96]]], ["These findings suggest that any relationship between a virus-induced inflammatory response and the occurrence of feline RCM is unlikely, but do not necessarily rule out this possibility because the present molecular biological study was limited by its small sample size, the localization of viral genomes within the heart and technical factors associated with real-time PCR.", [["heart", "ANATOMY", 316, 321], ["RCM", "DISEASE", 120, 123], ["feline", "ORGANISM", 113, 119], ["heart", "ORGAN", 316, 321], ["viral genomes", "DNA", 291, 304], ["a virus-induced inflammatory response", "PROBLEM", 53, 90], ["feline RCM", "PROBLEM", 113, 123], ["the present molecular biological study", "TEST", 194, 232], ["its small sample size", "PROBLEM", 248, 269], ["viral genomes within the heart and technical factors", "PROBLEM", 291, 343], ["inflammatory", "OBSERVATION_MODIFIER", 69, 81], ["feline RCM", "OBSERVATION", 113, 123], ["small", "OBSERVATION_MODIFIER", 252, 257], ["sample", "OBSERVATION_MODIFIER", 258, 264], ["size", "OBSERVATION_MODIFIER", 265, 269], ["viral genomes", "OBSERVATION", 291, 304], ["heart", "ANATOMY", 316, 321]]], ["On the other hand, it remains to be seen whether an immune-mediated pathway contributes to the pathogenesis of endocardial or endomyocardial inflammation, and further studies will be required in order to address this issue.DiscussionThe present observations confirm and extend the findings of previous studies and lead to the following conclusions.", [["endocardial", "ANATOMY", 111, 122], ["endomyocardial", "ANATOMY", 126, 140], ["endocardial or endomyocardial inflammation", "DISEASE", 111, 153], ["endocardial", "MULTI-TISSUE_STRUCTURE", 111, 122], ["endomyocardial", "ORGAN", 126, 140], ["an immune-mediated pathway", "PROBLEM", 49, 75], ["endocardial or endomyocardial inflammation", "PROBLEM", 111, 153], ["further studies", "TEST", 159, 174], ["previous studies", "TEST", 293, 309], ["endocardial", "ANATOMY", 111, 122], ["endomyocardial", "ANATOMY", 126, 140], ["inflammation", "OBSERVATION", 141, 153]]], ["Firstly, patchy and diffuse patterns of endocardial thickening are evident macroscopically in the LV, the former being much more common.", [["endocardial", "ANATOMY", 40, 51], ["LV", "ANATOMY", 98, 100], ["endocardial", "TISSUE", 40, 51], ["LV", "MULTI-TISSUE_STRUCTURE", 98, 100], ["endocardial thickening", "PROBLEM", 40, 62], ["patchy", "OBSERVATION_MODIFIER", 9, 15], ["diffuse", "OBSERVATION_MODIFIER", 20, 27], ["patterns", "OBSERVATION_MODIFIER", 28, 36], ["endocardial", "ANATOMY", 40, 51], ["thickening", "OBSERVATION", 52, 62], ["macroscopically", "OBSERVATION_MODIFIER", 75, 90], ["LV", "ANATOMY", 98, 100], ["much more common", "OBSERVATION_MODIFIER", 119, 135]]], ["Secondly, from a histological viewpoint, stellate, spindle-shaped or elongated mesenchymal cells proliferate vigorously in the endocardium, producing alcian blue-positive ground substance and collagen fibres; these cells are thought to contribute to endocardial lesion formation.", [["stellate", "ANATOMY", 41, 49], ["spindle", "ANATOMY", 51, 58], ["mesenchymal cells", "ANATOMY", 79, 96], ["endocardium", "ANATOMY", 127, 138], ["collagen fibres", "ANATOMY", 192, 207], ["cells", "ANATOMY", 215, 220], ["endocardial lesion", "ANATOMY", 250, 268], ["alcian blue", "CHEMICAL", 150, 161], ["endocardial lesion", "DISEASE", 250, 268], ["alcian blue", "CHEMICAL", 150, 161], ["stellate", "CELL", 41, 49], ["mesenchymal cells", "CELL", 79, 96], ["endocardium", "MULTI-TISSUE_STRUCTURE", 127, 138], ["alcian blue-positive ground substance", "GENE_OR_GENE_PRODUCT", 150, 187], ["collagen", "GENE_OR_GENE_PRODUCT", 192, 200], ["cells", "CELL", 215, 220], ["endocardial lesion", "PATHOLOGICAL_FORMATION", 250, 268], ["stellate, spindle-shaped or elongated mesenchymal cells", "CELL_TYPE", 41, 96], ["a histological viewpoint", "TEST", 15, 39], ["stellate, spindle-shaped or elongated mesenchymal cells proliferate", "PROBLEM", 41, 108], ["alcian blue", "TEST", 150, 161], ["endocardial lesion formation", "PROBLEM", 250, 278], ["stellate", "OBSERVATION_MODIFIER", 41, 49], ["spindle", "OBSERVATION_MODIFIER", 51, 58], ["shaped", "OBSERVATION_MODIFIER", 59, 65], ["elongated", "OBSERVATION_MODIFIER", 69, 78], ["mesenchymal cells", "OBSERVATION", 79, 96], ["proliferate", "OBSERVATION_MODIFIER", 97, 108], ["vigorously", "OBSERVATION_MODIFIER", 109, 119], ["endocardium", "ANATOMY", 127, 138], ["alcian blue", "OBSERVATION", 150, 161], ["positive ground substance", "OBSERVATION_MODIFIER", 162, 187], ["collagen fibres", "OBSERVATION_MODIFIER", 192, 207], ["thought to contribute to", "UNCERTAINTY", 225, 249], ["endocardial", "ANATOMY", 250, 261], ["lesion", "OBSERVATION", 262, 268]]], ["Thirdly, from an immunohistochemical viewpoint, the mesenchymal cells embedded within fibrous connective tissue show a tendency for smooth muscle differentiation.", [["mesenchymal cells", "ANATOMY", 52, 69], ["fibrous connective tissue", "ANATOMY", 86, 111], ["smooth muscle", "ANATOMY", 132, 145], ["mesenchymal cells", "CELL", 52, 69], ["fibrous connective tissue", "TISSUE", 86, 111], ["smooth muscle", "TISSUE", 132, 145], ["mesenchymal cells", "CELL_TYPE", 52, 69], ["an immunohistochemical viewpoint", "TEST", 14, 46], ["the mesenchymal cells", "PROBLEM", 48, 69], ["mesenchymal cells", "OBSERVATION", 52, 69], ["fibrous connective tissue", "OBSERVATION", 86, 111], ["smooth muscle differentiation", "OBSERVATION", 132, 161]]], ["Fourthly, in lesions with a patchy pattern, multiple LVFTs are invariably included within large trabecular or irregular broad bands of fibrous tissue, providing a framework for the formation of the fibrous bands.", [["lesions", "ANATOMY", 13, 20], ["LVFTs", "ANATOMY", 53, 58], ["trabecular", "ANATOMY", 96, 106], ["fibrous tissue", "ANATOMY", 135, 149], ["fibrous bands", "ANATOMY", 198, 211], ["LVFTs", "DISEASE", 53, 58], ["lesions", "CANCER", 13, 20], ["LVFTs", "CANCER", 53, 58], ["trabecular", "TISSUE", 96, 106], ["fibrous tissue", "TISSUE", 135, 149], ["lesions", "PROBLEM", 13, 20], ["a patchy pattern", "PROBLEM", 26, 42], ["multiple LVFTs", "PROBLEM", 44, 58], ["large trabecular or irregular broad bands of fibrous tissue", "PROBLEM", 90, 149], ["the fibrous bands", "PROBLEM", 194, 211], ["lesions", "OBSERVATION", 13, 20], ["patchy", "OBSERVATION_MODIFIER", 28, 34], ["pattern", "OBSERVATION_MODIFIER", 35, 42], ["multiple", "OBSERVATION_MODIFIER", 44, 52], ["LVFTs", "OBSERVATION", 53, 58], ["large", "OBSERVATION_MODIFIER", 90, 95], ["trabecular", "OBSERVATION_MODIFIER", 96, 106], ["irregular", "OBSERVATION_MODIFIER", 110, 119], ["broad bands", "OBSERVATION_MODIFIER", 120, 131], ["fibrous tissue", "OBSERVATION", 135, 149], ["fibrous bands", "OBSERVATION", 198, 211]]], ["Finally, the lack of any histological evidence of endocarditis or endomyocarditis and the absence of candidate viral genomes in cardiac tissue suggest that the occurrence of feline RCM is not significantly related to a virus-induced inflammatory response.", [["cardiac tissue", "ANATOMY", 128, 142], ["endocarditis", "DISEASE", 50, 62], ["endomyocarditis", "DISEASE", 66, 81], ["RCM", "DISEASE", 181, 184], ["cardiac tissue", "TISSUE", 128, 142], ["feline", "ORGANISM", 174, 180], ["candidate viral genomes", "DNA", 101, 124], ["endocarditis", "PROBLEM", 50, 62], ["endomyocarditis", "PROBLEM", 66, 81], ["viral genomes in cardiac tissue", "PROBLEM", 111, 142], ["feline RCM", "PROBLEM", 174, 184], ["a virus-induced inflammatory response", "PROBLEM", 217, 254], ["endocarditis", "OBSERVATION", 50, 62], ["viral genomes", "OBSERVATION", 111, 124], ["cardiac tissue", "ANATOMY", 128, 142], ["feline RCM", "OBSERVATION", 174, 184], ["inflammatory", "OBSERVATION_MODIFIER", 233, 245]]]], "69cc14915ab5b7184d9ec5cdb0be98279ccee0a5": [["Gain-of-function (GOF) research typically involves mutations that confer altered functionality of a protein or other molecule.", [["Gain", "TEST", 0, 4], ["mutations", "PROBLEM", 51, 60]]], ["These types of mutations have been used as powerful tools to understand basic bacterial and viral biology and pathogenhost interactions.", [["mutations", "PROBLEM", 15, 24]]], ["In recent years, a public discussion has surfaced, centering on the application of GOF research to highly pathogenic and potentially lethal viruses [1] .", [["lethal viruses", "PROBLEM", 133, 147]]], ["As the results from GOF research are salient to both the improved understanding of disease pathogenesis and the development of medical countermeasures to infectious diseases, the debate over its safety and value is of direct relevance to medical and public health practitioners.", [["infectious diseases", "DISEASE", 154, 173], ["disease pathogenesis", "PROBLEM", 83, 103], ["medical countermeasures", "TREATMENT", 127, 150], ["infectious diseases", "PROBLEM", 154, 173]]], ["This review article will provide a historical context for the current debate, describe the potential risks and benefits of this type of experimental study, and present some examples of how GOF research translates into tangible products of use to practicing clinicians.GOF: AN HISTORICAL PERSPECTIVEGenetic mutations can be classified in many ways, one of which is by their impact on protein function.", [["experimental study", "TEST", 136, 154], ["AN HISTORICAL PERSPECTIVEGenetic mutations", "PROBLEM", 273, 315]]], ["In the simplest terms, mutations can result in a protein's loss of function or GOF.", [["GOF", "GENE_OR_GENE_PRODUCT", 79, 82], ["GOF", "PROTEIN", 79, 82], ["mutations", "PROBLEM", 23, 32], ["a protein's loss of function", "PROBLEM", 47, 75], ["GOF", "PROBLEM", 79, 82]]], ["The distinction between the 2 phenotypes is not always clear.", [["not always", "UNCERTAINTY", 44, 54], ["clear", "OBSERVATION", 55, 60]]], ["GOF research, in this context, usually results in the introduction of changes to biological agents that might increase their ability to infect a host and cause disease by enhancing their transmissibility or pathogenicity [2] .", [["biological agents", "TREATMENT", 81, 98], ["disease", "PROBLEM", 160, 167], ["pathogenicity", "PROBLEM", 207, 220]]], ["DURC is a subset of microbiological research that, as defined by the US government, \"can be reasonably anticipated to provide knowledge, information, products, or technologies that could be directly misapplied to pose a significant threat with broad potential consequences to public health and safety, agricultural crops and other plants, animals, the environment, materiel, or national security\" [3, p.", [["DURC", "DISEASE", 0, 4]]], ["Some of the potential consequences of DURC that have been cited include the manipulation of pathogens for use as biological weapons and the development of mechanisms by which pathogens can evade countermeasures.", [["DURC", "GENE_OR_GENE_PRODUCT", 38, 42], ["DURC", "TREATMENT", 38, 42]]], ["DURC currently pertains to the select agents and toxins defined by the US Centers for Disease Prevention and Control and the US Department of Agriculture [4] .", [["DURC", "TREATMENT", 0, 4], ["toxins", "TREATMENT", 49, 55], ["Disease Prevention", "TREATMENT", 86, 104]]], ["Among these pathogens, highly pathogenic avian influenza virus (HPAI) is of high concern to both public health and agriculture authorities.GOF: AN HISTORICAL PERSPECTIVEPublic discourse on the controversies of influenza virus research is about a decade old, beginning in 2005 with the reconstitution of the 1918 influenza A(H1N1) [5] [6] [7] .", [["avian influenza virus", "DISEASE", 41, 62], ["HPAI", "DISEASE", 64, 68], ["influenza virus", "DISEASE", 210, 225], ["avian influenza virus", "ORGANISM", 41, 62], ["influenza virus", "ORGANISM", 210, 225], ["avian influenza virus", "SPECIES", 41, 62], ["HPAI", "SPECIES", 64, 68], ["these pathogens", "PROBLEM", 6, 21], ["highly pathogenic avian influenza virus", "PROBLEM", 23, 62], ["influenza virus", "PROBLEM", 210, 225], ["pathogens", "OBSERVATION", 12, 21]]], ["The more recent debates over the safety and merits of GOF research first surfaced in 2010, in the context of studies on the transmission dynamics of HPAI A(H5N1) (Figure 1 ).", [["HPAI", "DISEASE", 149, 153], ["HPAI A(H5N1)", "ORGANISM", 149, 161], ["HPAI A(H5N1)", "SPECIES", 149, 161]]], ["Laboratories at the University of Wisconsin (Madison) and Erasmus University Medical Center (EMC; Rotterdam, the Netherlands) performed a series of experiments [8, 9] that involved the mutation of 2 influenza A(H5N1) strains through multiple passaging.", [["2", "ORGANISM", 197, 198], ["influenza A(H5N1) strains", "ORGANISM", 199, 224], ["the mutation", "PROBLEM", 181, 193], ["2 influenza A(H5N1) strains", "PROBLEM", 197, 224], ["multiple passaging", "TREATMENT", 233, 251]]], ["The two laboratories identified specific amino acid changes that enhanced airborne transmissibility of the virus between ferrets-a standard animal influenza model that exhibits a natural history and pathology similar to what is observed in humans.", [["amino acid", "CHEMICAL", 41, 51], ["influenza", "DISEASE", 147, 156], ["amino acid", "CHEMICAL", 41, 51], ["amino acid", "AMINO_ACID", 41, 51], ["ferrets", "ORGANISM", 121, 128], ["humans", "ORGANISM", 240, 246], ["ferrets", "SPECIES", 121, 128], ["humans", "SPECIES", 240, 246], ["humans", "SPECIES", 240, 246], ["The two laboratories", "TEST", 0, 20], ["specific amino acid changes", "PROBLEM", 32, 59], ["the virus between ferrets", "PROBLEM", 103, 128], ["a standard animal influenza model", "PROBLEM", 129, 162], ["pathology", "PROBLEM", 199, 208], ["amino acid", "OBSERVATION", 41, 51], ["airborne transmissibility", "OBSERVATION", 74, 99]]], ["The potential translation from ferrets to humans raised concerns among funders (ie, the National Institutes of Health [NIH] ) and the broader biosecurity policy community that the research could be used for intentionally harmful purposes or result in an accidental release of pathogens from the laboratory into the general population.GOF: AN HISTORICAL PERSPECTIVEIn 2011, the Department of Health and Human Services (DHHS) convened the National Science Advisory Board for Biosecurity (NSABB)-an independent federal advisory committee chartered to provide advice on the biosecurity oversight of dual use research.", [["ferrets", "ORGANISM", 31, 38], ["humans", "ORGANISM", 42, 48], ["Human", "ORGANISM", 402, 407], ["humans", "SPECIES", 42, 48], ["Human", "SPECIES", 402, 407], ["humans", "SPECIES", 42, 48], ["pathogens", "PROBLEM", 276, 285]]], ["The NSABB was asked to weigh in on whether the GOF studies should be published in the public domain.", [["the GOF studies", "TEST", 43, 58]]], ["In March 2012, the NSABB recommended publication of both studies, with some minor changes to the EMC manuscript [11] .", [["both studies", "TEST", 52, 64]]], ["These deliberations led to the creation of a US framework for DURC studies [3, 12] and further stimulated a debate on GOF research within the scientific community [13] .GOF: AN HISTORICAL PERSPECTIVERecently, influenza virus researchers laid out a rationale for GOF experiments in the context of influenza A(H7N9) [14, 15] .", [["influenza A", "DISEASE", 296, 307], ["influenza virus", "ORGANISM", 209, 224], ["influenza A(H7N9)", "ORGANISM", 296, 313], ["a US framework", "TEST", 43, 57], ["DURC studies", "TEST", 62, 74], ["AN HISTORICAL PERSPECTIVERecently", "TREATMENT", 174, 207], ["influenza virus researchers", "TREATMENT", 209, 236], ["GOF experiments", "PROBLEM", 262, 277], ["influenza A", "PROBLEM", 296, 307]]], ["These arguments were met with some criticism [16] [17] [18] , especially with respect to the risks of accidental or intentional release of this HPAI.", [["HPAI", "DISEASE", 144, 148], ["this HPAI", "PROBLEM", 139, 148]]], ["Given the growing concern over this and other HPAI subtypes, the White House Office of Science and Technology Policy and the DHHS announced a moratorium, on 17 October 2014, on all new funding for GOF research on all influenza viruses, severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV) [2] .", [["HPAI", "DISEASE", 46, 50], ["influenza viruses", "DISEASE", 217, 234], ["acute respiratory syndrome coronavirus", "DISEASE", 243, 281], ["SARS-CoV)", "DISEASE", 283, 292], ["Middle East respiratory syndrome coronavirus", "DISEASE", 298, 342], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 236, 281], ["SARS-CoV", "ORGANISM", 283, 291], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 298, 342], ["MERS-CoV", "ORGANISM", 344, 352], ["severe acute respiratory syndrome coronavirus", "SPECIES", 236, 281], ["SARS-CoV", "SPECIES", 283, 291], ["Middle East respiratory syndrome coronavirus", "SPECIES", 298, 342], ["MERS-CoV", "SPECIES", 344, 352], ["GOF research", "PROBLEM", 197, 209], ["all influenza viruses", "PROBLEM", 213, 234], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 236, 281], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 298, 342], ["influenza viruses", "OBSERVATION", 217, 234], ["severe", "OBSERVATION_MODIFIER", 236, 242], ["acute", "OBSERVATION_MODIFIER", 243, 248], ["respiratory syndrome coronavirus", "OBSERVATION", 249, 281], ["Middle", "ANATOMY_MODIFIER", 298, 304], ["respiratory syndrome", "OBSERVATION", 310, 330]]], ["Additionally, the US government called for a voluntary moratorium on all such research, irrespective of funding source, while the risks and benefits of such experiments could be assessed.", [["the US government", "TEST", 14, 31], ["such experiments", "TREATMENT", 152, 168]]], ["On 15 and 16 December 2014, the National Academy of Sciences, National Research Council, and Institute of Medicine convened experts from the disciplines of infectious diseases, research ethics, and science policy to discuss the potential risks and benefits of GOF research in a public forum to help inform the federal government on how best to proceed in regulating GOF research on potentially dangerous biological agents [19] .Shortly after the meeting, the NIH notified a subset of researchers affected by the research pause that their work could resume [20] .", [["infectious diseases", "DISEASE", 156, 175], ["infectious", "OBSERVATION", 156, 166]]], ["Specifically, 5 research projects on MERS-CoV animal model development and 2 on HPAI were cleared to continue.GOF: AN HISTORICAL PERSPECTIVEThe discussion on the merits and risks of GOF research has not been limited to the United States, as the Dutch Court of Appeals recently handed down a verdict concerning EMC's objection to export license rules regarding the publication of HPAI GOF research [21] .", [["MERS-CoV", "ORGANISM", 37, 45], ["HPAI", "ORGANISM", 80, 84], ["MERS-CoV", "SPECIES", 37, 45], ["HPAI", "SPECIES", 80, 84], ["HPAI", "TREATMENT", 80, 84]]], ["Export licenses in the European Union are in place to prevent the proliferation of weapons of mass destruction and, thus, apply to specific biological agents, chemical agents, and technologies.", [["mass destruction", "PROBLEM", 94, 110], ["chemical agents", "TREATMENT", 159, 174], ["licenses", "OBSERVATION", 7, 15], ["mass", "OBSERVATION", 94, 98]]], ["Currently, all GOF research within the European Union requires export licenses for publication.GOF: AN HISTORICAL PERSPECTIVEA deliberative review process, headed by the NSABB, is currently underway [22] to evaluate the potential impacts of GOF research and to set criteria for what types of research can be conducted and made available in the public domain.", [["GOF", "OBSERVATION", 15, 18]]], ["A large part of the risk analysis will likely involve the potential for these pathogens to be misused either intentionally or accidentally.", [["the risk analysis", "TEST", 16, 33], ["these pathogens", "PROBLEM", 72, 87], ["large", "OBSERVATION_MODIFIER", 2, 7]]], ["The recent safety lapses at the Centers for Disease Control and Prevention and the NIH that could have resulted in exposure to anthrax and smallpox, respectively, have diminished public confidence in the ability of even high-containment laboratories to mitigate the risk of accidental release of pathogens of potential harm.", [["anthrax", "DISEASE", 127, 134], ["smallpox", "DISEASE", 139, 147], ["anthrax", "ORGANISM", 127, 134], ["The recent safety lapses", "PROBLEM", 0, 24], ["Disease Control", "TREATMENT", 44, 59], ["diminished", "OBSERVATION_MODIFIER", 168, 178]]], ["Though the actual risk of accidental release of highly pathogenic viruses may be low, public tolerance of that risk may be the ultimate determinant of what types of research are allowed to proceed.GOF: AN HISTORICAL PERSPECTIVEIncreasing attention has been brought to the use of alternative methods of investigation in areas that have historically been studied through GOF research.", [["highly pathogenic viruses", "PROBLEM", 48, 73], ["alternative methods", "TREATMENT", 279, 298]]], ["The relevance of these other methods is an important consideration for the scientific community, medical practitioners, and the general public, as the risks and benefits of each approach and the tangible outcomes they yield will vary according to the interests and needs of each sector.", [["each approach", "TREATMENT", 173, 186]]], ["As the GOF debate has transpired to date, the ramifications of this research for the practicing clinician have not been made clear.Animal ModelsThe development of novel prophylactic and therapeutic interventions invariably requires evaluation in animal models that, at least partially, recapitulate the disease in infected humans.", [["humans", "ORGANISM", 323, 329], ["humans", "SPECIES", 323, 329], ["humans", "SPECIES", 323, 329], ["novel prophylactic", "TREATMENT", 163, 181], ["therapeutic interventions", "TREATMENT", 186, 211], ["evaluation", "TEST", 232, 242], ["the disease in infected humans", "PROBLEM", 299, 329], ["novel", "OBSERVATION_MODIFIER", 163, 168], ["prophylactic", "OBSERVATION", 169, 181], ["disease", "OBSERVATION", 303, 310], ["infected", "OBSERVATION", 314, 322]]], ["Many emerging and reemerging zoonotic diseases lack relevant animal models that closely recapitulate human disease [27] .", [["zoonotic diseases", "DISEASE", 29, 46], ["human", "ORGANISM", 101, 106], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["reemerging zoonotic diseases", "PROBLEM", 18, 46]]], ["In these instances, GOF experiments are often needed to adapt virus isolates from humans to different, sometimes unnatural, mammalian hosts.", [["humans", "ORGANISM", 82, 88], ["humans", "SPECIES", 82, 88], ["humans", "SPECIES", 82, 88], ["GOF experiments", "PROBLEM", 20, 35], ["adapt virus isolates", "PROBLEM", 56, 76]]], ["Adaptation to a new host inherently involves the alteration of pathogens through mutation.", [["a new host", "PROBLEM", 14, 24], ["pathogens through mutation", "PROBLEM", 63, 89]]], ["As the development of appropriate animal models can be a rate-limiting step in the evaluation of prophylactic and therapeutic interventions, GOF modifications to viral strains can be an important tool toward accelerating the product development pipeline.Animal ModelsCoronaviruses such as SARS-CoV and MERS-CoV require meaningful small-animal models that elucidate viral pathogenesis and immunity.", [["SARS-CoV", "ORGANISM", 289, 297], ["MERS-CoV", "ORGANISM", 302, 310], ["SARS-CoV", "SPECIES", 289, 297], ["MERS-CoV", "SPECIES", 302, 310], ["the evaluation", "TEST", 79, 93], ["prophylactic and therapeutic interventions", "TREATMENT", 97, 139], ["GOF modifications", "TREATMENT", 141, 158], ["viral strains", "PROBLEM", 162, 175], ["Animal ModelsCoronaviruses", "PROBLEM", 254, 280], ["SARS", "PROBLEM", 289, 293], ["meaningful small-animal models", "PROBLEM", 319, 349], ["viral pathogenesis", "PROBLEM", 365, 383]]], ["The human isolates are manipulated either through natural evolution, targeted mutation, or repeated exposure to human factors in nonhuman hosts.", [["human", "ORGANISM", 4, 9], ["human", "ORGANISM", 112, 117], ["nonhuman", "ORGANISM", 129, 137], ["human factors", "PROTEIN", 112, 125], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 112, 117], ["The human isolates", "TREATMENT", 0, 18], ["targeted mutation", "PROBLEM", 69, 86]]], ["One of the more reliable SARS-CoV murine models was developed by modifying a human isolate through 15 serial passages, after which it was lethal to young mice [28] .", [["SARS-CoV", "ORGANISM", 25, 33], ["murine", "ORGANISM", 34, 40], ["human", "ORGANISM", 77, 82], ["mice", "ORGANISM", 154, 158], ["murine", "SPECIES", 34, 40], ["human", "SPECIES", 77, 82], ["mice", "SPECIES", 154, 158], ["SARS-CoV", "SPECIES", 25, 33], ["human", "SPECIES", 77, 82], ["mice", "SPECIES", 154, 158], ["a human isolate", "TREATMENT", 75, 90], ["SARS", "OBSERVATION", 25, 29]]], ["This mouse-adapted virus strain contained 6 coding mutations that conferred increased virulence, approximating many features of SARS-CoV disease in humans and thus providing a robust and reproducible challenge model for testing vaccines, antivirals, and other interventions [29] .", [["SARS-CoV disease", "DISEASE", 128, 144], ["mouse", "ORGANISM", 5, 10], ["SARS-CoV", "ORGANISM", 128, 136], ["humans", "ORGANISM", 148, 154], ["mouse", "SPECIES", 5, 10], ["humans", "SPECIES", 148, 154], ["mouse", "SPECIES", 5, 10], ["SARS-CoV", "SPECIES", 128, 136], ["humans", "SPECIES", 148, 154], ["adapted virus strain", "PROBLEM", 11, 31], ["6 coding mutations", "PROBLEM", 42, 60], ["increased virulence", "PROBLEM", 76, 95], ["SARS", "PROBLEM", 128, 132], ["CoV disease in humans", "PROBLEM", 133, 154], ["testing vaccines", "TREATMENT", 220, 236], ["antivirals", "TREATMENT", 238, 248], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["virulence", "OBSERVATION_MODIFIER", 86, 95], ["SARS", "OBSERVATION", 128, 132], ["CoV disease", "OBSERVATION", 133, 144]]], ["The development of an appropriate animal model for MERS-CoV, on the other hand, provides unique challenges because the viral receptor used for cell entry is radically different in mice.", [["cell", "ANATOMY", 143, 147], ["MERS-CoV", "ORGANISM", 51, 59], ["cell", "CELL", 143, 147], ["mice", "ORGANISM", 180, 184], ["viral receptor", "PROTEIN", 119, 133], ["mice", "SPECIES", 180, 184], ["MERS-CoV", "SPECIES", 51, 59], ["mice", "SPECIES", 180, 184], ["unique challenges", "TREATMENT", 89, 106], ["the viral receptor", "TREATMENT", 115, 133], ["cell entry", "PROBLEM", 143, 153]]], ["Models thus far have included transient transfection [30] and transgenic mice [31] , although it is still unclear whether these models accurately recapitulate human infection.", [["infection", "DISEASE", 165, 174], ["mice", "ORGANISM", 73, 77], ["human", "ORGANISM", 159, 164], ["mice", "SPECIES", 73, 77], ["human", "SPECIES", 159, 164], ["mice", "SPECIES", 73, 77], ["human", "SPECIES", 159, 164], ["transient transfection", "PROBLEM", 30, 52], ["human infection", "PROBLEM", 159, 174], ["infection", "OBSERVATION", 165, 174]]], ["Approximating human disease in these small-animal models might require further passaging in the presence of a humanized receptor, thus creating a potential for the development of GOF phenotypes.VaccinesMany live-attenuated vaccines, including some of the most successful vaccines ever developed, have been generated through GOF research.", [["human", "ORGANISM", 14, 19], ["GOF", "GENE_OR_GENE_PRODUCT", 179, 182], ["humanized receptor", "PROTEIN", 110, 128], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["Approximating human disease", "PROBLEM", 0, 27], ["further passaging", "TREATMENT", 71, 88], ["a humanized receptor", "TREATMENT", 108, 128], ["GOF phenotypes", "PROBLEM", 179, 193], ["Vaccines", "TREATMENT", 194, 202], ["attenuated vaccines", "TREATMENT", 212, 231], ["disease", "OBSERVATION", 20, 27], ["small", "OBSERVATION_MODIFIER", 37, 42], ["GOF phenotypes", "OBSERVATION", 179, 193]]], ["From polio to smallpox to influenza, liveattenuated vaccines elicit immunity against authentic epitopes on whole pathogens without causing disease.", [["smallpox", "DISEASE", 14, 22], ["influenza", "DISEASE", 26, 35], ["smallpox", "TREATMENT", 14, 22], ["influenza", "PROBLEM", 26, 35], ["liveattenuated vaccines", "TREATMENT", 37, 60], ["authentic epitopes", "PROBLEM", 85, 103], ["whole pathogens", "PROBLEM", 107, 122], ["disease", "PROBLEM", 139, 146]]], ["The live-attenuated measles vaccine was created by passaging the virus until mutations arose that altered virus tropism-a technique that could be considered, by current definitions, GOF research [32] .", [["measles", "ORGANISM", 20, 27], ["The live-attenuated measles vaccine", "TREATMENT", 0, 35], ["the virus", "PROBLEM", 61, 70], ["mutations", "PROBLEM", 77, 86], ["altered virus tropism", "PROBLEM", 98, 119]]], ["New research on highly pathogenic viruses has emphasized the different ways GOF mutations can generate even-more-effective live-attenuated vaccines.", [["GOF", "GENE_OR_GENE_PRODUCT", 76, 79], ["New research on highly pathogenic viruses", "PROBLEM", 0, 41], ["attenuated vaccines", "TREATMENT", 128, 147], ["highly", "OBSERVATION_MODIFIER", 16, 22], ["pathogenic", "OBSERVATION_MODIFIER", 23, 33], ["viruses", "OBSERVATION", 34, 41]]], ["Mutations within RNA virus polymerases, for example, modify replication fidelity to generate higher or lower mutation rates during viral replication.", [["RNA virus polymerases", "PROTEIN", 17, 38], ["Mutations within RNA virus polymerases", "PROBLEM", 0, 38], ["lower mutation rates", "PROBLEM", 103, 123], ["viral replication", "TREATMENT", 131, 148]]], ["These fidelity mutants could potentially alter viral tropism, modify key antigens, and increase resistance against novel therapeutic interventions or antibody responses, but they could also lead to a virus that is less fit [33, 34] .", [["viral tropism", "PROBLEM", 47, 60], ["novel therapeutic interventions", "TREATMENT", 115, 146], ["antibody responses", "PROBLEM", 150, 168], ["a virus", "PROBLEM", 198, 205]]], ["These particular types of experiments have been carried out on a range of viruses, including alphaviruses [35, 36] and picornaviruses [37] .", [["alphaviruses", "PROBLEM", 93, 105], ["picornaviruses", "PROBLEM", 119, 133]]], ["The introduction of GOF mutations not only attenuates the virus but also provides improved understanding of the mechanics of viral replication, thus potentially uncovering new strategies in the development of vaccines against emerging pathogens.Therapeutic InterventionsThe generation of escape mutants in the presence of an investigational agent is common practice for the evaluation of antibiotics, antivirals, and other monoclonal antibodies.", [["GOF", "GENE_OR_GENE_PRODUCT", 20, 23], ["GOF", "DNA", 20, 23], ["monoclonal antibodies", "PROTEIN", 423, 444], ["GOF mutations", "PROBLEM", 20, 33], ["the virus", "PROBLEM", 54, 63], ["viral replication", "TREATMENT", 125, 142], ["vaccines", "TREATMENT", 209, 217], ["emerging pathogens", "PROBLEM", 226, 244], ["Therapeutic Interventions", "TREATMENT", 245, 270], ["escape mutants", "PROBLEM", 288, 302], ["an investigational agent", "TREATMENT", 322, 346], ["the evaluation", "TEST", 370, 384], ["antibiotics", "TREATMENT", 388, 399], ["antivirals", "TREATMENT", 401, 411], ["other monoclonal antibodies", "TEST", 417, 444], ["viral replication", "OBSERVATION", 125, 142], ["escape mutants", "OBSERVATION", 288, 302]]], ["GOF experiments with HPAIs and highly pathogenic human influenza viruses, for example, have identified specific mutations that can confer multidrug resistance [38, 39] .", [["HPAIs", "CHEMICAL", 21, 26], ["influenza viruses", "DISEASE", 55, 72], ["HPAIs", "GENE_OR_GENE_PRODUCT", 21, 26], ["human", "ORGANISM", 49, 54], ["influenza viruses", "ORGANISM", 55, 72], ["human", "SPECIES", 49, 54], ["influenza viruses", "SPECIES", 55, 72], ["human influenza viruses", "SPECIES", 49, 72], ["HPAIs", "PROBLEM", 21, 26], ["highly pathogenic human influenza viruses", "PROBLEM", 31, 72], ["specific mutations", "PROBLEM", 103, 121]]], ["GOF experiments are necessary in this context because naturally occurring resistant strains may not yet exist or the complex background of naturally occurring mutations may preclude identification of the amino acid residues that are critical to resistance [40] .", [["amino acid", "CHEMICAL", 204, 214], ["amino acid", "CHEMICAL", 204, 214], ["amino acid", "AMINO_ACID", 204, 214], ["GOF experiments", "PROBLEM", 0, 15], ["resistant strains", "PROBLEM", 74, 91], ["naturally occurring mutations", "PROBLEM", 139, 168], ["the amino acid residues", "PROBLEM", 200, 223]]], ["These GOF studies are equally important in research on antivirals and antibiotics and can help inform the development of combination therapies.", [["These GOF studies", "TEST", 0, 17], ["antivirals", "TREATMENT", 55, 65], ["antibiotics", "TREATMENT", 70, 81], ["combination therapies", "TREATMENT", 121, 142]]], ["Passive immunotherapy, which often includes a combination of products, is particularly dependent on GOF experiments for evaluating efficacy [41] [42] [43] , as seen in the current Ebola outbreak that has prompted a robust program to evaluate combination monoclonal antibody therapies [44, 45] .Disease SurveillanceIn the past half-century, GOF research has contributed to an improved understanding of the epidemiology of emerging pathogens and has informed efforts to conduct surveillance for future outbreaks.", [["Ebola", "DISEASE", 180, 185], ["Ebola", "ORGANISM", 180, 185], ["Passive immunotherapy", "TREATMENT", 0, 21], ["a combination of products", "TREATMENT", 44, 69], ["monoclonal antibody therapies", "TREATMENT", 254, 283], ["Disease", "PROBLEM", 294, 301], ["surveillance", "TEST", 476, 488]]], ["In the context of influenza, data, derived from GOF research, on the relative transmissibility of hemagglutinin mutations has aided in the interpretation of molecular surveillance data [46] .", [["influenza", "DISEASE", 18, 27], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 98, 111], ["influenza", "PROBLEM", 18, 27], ["hemagglutinin mutations", "PROBLEM", 98, 121], ["molecular surveillance data", "TEST", 157, 184], ["influenza", "OBSERVATION", 18, 27]]], ["Specifically, the initial influenza A(H5N1) [8, 9] and later influenza A(H7N9) experiments identified amino acid changes in influenza virus hemagglutinin or RNA polymerase through viral passaging or site-directed mutagenesis.", [["amino acid", "CHEMICAL", 102, 112], ["amino acid", "CHEMICAL", 102, 112], ["influenza A(H5N1)", "ORGANISM", 26, 43], ["influenza A", "ORGANISM", 61, 72], ["amino acid", "AMINO_ACID", 102, 112], ["influenza virus hemagglutinin", "ORGANISM", 124, 153], ["influenza virus hemagglutinin", "PROTEIN", 124, 153], ["RNA polymerase", "PROTEIN", 157, 171], ["influenza virus hemagglutinin", "SPECIES", 124, 153], ["H7N9", "SPECIES", 73, 77], ["influenza virus", "SPECIES", 124, 139], ["the initial influenza A(H5N1)", "TEST", 14, 43], ["later influenza A(H7N9) experiments", "PROBLEM", 55, 90], ["amino acid changes", "PROBLEM", 102, 120], ["influenza virus hemagglutinin", "TREATMENT", 124, 153], ["RNA polymerase", "TREATMENT", 157, 171], ["viral passaging", "TREATMENT", 180, 195], ["amino acid", "OBSERVATION", 102, 112]]], ["This research elucidated mechanisms by which naturally occurring influenza virus strains might evolve to replicate more efficiently and transmit more easily within mammalian hosts [47, 48] .", [["influenza virus", "ORGANISM", 65, 80], ["influenza virus strains", "PROBLEM", 65, 88]]], ["The results of these experiments can be used to cross-reference traits found among circulating strains and help predict transmission patterns and pathogenicity [49] .", [["these experiments", "TEST", 15, 32], ["circulating strains", "PROBLEM", 83, 102], ["pathogenicity", "PROBLEM", 146, 159]]], ["As the field of disease surveillance evolves to accommodate a growing repository of viral sequences, GOF research will also play an important role in assessing the public health significance of genotypic variation.Disease SurveillanceThough current understanding of the relationship between genotypic data and phenotypic expression is suboptimal, the increasing reliance by the clinical community on molecular diagnostic tools may help to reduce that uncertainty.", [["viral sequences", "DNA", 84, 99], ["disease surveillance", "TEST", 16, 36], ["viral sequences", "TEST", 84, 99], ["Disease", "PROBLEM", 214, 221], ["genotypic data", "TEST", 291, 305], ["disease", "OBSERVATION", 16, 23]]], ["As costs of whole-genome sequencing continue to decrease, data from these techniques are likely to become more central to disease surveillance programs.", [["whole-genome sequencing", "TREATMENT", 12, 35], ["these techniques", "TEST", 68, 84]]], ["The results of GOF experimentation can also help inform decisions about countermeasure selection and stockpiling, particularly in the context of influenza surveillance programs [50] .", [["influenza", "DISEASE", 145, 154], ["GOF experimentation", "TREATMENT", 15, 34], ["countermeasure selection", "TREATMENT", 72, 96], ["stockpiling", "TREATMENT", 101, 112], ["influenza surveillance programs", "TREATMENT", 145, 176]]], ["The improved understanding of how HPAIs evolve to transmit more efficiently has also factored into decisions about the creation of prepandemic vaccine stockpiles.THE ROLE OF CLINICIANS IN THE GOF RESEARCH DEBATEThe world has been witness to a number of emerging infectious disease pandemics over the past several decades.", [["infectious disease pandemics", "DISEASE", 262, 290], ["HPAIs", "GENE_OR_GENE_PRODUCT", 34, 39], ["prepandemic vaccine stockpiles", "TREATMENT", 131, 161], ["emerging infectious disease pandemics", "PROBLEM", 253, 290], ["infectious", "OBSERVATION", 262, 272]]], ["Each time, clinical and public health practitioners were on the front lines, providing care and treatment and finding ways to interrupt transmission, and were ultimately responsible for containing the outbreak.", [["treatment", "TREATMENT", 96, 105]]], ["Healthcare providers require effective medical countermeasures and epidemiologic information to assess risk and support decisions about treatment and prevention.", [["effective medical countermeasures", "TREATMENT", 29, 62], ["treatment", "TREATMENT", 136, 145]]], ["Recent outbreaks of infection due to Ebola virus, MERS-CoV, and pandemic influenza virus, however, continue to demonstrate that medical and public health readiness for emerging infections is not always optimal and could benefit from more research and development.", [["infection", "DISEASE", 20, 29], ["Ebola virus", "DISEASE", 37, 48], ["influenza virus", "DISEASE", 73, 88], ["infections", "DISEASE", 177, 187], ["Ebola virus", "ORGANISM", 37, 48], ["MERS-CoV", "ORGANISM", 50, 58], ["pandemic influenza virus", "ORGANISM", 64, 88], ["Ebola virus", "SPECIES", 37, 48], ["pandemic influenza virus", "SPECIES", 64, 88], ["Ebola virus", "SPECIES", 37, 48], ["MERS-CoV", "SPECIES", 50, 58], ["pandemic influenza virus", "SPECIES", 64, 88], ["infection", "PROBLEM", 20, 29], ["Ebola virus", "PROBLEM", 37, 48], ["MERS", "PROBLEM", 50, 54], ["CoV", "PROBLEM", 55, 58], ["pandemic influenza virus", "PROBLEM", 64, 88], ["emerging infections", "PROBLEM", 168, 187], ["infection", "OBSERVATION", 20, 29], ["Ebola virus", "OBSERVATION", 37, 48], ["influenza virus", "OBSERVATION", 73, 88]]], ["As outlined above, GOF research plays a significant role in ensuring that clinicians have the tools they need to respond to infectious disease outbreaks.", [["infectious disease outbreaks", "PROBLEM", 124, 152]]], ["As recent lapses at highprofile laboratories have illustrated, there remains the potential that bacterial and viral strains can escape even the most secure environments.", [["recent lapses at highprofile laboratories", "PROBLEM", 3, 44], ["bacterial and viral strains", "PROBLEM", 96, 123], ["bacterial", "OBSERVATION_MODIFIER", 96, 105], ["viral strains", "OBSERVATION", 110, 123]]]], "9cce4e912a4c2d4dc522dac1f147cf24cf8ef459": [["IntroductionIn December 2019, a disease, later named COVID-19, was identified in Wuhan of China and within 3 months more than 100 countries have been affected by devastating consequences (Wang and Su 2020) .", [["a disease", "PROBLEM", 30, 39]]], ["On 11 March 2020, it was found that the spread of COVID-19 is caused by the new Coronavirus SARS-CoV-2 and it was announced as a pandemic (Figueiredo et al. 2020 ).", [["COVID-19", "CHEMICAL", 50, 58], ["SARS", "DISEASE", 92, 96], ["Coronavirus SARS-CoV-2", "ORGANISM", 80, 102], ["COVID-19", "SPECIES", 50, 58], ["Coronavirus SARS-CoV", "SPECIES", 80, 100], ["COVID", "TEST", 50, 55], ["the new Coronavirus SARS", "PROBLEM", 72, 96], ["CoV", "TEST", 97, 100]]], ["The first confirmed case of COVID-19 in India was identified on 30 January 2020 in Kerala and hiked to three by 3 February when three students returned from Wuhan, China, and the first death was recorded on 12 March.", [["death", "DISEASE", 185, 190], ["COVID", "TEST", 28, 33]]], ["Till 3 May 2020, the cumulative number of total infection by COVID-19 was more than forty thousand across India (GOI 2020) .", [["infection", "DISEASE", 48, 57], ["total infection", "PROBLEM", 42, 57], ["COVID", "TEST", 61, 66], ["total", "OBSERVATION_MODIFIER", 42, 47], ["infection", "OBSERVATION", 48, 57]]], ["West Bengal the fourth-most densely inhabited state in the country recorded the first positive case of COVID-19 on 17 March 2020 after a UK-returned student was tested positive.", [["COVID", "TEST", 103, 108], ["a UK", "TEST", 135, 139]]], ["To avert the infection, countries have strictly restricted the movement of people and transportation, reducing human interactions, enforcing strict quarantine, prohibiting large-scale private and public gatherings, encouraging social-distancing, and restricting private and public transportations and economic behaviour (Fernandes 2020; He et al. 2020; Wang and Su 2020) .IntroductionIndia has been following a nationwide lockdown since 24 March 2020, which was initiated with a voluntary public curfew on 22 March, followed by a 21-day lockdown starting from 24 March.", [["infection", "DISEASE", 13, 22], ["people", "ORGANISM", 75, 81], ["human", "ORGANISM", 111, 116], ["people", "SPECIES", 75, 81], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["the infection", "PROBLEM", 9, 22], ["infection", "OBSERVATION", 13, 22]]], ["Lockdown of the production sectors, restriction on human mobility, and controlled public transportation system have resulted in the lowering of emission of pollutants.", [["human", "ORGANISM", 51, 56], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["the production sectors", "TREATMENT", 12, 34], ["human mobility", "TREATMENT", 51, 65]]], ["Studies by various scholars have shown how the lockdown has improved the ambient air quality, like in India (Gautam 2020; Mahato et al. 2020; Sikarwar and Rani 2020; Srivastava et al. 2020) , the USA (Berman and Ebisu 2020), Mexico (M\u00e9ndez-Arriaga 2020), Kazakhstan (Kerimray et al. 2020) , Iran (Abdul Halim et al. 2018) , China (Fan et al. 2020; Zambrano-monserrate et al. 2020 ) especially in Wuhan (Cole et al. 2020; Lu et al. 2020; Sicard et al. 2020; Song et al. 2016; Wang and Su 2020) , Barcelona in Spain (Tob\u00edas et al. 2020) , Sao-Paulo in Brazil (Nakada and Urban 2020) , Milan in Italy (Collivignarelli et al. 2020) , and Sal\u00e9 City in Morocco (Otmani et al. 2020) .IntroductionIn India, air pollution has become a topic of intense debate at all levels mainly because of the enhanced anthropogenic activities, e.g. rapid urbanization, higher population growth, increased energy consumption, vehicular emission, and industrial emission (Dadhich et al. 2018; Ghose et al. 2005; Gupta et al. 2008) .", [["Mexico (M\u00e9ndez-Arriaga", "TREATMENT", 225, 247], ["Zambrano", "TREATMENT", 348, 356], ["the enhanced anthropogenic activities", "PROBLEM", 782, 819], ["higher population growth", "PROBLEM", 846, 870], ["increased energy consumption", "PROBLEM", 872, 900], ["vehicular emission", "PROBLEM", 902, 920], ["air pollution", "OBSERVATION", 699, 712], ["anthropogenic activities", "OBSERVATION", 795, 819], ["increased", "OBSERVATION_MODIFIER", 872, 881], ["energy consumption", "OBSERVATION", 882, 900], ["vehicular emission", "OBSERVATION", 902, 920]]], ["The contribution of urban areas in the nation's GDP is gradually increasing in India (Ghose et al. 2005) .", [["GDP", "CHEMICAL", 48, 51], ["GDP", "SIMPLE_CHEMICAL", 48, 51], ["urban", "OBSERVATION_MODIFIER", 20, 25], ["areas", "OBSERVATION_MODIFIER", 26, 31], ["gradually", "OBSERVATION_MODIFIER", 55, 64], ["increasing", "OBSERVATION_MODIFIER", 65, 75]]], ["Hence, the pollution due to vehicular emission (Chowdhury 2015) , thermal power plant (Ghose et al. 2004 ), small-scale industries, industrial clusters, residential areas (Gupta et al. 2008) , and street shops (NGT) are increasing in Kolkata and Howrah.", [["vehicular emission", "PROBLEM", 28, 46], ["thermal power plant", "TREATMENT", 66, 85], ["small-scale industries", "PROBLEM", 108, 130], ["industrial clusters", "PROBLEM", 132, 151], ["NGT", "TREATMENT", 211, 214], ["vehicular emission", "OBSERVATION", 28, 46], ["small", "OBSERVATION_MODIFIER", 108, 113], ["industrial clusters", "OBSERVATION", 132, 151], ["increasing", "OBSERVATION_MODIFIER", 220, 230]]], ["Kolkata shares minimum areas for road connectivity only 6%, lesser than Mumbai and Delhi, and the encroachment of roads, on-road illegal parking adds fuel to this problem (Chakrabartty and Gupta 2014) .", [["road connectivity", "TEST", 33, 50], ["encroachment", "OBSERVATION", 98, 110]]], ["Improving economic conditions and more women's participation in outside jobs has increased the demand for private cars (Chakrabartty and Gupta 2014) .", [["women", "ORGANISM", 39, 44], ["women", "SPECIES", 39, 44], ["Improving economic conditions", "PROBLEM", 0, 29]]], ["In Kolkata vehicular emission, industrial centres and domestic sources contribute 50%, 48%, and 2% of the total pollution and heavy industries shares 56 percent and 44 percent is shared by the small-scale industries of the total industrial emission (Government of West Bengal 2019).", [["industrial centres", "OBSERVATION", 31, 49], ["small", "OBSERVATION_MODIFIER", 193, 198]]], ["This study aims to evaluate the changes in air quality in terms of pollutant concentration during the implementation of the lockdown measures considering the COVID-19 pandemic in Kolkata and Howrah, the 'twin cities' of West Bengal.Study areaKolkata at the eastern bank and Howrah at the western bank of Hooghly River are 'the twin city' of West Bengal (Fig. 1) .", [["This study", "TEST", 0, 10], ["the changes in air quality", "PROBLEM", 28, 54], ["the lockdown measures", "TREATMENT", 120, 141], ["air quality", "OBSERVATION", 43, 54], ["pollutant concentration", "OBSERVATION", 67, 90]]], ["Kolkata and Howrah rank 9th and 30th in world population ranking with a population density of 24,252 persons/km 2 and 20,817 persons/km 2 , respectively (Census of India 2011).", [["persons", "SPECIES", 101, 108], ["persons", "SPECIES", 125, 132]]], ["The population of Kolkata and Howrah is ever increasing due to population growth and labour influx (Debnath et al. 2018) .Study areaThe pollution level of Kolkata is close to Delhi and higher than that of Mumbai and Chennai in India (Roy et al. 2015) .", [["population growth", "PROBLEM", 63, 80], ["labour influx", "PROBLEM", 85, 98], ["Study area", "TEST", 122, 132]]], ["The study revealed another alarming trend that Kolkata's air quality is declining faster than that of Delhi.", [["The study", "TEST", 0, 9], ["Kolkata's air quality", "TEST", 47, 68]]], ["Kolkata and Howrah industrial belt are considered to be one of the highly industrialized Fig. 1 Location of the study area districts in West Bengal where industries like engineering, casting, steel fabrication, shipbuilding, consumer goods industries, construction pressure die casting, forging, electric installations, manufacturing of industrial electrical goods accessories, etc. are highly concentrated (Upadhyay et al. 2014) .", [["Howrah industrial belt", "TREATMENT", 12, 34], ["casting, steel fabrication", "TREATMENT", 183, 209], ["construction pressure die casting", "TREATMENT", 252, 285], ["electric installations", "TREATMENT", 296, 318], ["highly", "OBSERVATION_MODIFIER", 387, 393], ["concentrated", "OBSERVATION_MODIFIER", 394, 406]]], ["Vehicular emissions from continuously increasing vehicles contribute a large in polluting air, and the number has increased 8 times from 1951 to 2001 (Chowdhury 2015) .", [["Vehicular emissions", "PROBLEM", 0, 19], ["continuously increasing vehicles", "PROBLEM", 25, 57], ["a large in polluting air", "PROBLEM", 69, 93], ["continuously", "OBSERVATION_MODIFIER", 25, 37], ["increasing", "OBSERVATION_MODIFIER", 38, 48], ["large", "OBSERVATION_MODIFIER", 71, 76], ["polluting air", "OBSERVATION", 80, 93], ["number", "OBSERVATION_MODIFIER", 103, 109], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["8 times", "OBSERVATION_MODIFIER", 124, 131]]], ["After the implementation of various measures still, vehicular emission is very high and threatening at traffic intersections in Kolkata (Ghose et al. 2004 (Ghose et al. , 2005 .", [["various measures", "TREATMENT", 28, 44], ["vehicular emission", "TEST", 52, 70], ["high", "OBSERVATION_MODIFIER", 79, 83]]], ["The northern part of Kolkata is mainly characterized by the residential areas, small-scale industries, and Cossipore thermal power station and is surrounded by Hooghly River.", [["residential", "OBSERVATION_MODIFIER", 60, 71], ["areas", "OBSERVATION_MODIFIER", 72, 77], ["small", "OBSERVATION_MODIFIER", 79, 84], ["-scale", "OBSERVATION_MODIFIER", 84, 90]]], ["The location of Dhapa dumping ground and east Kolkata wetland impacts the ambient air quality in the eastern part as well as the small-scale industries, and high traffic junctions in the central Kolkata pollute the air (Gupta et al. 2008) .", [["Dhapa dumping ground", "PROBLEM", 16, 36], ["dumping ground", "OBSERVATION", 22, 36], ["ambient", "OBSERVATION_MODIFIER", 74, 81], ["air quality", "OBSERVATION", 82, 93], ["small", "OBSERVATION_MODIFIER", 129, 134], ["high", "OBSERVATION_MODIFIER", 157, 161], ["traffic junctions", "OBSERVATION", 162, 179], ["central", "ANATOMY_MODIFIER", 187, 194], ["air", "ANATOMY", 215, 218]]], ["Due to densely distributed small-scale industries without any pollution controlling measures, unplanned traffic flow, and congestion, Howrah city is to endure higher pollution of ambient air (Upadhyay et al. 2014) .Study areaUrban morphology differs from north Kolkata to south.", [["congestion", "DISEASE", 122, 132], ["densely distributed small-scale industries", "PROBLEM", 7, 49], ["congestion", "PROBLEM", 122, 132], ["densely", "OBSERVATION_MODIFIER", 7, 14], ["distributed", "OBSERVATION_MODIFIER", 15, 26], ["small", "OBSERVATION_MODIFIER", 27, 32], ["-scale", "OBSERVATION_MODIFIER", 32, 38], ["flow", "OBSERVATION_MODIFIER", 112, 116], ["congestion", "OBSERVATION", 122, 132]]], ["North Kolkata is condensed with old buildings and the roads which are very narrow and traffic congestion is another problem but high-rise buildings, highways with more space, and traffic congestion can only be noticed during office hours in the southern Kolkata (Mondal et al. 2000) .", [["congestion", "DISEASE", 94, 104], ["congestion", "DISEASE", 187, 197], ["traffic congestion", "PROBLEM", 86, 104], ["traffic congestion", "PROBLEM", 179, 197], ["very", "OBSERVATION_MODIFIER", 70, 74], ["narrow", "OBSERVATION_MODIFIER", 75, 81], ["congestion", "OBSERVATION", 94, 104], ["high", "OBSERVATION_MODIFIER", 128, 132], ["rise", "OBSERVATION_MODIFIER", 133, 137], ["congestion", "OBSERVATION", 187, 197]]], ["Small-scale industries (Datta et al. 2016) , burning ghats, thermal power stations (Chowdhury 2015) contribute a lot to the level of pollution in both Kolkata and Howrah municipal corporation.", [["Small-scale industries", "PROBLEM", 0, 22], ["-scale", "OBSERVATION_MODIFIER", 5, 11]]], ["Major clusters of polluting sites in Kolkata are Pyrabagan, Maniktala (Battery Patti), Topsia, Picnic Garden, Tangra-Tijalia-Topsia (Charma Patti), Tangra-Kill Khana-Pangladanga, Hazra-Ritchie Road, Raja Bazar, Khiddapore-Garden Reach-Metiabruz, Cossipore-Chitpur, Bowbazar, Mullick Bazar, Jadubabur Bazar, Maniktala-PhoolBagan, Taratola Industrial Estate, Dhapa Landfills, MollarBheri, etc. (Datta et al. 2016) .", [["Pyrabagan", "TREATMENT", 49, 58], ["Topsia", "TEST", 87, 93], ["Tangra", "TEST", 110, 116], ["Tijalia", "TEST", 117, 124], ["Tangra", "TEST", 148, 154], ["Khana", "TEST", 160, 165], ["Pangladanga", "TREATMENT", 166, 177], ["Khiddapore", "TREATMENT", 211, 221], ["Metiabruz", "TREATMENT", 235, 244], ["Cossipore", "TREATMENT", 246, 255], ["Chitpur", "TREATMENT", 256, 263], ["Bowbazar", "TREATMENT", 265, 273], ["Mullick Bazar", "TREATMENT", 275, 288], ["Jadubabur Bazar", "TREATMENT", 290, 305], ["Maniktala", "TREATMENT", 307, 316], ["PhoolBagan", "TREATMENT", 317, 327], ["Dhapa Landfills", "TREATMENT", 357, 372], ["clusters", "OBSERVATION_MODIFIER", 6, 14], ["polluting sites", "OBSERVATION", 18, 33]]], ["Based on health effects and level of pollution, Central Pollution Control Board categorized the industrial activities in red, orange, green, and white aiming to control the level of pollution and understand the pattern of industries under section 18(1) (b) of water (Prevention and control of pollution) (West Bengal Pollution Control Board 1981) .", [["level of pollution", "TREATMENT", 28, 46], ["Central Pollution Control Board", "TREATMENT", 48, 79], ["water (Prevention", "TREATMENT", 260, 277]]], ["Air quality is monitored automatically at six points in Kolkata Municipal Corporation, one at Bidhannagar and three locations in Howrah Municipal Corporation.Study areaBallygunge Ballygunge is situated at the central part of KMC, and this area is known for condensed small-scale industries.", [["Study areaBallygunge", "TEST", 158, 178], ["condensed small-scale industries", "PROBLEM", 257, 289], ["central", "ANATOMY_MODIFIER", 209, 216], ["small", "OBSERVATION_MODIFIER", 267, 272], ["scale industries", "OBSERVATION", 273, 289]]], ["It has recorded a high pollution level due to major road intersections near like Park Circus Seven Point Crossing, Gariahat, Rashbehari, and Hazara More (Chowdhury 2015) .", [["a high pollution level", "PROBLEM", 16, 38]]], ["Tannery processing industries of Park circus and Kustia are adjoined to the station as an important industrial cluster.Study areaFort William and Victoria This part is situated in the western part of Kolkata near Hooghly River, and the main source of pollution is vehicular emission.", [["Kustia", "CHEMICAL", 49, 55], ["Park circus", "OBSERVATION", 33, 44], ["industrial cluster", "OBSERVATION", 100, 118], ["main", "OBSERVATION_MODIFIER", 236, 240], ["pollution", "OBSERVATION", 251, 260], ["vehicular emission", "OBSERVATION", 264, 282]]], ["The major roads those have connected this area with the other part of Kolkata are Khidirpur Road, Acharya Jagadish Chandra Bose Road, and Jawaharlal Nehru Road also Esplanade is another important traffic intersection.Study areaJadavpur Jadavpur where vehicular emission is very important is another automated station which is located in the southern part of the study area.", [["Bose Road", "OBSERVATION", 123, 132], ["vehicular emission", "OBSERVATION", 251, 269]]], ["Jadavpur is highly connected by roads and highly congested, and the major traffic intersections are the intersection of King Anwar Shah and Gariahat road and the flyovers near the K8 bus stand.", [["K8", "PROTEIN", 180, 182], ["Jadavpur", "TREATMENT", 0, 8], ["highly", "OBSERVATION_MODIFIER", 42, 48], ["congested", "OBSERVATION", 49, 58], ["major", "OBSERVATION_MODIFIER", 68, 73], ["traffic intersections", "OBSERVATION", 74, 95]]], ["The queue of the vehicles is seen from South City Mall to Jadavpur PS in the morning from 8.00 am to 11 am and in the afternoon as well as night from 7.30 to 8.30 and 9.00 pm (Nandi 2017) .Study areaRabindra Sarovar Rabindra Sarovar Station is located at the central Kolkata and is affected by high vehicular emission due to the high traffic intersections and roads like Tallygaunge Phari (Chowdhury 2015) .", [["Jadavpur PS", "TEST", 58, 69], ["Study", "TEST", 189, 194], ["central", "ANATOMY_MODIFIER", 259, 266], ["high", "OBSERVATION_MODIFIER", 294, 298], ["vehicular emission", "OBSERVATION", 299, 317]]], ["Goal Park is the intersection of Gariahat Road and Dr. MeghnathSaha Road, the intersection of Debika Kumar road and Baroj Road, Rashbihari, and Hazra intersection are major traffic intersection.Study areaRabindra Bharati University (RBU) This station is the northernmost among the other stations in KMC.", [["major", "OBSERVATION_MODIFIER", 167, 172], ["traffic intersection", "OBSERVATION", 173, 193]]], ["An important entry point in Kolkata is Vivekananda Setu, and the road is always congested with loaded trucks (Ghose et al. 2005 ) and also it is influenced by the nearby Cossipore thermal power station, high traffic congestion, electro-plating industry, and dyeing industry (Karar et al. 2006) , Gold smelting stations (red category industry), and burning ghats are important sources of pollution near RBU (Ghose et al. 2005) .Study areaBidhannagar Bidhannagar is one of the busiest areas.", [["high traffic congestion", "PROBLEM", 203, 226], ["electro-plating industry", "TREATMENT", 228, 252], ["burning ghats", "PROBLEM", 348, 361], ["congested", "OBSERVATION", 80, 89], ["high", "OBSERVATION_MODIFIER", 203, 207], ["traffic congestion", "OBSERVATION", 208, 226]]], ["The location of the administrative centres of West Bengal near Salt Lake is connected through Biddhannagar Road Railway Station which is a reason for higher traffic as well as human mobility in this part.", [["human", "ORGANISM", 176, 181], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 176, 181]]], ["Uncontrolled traffic movement, a higher number of auto-rickshaw, bus, and taxi are very important for traffic congestion.Study areaIn Howrah Municipal Corporation, only three automated stations among which Belur Math is located in the northern part of HMC, Ghusuri near Liluah Station, and Padmapukur at the southern part of HMC are set to record pollutants' data.", [["congestion", "DISEASE", 110, 120], ["HMC", "CELL", 325, 328], ["Uncontrolled traffic movement", "PROBLEM", 0, 29], ["traffic congestion", "PROBLEM", 102, 120], ["traffic movement", "OBSERVATION", 13, 29], ["congestion", "OBSERVATION", 110, 120]]], ["Howrah is an industrial centre in West Bengal, and unplanned growth of the city and squatter settlement are responsible for relatively higher pollution in Howrah, West Bengal.Study areaBelur Math The station is located at the northernmost part of HMC and affected by the nearby manufacturing industries like aluminium production, plastic production, chemical industries, and electronics.", [["aluminium", "CHEMICAL", 308, 317], ["aluminium", "CHEMICAL", 308, 317], ["aluminium", "SIMPLE_CHEMICAL", 308, 317], ["aluminium production", "PROBLEM", 308, 328], ["aluminium production", "OBSERVATION", 308, 328]]], ["Within 200 m of radius, the Belur Bazar traffic intersection and Belur Bus terminus are the important traffic intersection and the two main roads that have crossed from the eastern and the western part of the station are Al Banerjee Road and Girish Ghosh Road and another important road is Ramlochan Street.Study areaGhusuri Ghusuri has its name in history as an industrial centre in West Bengal.", [["Belur Bus terminus", "PROTEIN", 65, 83], ["radius", "ANATOMY", 16, 22]]], ["This part is now famous for plastic and aluminium industries which are categorized as the 'red' by WBPCB, 2018.", [["aluminium", "CHEMICAL", 40, 49], ["aluminium", "CHEMICAL", 40, 49], ["plastic and aluminium industries", "TREATMENT", 28, 60]]], ["Highly condensed settlement patterns are mainly characterized by squatter settlement.Study areaPadmapukur Padmapukur is the southernmost station in HMC.", [["HMC", "CELL", 148, 151], ["HMC", "CELL_LINE", 148, 151], ["settlement patterns", "OBSERVATION", 17, 36]]], ["The level of pollution is relatively higher in this part, an intersection of Andul Road, NH 117, Botanical Garden road.Data sourcesTo study the changes in air quality during the lockdown period, the data from ten monitoring sites in Kolkata Municipal Corporation (KMC), as well as in Howrah Municipal Corporation (HMC) ( Table 1) , are taken into consideration.", [["the data", "TEST", 195, 203], ["pollution", "OBSERVATION", 13, 22], ["relatively", "OBSERVATION_MODIFIER", 26, 36], ["higher", "OBSERVATION_MODIFIER", 37, 43], ["Garden road", "OBSERVATION", 107, 118], ["air quality", "OBSERVATION", 155, 166]]], ["Monitoring station Bidhannagar is considered for spatial mapping purposes only for better understanding and excluded from all the statistical analysis because the eastern part is only covered by this station but does not come under KMC.", [["spatial mapping purposes", "TEST", 49, 73], ["the statistical analysis", "TEST", 126, 150]]], ["The daily concentration of seven pollutants including particulate matter (PM 2.5 and PM 10 ), nitrogen dioxides (NO 2 ), sulphur dioxide (SO 2 ), ammonia (NH 3 ) on 24 h interval on the other hand ozone (O 3 ), and carbon monoxide (CO) have been taken into consideration on an 8-h interval for air quality assessment from the Central Pollution Control Board online portal for air quality data dissemination (https ://app.cpcbc cr.com/ccr/#/caaqm -dashb oard-all/caaqm -landi ng) to give an inclusive analysis of the air quality data under the national ambient air quality standards.", [["nitrogen dioxides", "CHEMICAL", 94, 111], ["NO", "CHEMICAL", 113, 115], ["sulphur dioxide", "CHEMICAL", 121, 136], ["SO 2", "CHEMICAL", 138, 142], ["ammonia", "CHEMICAL", 146, 153], ["NH", "CHEMICAL", 155, 157], ["ozone", "CHEMICAL", 197, 202], ["O 3", "CHEMICAL", 204, 207], ["carbon monoxide", "CHEMICAL", 215, 230], ["nitrogen dioxides", "CHEMICAL", 94, 111], ["NO 2", "CHEMICAL", 113, 117], ["sulphur dioxide", "CHEMICAL", 121, 136], ["SO 2", "CHEMICAL", 138, 142], ["ammonia", "CHEMICAL", 146, 153], ["NH 3 )", "CHEMICAL", 155, 161], ["ozone", "CHEMICAL", 197, 202], ["O 3", "CHEMICAL", 204, 207], ["carbon monoxide", "CHEMICAL", 215, 230], ["CO", "CHEMICAL", 232, 234], ["nitrogen dioxides", "SIMPLE_CHEMICAL", 94, 111], ["NO 2", "SIMPLE_CHEMICAL", 113, 117], ["sulphur dioxide", "SIMPLE_CHEMICAL", 121, 136], ["SO 2", "SIMPLE_CHEMICAL", 138, 142], ["ammonia", "SIMPLE_CHEMICAL", 146, 153], ["ozone", "SIMPLE_CHEMICAL", 197, 202], ["carbon monoxide", "SIMPLE_CHEMICAL", 215, 230], ["CO", "SIMPLE_CHEMICAL", 232, 234], ["The daily concentration of seven pollutants", "TREATMENT", 0, 43], ["particulate matter (PM", "TREATMENT", 54, 76], ["nitrogen dioxides", "TREATMENT", 94, 111], ["sulphur dioxide", "TREATMENT", 121, 136], ["ammonia (NH", "TREATMENT", 146, 157], ["carbon monoxide (CO", "TREATMENT", 215, 234], ["air quality assessment", "TEST", 294, 316], ["app.cpcbc", "TEST", 417, 426], ["cr.com", "TEST", 427, 433], ["/ccr/#/caaqm", "TEST", 433, 445], ["all/caaqm -landi ng", "TREATMENT", 458, 477], ["the air quality data", "TEST", 512, 532], ["portal", "ANATOMY", 365, 371]]], ["In the AQI system PM 2.5 , PM 10 , NO 2 , SO 2 , NH 3 , CO, O 3, and Pb but here Pb is excluded because the concentration of this pollutant is not available in real time and cannot be taken into consideration for real-time AQI calculation (CPCB 2014).", [["PM 10 , NO 2 , SO 2 , NH 3 , CO, O 3, and Pb", "CHEMICAL", 27, 71], ["Pb", "CHEMICAL", 81, 83], ["NO 2", "CHEMICAL", 35, 39], ["SO 2", "CHEMICAL", 42, 46], ["NH 3", "CHEMICAL", 49, 53], ["CO", "CHEMICAL", 56, 58], ["O 3", "CHEMICAL", 60, 63], ["Pb", "CHEMICAL", 69, 71], ["Pb", "CHEMICAL", 81, 83], ["NO 2", "SIMPLE_CHEMICAL", 35, 39], ["SO 2", "SIMPLE_CHEMICAL", 42, 46], ["NH 3", "SIMPLE_CHEMICAL", 49, 53], ["CO, O 3", "SIMPLE_CHEMICAL", 56, 63], ["Pb", "SIMPLE_CHEMICAL", 69, 71], ["Pb", "SIMPLE_CHEMICAL", 81, 83], ["CO", "TEST", 56, 58], ["Pb", "TEST", 69, 71], ["Pb", "TEST", 81, 83]]], ["These data are also verified from different sources like AQI-India (https ://app.cpcbc cr.com/AQI_India /) under the Central Pollution Control Board, WBPCB (https ://emis.wbpcb .gov.in/airqu ality /JSP/aq/distr ictwi seRep ort.jsp) under West Bengal Pollution Control Board and OpenAqportal (https ://opena q.org/#/locat ion/Arya%20Nag ar,%20Bah adurg arh%20-%20HSP CB?_k=cpmf3 4).Data sourcesConcentrations of NO 2 (0.25\u00b0 level-3 (L3) daily OMI tropospheric) for the period of 22 February to 3 May of 2019 and 2020 were acquired from Giovanni interface (https ://giova nni.gsfc.nasa.gov/giova nni/), derived from the NASA Goddard EarthSciences Data Active Archive Center (GES DISC; https ://disc.sci.gsfc.nasa.gov).Data analysisThe air quality index (AQI) is a measure of the cumulative effect of individual pollutants concentration on the quality of air in different places, but the modification of the method which is termed as National Air Quality Index (NAQI) is based on the maximum operator approach to avoid the uncertainty (CPCB 2014; Dadhich et al. 2018; Joshi and Mahadev 2011; Mahato et al. 2020) .", [["NO", "CHEMICAL", 411, 413], ["NO 2", "CHEMICAL", 411, 415], ["ort", "PROTEIN", 223, 226], ["cpmf3 4", "PROTEIN", 372, 379], [".gov.in/airqu ality /JSP/aq/distr ictwi seRep ort", "SPECIES", 177, 226], ["Arya", "TEST", 325, 329], ["Nag ar", "TEST", 332, 338], ["arh", "TEST", 352, 355], ["cpmf3", "TEST", 372, 377], ["Data sourcesConcentrations", "TEST", 381, 407], ["OMI tropospheric", "TEST", 442, 458], ["nni.gsfc.nasa", "TREATMENT", 570, 583], ["Data analysis", "TEST", 716, 729], ["The air quality index", "TEST", 729, 750], ["individual pollutants concentration", "PROBLEM", 798, 833], ["the method", "TREATMENT", 901, 911], ["L3", "ANATOMY", 432, 434], ["DISC", "ANATOMY", 677, 681], ["air", "OBSERVATION_MODIFIER", 733, 736], ["quality", "OBSERVATION_MODIFIER", 737, 744], ["index", "OBSERVATION_MODIFIER", 745, 750], ["pollutants", "OBSERVATION_MODIFIER", 809, 819], ["concentration", "OBSERVATION_MODIFIER", 820, 833], ["air", "OBSERVATION", 852, 855]]], ["Central pollution control board (CPCB), India, monitors the ambient air continuously and has been using the EPA-US method to calculate the air quality indices (AQI) (Chaurasia et al. 2013; Kumar and Dash 2018) .", [["the EPA", "TEST", 104, 111]]], ["Calculation of Sub-indices for each and individual pollutant and then the aggregation of breakpoint values (sub-indices), which depend upon the Indian National Ambient Air Quality Standards (NAAQS), are the two steps involved in AQI calculation.", [["Sub-indices", "TEST", 15, 26], ["breakpoint values", "TEST", 89, 106], ["AQI calculation", "TEST", 229, 244], ["Sub", "OBSERVATION_MODIFIER", 15, 18]]], ["The maximum value of the sub-indices is taken as the AQI.", [["the sub-indices", "TEST", 21, 36], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["sub", "OBSERVATION_MODIFIER", 25, 28]]], ["The AQI standards are displayed in the number form that describes the quality rating (potential health effects) as shown in Table 2 .Data analysisAs the study is carried out in KMC and HMC, the municipal ward boundary map is designed in a GIS environment.", [["HMC", "CELL", 185, 188], ["HMC", "CELL_LINE", 185, 188], ["The AQI standards", "TREATMENT", 0, 17], ["Data analysis", "TEST", 133, 146], ["the study", "TEST", 149, 158]]], ["ArcGIS 10.3, distributed by the Environmental Systems Research Institute (ESRI), has been employed for spatial analysis to identify air pollution levels.", [["ArcGIS", "TEST", 0, 6], ["spatial analysis", "TEST", 103, 119], ["air pollution levels", "PROBLEM", 132, 152]]], ["Based on the ten monitoring sites, the interpolated maps of each pollutant and AQI have been generated from pre-lockdown tenure to during lockdown tenure.", [["the interpolated maps", "TEST", 35, 56]]], ["In this study, inverse distance weighting (IDW) interpolator by linear combination model has been used because it is easy to operate than others without any pre-program assumptions to opt for a semi-variogram model (Jumaah et al. 2019; Poshtmasari et al. 2012) .Data analysisANOVA (Two-way), cluster analysis (single linkage) based on the Euclidean distance and Ward's methods, and Pearson moment correlation coefficient (r) were computed using the IBM SPSS version23.", [["IBM SPSS version23", "DNA", 449, 467], ["this study", "TEST", 3, 13], ["inverse distance weighting (IDW) interpolator", "TREATMENT", 15, 60], ["linear combination model", "TREATMENT", 64, 88], ["a semi-variogram model", "TEST", 192, 214], ["Data analysisANOVA", "TEST", 262, 280], ["cluster analysis", "TEST", 292, 308], ["Ward's methods", "TEST", 362, 376]]], ["The ANOVA helps to understand the variation in air quality index in each location as well as in prelockdown and during lockdown tenure, while correlation analysis denotes the degree of association among the different pollutants is done using JMP 15.", [["correlation analysis", "TEST", 142, 162], ["JMP", "TREATMENT", 242, 245]]], ["Box plots are especially valid for comparing two or more distribution and also present a graphical display based on the order-statistic summaries of median and quartiles.", [["Box plots", "TEST", 0, 9]]], ["Using MS Excel line graphs for each pollutant is graphically represented.Observed concentration of the air pollutantsThe concentration of the pollutants in the study area is summarized (Table 3) to understand the changes in maximum-minimum concentration and mean concentration of the pollutants, for all the concerned recording stations of the 'twin city' for the pre-lockdown (PL) period from 22 February to 21 March and the during lockdown (DL) period from 24 March to 3 May 2020.", [["MS Excel line graphs", "TREATMENT", 6, 26], ["the air pollutants", "PROBLEM", 99, 117], ["the pre-lockdown (PL)", "TREATMENT", 360, 381], ["the during lockdown (DL)", "TREATMENT", 422, 446], ["air pollutants", "OBSERVATION", 103, 117], ["concentration", "OBSERVATION_MODIFIER", 121, 134], ["pollutants", "OBSERVATION_MODIFIER", 142, 152]]], ["The effect of PM 2.5 and PM 10 is severe on the health of people as it results in severe breathing problems as well as lung problems (Ashhar et al. 2007 ).", [["lung", "ANATOMY", 119, 123], ["PM 2.5", "CHEMICAL", 14, 20], ["lung problems", "DISEASE", 119, 132], ["people", "ORGANISM", 58, 64], ["lung", "ORGAN", 119, 123], ["people", "SPECIES", 58, 64], ["severe breathing problems", "PROBLEM", 82, 107], ["lung problems", "PROBLEM", 119, 132], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["breathing", "OBSERVATION", 89, 98], ["lung", "ANATOMY", 119, 123]]], ["Particulate matter is the most important pollutant in Kolkata, caused almost 10,000 premature deaths in Kolkata in 1995 (Kazimuddin and Banerjee 2015) .", [["deaths", "DISEASE", 94, 100]]], ["For all the stations, a sharp reduction has been noted in the concentration of PM 2.5 and PM 10 from the prelockdown to during lockdown.", [["a sharp reduction", "TREATMENT", 22, 39]]], ["The highest concentration with an amount of 149.68 \u00b5g/m 3 has been monitored at Ballygunge because the station is nearest to the Garden reach and other small-scale industrial centres in the area for PM 2.5 in Kolkata, whereas Gusuri is one of the most industrial centres in Howrah and has recorded an amount of 333.52 \u00b5g/m 3 for PM 10 in Howrah at 24 h interval as well.", [["Gusuri", "CHEMICAL", 226, 232], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["concentration", "OBSERVATION_MODIFIER", 12, 25], ["amount", "OBSERVATION_MODIFIER", 34, 40], ["small", "OBSERVATION_MODIFIER", 152, 157], ["amount", "OBSERVATION_MODIFIER", 301, 307]]], ["In the pre-lockdown tenure, the monitored amount of PM 2.5 is above the level of the AQI standards because of intensive industrial belts such as paper pulp, chemical industries, textile, rubber, and iron as well as high traffic congestion and emission from the thermal power plants which are associated with the corresponding stations (Spiroska et al. 2013 ).", [["pulp", "ANATOMY", 151, 155], ["iron", "CHEMICAL", 199, 203], ["iron", "CHEMICAL", 199, 203], ["pulp", "TISSUE", 151, 155], ["iron", "SIMPLE_CHEMICAL", 199, 203], ["intensive industrial belts", "TREATMENT", 110, 136], ["paper pulp", "PROBLEM", 145, 155], ["iron", "TREATMENT", 199, 203], ["high traffic congestion", "PROBLEM", 215, 238], ["the thermal power plants", "TREATMENT", 257, 281], ["pulp", "ANATOMY", 151, 155], ["chemical industries", "OBSERVATION", 157, 176], ["congestion", "OBSERVATION", 228, 238], ["thermal", "OBSERVATION_MODIFIER", 261, 268], ["power plants", "OBSERVATION", 269, 281]]], ["The reduction of 2.75 times of PM 10 at Ghusuri along with the mean difference between the pre-lockdown and during lockdown is 125.4 \u00b5g/m 3 .", [["The reduction", "TREATMENT", 0, 13], ["reduction", "OBSERVATION_MODIFIER", 4, 13]]], ["On the other hand, minimum concentration has been recorded at Belur Math with a mean Table 2 Proposed breakpoints for AQI scale 0-500. concentration of 41.57 (\u00b5g/m 3 ) after the imposition of lockdown.", [["AQI scale", "TEST", 118, 127], ["concentration", "TEST", 135, 148]]], ["The complete lockdown has reduced the power consumption, traffic congestion, and emission from the production units to a very minimal level.", [["traffic congestion", "PROBLEM", 57, 75], ["reduced", "OBSERVATION_MODIFIER", 26, 33], ["power consumption", "OBSERVATION", 38, 55], ["congestion", "OBSERVATION", 65, 75]]], ["The 'Red' category industries like chemical industries, plastic industries, electronic industries, etc. and jute, paper pulp industries are responsible for high emission.", [["pulp", "ANATOMY", 120, 124], ["pulp", "TISSUE", 120, 124], ["high emission", "PROBLEM", 156, 169], ["chemical industries", "OBSERVATION", 35, 54], ["pulp industries", "OBSERVATION", 120, 135]]], ["Severe degradation of air quality is also caused by NO 2 and affects health severely such as breathing problems, headache, and corrosion of teeth (Ashhar et al. 2007) .", [["teeth", "ANATOMY", 140, 145], ["NO", "CHEMICAL", 52, 54], ["breathing problems", "DISEASE", 93, 111], ["headache", "DISEASE", 113, 121], ["NO 2", "CHEMICAL", 52, 56], ["NO 2", "GENE_OR_GENE_PRODUCT", 52, 56], ["teeth", "ORGAN", 140, 145], ["Severe degradation of air quality", "PROBLEM", 0, 33], ["breathing problems", "PROBLEM", 93, 111], ["headache", "PROBLEM", 113, 121], ["corrosion of teeth", "PROBLEM", 127, 145], ["air quality", "OBSERVATION", 22, 33], ["teeth", "ANATOMY", 140, 145]]], ["It is emitted from both the natural sources of the nitrogen cycle by the process of biological processes, lighting effect, and the anthropogenic sources as vehicular emission from the highly congested traffic flow (Ibe et al. 2020) .", [["nitrogen", "CHEMICAL", 51, 59], ["the nitrogen cycle", "TREATMENT", 47, 65], ["vehicular emission", "TEST", 156, 174], ["the highly congested traffic flow", "PROBLEM", 180, 213], ["vehicular emission", "OBSERVATION", 156, 174], ["highly", "OBSERVATION_MODIFIER", 184, 190], ["congested", "OBSERVATION", 191, 200]]], ["During weekends, average traffic flow is 2.3 \u00d7 10 4 and it is raised to 2.8 \u00d7 10 4 during weekdays near industrial centres in Kolkata (Gupta et al. 2008) .", [["average traffic flow", "TEST", 17, 37]]], ["From studies, it has been found that the NO 2 concentration is double than of the CPCB standard of 60 in the residential areas (Bhattacharjee 2008) .", [["NO", "CHEMICAL", 41, 43], ["NO 2", "CHEMICAL", 41, 45], ["NO 2", "GENE_OR_GENE_PRODUCT", 41, 45]]], ["The highest concentration of NO 2 has been recorded at Belur Math in HMC and a reduction of 3.24 times during lockdown from the pre-lockdown phase.", [["NO", "CHEMICAL", 29, 31], ["NO 2", "CHEMICAL", 29, 33], ["NO 2", "GENE_OR_GENE_PRODUCT", 29, 33], ["HMC", "CELL_LINE", 69, 72], ["a reduction", "TREATMENT", 77, 88], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["concentration", "OBSERVATION_MODIFIER", 12, 25]]], ["The minimum value is recorded during the lockdown period at Padmapukur, HMC.", [["HMC", "CELL_LINE", 72, 75], ["The minimum value", "TEST", 0, 17], ["minimum", "OBSERVATION_MODIFIER", 4, 11]]], ["During the complete lockdown period, Belur Math has recorded the highest concentration and followed by Victoria, Fort William, Ghusuri, Rabindra Bharati, Padmapukur, Jadavpur, Ballygunge, and Rabindra Sarovar.", [["Rabindra Bharati", "TREATMENT", 136, 152], ["Padmapukur", "TREATMENT", 154, 164], ["Jadavpur", "TREATMENT", 166, 174], ["Ballygunge", "TREATMENT", 176, 186], ["Rabindra Sarovar", "TREATMENT", 192, 208]]], ["SO 2 with a higher amount may cause death only if anyone is already suffering from previous respiratory problems like emphysema and the effect is more on the older people than young people (Ashhar et al. 2007) .Observed concentration of the air pollutantsSO 2 as an atmospheric gas is released when coal is burnt, decaying of grassland or vegetation, volcanoes, and ocean.", [["respiratory", "ANATOMY", 92, 103], ["death", "DISEASE", 36, 41], ["respiratory problems", "DISEASE", 92, 112], ["emphysema", "DISEASE", 118, 127], ["SO 2", "CHEMICAL", 255, 259], ["coal", "CHEMICAL", 299, 303], ["SO 2", "GENE_OR_GENE_PRODUCT", 0, 4], ["people", "ORGANISM", 164, 170], ["people", "ORGANISM", 182, 188], ["people", "SPECIES", 164, 170], ["people", "SPECIES", 182, 188], ["death", "PROBLEM", 36, 41], ["previous respiratory problems", "PROBLEM", 83, 112], ["emphysema", "PROBLEM", 118, 127], ["the air pollutants", "PROBLEM", 237, 255], ["an atmospheric gas", "TEST", 263, 281], ["grassland", "PROBLEM", 326, 335], ["vegetation", "PROBLEM", 339, 349], ["respiratory", "ANATOMY", 92, 103], ["emphysema", "OBSERVATION", 118, 127], ["concentration", "OBSERVATION_MODIFIER", 220, 233], ["air pollutants", "OBSERVATION", 241, 255], ["vegetation", "OBSERVATION", 339, 349]]], ["It is a precursor of acid rain in the form of sulphuric acid (H 2 SO 4 ), deposits in the surface and sub-surface, and also in oxidized form as sulphate having a dominating role in 'radiative forcing' of climate (Cox 2003; Wang et al. 2006) .", [["surface", "ANATOMY", 90, 97], ["surface", "ANATOMY", 106, 113], ["sulphuric acid", "CHEMICAL", 46, 60], ["H 2 SO 4", "CHEMICAL", 62, 70], ["sulphate", "CHEMICAL", 144, 152], ["sulphuric acid", "CHEMICAL", 46, 60], ["H 2 SO 4", "CHEMICAL", 62, 70], ["sulphate", "CHEMICAL", 144, 152], ["sulphuric acid", "SIMPLE_CHEMICAL", 46, 60], ["H 2 SO 4", "SIMPLE_CHEMICAL", 62, 70], ["surface", "CELLULAR_COMPONENT", 90, 97], ["sulphate", "SIMPLE_CHEMICAL", 144, 152], ["acid rain", "PROBLEM", 21, 30], ["sulphuric acid", "TREATMENT", 46, 60], ["deposits in the surface", "PROBLEM", 74, 97], ["sulphuric acid", "OBSERVATION", 46, 60], ["deposits", "OBSERVATION", 74, 82], ["surface", "ANATOMY_MODIFIER", 90, 97], ["sub", "OBSERVATION_MODIFIER", 102, 105], ["surface", "ANATOMY_MODIFIER", 106, 113]]], ["From the study, it has been found that 60%, 36%, and 7.8% are released from transport, industrial, transport, and other activities share very little in India (Garg et al. 2001 ).", [["the study", "TEST", 5, 14]]], ["The concentration of SO2 tends to be higher during the high traffic hours in urban areas (Gaur et al. 2014) .", [["SO2", "CHEMICAL", 21, 24], ["SO2", "CHEMICAL", 21, 24], ["SO2", "SIMPLE_CHEMICAL", 21, 24], ["The concentration of SO2", "TREATMENT", 0, 24], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["higher", "OBSERVATION_MODIFIER", 37, 43]]], ["A four-time reduction in mean concentration is noted from pre-lockdown to during the lockdown period at Ghusuri in HMC.Observed concentration of the air pollutantsOzone is produced and directly emitted because of reactions among nitrogen oxide (primary pollutant), certain organic compounds, and precursor of methane (CH 4 ) mixed in the air under the influence of ultraviolet rays (Arbilla et al. 2002) .", [["Ozone", "CHEMICAL", 163, 168], ["nitrogen oxide", "CHEMICAL", 229, 243], ["methane", "CHEMICAL", 309, 316], ["CH 4", "CHEMICAL", 318, 322], ["Ozone", "CHEMICAL", 163, 168], ["nitrogen oxide", "CHEMICAL", 229, 243], ["methane", "CHEMICAL", 309, 316], ["CH 4", "CHEMICAL", 318, 322], ["HMC", "CELL", 115, 118], ["Ozone", "SIMPLE_CHEMICAL", 163, 168], ["nitrogen oxide", "SIMPLE_CHEMICAL", 229, 243], ["methane", "SIMPLE_CHEMICAL", 309, 316], ["HMC", "CELL_LINE", 115, 118], ["A four-time reduction", "TREATMENT", 0, 21], ["mean concentration", "PROBLEM", 25, 43], ["the air pollutants", "PROBLEM", 145, 163], ["reactions", "PROBLEM", 213, 222], ["nitrogen oxide", "TREATMENT", 229, 243], ["certain organic compounds", "PROBLEM", 265, 290], ["precursor of methane (CH", "TREATMENT", 296, 320], ["ultraviolet rays", "TREATMENT", 365, 381], ["four-time", "OBSERVATION_MODIFIER", 2, 11], ["reduction", "OBSERVATION_MODIFIER", 12, 21], ["mean concentration", "OBSERVATION", 25, 43], ["air pollutants", "OBSERVATION", 149, 163], ["organic compounds", "OBSERVATION", 273, 290], ["air", "ANATOMY", 338, 341]]], ["The lifespan of ozone varies from an hour to a day in the normal situation but in the polluted urban atmosphere, it may vary from day to week.", [["ozone", "CHEMICAL", 16, 21], ["ozone", "CHEMICAL", 16, 21], ["ozone", "SIMPLE_CHEMICAL", 16, 21], ["lifespan", "OBSERVATION_MODIFIER", 4, 12], ["ozone", "OBSERVATION_MODIFIER", 16, 21]]], ["Temperature affects the formation of ozone and also the magnitudes of concentration in the atmosphere because the decreasing temperature results in the decomposition of the precursors as well as the high solar radiation amplifies the production of ozone in the atmosphere (Pulikesi et al. 2006 ).", [["ozone", "CHEMICAL", 37, 42], ["ozone", "CHEMICAL", 248, 253], ["ozone", "CHEMICAL", 37, 42], ["ozone", "CHEMICAL", 248, 253], ["ozone", "SIMPLE_CHEMICAL", 37, 42], ["ozone", "SIMPLE_CHEMICAL", 248, 253], ["the decreasing temperature", "PROBLEM", 110, 136], ["the high solar radiation", "TREATMENT", 195, 219], ["decreasing", "OBSERVATION_MODIFIER", 114, 124], ["high", "OBSERVATION_MODIFIER", 199, 203], ["solar radiation", "OBSERVATION", 204, 219], ["ozone", "OBSERVATION_MODIFIER", 248, 253]]], ["Victoria and its adjoining areas are prominent for the concentration of O 3 , which varies from 10.1 to 92.60 \u00b5g/m 3 in the pre-lockdown period but the concentration has hiked to 24.02-108.53 \u00b5g/m 3 in the during lockdown period.Observed concentration of the air pollutantsNO, as a harmless gas is directly emitted from the vehicle (85-87.5) and then transformed into NO 2 in reaction with the O 3 and the other nitrogen compounds by other chemical processes, the combination of NO 2 and NO is known as NOx (Palmgren et al. 1996) .", [["NO", "CHEMICAL", 273, 275], ["NO", "CHEMICAL", 368, 370], ["NO", "CHEMICAL", 479, 481], ["NO", "CHEMICAL", 488, 490], ["NOx", "CHEMICAL", 503, 506], ["O 3", "CHEMICAL", 72, 75], ["NO", "CHEMICAL", 273, 275], ["NO 2", "CHEMICAL", 368, 372], ["O 3", "CHEMICAL", 394, 397], ["nitrogen", "CHEMICAL", 412, 420], ["NO 2", "CHEMICAL", 479, 483], ["NO", "CHEMICAL", 488, 490], ["NOx", "CHEMICAL", 503, 506], ["NO", "SIMPLE_CHEMICAL", 273, 275], ["NO 2", "SIMPLE_CHEMICAL", 368, 372], ["O 3", "SIMPLE_CHEMICAL", 394, 397], ["nitrogen compounds", "SIMPLE_CHEMICAL", 412, 430], ["NO 2", "SIMPLE_CHEMICAL", 479, 483], ["NO", "SIMPLE_CHEMICAL", 488, 490], ["NOx", "SIMPLE_CHEMICAL", 503, 506], ["the concentration", "TEST", 148, 165], ["the air pollutants", "PROBLEM", 255, 273], ["a harmless gas", "PROBLEM", 280, 294], ["adjoining", "OBSERVATION_MODIFIER", 17, 26], ["areas", "OBSERVATION_MODIFIER", 27, 32], ["prominent", "OBSERVATION_MODIFIER", 37, 46], ["concentration", "OBSERVATION_MODIFIER", 238, 251], ["air pollutants", "OBSERVATION", 259, 273]]], ["The ratio between NO and NOx is very important and known as the 'Leighton ratio' in the atmosphere and controls the magnitude of O 3 (Leighton 1962) .Observed concentration of the air pollutantsOzone concentration has been hiked because ozone can be degraded and regenerated by NO x and more degradation is associated with urban areas where local scale ozone depletion is found near high NO x emitting zone (Arbilla et al. 2002) .", [["NO", "CHEMICAL", 18, 20], ["NOx", "CHEMICAL", 25, 28], ["Ozone", "CHEMICAL", 194, 199], ["ozone", "CHEMICAL", 237, 242], ["NO", "CHEMICAL", 278, 280], ["ozone", "CHEMICAL", 353, 358], ["NO", "CHEMICAL", 388, 390], ["NO", "CHEMICAL", 18, 20], ["NOx", "CHEMICAL", 25, 28], ["O 3", "CHEMICAL", 129, 132], ["Ozone", "CHEMICAL", 194, 199], ["ozone", "CHEMICAL", 237, 242], ["NO", "CHEMICAL", 278, 280], ["ozone", "CHEMICAL", 353, 358], ["NO", "CHEMICAL", 388, 390], ["NO", "SIMPLE_CHEMICAL", 18, 20], ["NOx", "SIMPLE_CHEMICAL", 25, 28], ["Ozone", "SIMPLE_CHEMICAL", 194, 199], ["ozone", "SIMPLE_CHEMICAL", 237, 242], ["NO", "SIMPLE_CHEMICAL", 278, 280], ["ozone", "SIMPLE_CHEMICAL", 353, 358], ["The ratio", "TEST", 0, 9], ["the 'Leighton ratio'", "TREATMENT", 60, 80], ["the air pollutants", "PROBLEM", 176, 194], ["Ozone concentration", "PROBLEM", 194, 213], ["local scale ozone depletion", "TREATMENT", 341, 368], ["air pollutants", "OBSERVATION", 180, 194], ["ozone depletion", "OBSERVATION", 353, 368]]], ["During the lockdown period, the emission of NO 2 is reduced and has limited the degeneration process of ozone, results in continuous hiking of ozone in the atmosphere.Observed concentration of the air pollutantsCO is a trace gas, emitted due to incomplete combustion of fossil fuel and reaction among oxidation of hydrocarbons, volatile organic compounds, and methane, also from the vehicle, industrial hubs, open burning as well as aircraft emission (Jaffe 2012 ) and wood fires (Aneja et al. 2001; Gaur et al. 2014; Njoku et al. 2016 ).", [["NO", "CHEMICAL", 44, 46], ["ozone", "CHEMICAL", 104, 109], ["ozone", "CHEMICAL", 143, 148], ["pollutantsCO", "CHEMICAL", 201, 213], ["methane", "CHEMICAL", 360, 367], ["NO 2", "CHEMICAL", 44, 48], ["ozone", "CHEMICAL", 104, 109], ["ozone", "CHEMICAL", 143, 148], ["pollutantsCO", "CHEMICAL", 201, 213], ["hydrocarbons", "CHEMICAL", 314, 326], ["methane", "CHEMICAL", 360, 367], ["NO 2", "SIMPLE_CHEMICAL", 44, 48], ["ozone", "SIMPLE_CHEMICAL", 104, 109], ["ozone", "SIMPLE_CHEMICAL", 143, 148], ["pollutantsCO", "SIMPLE_CHEMICAL", 201, 213], ["hydrocarbons", "SIMPLE_CHEMICAL", 314, 326], ["volatile organic compounds", "SIMPLE_CHEMICAL", 328, 354], ["methane", "SIMPLE_CHEMICAL", 360, 367], ["the degeneration process of ozone", "PROBLEM", 76, 109], ["the air pollutantsCO", "PROBLEM", 193, 213], ["a trace gas", "PROBLEM", 217, 228], ["fossil fuel", "PROBLEM", 270, 281], ["open burning", "PROBLEM", 409, 421], ["reduced", "OBSERVATION_MODIFIER", 52, 59], ["degeneration", "OBSERVATION", 80, 92], ["ozone", "OBSERVATION_MODIFIER", 104, 109], ["concentration", "OBSERVATION_MODIFIER", 176, 189], ["air pollutantsCO", "OBSERVATION", 197, 213], ["trace", "OBSERVATION_MODIFIER", 219, 224], ["gas", "OBSERVATION", 225, 228], ["combustion", "OBSERVATION", 256, 266], ["fossil fuel", "OBSERVATION", 270, 281], ["hydrocarbons", "OBSERVATION_MODIFIER", 314, 326], ["volatile", "OBSERVATION_MODIFIER", 328, 336], ["organic compounds", "OBSERVATION", 337, 354]]], ["The diurnal pattern varies highly based on human activities in urban centres (Jaffe 2012) .", [["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["The diurnal pattern", "TEST", 0, 19], ["diurnal", "OBSERVATION_MODIFIER", 4, 11], ["pattern", "OBSERVATION_MODIFIER", 12, 19], ["varies", "OBSERVATION_MODIFIER", 20, 26], ["highly", "OBSERVATION_MODIFIER", 27, 33]]], ["National Green Tribunal (2019) reported that street food stalls on footpaths use charcoal, dump cake, and other materials as fuel are the sources of severe pollution in Kolkata.", [["charcoal", "CHEMICAL", 81, 89], ["charcoal", "TREATMENT", 81, 89], ["dump cake", "TREATMENT", 91, 100], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["pollution", "OBSERVATION", 156, 165]]], ["Victoria has recorded the highest concentration of CO that ranges from 0.44 to 2.28 mg/m 3 in the pre-lockdown phase and is reduced to 0.44-1.77 mg/m 3 .", [["CO", "CHEMICAL", 51, 53], ["CO", "SIMPLE_CHEMICAL", 51, 53]]], ["During the pre-lockdown phase, the highest concentration is found in Victoria because the vehicle is very important source of CO, and the traffic intersections near Victoria contribute a lot to the atmosphere.", [["CO", "CHEMICAL", 126, 128], ["CO", "SIMPLE_CHEMICAL", 126, 128]]], ["Hence, the minimum concentrated zone of CO is Rabindra Bharati.Observed concentration of the air pollutantsNH 3 is an alkynes gas, emitted from both the anthropogenic processes (animal waste, fertilizer, waste management, vehicular emission, incomplete burning of homecooking fuel, and dumping stations) and atmospheric processes (Fenn et al. 2018) .", [["pollutantsNH", "CHEMICAL", 97, 109], ["CO", "CHEMICAL", 40, 42], ["pollutantsNH 3", "CHEMICAL", 97, 111], ["alkynes", "CHEMICAL", 118, 125], ["CO", "SIMPLE_CHEMICAL", 40, 42], ["the air pollutantsNH", "PROBLEM", 89, 109], ["an alkynes gas", "PROBLEM", 115, 129], ["animal waste", "TREATMENT", 178, 190], ["fertilizer", "TREATMENT", 192, 202], ["waste management", "TREATMENT", 204, 220], ["vehicular emission", "PROBLEM", 222, 240], ["incomplete burning of homecooking fuel", "PROBLEM", 242, 280], ["concentration", "OBSERVATION_MODIFIER", 72, 85], ["air pollutantsNH", "OBSERVATION", 93, 109], ["alkynes gas", "OBSERVATION", 118, 129], ["anthropogenic processes", "OBSERVATION", 153, 176], ["vehicular", "ANATOMY", 222, 231]]], ["In Kolkata, a high concentration of NH 3 can be traced out where the land use pattern is dominated by industrial, commercial, and residential areas associated with dumping stations (Gupta et al. 2008) .", [["NH", "CHEMICAL", 36, 38], ["NH 3", "CHEMICAL", 36, 40], ["a high concentration of NH 3", "TREATMENT", 12, 40], ["industrial", "OBSERVATION_MODIFIER", 102, 112]]], ["During the pre-lockdown phase, NH 3 has taken the highest concentration at Jadavpur.", [["NH", "CHEMICAL", 31, 33], ["NH 3", "CHEMICAL", 31, 35], ["NH 3", "GENE_OR_GENE_PRODUCT", 31, 35]]], ["The engrossment ranges from 15.07-79.76 to 5.81-15.04 \u00b5g/m 3 the during lockdown phase.", [["The engrossment", "TEST", 0, 15], ["ranges", "OBSERVATION_MODIFIER", 16, 22]]], ["The mean concentration has dropped from 26.6 to 9.1 \u00b5g/m 3 , almost a three times reduction from the pre-lockdown to during lockdown.Observed concentration of the air pollutantsLine graphs (Fig. 2) have been drawn based on pollutant concentration data for all the stations in KMC and HMC are averaged and then plotted.", [["HMC", "CELL", 284, 287], ["HMC", "CELL_LINE", 284, 287], ["The mean concentration", "TEST", 0, 22], ["the air pollutants", "PROBLEM", 159, 177], ["Line graphs", "TEST", 177, 188], ["pollutant concentration data", "TEST", 223, 251], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["concentration", "OBSERVATION_MODIFIER", 9, 22], ["air pollutants", "OBSERVATION", 163, 177]]], ["It represents the trend of the concentration of the pollutants.", [["trend", "OBSERVATION_MODIFIER", 18, 23], ["pollutants", "OBSERVATION", 52, 62]]], ["NO 2 , SO 2 , CO, O 3 , NH 3 have been recorded at a satisfactory level but it has been noted that PM 2.5 and PM 10 are above the satisfactory level in the pre-lockdown phase and can be considered as the main pollutants in both KMC and HMC.", [["NO", "CHEMICAL", 0, 2], ["NO 2", "CHEMICAL", 0, 4], ["SO 2", "CHEMICAL", 7, 11], ["CO", "CHEMICAL", 14, 16], ["O 3 , NH 3", "CHEMICAL", 18, 28], ["NO 2", "SIMPLE_CHEMICAL", 0, 4], ["SO 2", "SIMPLE_CHEMICAL", 7, 11], ["CO", "SIMPLE_CHEMICAL", 14, 16], ["O 3", "SIMPLE_CHEMICAL", 18, 21], ["NH 3", "SIMPLE_CHEMICAL", 24, 28], ["HMC", "CELL", 236, 239], ["HMC", "CELL_LINE", 236, 239], ["CO, O 3 , NH 3", "TEST", 14, 28]]], ["But during the lockdown phase, the concentration has been reduced to a satisfactory level for all the pollutants except O 3 .", [["O 3", "CHEMICAL", 120, 123]]], ["The main scaling down can be noted for PM 2.5 and PM 10 from the pre-lockdown to the complete lockdown period.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["scaling", "OBSERVATION_MODIFIER", 9, 16]]], ["AQI is the combined form of all the pollutants is also showing that during the lockdown period the air quality has improved to the 'good' category.Observed concentration of the air pollutantsThe box plots (Fig. 3 ) of all stations are depicting the change in AQI from pre-lockdown to during lockdown.", [["AQI", "PROTEIN", 259, 262], ["the air pollutants", "PROBLEM", 173, 191], ["The box plots", "TEST", 191, 204], ["the change in AQI", "PROBLEM", 245, 262], ["pollutants", "OBSERVATION", 36, 46], ["air", "OBSERVATION_MODIFIER", 99, 102], ["air pollutants", "OBSERVATION", 177, 191]]], ["In pre-lockdown tenure, the station Ballygunge in Kolkata Municipal Corporation has been noted for 'poor' air quality as prescribed by CPCB (2014) ( Table 2 ) because of the nearby polluting sites like Topsia, Kosba, and Mullickbazar industrial sites (Gupta et al. 2008) .Observed concentration of the air pollutantsMost of the stations have recorded 'good' to 'satisfactory' air quality during the lockdown period in both the municipal corporations.", [["the air pollutants", "PROBLEM", 298, 316], ["air pollutants", "OBSERVATION", 302, 316]]], ["Among all the stations Ballygunge has recorded highest AQI during the pre-lockdown phase and the median value is 163.67 but during lockdown phase the median of AQI has reduced to 58.29.", [["AQI", "DNA", 55, 58]]], ["The lowest AQI has been recorded during the lockdown period at Belur Math in Howrah Municipal Corporation.Cluster analysisCluster analysis is a multivariate analysis that has been used to determine the grouping pattern of the monitoring stations in the pre-lockdown and during the lockdown phase based on AQI (Fig. 4) .", [["AQI", "DNA", 11, 14], ["Cluster analysisCluster analysis", "TEST", 106, 138], ["a multivariate analysis", "TEST", 142, 165]]], ["Euclidean distance and Ward's methods were employed to measure the distance among stations (David et al. 2019 ).Cluster analysisIn the pre-lockdown phase, the stations Jadavpur, Rabindra Sarovar, Fort William, and Victoria located in the central part of the study area are in the first cluster notifying the (Fig. 4a) .", [["Ward's methods", "TREATMENT", 23, 37], ["central", "ANATOMY_MODIFIER", 238, 245]]], ["The AQI is similar for these stations RBU, Ghusuri, Ballygunge, and Padmapukur and has made a cluster because Ghusuri and RBU are affected by the nearby Cossipore thermal power station whereas Ballygunge is located among the local small-scale industries in KMC, and Padmapukur is also affected by pollution from smallscale industries in HMC.", [["Ballygunge", "CHEMICAL", 193, 203], ["HMC", "CELL", 337, 340], ["HMC", "CELL_LINE", 337, 340]]], ["Fort William, Rabindra Bharati University, Victoria, and Ghusuri have made a cluster, and the rest of the stations have made the other clusters.Spatial distribution of pollutantsThe cluster analysis has shown the pattern of clusters of the stations based on the AQI.", [["AQI", "DNA", 262, 265], ["The cluster analysis", "TEST", 178, 198], ["pollutants", "OBSERVATION", 168, 178], ["pattern", "OBSERVATION_MODIFIER", 213, 220], ["clusters", "OBSERVATION_MODIFIER", 224, 232]]], ["Spatial variability has been represented in the form of a spatio-temporal map for the pollutants and the AQI from the pre-lockdown phase to during the lockdown phase for few selected days.", [["Spatial variability", "PROBLEM", 0, 19], ["the pollutants", "PROBLEM", 82, 96]]], ["The variability is represented based on the pollutants for each of the stations.", [["variability", "OBSERVATION_MODIFIER", 4, 15]]], ["Different factors like vehicular emission are a most important factor for Kolkata and the decennial growth of vehicle is like two wheelers almost 70% followed by four wheelers (20%), three wheeler (10-14%), and bus (8-13%) and the high traffic flow junctions are Park Circus even point junction, B.B.D Bag, Gariahat, Rashbehari, Ballygunge, M.G Road (Chowdhury 2015) .", [["Different factors like vehicular emission", "PROBLEM", 0, 41], ["the high traffic flow junctions", "TREATMENT", 227, 258], ["vehicular emission", "OBSERVATION", 23, 41], ["flow junctions", "OBSERVATION", 244, 258]]], ["Kolkata-Howrah industrial belt is another important source of pollution.", [["pollution", "OBSERVATION", 62, 71]]], ["The main sites of industrial pollution are Pyarabagan, Garden Reach, Taratala, Mallickbazar, Dhapa, and Cossipore thermal power station (Datta et al. 2016 ).", [["Pyarabagan", "CHEMICAL", 43, 53], ["Pyarabagan", "TREATMENT", 43, 53], ["Taratala", "TREATMENT", 69, 77], ["main", "OBSERVATION_MODIFIER", 4, 8], ["sites", "OBSERVATION_MODIFIER", 9, 14], ["industrial pollution", "OBSERVATION", 18, 38]]], ["PM 2.5 , PM 10, and NO 2 are the major pollutants in Kolkata and its adjoining areas (Datta et al. 2016) .", [["PM 2.5 , PM 10, and", "CHEMICAL", 0, 19], ["NO", "CHEMICAL", 20, 22], ["NO 2", "CHEMICAL", 20, 24], ["NO 2", "SIMPLE_CHEMICAL", 20, 24], ["major", "OBSERVATION_MODIFIER", 33, 38], ["pollutants", "OBSERVATION", 39, 49]]], ["To avoid the climatic variables in the present study, the maps are used to show how the difference in level of pollution between two consecutive years.", [["the present study", "TEST", 35, 52], ["the maps", "TEST", 54, 62]]], ["In 2019 due to the activity of industries, thermal power stations, vehicular and street shops, etc. the concentration of both PM 2.5 and PM 10 which are shown in red colour on the map was very high as in Fig. 5a while in 2020 on the same period the concentration of particulate matters in the atmosphere is considerably much lesser than the previous year (Fig. 5b) , due to restricted emission from vehicles, construction sites, and factories during complete lockdown tenure.Spatial distribution of pollutants24-hour timely averaged map of NO 2 (1/cm 2 ) from 24 March to 3 May 2019 (Fig. 6a ) from the NASA Giovanni and concentration from 24 March to 3 May 2020 (Fig. 6b) , the tenure of the complete of lockdown in India is compared.", [["NO", "CHEMICAL", 540, 542], ["NO 2", "CHEMICAL", 540, 544], ["red colour", "TEST", 162, 172], ["the map", "TEST", 176, 183], ["pollutants24", "TEST", 499, 511], ["map", "TEST", 533, 536], ["the NASA Giovanni and concentration", "TREATMENT", 599, 634], ["vehicular", "ANATOMY", 67, 76], ["concentration", "OBSERVATION_MODIFIER", 104, 117], ["red colour", "OBSERVATION", 162, 172], ["high", "OBSERVATION_MODIFIER", 193, 197], ["particulate matters", "OBSERVATION", 266, 285], ["considerably", "OBSERVATION_MODIFIER", 307, 319], ["much", "OBSERVATION_MODIFIER", 320, 324], ["lesser", "OBSERVATION_MODIFIER", 325, 331], ["distribution", "OBSERVATION_MODIFIER", 483, 495]]], ["Here a significant reduction has been seen in the NO 2 concentration over Kolkata and Howrah as well as West Bengal as compared to the same phase of the previous year.Spatial distribution of pollutantsTo show the spatial variability of pollutants in the pre-lockdown and during the lockdown phase in particularly Kolkata and Howrah Municipal Corporation, 1 March and 13 March during the pre-lockdown span, 24 March, the day when lockdown started, 7 April and 3 May during lockdown, are chosen.", [["NO", "CHEMICAL", 50, 52], ["NO 2", "CHEMICAL", 50, 54], ["NO 2", "SIMPLE_CHEMICAL", 50, 54], ["a significant reduction", "PROBLEM", 5, 28], ["significant", "OBSERVATION_MODIFIER", 7, 18], ["reduction", "OBSERVATION", 19, 28], ["pollutants", "OBSERVATION", 191, 201], ["spatial", "OBSERVATION_MODIFIER", 213, 220], ["variability", "OBSERVATION_MODIFIER", 221, 232], ["pollutants", "OBSERVATION", 236, 246]]], ["A high concentration of PM 2.5 is recorded especially near Ghusuri, Howrah (Fig. 7) .", [["A high concentration of PM", "TREATMENT", 0, 26], ["high", "OBSERVATION_MODIFIER", 2, 6], ["concentration", "OBSERVATION_MODIFIER", 7, 20]]], ["Another two most important concentration zones can be found near RBU due to its stone-throwing distance to Cossipore power station as the main source of PM 2.5 and PM 10 and another is near Ballygunge as this part is surrounded by nearby industrial centres like Mullick Bazar, Picnic Garden, Topsia and Kasba (Das et al. 2015) .", [["its stone", "PROBLEM", 76, 85], ["stone", "OBSERVATION", 80, 85], ["main", "OBSERVATION_MODIFIER", 138, 142], ["industrial centres", "OBSERVATION", 238, 256]]], ["On 13 March, the reduction in concentration can be noticed only at Ghusuri.", [["the reduction in concentration", "TREATMENT", 13, 43], ["reduction", "OBSERVATION_MODIFIER", 17, 26]]], ["On 24 March, the concentration has flattened due to the Janta Curfew on 22 March, shutting down of the industries, reduction in traffic flow, shutting down of street cooking shops, and reduction in power consumption (The Economics Times 2020).", [["reduction", "OBSERVATION_MODIFIER", 115, 124], ["traffic flow", "OBSERVATION", 128, 140], ["reduction", "OBSERVATION_MODIFIER", 185, 194], ["power consumption", "OBSERVATION", 198, 215]]], ["On 7 April, a slight increase can be noted and then again a fall in concentration is reported.", [["a slight increase", "PROBLEM", 12, 29], ["a fall in concentration", "PROBLEM", 58, 81], ["slight", "OBSERVATION_MODIFIER", 14, 20], ["increase", "OBSERVATION", 21, 29]]], ["Ghusuri recorded medium concentration also during the lockdown period.", [["Ghusuri", "CHEMICAL", 0, 7], ["Ghusuri", "SIMPLE_CHEMICAL", 0, 7], ["medium concentration", "OBSERVATION_MODIFIER", 17, 37]]], ["The pattern of concentration of PM 10 is the same as PM 2.5 , it may be because of almost the same sources of emission (Ibe et al. 2020) .Spatial distribution of pollutantsMajor NO 2 emitting zones ( Fig. 9) (Karar et al. 2006 ).", [["NO", "CHEMICAL", 178, 180], ["NO", "CHEMICAL", 178, 180], ["concentration of PM", "TEST", 15, 34], ["concentration", "OBSERVATION_MODIFIER", 15, 28], ["pollutants", "OBSERVATION", 162, 172], ["emitting", "OBSERVATION_MODIFIER", 183, 191], ["zones", "OBSERVATION_MODIFIER", 192, 197]]], ["Victoria has recorded higher NO 2 concentrations because of the nearby traffic intersections like Khidirpur Road, Acharya Jagadish Chandra Bose Road, Jawaharlal Nehru Road, and Esplanade.", [["NO", "CHEMICAL", 29, 31], ["NO 2", "CHEMICAL", 29, 33], ["NO 2", "SIMPLE_CHEMICAL", 29, 33]]], ["Zones of medium concentration are found in the extreme western Kolkata, limited areas of central Kolkata, and the eastern part of Kolkata due to high traffic flow (Gupta et al. 2008) .", [["medium concentration", "PROBLEM", 9, 29], ["high traffic flow", "PROBLEM", 145, 162], ["medium concentration", "OBSERVATION_MODIFIER", 9, 29], ["central", "ANATOMY_MODIFIER", 89, 96], ["high", "OBSERVATION_MODIFIER", 145, 149], ["traffic flow", "OBSERVATION", 150, 162]]], ["From 13 march before lockdown a slight reduction can be seen (Fig. 9 ) due to less traffic flow in Kolkata, a moderate concentration is reported.", [["a slight reduction", "TREATMENT", 30, 48], ["slight", "OBSERVATION_MODIFIER", 32, 38], ["reduction", "OBSERVATION", 39, 48], ["moderate", "OBSERVATION_MODIFIER", 110, 118], ["concentration", "OBSERVATION", 119, 132]]], ["On the day of 24 March when the most important stations like Blur Math and Victoria have recorded very minimum concentration of NO 2 with an amount of 22.85 \u00b5g/m 3 and 19.01 \u00b5g/m 3 , respectively, the concentration was scaled down due to Janta Curfew on 22 March that can be a probable factor, and after 24 March concentration pattern is almost the same for all the stations.Spatial distribution of pollutantsThe major concentration of NH 3 (Fig. 10) is identified near RBU (54.01 \u00b5g/m 3 ) and Belur Math (41.47 \u00b5g/m 3 ) on 1 March.", [["NO", "CHEMICAL", 128, 130], ["NH", "CHEMICAL", 436, 438], ["NO 2", "CHEMICAL", 128, 132], ["NH 3", "CHEMICAL", 436, 440], ["RBU", "CHEMICAL", 470, 473], ["NO 2", "SIMPLE_CHEMICAL", 128, 132], ["pollutants", "OBSERVATION", 399, 409], ["major", "OBSERVATION_MODIFIER", 413, 418], ["concentration", "OBSERVATION_MODIFIER", 419, 432]]], ["The NH 3 concentration at Kosba is high because of animal wastes, livestock, and fertilizer (Carmichael et al. 2003 ) as a result the concentration at this station is highest during the pre-lockdown period.", [["NH 3", "CHEMICAL", 4, 8], ["NH 3", "CHEMICAL", 4, 8], ["NH 3", "GENE_OR_GENE_PRODUCT", 4, 8], ["animal wastes", "TREATMENT", 51, 64]]], ["The concentration has reduced at this part to 8.83 on 3 May, and on the other hand, Rabindra Bharati University (22.52) has recorded a relatively higher amount on that particular day.", [["concentration", "OBSERVATION_MODIFIER", 4, 17], ["reduced", "OBSERVATION_MODIFIER", 22, 29]]], ["Dhapa solid waste dumping station in the east margin of Kolkata is responsible for higher NH 3 emission.", [["Dhapa", "CHEMICAL", 0, 5], ["NH 3", "CHEMICAL", 90, 94], ["waste", "OBSERVATION_MODIFIER", 12, 17], ["dumping station", "OBSERVATION", 18, 33], ["east margin", "OBSERVATION_MODIFIER", 41, 52]]], ["All the probable sources were active during the pre-lockdown phase but emission started reducing after the Janta Curfew and during the countrywide lockdown.Spatial distribution of pollutantsSmall-scale industries in Howrah accelerate pollution level and are responsible for high SO 2 concentration (Fig. 11) .", [["SO 2", "CHEMICAL", 279, 283], ["the Janta Curfew", "TREATMENT", 103, 119], ["pollutantsSmall-scale industries", "PROBLEM", 180, 212], ["probable", "UNCERTAINTY", 8, 16], ["active", "OBSERVATION_MODIFIER", 30, 36], ["distribution", "OBSERVATION_MODIFIER", 164, 176], ["pollutants", "OBSERVATION_MODIFIER", 180, 190], ["Small", "OBSERVATION_MODIFIER", 190, 195], ["scale", "OBSERVATION_MODIFIER", 196, 201], ["industries", "OBSERVATION_MODIFIER", 202, 212]]], ["The southern part has very minimum emission, but the northern, central, and north-western parts have recorded higher SO 2 emission on 1 March.", [["SO 2", "CHEMICAL", 117, 121]]], ["Concentration is moderately distributed in the northern part near Belur Math, RBU, and Ghusuri but all the parts have a sharp reduction in SO 2 emission on 13 March (Fig. 11) .", [["SO 2", "CHEMICAL", 139, 143], ["a sharp reduction", "TREATMENT", 118, 135], ["moderately", "OBSERVATION_MODIFIER", 17, 27], ["distributed", "OBSERVATION_MODIFIER", 28, 39], ["sharp", "OBSERVATION_MODIFIER", 120, 125], ["reduction", "OBSERVATION_MODIFIER", 126, 135]]], ["Among the stations, Ghusuri has recorded high SO 2 concentration on 1 March during the pre-lockdown phase with an amount of 67.39 \u00b5g/m 3 as this part is highly industrialized, and industries like electronics, plastics, etc. which are considered under the 'red' category by WBPCB, 2018.", [["Ghusuri", "CHEMICAL", 20, 27], ["SO 2", "CHEMICAL", 46, 50]]], ["On 24 March and 7 April, only areas near Belur Math and marginal eastern parts are recorded moderate SO 2 emission and on 3 May, the SO 2 emission has been flattened all over the study area as the most polluted sites noted the very minimum amount of SO 2 concentration with an amount of 6.73 \u00b5g/m 3 and 8.36 \u00b5g/m 3 at Ghusuri and Belur Math, respectively, due shut down of all the industrial industries.Spatial distribution of pollutantsThe concentration of CO is monitored on 8-hrs interval.", [["SO 2", "CHEMICAL", 250, 254], ["SO 2", "CHEMICAL", 250, 254], ["CO", "CHEMICAL", 458, 460], ["CO", "SIMPLE_CHEMICAL", 458, 460], ["marginal", "OBSERVATION_MODIFIER", 56, 64], ["eastern", "OBSERVATION_MODIFIER", 65, 72], ["moderate", "OBSERVATION_MODIFIER", 92, 100], ["flattened", "OBSERVATION_MODIFIER", 156, 165], ["very", "OBSERVATION_MODIFIER", 227, 231], ["minimum", "OBSERVATION_MODIFIER", 232, 239], ["amount", "OBSERVATION_MODIFIER", 240, 246], ["industrial industries", "OBSERVATION", 381, 402], ["pollutants", "OBSERVATION", 427, 437], ["concentration", "OBSERVATION_MODIFIER", 441, 454]]], ["Medium to high CO concentrations have been observed in KMC and HMC (Fig. 12) .", [["CO", "CHEMICAL", 15, 17], ["CO", "SIMPLE_CHEMICAL", 15, 17], ["HMC", "CELL_LINE", 63, 66], ["high CO concentrations", "PROBLEM", 10, 32]]], ["Vehicular emission contributes almost 90% of the total CO in the urban atmosphere (Jaffe 2012) , and it has been found that the concentration of CO is 1.3-6.8 times higher near the highly intensified vehicle zones than the urban periphery (Brice and Roesler 1966) .", [["CO", "CHEMICAL", 55, 57], ["CO", "CHEMICAL", 145, 147], ["CO", "SIMPLE_CHEMICAL", 55, 57], ["CO", "SIMPLE_CHEMICAL", 145, 147], ["Vehicular emission", "TEST", 0, 18], ["the concentration of CO", "TEST", 124, 147], ["concentration", "OBSERVATION_MODIFIER", 128, 141], ["highly", "OBSERVATION_MODIFIER", 181, 187], ["intensified", "OBSERVATION_MODIFIER", 188, 199]]], ["It has a key role in controlling the oxidation processes of the atmosphere by performing as a sink for a larger fraction of the reactive hydroxyl radicals existing in the lower troposphere.", [["hydroxyl", "CHEMICAL", 137, 145], ["hydroxyl", "CHEMICAL", 137, 145], ["reactive hydroxyl radicals", "SIMPLE_CHEMICAL", 128, 154], ["the reactive hydroxyl radicals", "TREATMENT", 124, 154], ["reactive", "OBSERVATION_MODIFIER", 128, 136], ["hydroxyl radicals", "OBSERVATION", 137, 154], ["lower", "ANATOMY_MODIFIER", 171, 176], ["troposphere", "ANATOMY_MODIFIER", 177, 188]]], ["The concentration of the gas Fig. 11 Spatio-temporal change of SO 2 (2020) Fig. 12 Spatio-temporal change of CO (2020) in the urban atmosphere is highly controlled by the pattern of emission and spread of the gasoline by the motor vehicle (Jaffe 2012 ) and due to high vehicular emission and burning of woods and fossil fuel for cooking in residential areas and street-side shops.", [["gasoline", "CHEMICAL", 209, 217], ["CO", "CHEMICAL", 109, 111], ["the gas Fig", "TEST", 21, 32], ["high vehicular emission", "PROBLEM", 264, 287], ["fossil fuel", "TREATMENT", 313, 324], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["gas Fig", "OBSERVATION", 25, 32], ["temporal", "OBSERVATION_MODIFIER", 44, 52], ["change", "OBSERVATION", 53, 59], ["vehicular emission", "OBSERVATION", 269, 287], ["fossil fuel", "OBSERVATION", 313, 324]]], ["During the pre-lockdown period, Victoria with high traffic flow during the office hours, important traffic intersections which are Khidirpur Road, Acharya Jagadish Chandra Bose Road, Jawaharlal Nehru Road and Esplanade traffic intersection result in the highest CO concentration (2.28 mg/m 3 ) and the lowest concentration has been recorded at Ballygunge (0.72 mg/m 3 ) on 1 March.", [["Ballygunge", "CHEMICAL", 344, 354], ["CO", "CHEMICAL", 262, 264], ["CO", "SIMPLE_CHEMICAL", 262, 264], ["the highest CO concentration", "TREATMENT", 250, 278], ["high", "OBSERVATION_MODIFIER", 46, 50], ["traffic flow", "OBSERVATION", 51, 63]]], ["CO is released mainly from Kasba, Picnic Garden, Mullick Bazar, and Topsiais which is known for industrial activities that affect the neighbouring stations which are Victoria, FortWilliam, and Ballygunge (Datta et al. 2016) .", [["CO", "CHEMICAL", 0, 2], ["CO", "SIMPLE_CHEMICAL", 0, 2], ["Topsiais", "TREATMENT", 68, 76]]], ["From 24 March, the day of lockdown, a mark reduction in CO concentration is noticed but a centre with relatively higher concentration is found near Victoria where the concentration reduced from 2.28 on 1 March to 0.64 on 3 May and this is the highest concentration among the other stations on that very particular day and later no such considerable changes have been observed.Spatial distribution of pollutantsThe spatial pattern of ozone concentration is different from the other pollutants (Fig. 13 ).", [["ozone", "CHEMICAL", 433, 438], ["CO", "CHEMICAL", 56, 58], ["ozone", "CHEMICAL", 433, 438], ["CO", "SIMPLE_CHEMICAL", 56, 58], ["ozone", "SIMPLE_CHEMICAL", 433, 438], ["a mark reduction in CO concentration", "TREATMENT", 36, 72], ["ozone concentration", "PROBLEM", 433, 452], ["concentration", "OBSERVATION_MODIFIER", 167, 180], ["reduced", "OBSERVATION_MODIFIER", 181, 188], ["pollutants", "OBSERVATION", 400, 410], ["spatial", "OBSERVATION_MODIFIER", 414, 421], ["pattern", "OBSERVATION_MODIFIER", 422, 429], ["ozone concentration", "OBSERVATION", 433, 452], ["different", "OBSERVATION_MODIFIER", 456, 465]]], ["Ozone concentration is inversely related to NH 3 (\u2212 0.63) and NO 2 (\u2212 0.15), which is the reason for relatively higher concentration during the pre-lockdown phase and it can also be found from the correlation matrix (Fig. 15 ).", [["Ozone", "CHEMICAL", 0, 5], ["NO", "CHEMICAL", 62, 64], ["Ozone", "CHEMICAL", 0, 5], ["NH 3 (\u2212 0.63)", "CHEMICAL", 44, 57], ["NO 2", "CHEMICAL", 62, 66], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["NO 2", "SIMPLE_CHEMICAL", 62, 66], ["matrix", "CELLULAR_COMPONENT", 209, 215], ["Ozone concentration", "PROBLEM", 0, 19]]], ["The lowest concentration of O 3 has been recorded at Jadavpur on 1 March (20.15 \u00b5g/m 3 ), in contrast the NO 2 and NH 3 concentrations are 52.09 \u00b5g/m 3 and 36.33 \u00b5g/m 3 , respectively.", [["NO", "CHEMICAL", 106, 108], ["NH", "CHEMICAL", 115, 117], ["O 3", "CHEMICAL", 28, 31], ["NO 2", "CHEMICAL", 106, 110], ["NH 3", "CHEMICAL", 115, 119], ["NO 2", "SIMPLE_CHEMICAL", 106, 110], ["NH 3", "SIMPLE_CHEMICAL", 115, 119], ["lowest", "OBSERVATION_MODIFIER", 4, 10], ["concentration", "OBSERVATION_MODIFIER", 11, 24]]], ["Here NH 3 concentration is the second highest after Belur Math at Jadavpur supporting the significant inverse relationship between NH 3 and O 3 (\u2212 0.64).", [["NH 3", "CHEMICAL", 5, 9], ["NH 3", "CHEMICAL", 131, 135], ["O 3", "CHEMICAL", 140, 143], ["NH 3", "GENE_OR_GENE_PRODUCT", 5, 9], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["inverse", "OBSERVATION", 102, 109]]], ["Another important station is Ghusuri where the second lowest O 3 concentration has been recorded with 73.19 \u00b5g/m 3 and 18.82 \u00b5g/m 3 amount of NO 2 and NH 3 being recorded.", [["NO", "CHEMICAL", 142, 144], ["O 3", "CHEMICAL", 61, 64], ["NO 2", "CHEMICAL", 142, 146], ["NH 3", "CHEMICAL", 151, 155], ["NO 2", "SIMPLE_CHEMICAL", 142, 146]]], ["The nearby Cossipore thermal power station near RBU is responsible for higher pollution and is also characterized by a high concentration of PM 2.5 , PM 10, and NO 2 as well on 1 March.", [["RBU", "CHEMICAL", 48, 51], ["NO", "CHEMICAL", 161, 163], ["NO", "CHEMICAL", 161, 163], ["responsible for", "UNCERTAINTY", 55, 70], ["higher pollution", "OBSERVATION", 71, 87]]], ["Only the central Kolkata has recorded a higher O 3 concentration near Victoria (65.76 \u00b5g/m 3 ) and Rabindra Sarovar (45.00 \u00b5g/m 3 ).", [["O 3", "CHEMICAL", 47, 50], ["central", "ANATOMY_MODIFIER", 9, 16]]], ["The concentration of O 3 is substantially reduced on 13 March 2020, the day of Janta Curfew because of the partial lockdown of 14 h.", [["O 3", "CHEMICAL", 21, 24], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["reduced", "OBSERVATION_MODIFIER", 42, 49]]], ["On 7 April, high concentration is recorded Fig. 13 Spatio-temporal change of O 3 (2020) again and the areal extent is more than 24 march most importantly the hiking in the concentration in the northern part and Ballygunge adjoined areas because till 24 march, these parts have recorded minimum concentration continuously.", [["O 3", "CHEMICAL", 77, 80], ["temporal", "OBSERVATION_MODIFIER", 58, 66], ["change", "OBSERVATION", 67, 73], ["areal", "OBSERVATION_MODIFIER", 102, 107], ["extent", "OBSERVATION_MODIFIER", 108, 114]]], ["After 24 march, the concentration has reduced remarkably and a relatively higher concentration has been recorded on 3 May, the relaxation in the lockdown in KMC and HMC results in this.", [["HMC", "CELL_LINE", 165, 168]]], ["The role of atmospheric chemistry is important here.", [["atmospheric chemistry", "TEST", 12, 33]]], ["The minimum concentration of other pollutants may result in the increase O 3 concentration because hiking of O 3 is caused by lower titration of O 3 by NO due to the minimum emission of NOx from the vehicle (Sicard et al. 2020) and with a decreasing carbonaceous concentration increase the atmospheric visibility that promotes penetration of solar radiation favouring ozone formation ) that can be understood from the concentration pattern of O 3 .", [["NO", "CHEMICAL", 152, 154], ["NOx", "CHEMICAL", 186, 189], ["ozone", "CHEMICAL", 368, 373], ["O 3", "CHEMICAL", 73, 76], ["O 3", "CHEMICAL", 109, 112], ["O 3", "CHEMICAL", 145, 148], ["NO", "CHEMICAL", 152, 154], ["NOx", "CHEMICAL", 186, 189], ["ozone", "CHEMICAL", 368, 373], ["O 3", "CHEMICAL", 443, 446], ["O 3", "SIMPLE_CHEMICAL", 145, 148], ["NO", "SIMPLE_CHEMICAL", 152, 154], ["NOx", "SIMPLE_CHEMICAL", 186, 189], ["ozone", "SIMPLE_CHEMICAL", 368, 373], ["a decreasing carbonaceous concentration", "TREATMENT", 237, 276], ["solar radiation favouring ozone formation", "TREATMENT", 342, 383], ["atmospheric visibility", "OBSERVATION", 290, 312]]], ["The highest concentration of O 3 has been recorded at Rabindra Bharati (53.66 \u00b5g/m 3 ), and very minimum concentration of NO 2 (15.61 \u00b5g/m 3 ) and NH 3 (22.52 \u00b5g/m 3 ) has been noted on 3 May.", [["NO", "CHEMICAL", 122, 124], ["O 3", "CHEMICAL", 29, 32], ["NO 2", "CHEMICAL", 122, 126], ["NH 3", "CHEMICAL", 147, 151], ["O 3", "SIMPLE_CHEMICAL", 29, 32], ["NO 2", "SIMPLE_CHEMICAL", 122, 126], ["NH", "TEST", 147, 149], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["concentration", "OBSERVATION_MODIFIER", 12, 25]]], ["Particularly, this part of the study area suffers from severe vehicular emission (Chakrabartty and Gupta 2014) but during the lockdown period, the concentration of NO 2 has been remarkably reduced.Spatial distribution of pollutantsAQI has fallen to 25 on 3 May from 325 on 1 march.", [["NO", "CHEMICAL", 164, 166], ["NO 2", "CHEMICAL", 164, 168], ["NO 2", "GENE_OR_GENE_PRODUCT", 164, 168], ["the study", "TEST", 27, 36], ["severe vehicular emission", "PROBLEM", 55, 80], ["Spatial distribution of pollutantsAQI", "PROBLEM", 197, 234], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["vehicular emission", "OBSERVATION", 62, 80], ["reduced", "OBSERVATION_MODIFIER", 189, 196], ["distribution", "OBSERVATION_MODIFIER", 205, 217]]], ["In the map (Fig. 14) , the higher concentration of the pollutants in the atmosphere is responsible for higher AQI and the opposite scenario can be observed during the lockdown period.", [["higher AQI", "PROBLEM", 103, 113], ["higher", "OBSERVATION_MODIFIER", 27, 33], ["concentration", "OBSERVATION_MODIFIER", 34, 47], ["pollutants", "OBSERVATION", 55, 65], ["responsible for", "UNCERTAINTY", 87, 102], ["higher AQI", "OBSERVATION", 103, 113]]], ["Ballygunge followed by Ghusuri and Rabindra Bharati has recorded the highest AQI, and it can be noted as 304.31, 302.12, and 300.97 on 1 March during the pre-lockdown time which is considered as the 'poor' air quality and other stations have recoded moderate air quality.", [["Ballygunge", "TREATMENT", 0, 10], ["the 'poor' air quality", "PROBLEM", 195, 217], ["moderate", "OBSERVATION_MODIFIER", 250, 258], ["air quality", "OBSERVATION", 259, 270]]], ["On 13 March, the pollution level has reduced half as the news of the COVID-19 spread and awareness started growing and major changes can be noticed on 24 March the day lockdown started just after the 14-h 'Janta Curfew' on 22 March.", [["the pollution level", "TEST", 13, 32], ["the COVID", "TEST", 65, 74], ["the 14-h 'Janta Curfew'", "TREATMENT", 196, 219]]], ["The levels of pollution have reduced almost six times for Ballygunge from 304.31 to only 50.29, from 302.12 to 78.87 in Ghusuri, and from 300.97 to 65.33 on 24 march as the restriction on human, and vehicular mobility was imposed as well as the effects of the Janta Curfew.", [["human", "ORGANISM", 188, 193], ["human", "SPECIES", 188, 193], ["human", "SPECIES", 188, 193], ["Ballygunge", "TEST", 58, 68], ["the Janta Curfew", "TREATMENT", 256, 272], ["pollution", "OBSERVATION", 14, 23], ["vehicular mobility", "OBSERVATION", 199, 217]]], ["A slight reduction in AQI and can be categorized under 'moderately polluted' on 13 March.", [["A slight reduction in AQI", "PROBLEM", 0, 25], ["slight", "OBSERVATION_MODIFIER", 2, 8], ["reduction", "OBSERVATION_MODIFIER", 9, 18]]], ["On 24 March, air quality is improved to 'good' but a slight degradation can be observed on 7 April and then again the air quality has remarkably improved as the highest polluting sites started improving along with the moderately polluted stations like Jadavpur, Rabindra Sarovar, Victoria.", [["a slight degradation", "PROBLEM", 51, 71], ["the highest polluting sites", "PROBLEM", 157, 184], ["Jadavpur", "TREATMENT", 252, 260], ["air", "OBSERVATION", 118, 121], ["remarkably", "OBSERVATION_MODIFIER", 134, 144], ["improved", "OBSERVATION_MODIFIER", 145, 153]]], ["On 3 may, the AQIs have been calculated for Ballygunge (51.67), Rabindra Bharati University (53.63), and Ghusri (52.01) and the results are the indication of 'good' air quality in KMC and HMC.Co-relationship between the ambient air pollutantsTo analyse the association among the pollutants, multiple correlation matrixes are conducted for pre-lockdown and during the lockdown phases (Fig. 15 ).", [["HMC", "CELL", 188, 191], ["HMC", "CELL_LINE", 188, 191], ["Ballygunge", "TEST", 44, 54], ["Ghusri", "TEST", 105, 111], ["the ambient air pollutants", "TREATMENT", 216, 242], ["pre-lockdown", "TREATMENT", 339, 351], ["air pollutants", "OBSERVATION", 228, 242]]], ["In the diagram, the monochromatic red colour is showing positive correlations and the blue colour is representing the negative correlations.", [["the monochromatic red colour", "TEST", 16, 44], ["the blue colour", "TEST", 82, 97]]], ["On the other hand, scatter plots are also showing the distributional pattern.", [["scatter plots", "TEST", 19, 32], ["scatter plots", "OBSERVATION", 19, 32], ["distributional pattern", "OBSERVATION", 54, 76]]], ["PM 2.5 has a strong significant relationship with PM 10 (r = 0.99) (Ibe et al. 2020) .", [["strong", "OBSERVATION_MODIFIER", 13, 19], ["significant", "OBSERVATION_MODIFIER", 20, 31]]], ["Due to the reduction in traffic congestion, the lockdown of industrial areas, the emission of these particulates also has reduced.", [["traffic congestion", "PROBLEM", 24, 42], ["reduction", "OBSERVATION_MODIFIER", 11, 20], ["traffic congestion", "OBSERVATION", 24, 42], ["industrial", "OBSERVATION_MODIFIER", 60, 70], ["areas", "OBSERVATION_MODIFIER", 71, 76], ["particulates", "OBSERVATION_MODIFIER", 100, 112], ["reduced", "OBSERVATION_MODIFIER", 122, 129]]], ["PM 2.5 is highly associated with CO and NO 2 because the high concentration of both the pollutants is recorded near highly intensified traffic junction and industrial belts.", [["traffic junction", "ANATOMY", 135, 151], ["NO", "CHEMICAL", 40, 42], ["CO", "CHEMICAL", 33, 35], ["NO 2", "CHEMICAL", 40, 44], ["CO", "SIMPLE_CHEMICAL", 33, 35], ["NO 2", "GENE_OR_GENE_PRODUCT", 40, 44], ["traffic junction", "CELLULAR_COMPONENT", 135, 151], ["CO", "TEST", 33, 35], ["industrial belts", "TREATMENT", 156, 172], ["pollutants", "OBSERVATION", 88, 98], ["industrial belts", "OBSERVATION", 156, 172]]], ["During the lockdown period, the relations among the parameters have drastically changed which can be seen as correlations have taken a new dimension when there is a mark reduction in the concentration of pollutants.", [["a mark reduction", "TREATMENT", 163, 179], ["reduction", "OBSERVATION_MODIFIER", 170, 179]]], ["Significantly moderate correlations have been traced out between NH 3 and NO 2 , PM 2.5 , PM 10 , except these all the relations are insignificant during the pre-lockdown phase.", [["NO", "CHEMICAL", 74, 76], ["NH 3", "CHEMICAL", 65, 69], ["NO 2", "CHEMICAL", 74, 78], ["NO 2", "GENE_OR_GENE_PRODUCT", 74, 78], ["Significantly moderate correlations", "PROBLEM", 0, 35], ["moderate", "OBSERVATION_MODIFIER", 14, 22], ["insignificant", "OBSERVATION", 133, 146]]], ["But the correlations have become significant during the lockdown phase.", [["significant", "OBSERVATION_MODIFIER", 33, 44]]], ["NH 3 has positive significant correlations with PM 2.5 (r = 0.87), SO 2 (r = 0.79) and O 3 (r = 0.73), PM 10 (r = 0.67), CO (r = 0.61).", [["NH", "CHEMICAL", 0, 2], ["NH 3", "CHEMICAL", 0, 4], ["O 3", "CHEMICAL", 87, 90], ["CO", "CHEMICAL", 121, 123], ["NH 3", "GENE_OR_GENE_PRODUCT", 0, 4], ["PM", "TEST", 48, 50], ["O", "TEST", 87, 88], ["CO", "TEST", 121, 123], ["significant", "OBSERVATION_MODIFIER", 18, 29]]], ["A moderately significant correlation (r = 0.54) has been found between these two components.Co-relationship between the ambient air pollutantsCO is only strongly correlated with PM 2.5 (r = 0.73), and NO 2 (r = 0.77) where the concentration of both the pollutants was high.", [["pollutantsCO", "CHEMICAL", 132, 144], ["NO", "CHEMICAL", 201, 203], ["pollutantsCO", "CHEMICAL", 132, 144], ["NO 2", "CHEMICAL", 201, 205], ["NO 2", "SIMPLE_CHEMICAL", 201, 205], ["A moderately significant correlation", "PROBLEM", 0, 36], ["the ambient air pollutantsCO", "TEST", 116, 144], ["moderately", "OBSERVATION_MODIFIER", 2, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["two", "OBSERVATION_MODIFIER", 77, 80], ["components", "OBSERVATION_MODIFIER", 81, 91], ["pollutants", "OBSERVATION", 253, 263], ["high", "OBSERVATION", 268, 272]]], ["Olszyna and Heicklen (1972) showed in an experiment that O 3 is consumed and solid aerosol is formed very rapidly in reaction with NH 3 but it is not reproducible.", [["O 3", "CHEMICAL", 57, 60], ["NH 3", "CHEMICAL", 131, 135], ["not", "UNCERTAINTY", 146, 149], ["reproducible", "OBSERVATION_MODIFIER", 150, 162]]], ["A high concentration of NH 3 in the pre-lockdown phase and chemical reaction in the atmosphere reduces the amount of Ozone.", [["NH 3", "CHEMICAL", 24, 28], ["Ozone", "CHEMICAL", 117, 122], ["NH 3", "CHEMICAL", 24, 28], ["Ozone", "CHEMICAL", 117, 122], ["Ozone", "SIMPLE_CHEMICAL", 117, 122], ["A high concentration of NH", "TREATMENT", 0, 26], ["chemical reaction", "PROBLEM", 59, 76], ["high concentration", "OBSERVATION_MODIFIER", 2, 20], ["chemical reaction", "OBSERVATION", 59, 76], ["atmosphere", "OBSERVATION_MODIFIER", 84, 94], ["amount", "OBSERVATION_MODIFIER", 107, 113], ["Ozone", "OBSERVATION_MODIFIER", 117, 122]]], ["On the other hand, during the lockdown period the correlation has a significant positive correlation (r = 0.72*) because the reaction is not possible when the amount is not significant (Olszyna and Heicklen 1972) .Co-relationship between the ambient air pollutantsThe processes which are related to the ozone formation are still not revealed so well and are still a challenge and need more studies (Monks et al. 2015) .", [["ozone", "CHEMICAL", 303, 308], ["ozone", "CHEMICAL", 303, 308], ["ozone", "SIMPLE_CHEMICAL", 303, 308], ["the reaction", "PROBLEM", 121, 133], ["the ambient air pollutants", "TREATMENT", 238, 264], ["the ozone formation", "PROBLEM", 299, 318], ["more studies", "TEST", 385, 397], ["not possible", "UNCERTAINTY", 137, 149], ["not", "UNCERTAINTY", 169, 172], ["significant", "OBSERVATION_MODIFIER", 173, 184], ["air pollutants", "OBSERVATION", 250, 264], ["ozone", "OBSERVATION", 303, 308]]], ["Ozone is also negatively correlated with NO 2 in the urban atmosphere (Palmgren et al. 1996; Pires 2012; Wilby 2008) .", [["Ozone", "CHEMICAL", 0, 5], ["NO", "CHEMICAL", 41, 43], ["Ozone", "CHEMICAL", 0, 5], ["NO 2", "CHEMICAL", 41, 45], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["NO 2", "GENE_OR_GENE_PRODUCT", 41, 45]]], ["The photochemical production of ozone in the lower atmosphere (troposphere) is the result of the hydroxyl radical oxidation of carbon monoxide, methane, and non-methane hydrocarbons in the occurrence of nitrogen dioxide (Monks et al. 2015) .", [["ozone", "CHEMICAL", 32, 37], ["hydroxyl", "CHEMICAL", 97, 105], ["carbon monoxide", "CHEMICAL", 127, 142], ["methane", "CHEMICAL", 144, 151], ["non-methane hydrocarbons", "CHEMICAL", 157, 181], ["nitrogen dioxide", "CHEMICAL", 203, 219], ["ozone", "CHEMICAL", 32, 37], ["hydroxyl", "CHEMICAL", 97, 105], ["carbon monoxide", "CHEMICAL", 127, 142], ["methane", "CHEMICAL", 144, 151], ["non-methane hydrocarbons", "CHEMICAL", 157, 181], ["nitrogen dioxide", "CHEMICAL", 203, 219], ["ozone", "SIMPLE_CHEMICAL", 32, 37], ["hydroxyl radical", "SIMPLE_CHEMICAL", 97, 113], ["carbon monoxide", "SIMPLE_CHEMICAL", 127, 142], ["methane", "SIMPLE_CHEMICAL", 144, 151], ["non-methane hydrocarbons", "SIMPLE_CHEMICAL", 157, 181], ["nitrogen dioxide", "SIMPLE_CHEMICAL", 203, 219], ["the hydroxyl radical oxidation", "TREATMENT", 93, 123], ["carbon monoxide", "TREATMENT", 127, 142], ["methane", "TREATMENT", 144, 151], ["non-methane hydrocarbons", "TREATMENT", 157, 181], ["nitrogen dioxide", "TREATMENT", 203, 219], ["photochemical", "OBSERVATION_MODIFIER", 4, 17], ["production", "OBSERVATION_MODIFIER", 18, 28], ["ozone", "OBSERVATION_MODIFIER", 32, 37], ["lower", "ANATOMY_MODIFIER", 45, 50]]], ["In brief, ozone is produced depends mainly on the photolysis of nitrogen dioxide and the association of the photoproduct with O 2 via a reaction (Monks et al. 2015; Pires 2012) .Co-relationship between the ambient air pollutantsThe reactions between these two components result in the degeneration and regeneration of ozone (Pires 2012) .", [["ozone", "CHEMICAL", 10, 15], ["nitrogen dioxide", "CHEMICAL", 64, 80], ["ozone", "CHEMICAL", 318, 323], ["ozone", "CHEMICAL", 10, 15], ["nitrogen dioxide", "CHEMICAL", 64, 80], ["O 2", "CHEMICAL", 126, 129], ["ozone", "CHEMICAL", 318, 323], ["ozone", "SIMPLE_CHEMICAL", 10, 15], ["nitrogen dioxide", "SIMPLE_CHEMICAL", 64, 80], ["O 2", "SIMPLE_CHEMICAL", 126, 129], ["ozone", "SIMPLE_CHEMICAL", 318, 323], ["nitrogen dioxide", "TREATMENT", 64, 80], ["the ambient air pollutants", "TREATMENT", 202, 228], ["The reactions", "PROBLEM", 228, 241], ["the degeneration", "PROBLEM", 281, 297], ["ozone", "OBSERVATION", 10, 15], ["air pollutants", "OBSERVATION", 214, 228], ["two", "OBSERVATION_MODIFIER", 256, 259], ["components", "OBSERVATION_MODIFIER", 260, 270], ["degeneration", "OBSERVATION", 285, 297], ["regeneration", "OBSERVATION_MODIFIER", 302, 314], ["ozone", "OBSERVATION_MODIFIER", 318, 323]]], ["The high incursion of NO 2 from the vehicle and industrial areas degrade ozone in the atmosphere by chemical reactions (Cox 2003) .", [["NO", "CHEMICAL", 22, 24], ["ozone", "CHEMICAL", 73, 78], ["NO 2", "CHEMICAL", 22, 26], ["ozone", "CHEMICAL", 73, 78], ["NO 2", "GENE_OR_GENE_PRODUCT", 22, 26], ["ozone", "SIMPLE_CHEMICAL", 73, 78], ["chemical reactions", "PROBLEM", 100, 118], ["high", "OBSERVATION_MODIFIER", 4, 8], ["incursion", "OBSERVATION_MODIFIER", 9, 18], ["ozone", "OBSERVATION_MODIFIER", 73, 78]]], ["NO 2 is broken down into NO that reacts with O 3 in the presence of UV, then again NO reacts with O 3 and NO 2 and O 2 are the outcomes (Ebi and McGregor 2008) .", [["NO", "CHEMICAL", 0, 2], ["NO", "CHEMICAL", 25, 27], ["NO", "CHEMICAL", 83, 85], ["NO", "CHEMICAL", 106, 108], ["NO 2", "CHEMICAL", 0, 4], ["NO", "CHEMICAL", 25, 27], ["O 3", "CHEMICAL", 45, 48], ["NO", "CHEMICAL", 83, 85], ["O 3", "CHEMICAL", 98, 101], ["NO", "CHEMICAL", 106, 108], ["O 2", "CHEMICAL", 115, 118], ["NO 2", "SIMPLE_CHEMICAL", 0, 4], ["NO", "SIMPLE_CHEMICAL", 25, 27], ["O 3", "SIMPLE_CHEMICAL", 45, 48], ["NO", "SIMPLE_CHEMICAL", 83, 85], ["O 3", "SIMPLE_CHEMICAL", 98, 101], ["NO 2", "SIMPLE_CHEMICAL", 106, 110], ["O 2", "SIMPLE_CHEMICAL", 115, 118], ["broken", "OBSERVATION", 8, 14], ["NO", "UNCERTAINTY", 25, 27], ["UV", "OBSERVATION", 68, 70]]], ["This phenomenon is normal during the weekdays but during weekends NO 2 concentration is reduced and O 3 is increased in the urban atmosphere (Atkinson-Palombo et al. 2006) ; the lockdown has affected the emission in the same manner and to some extent more than that.", [["NO", "CHEMICAL", 66, 68], ["NO 2", "CHEMICAL", 66, 70], ["O 3", "CHEMICAL", 100, 103], ["NO 2", "SIMPLE_CHEMICAL", 66, 70], ["O 3", "GENE_OR_GENE_PRODUCT", 100, 103], ["normal", "OBSERVATION", 19, 25], ["increased", "OBSERVATION_MODIFIER", 107, 116], ["some extent", "OBSERVATION_MODIFIER", 239, 250]]], ["A study by Cox (2003) showed that the area of ozone depletion is highly associated with NO 2 emitting areas.", [["ozone", "CHEMICAL", 46, 51], ["NO", "CHEMICAL", 88, 90], ["ozone", "CHEMICAL", 46, 51], ["NO", "CHEMICAL", 88, 90], ["ozone", "SIMPLE_CHEMICAL", 46, 51], ["NO", "SIMPLE_CHEMICAL", 88, 90], ["A study", "TEST", 0, 7], ["ozone depletion", "PROBLEM", 46, 61], ["area", "OBSERVATION_MODIFIER", 38, 42], ["ozone depletion", "OBSERVATION", 46, 61], ["emitting", "OBSERVATION_MODIFIER", 93, 101]]], ["From Fig. 15 , it can be noticed that the NO 2 and the O 3 had a negative correlation in the pre-lockdown phase but later the relation has turned into a positive correlation because of the amount if NO 2 is not considered for the reaction in the lower atmosphere, less amount of NO 2 does not affect too much to the concentration of O 3 (Pires 2012 ).", [["NO", "CHEMICAL", 42, 44], ["NO", "CHEMICAL", 199, 201], ["NO", "CHEMICAL", 279, 281], ["NO 2", "CHEMICAL", 42, 46], ["O 3", "CHEMICAL", 55, 58], ["NO 2", "CHEMICAL", 199, 203], ["NO 2", "CHEMICAL", 279, 283], ["O 3", "CHEMICAL", 333, 336], ["NO 2", "SIMPLE_CHEMICAL", 42, 46], ["NO 2", "GENE_OR_GENE_PRODUCT", 199, 203], ["NO 2", "SIMPLE_CHEMICAL", 279, 283], ["the reaction", "PROBLEM", 226, 238]]], ["In the lower atmosphere, particulate matters also act like sink so PM 2.5 and PM 10 concentration result in reducing the sink of hydroperoxy radicals and boosting the ozone concentration (Li et al. 2019 ).Analysis of variance (ANOVA)ANOVA two-way has been used to understand the variance of means of air quality index AQI for all the stations (9) of both Kolkata and Howrah (Table 4 ).", [["ozone", "CHEMICAL", 167, 172], ["hydroperoxy", "CHEMICAL", 129, 140], ["ozone", "CHEMICAL", 167, 172], ["hydroperoxy radicals", "SIMPLE_CHEMICAL", 129, 149], ["ozone", "SIMPLE_CHEMICAL", 167, 172], ["hydroperoxy radicals", "TREATMENT", 129, 149], ["lower", "ANATOMY_MODIFIER", 7, 12]]], ["After performing ANOVA two-way, it has been found that period (from pre-lockdown to during lockdown phase) has a very important role in reducing AQI, F(1,611) = 465.723, p < 0.0001 is a highly significant factor for the changing AQI.", [["AQI", "PROTEIN", 229, 232]]], ["The effect of interaction on the AQI is also found significant F(8,611) = 6.045, p < 0.0001.", [["AQI", "DNA", 33, 36]]], ["Table 4 shows the pairwise comparisons within the station of AQI from the pre-lockdown phase to during the lockdown phase, and the mean difference within the station is highly significant with p < 0.0001 of all the stations.", [["significant", "OBSERVATION_MODIFIER", 176, 187]]], ["The estimated mean differences of AQI between the lockdown period and the pre-lockdown period are considered for all the stations (Fig. 16) .", [["mean", "OBSERVATION_MODIFIER", 14, 18], ["differences", "OBSERVATION_MODIFIER", 19, 30]]], ["The air quality was 'poor' at Ballygunge, Rabindra Bharati University, and Ghusuri, but the air quality has remarkably improved in the lockdown period.ConclusionThe study has been yielded with a significant outcome that the lockdown has remarkably reduced the pollution level and air quality has improved from the 'poor' category to the 'good' category from the pre-lockdown period to during the lockdown period in KMC and HMC.", [["HMC", "CELL", 423, 426], ["HMC", "CELL_LINE", 423, 426], ["The study", "TEST", 161, 170], ["air quality", "OBSERVATION", 4, 15], ["air quality", "OBSERVATION", 92, 103], ["remarkably", "OBSERVATION_MODIFIER", 108, 118], ["improved", "OBSERVATION_MODIFIER", 119, 127], ["reduced", "OBSERVATION_MODIFIER", 248, 255], ["air", "OBSERVATION_MODIFIER", 280, 283], ["improved", "OBSERVATION_MODIFIER", 296, 304]]], ["PM 2.5 and PM 10 are responsible for pollution in KMC and HMC though the belowpermissible-level concentration of NO 2 has been recorded in both the municipal corporations, it is a very important pollutant and has reduced specifically during the lockdown.", [["NO", "CHEMICAL", 113, 115], ["NO 2", "CHEMICAL", 113, 117], ["NO 2", "SIMPLE_CHEMICAL", 113, 117], ["the belowpermissible-level concentration", "TEST", 69, 109], ["municipal corporations", "OBSERVATION", 148, 170]]], ["In the northern part of KMC near RBU due to the continuation of thermal power production, the pollution level is relatively higher and the other two important centres, Ghusuri and Ballygunge, are worst affected by small-scale industries and after the lockdown, the pollution level has flattened.", [["thermal power production", "TREATMENT", 64, 88], ["the pollution level", "TEST", 90, 109], ["the pollution level", "TEST", 261, 280], ["relatively", "OBSERVATION_MODIFIER", 113, 123], ["higher", "OBSERVATION_MODIFIER", 124, 130], ["worst", "OBSERVATION_MODIFIER", 196, 201], ["small", "OBSERVATION_MODIFIER", 214, 219], ["flattened", "OBSERVATION_MODIFIER", 285, 294]]], ["The relationships among the pollutants have also transformed with the changing magnitude of the pollutants as during the pre-lockdown phase, the some significant and some insignificant relationships have been found but during the lockdown phase, all the relationships have become very significant.", [["the pre-lockdown phase", "TEST", 117, 139], ["significant", "OBSERVATION_MODIFIER", 150, 161]]], ["Most interestingly, the concentration of O 3 increased after the imposition lockdown as it is related inversely with NH 3 and NO 2 .", [["NO", "CHEMICAL", 126, 128], ["O 3", "CHEMICAL", 41, 44], ["NH 3", "CHEMICAL", 117, 121], ["NO 2", "CHEMICAL", 126, 130], ["O 3", "GENE_OR_GENE_PRODUCT", 41, 44], ["NH 3", "GENE_OR_GENE_PRODUCT", 117, 121], ["NO 2", "GENE_OR_GENE_PRODUCT", 126, 130], ["the imposition lockdown", "TREATMENT", 61, 84]]], ["The major pollutants are PM 2.5 , PM 10, and NO 2 and have markedly condensed from prelockdown to during the lockdown period.", [["NO", "CHEMICAL", 45, 47], ["NO 2", "CHEMICAL", 45, 49], ["markedly condensed", "PROBLEM", 59, 77], ["major", "OBSERVATION_MODIFIER", 4, 9], ["pollutants", "OBSERVATION", 10, 20], ["markedly", "OBSERVATION_MODIFIER", 59, 67], ["condensed", "OBSERVATION", 68, 77]]], ["The Cossipore thermal power station, small-scale industrial hubs, and traffic are the main sources of pollution, but the imposition of lockdown all over the country has resulted in a quick fall in the concentration of pollutants.", [["The Cossipore thermal power station", "TREATMENT", 0, 35], ["a quick fall", "PROBLEM", 181, 193], ["small", "OBSERVATION_MODIFIER", 37, 42], ["-scale", "OBSERVATION_MODIFIER", 42, 48], ["industrial hubs", "OBSERVATION", 49, 64], ["main", "OBSERVATION_MODIFIER", 86, 90], ["pollution", "OBSERVATION", 102, 111]]], ["Implementations of lockdown at this temporal and regional scale are not possible, but the situation has proved that the recovery of the environment is very rapid when human interventions are very less.", [["human", "ORGANISM", 167, 172], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["lockdown", "TREATMENT", 19, 27], ["human interventions", "TREATMENT", 167, 186], ["not possible", "UNCERTAINTY", 68, 80]]]], "75f738d7c0c45a44ac72d7cee16b2f5f1c1afd0a": [["INTRODUCTIONThe Players: mRNAs, tRNAs, and the Ribosome T he primary genetic information contained in messenger RNA (mRNA) is bundled into packets of three nucleotides termed codons (reviewed in Ref 1) .", [["nucleotides", "CHEMICAL", 156, 167], ["Ribosome T", "GENE_OR_GENE_PRODUCT", 47, 57], ["Players:", "RNA", 16, 24], ["mRNAs", "RNA", 25, 30], ["tRNAs", "RNA", 32, 37], ["Ribosome T", "PROTEIN", 47, 57], ["messenger RNA", "RNA", 102, 115], ["mRNA", "RNA", 117, 121], ["tRNAs", "TREATMENT", 32, 37], ["three nucleotides termed codons", "PROBLEM", 150, 181]]], ["Each codon is recognized by the anticodon loop of a specific transfer RNA (tRNA), the 3 ends of which are charged with specific amino acids.", [["amino acids", "CHEMICAL", 128, 139], ["amino acids", "CHEMICAL", 128, 139], ["amino acids", "AMINO_ACID", 128, 139], ["anticodon loop", "DNA", 32, 46], ["transfer RNA", "RNA", 61, 73], ["specific amino acids", "TREATMENT", 119, 139], ["anticodon loop", "OBSERVATION", 32, 46]]], ["Thus, each codon encodes a specific amino acid (or information instructing the translational apparatus to terminate translation).", [["amino acid", "CHEMICAL", 36, 46], ["amino acid", "CHEMICAL", 36, 46], ["amino acid", "AMINO_ACID", 36, 46], ["a specific amino acid", "TREATMENT", 25, 46]]], ["The ribosome is an ancient molecular machine that brings mRNAs and tRNAs together to synthesize the proteins encoded by the mRNAs using the amino acids supplied by the tRNAs (reviewed in Ref 2) .", [["amino acids", "CHEMICAL", 140, 151], ["amino acids", "CHEMICAL", 140, 151], ["ribosome", "CELLULAR_COMPONENT", 4, 12], ["amino acids", "AMINO_ACID", 140, 151], ["mRNAs", "RNA", 57, 62], ["mRNAs", "RNA", 124, 129], ["an ancient molecular machine", "TREATMENT", 16, 44], ["mRNAs and tRNAs", "TREATMENT", 57, 72], ["the amino acids", "TREATMENT", 136, 151]]], ["The ribosome is composed of multiple RNAs (called ribosomal RNAs, rRNAs) and proteins divided into two separate subunits (SU), of peptide synthesis and ensure the directionality of ribosome movement along the mRNA.", [["ribosome", "ANATOMY", 4, 12], ["ribosome", "ANATOMY", 181, 189], ["ribosome", "CELLULAR_COMPONENT", 4, 12], ["ribosomal", "CELLULAR_COMPONENT", 50, 59], ["rRNAs", "CELLULAR_COMPONENT", 66, 71], ["SU", "GENE_OR_GENE_PRODUCT", 122, 124], ["multiple RNAs", "RNA", 28, 41], ["ribosomal RNAs", "RNA", 50, 64], ["rRNAs", "RNA", 66, 71], ["SU", "PROTEIN", 122, 124], ["mRNA", "RNA", 209, 213], ["multiple RNAs", "PROBLEM", 28, 41], ["ribosomal RNAs", "TREATMENT", 50, 64], ["proteins", "TREATMENT", 77, 85], ["peptide synthesis", "TREATMENT", 130, 147], ["ribosome", "OBSERVATION", 4, 12], ["multiple", "OBSERVATION_MODIFIER", 28, 36], ["RNAs", "OBSERVATION", 37, 41], ["ribosome movement", "OBSERVATION", 181, 198], ["mRNA", "ANATOMY", 209, 213]]], ["Given the triplet nature of codons, each mRNA contains three potential translational reading frames.", [["mRNA", "RNA", 41, 45], ["translational reading frames", "DNA", 71, 99]]], ["Thus, one of the central questions in molecular and structural biology is to understand how the ribosome initially chooses the 'correct' reading frame, and how it manages to coordinate the activities of multiple functional centers so as to maintain reading frame throughout the course of translating mRNAs.TRANSLATIONAL READING FRAME: ESTABLISHMENT AND MAINTENANCEThe issue of translational reading frame establishment also appears to have ancient origins: the so-called 'universal' start signal for protein translation is specified by a single codon, AUG, encoding methionine.", [["ribosome", "ANATOMY", 96, 104], ["methionine", "CHEMICAL", 566, 576], ["methionine", "CHEMICAL", 566, 576], ["ribosome", "CELLULAR_COMPONENT", 96, 104], ["methionine", "AMINO_ACID", 566, 576], ["mRNAs", "RNA", 300, 305], ["AUG", "DNA", 552, 555], ["protein translation", "PROBLEM", 500, 519], ["encoding methionine", "TREATMENT", 557, 576]]], ["In eukaryotes, the correct reading frame of an mRNA is generally defined by the first AUG (as read from the 5 to 3 direction) which denotes where translation is to begin, while in polycistronic prokaryotic mRNAs containing multiple open reading frames (ORFs), reinitiation of translation is a bit more complicated (reviewed in Ref 4) .", [["mRNA", "RNA", 47, 51], ["AUG", "DNA", 86, 89], ["polycistronic prokaryotic mRNAs", "RNA", 180, 211], ["open reading frames", "DNA", 232, 251], ["ORFs", "DNA", 253, 257], ["polycistronic prokaryotic mRNAs", "PROBLEM", 180, 211], ["multiple", "OBSERVATION_MODIFIER", 223, 231]]], ["While translation initiation at non-AUG codons, and ribosomal bypassing of the first (or even subsequent) AUG codons have been well documented, these tend to be exceptions to the general rule, and in fact have served as useful tools to further our understanding of this general rule that the first AUG defines translational reading frame (reviewed in Ref 5) .", [["ribosomal", "ANATOMY", 52, 61], ["ribosomal", "CELLULAR_COMPONENT", 52, 61], ["non-AUG codons", "DNA", 32, 46], ["AUG codons", "DNA", 106, 116], ["AUG", "DNA", 298, 301], ["translational reading frame", "DNA", 310, 337], ["non-AUG codons", "TREATMENT", 32, 46], ["ribosomal bypassing", "TREATMENT", 52, 71], ["AUG codons", "PROBLEM", 106, 116]]], ["Indeed, data emerging from ribosome profiling experiments suggests that a significant fraction of translation initiation events occur at a small subset of non-AUG codons.", [["non-AUG codons", "DNA", 155, 169], ["ribosome profiling experiments", "TEST", 27, 57], ["translation initiation events", "PROBLEM", 98, 127]]], ["6Establishment of Translational Reading FrameTo understand how translational reading frame is established, it is important to understand how the structure of the ribosome affects its function.", [["ribosome", "ANATOMY", 162, 170], ["ribosome", "CELLULAR_COMPONENT", 162, 170], ["Translational Reading FrameTo", "DNA", 18, 47], ["translational reading frame", "DNA", 63, 90]]], ["The SSU contains a single rRNA species in all organisms, which ranges in size from 16S in bacteria and archae, to 18S in eukaryotes, and contains a minimum of 21 proteins, which expands to up to 33 in higher organisms (reviewed in Ref 7) .", [["SSU", "CELLULAR_COMPONENT", 4, 7], ["archae", "GENE_OR_GENE_PRODUCT", 103, 109], ["18S", "GENE_OR_GENE_PRODUCT", 114, 117], ["SSU", "DNA", 4, 7], ["16S", "DNA", 83, 86], ["18S", "DNA", 114, 117], ["21 proteins", "PROTEIN", 159, 170], ["The SSU", "TEST", 0, 7], ["a single rRNA species", "PROBLEM", 17, 38], ["all organisms", "PROBLEM", 42, 55], ["bacteria", "PROBLEM", 90, 98], ["archae", "TEST", 103, 109], ["single", "OBSERVATION_MODIFIER", 19, 25], ["rRNA species", "OBSERVATION", 26, 38], ["all organisms", "OBSERVATION_MODIFIER", 42, 55], ["ranges", "OBSERVATION_MODIFIER", 63, 69], ["size", "OBSERVATION_MODIFIER", 73, 77], ["bacteria", "OBSERVATION_MODIFIER", 90, 98], ["minimum", "OBSERVATION_MODIFIER", 148, 155], ["21 proteins", "OBSERVATION_MODIFIER", 159, 170]]], ["As discussed above, base pairing interactions between mRNA codons and tRNA anticodons occur in the decoding center of the SSU, which is located near the 3 end of its rRNA.", [["SSU", "CELLULAR_COMPONENT", 122, 125], ["rRNA", "CELLULAR_COMPONENT", 166, 170], ["mRNA codons", "RNA", 54, 65], ["tRNA anticodons", "RNA", 70, 85], ["SSU", "DNA", 122, 125], ["3 end", "DNA", 153, 158], ["rRNA", "DNA", 166, 170], ["base pairing interactions", "PROBLEM", 20, 45], ["mRNA codons", "TREATMENT", 54, 65], ["tRNA anticodons", "TREATMENT", 70, 85], ["tRNA anticodons", "OBSERVATION", 70, 85], ["SSU", "OBSERVATION_MODIFIER", 122, 125], ["rRNA", "OBSERVATION_MODIFIER", 166, 170]]], ["The LSU of bacteria and archae contain two rRNAs, 23S and 5S, and approximately 31 proteins.", [["archae", "GENE_OR_GENE_PRODUCT", 24, 30], ["23S", "CELLULAR_COMPONENT", 50, 53], ["5S", "CELLULAR_COMPONENT", 58, 60], ["LSU", "DNA", 4, 7], ["rRNAs", "RNA", 43, 48], ["23S", "DNA", 50, 53], ["5S", "DNA", 58, 60], ["The LSU of bacteria", "TEST", 0, 19], ["archae", "TEST", 24, 30], ["two rRNAs", "TEST", 39, 48], ["23S", "TEST", 50, 53], ["bacteria", "OBSERVATION", 11, 19], ["two rRNAs", "OBSERVATION", 39, 48], ["31 proteins", "OBSERVATION_MODIFIER", 80, 91]]], ["In eukaryotes, the proteinacious component has expanded to up to 49 proteins, and a small fragment of the 23S rRNA appears to have become detached and evolved into a separate rRNA, called 5.8S.", [["23S", "CELLULAR_COMPONENT", 106, 109], ["rRNA", "CELLULAR_COMPONENT", 110, 114], ["rRNA", "CELLULAR_COMPONENT", 175, 179], ["proteinacious component", "PROTEIN", 19, 42], ["49 proteins", "PROTEIN", 65, 76], ["23S rRNA", "RNA", 106, 114], ["rRNA", "DNA", 175, 179], ["the proteinacious component", "PROBLEM", 15, 42], ["a small fragment of the 23S rRNA", "PROBLEM", 82, 114], ["proteinacious", "OBSERVATION_MODIFIER", 19, 32], ["component", "OBSERVATION_MODIFIER", 33, 42], ["expanded", "OBSERVATION_MODIFIER", 47, 55], ["small", "OBSERVATION_MODIFIER", 84, 89], ["fragment", "OBSERVATION", 90, 98], ["23S rRNA", "OBSERVATION", 106, 114], ["appears to have", "UNCERTAINTY", 115, 130], ["detached", "OBSERVATION", 138, 146]]], ["Interestingly, while 5.8S rRNA is a distinct molecule, structural analyses reveals that it is physically located in the same place, along the 'rear' solvent accessible side of the LSU, as its corresponding sequence in bacterial and archaeal ribosomes.", [["ribosomes", "ANATOMY", 241, 250], ["ribosomes", "CELLULAR_COMPONENT", 241, 250], ["5.8S rRNA", "DNA", 21, 30], ["LSU", "DNA", 180, 183], ["bacterial and archaeal ribosomes", "PROTEIN", 218, 250], ["structural analyses", "TEST", 55, 74], ["LSU", "OBSERVATION", 180, 183], ["bacterial", "OBSERVATION_MODIFIER", 218, 227], ["archaeal ribosomes", "OBSERVATION", 232, 250]]], ["[8] [9] [10] Also different is the expansion of the major LSU rRNA in eukaryotes, ranging from 25S rRNA in yeast to 28S rRNA in metazoans.", [["LSU", "GENE_OR_GENE_PRODUCT", 58, 61], ["rRNA", "CELLULAR_COMPONENT", 62, 66], ["25S", "CELLULAR_COMPONENT", 95, 98], ["rRNA", "CELLULAR_COMPONENT", 99, 103], ["28S", "GENE_OR_GENE_PRODUCT", 116, 119], ["rRNA", "CELLULAR_COMPONENT", 120, 124], ["major LSU rRNA", "DNA", 52, 66], ["25S rRNA", "RNA", 95, 103], ["28S rRNA", "RNA", 116, 124], ["yeast", "SPECIES", 107, 112], ["yeast", "SPECIES", 107, 112], ["expansion", "OBSERVATION_MODIFIER", 35, 44], ["major", "OBSERVATION_MODIFIER", 52, 57], ["LSU rRNA", "OBSERVATION", 58, 66], ["ranging", "OBSERVATION_MODIFIER", 82, 89], ["25S rRNA", "OBSERVATION", 95, 103], ["yeast to", "OBSERVATION_MODIFIER", 107, 115], ["28S rRNA", "OBSERVATION", 116, 124]]], ["The LSU interacts with the SSU, and contains three distinct pockets for binding of tRNAs: the A-site specifically binds aa-tRNAs, the P-site binds initiator tRNAs and tRNAs linked to elongating polypeptides (peptidyl-tRNAs), and the E-site binds deacylated tRNAs.", [["LSU", "CELLULAR_COMPONENT", 4, 7], ["SSU", "CELLULAR_COMPONENT", 27, 30], ["aa-tRNAs", "GENE_OR_GENE_PRODUCT", 120, 128], ["peptidyl-tRNAs", "GENE_OR_GENE_PRODUCT", 208, 222], ["LSU", "DNA", 4, 7], ["SSU", "DNA", 27, 30], ["tRNAs", "RNA", 83, 88], ["A-site", "DNA", 94, 100], ["aa-tRNAs", "DNA", 120, 128], ["P-site", "DNA", 134, 140], ["initiator tRNAs", "RNA", 147, 162], ["tRNAs", "RNA", 167, 172], ["elongating polypeptides", "RNA", 183, 206], ["peptidyl-tRNAs", "RNA", 208, 222], ["E-site", "DNA", 233, 239], ["deacylated tRNAs", "RNA", 246, 262], ["the SSU", "TREATMENT", 23, 30], ["the P-site binds initiator tRNAs", "TREATMENT", 130, 162], ["tRNAs", "TREATMENT", 167, 172], ["elongating polypeptides", "TREATMENT", 183, 206], ["peptidyl-tRNAs", "TREATMENT", 208, 222], ["the E-site binds deacylated tRNAs", "TREATMENT", 229, 262], ["distinct", "OBSERVATION_MODIFIER", 51, 59], ["pockets", "OBSERVATION", 60, 67], ["deacylated tRNAs", "OBSERVATION", 246, 262]]], ["Nascent peptides are extruded from the PTC through a tunnel where they exit from the 'back' side of the LSU.", [["PTC", "CANCER", 39, 42], ["LSU", "CELLULAR_COMPONENT", 104, 107], ["LSU", "DNA", 104, 107], ["Nascent peptides", "TREATMENT", 0, 16], ["the PTC", "TREATMENT", 35, 42], ["a tunnel", "TREATMENT", 51, 59], ["peptides", "OBSERVATION", 8, 16], ["extruded", "OBSERVATION_MODIFIER", 21, 29], ["PTC", "OBSERVATION", 39, 42], ["tunnel", "OBSERVATION", 53, 59]]], ["10 In addition, trans-acting factors involved in delivering aa-tRNAs and involved in termination are recruited through interactions with both the SSU and LSU.", [["SSU", "CELLULAR_COMPONENT", 146, 149], ["LSU", "CELLULAR_COMPONENT", 154, 157], ["trans-acting factors", "PROTEIN", 16, 36], ["aa-tRNAs", "PROTEIN", 60, 68], ["SSU", "DNA", 146, 149], ["LSU", "DNA", 154, 157]]], ["11 While these functional centers are the features of the ribosome most pertinent to this chapter, it should be noted that the ribosome contains additional functional elements.Establishment of Translational Reading FrameReturning to the question of reading frame establishment, translation initiation differs between bacteria/archae, and eukaryotes.", [["ribosome", "CELLULAR_COMPONENT", 58, 66], ["ribosome", "CELLULAR_COMPONENT", 127, 135], ["archae", "GENE_OR_GENE_PRODUCT", 326, 332], ["functional elements", "DNA", 156, 175], ["reading frame establishment", "PROBLEM", 249, 276], ["bacteria/archae", "PROBLEM", 317, 332], ["functional elements", "OBSERVATION", 156, 175]]], ["In bacteria/archae, special sequences (the Shine-Dalgarno sequence, or SD) located near the 5 ends of their mRNAs are complementary to sequence located near the 3 end of the 16S rRNA (the anti-SD sequence).", [["archae", "GENE_OR_GENE_PRODUCT", 12, 18], ["16S", "GENE_OR_GENE_PRODUCT", 174, 177], ["rRNA", "CELLULAR_COMPONENT", 178, 182], ["Shine-Dalgarno sequence", "DNA", 43, 66], ["5 ends", "DNA", 92, 98], ["mRNAs", "RNA", 108, 113], ["3 end", "DNA", 161, 166], ["16S rRNA", "DNA", 174, 182], ["anti-SD sequence", "DNA", 188, 204], ["bacteria", "PROBLEM", 3, 11], ["archae", "PROBLEM", 12, 18], ["special sequences", "TEST", 20, 37], ["the Shine-Dalgarno sequence", "TEST", 39, 66], ["archae", "ANATOMY", 12, 18]]], ["This complementarity enables the SD on the mRNA to hybridize with the anti-SD on the SSU, properly positioning the initiation codon in the P-site of the decoding center in the SSU, and independent initiation events can be directed on polycistronic mRNAs by separate SD sequences 5 of each initiation site.", [["anti-SD", "GENE_OR_GENE_PRODUCT", 70, 77], ["SSU", "CELLULAR_COMPONENT", 85, 88], ["mRNA", "RNA", 43, 47], ["anti-SD", "DNA", 70, 77], ["SSU", "DNA", 85, 88], ["initiation codon", "DNA", 115, 131], ["P-site", "DNA", 139, 145], ["SSU", "DNA", 176, 179], ["polycistronic mRNAs", "RNA", 234, 253], ["SD sequences 5 of each initiation site", "DNA", 266, 304], ["polycistronic mRNAs", "TREATMENT", 234, 253]]], ["12 Furthermore, variability in the distance between the SD and the initiation codon means that the SD is not sufficient to determine reading frame by itself: this process also requires initiator tRNA and initiation factor 2 (IF2).", [["tRNA and initiation factor 2", "GENE_OR_GENE_PRODUCT", 195, 223], ["IF2", "GENE_OR_GENE_PRODUCT", 225, 228], ["initiation codon", "DNA", 67, 83], ["initiator tRNA and initiation factor 2", "PROTEIN", 185, 223], ["IF2", "PROTEIN", 225, 228], ["initiator tRNA", "TREATMENT", 185, 199], ["variability", "OBSERVATION_MODIFIER", 16, 27]]], ["In eukaryotes, correct positioning of the initiator AUG on the ribosome is a much more complex process involving many more steps and trans-acting factors.", [["ribosome", "CELLULAR_COMPONENT", 63, 71], ["initiator AUG", "DNA", 42, 55], ["trans-acting factors", "PROTEIN", 133, 153], ["the initiator AUG", "TREATMENT", 38, 55], ["positioning", "OBSERVATION_MODIFIER", 23, 34], ["much more complex", "OBSERVATION_MODIFIER", 77, 94], ["process", "OBSERVATION", 95, 102], ["more steps", "OBSERVATION_MODIFIER", 118, 128]]], ["This includes recruitment of the SSU in complex with initiator tRNA and other IFs to the 5 end of the mRNA and scanning of this 43S preinitiation complex along the mRNA in the 3 direction.", [["SSU", "CELLULAR_COMPONENT", 33, 36], ["IFs", "GENE_OR_GENE_PRODUCT", 78, 81], ["43S", "GENE_OR_GENE_PRODUCT", 128, 131], ["SSU", "DNA", 33, 36], ["initiator tRNA", "RNA", 53, 67], ["IFs", "PROTEIN", 78, 81], ["5 end", "RNA", 89, 94], ["mRNA", "RNA", 102, 106], ["43S preinitiation complex", "PROTEIN", 128, 153], ["mRNA", "RNA", 164, 168], ["initiator tRNA", "TREATMENT", 53, 67], ["the mRNA", "TEST", 98, 106], ["scanning", "TEST", 111, 119], ["recruitment", "OBSERVATION_MODIFIER", 14, 25]]], ["Nonetheless, recruitment of the initiator-Met-tRNA to the correct AUG remains the central element in reading frame establishment.", [["Met", "CHEMICAL", 42, 45], ["Met", "GENE_OR_GENE_PRODUCT", 42, 45], ["initiator-Met-tRNA", "DNA", 32, 50], ["AUG", "DNA", 66, 69], ["the initiator", "TREATMENT", 28, 41], ["central element", "OBSERVATION", 82, 97]]], ["13 Similarly, initiator tRNAs are universally recruited to the ribosomal P-site (again with a few exceptions that have been of great utility).", [["ribosomal", "ANATOMY", 63, 72], ["ribosomal", "CELLULAR_COMPONENT", 63, 72], ["initiator tRNAs", "RNA", 14, 29], ["ribosomal P-site", "DNA", 63, 79], ["initiator tRNAs", "TREATMENT", 14, 29]]], ["Recruitment of tRNA to this site is unique to translation initiation: during the remaining course of mRNA translation, subsequent aa-RNAs, and even protein factors that mediate translation termination are recruited to the A-site.", [["tRNA", "CELLULAR_COMPONENT", 15, 19], ["aa-RNAs", "GENE_OR_GENE_PRODUCT", 130, 137], ["aa-RNAs", "PROTEIN", 130, 137], ["protein factors", "PROTEIN", 148, 163], ["Recruitment of tRNA", "TREATMENT", 0, 19], ["mRNA translation", "TREATMENT", 101, 117], ["subsequent aa-RNAs", "TEST", 119, 137], ["even protein factors", "PROBLEM", 143, 163]]], ["In bacteria and archae, the initiator-Met-tRNA is formylated (fMet-tRNA), unlike elongator Met-tRNAs.", [["Met", "CHEMICAL", 38, 41], ["archae", "GENE_OR_GENE_PRODUCT", 16, 22], ["Met", "GENE_OR_GENE_PRODUCT", 38, 41], ["fMet-tRNA", "GENE_OR_GENE_PRODUCT", 62, 71], ["elongator Met-tRNAs", "GENE_OR_GENE_PRODUCT", 81, 100], ["initiator-Met-tRNA", "PROTEIN", 28, 46], ["fMet", "PROTEIN", 62, 66], ["tRNA", "PROTEIN", 67, 71], ["elongator Met-tRNAs", "PROTEIN", 81, 100], ["bacteria", "PROBLEM", 3, 11], ["archae", "PROBLEM", 16, 22], ["bacteria", "OBSERVATION", 3, 11], ["elongator Met-tRNAs", "OBSERVATION", 81, 100]]], ["Eukaryotes encode two distinct species of Met-tRNAs, one specializing in initiation, the other in elongation.", [["Met-tRNAs", "GENE_OR_GENE_PRODUCT", 42, 51], ["Met-tRNAs", "PROTEIN", 42, 51], ["two", "OBSERVATION_MODIFIER", 18, 21], ["distinct", "OBSERVATION_MODIFIER", 22, 30], ["species", "OBSERVATION_MODIFIER", 31, 38], ["elongation", "OBSERVATION_MODIFIER", 98, 108]]], ["While the mechanics of translation initiation differ greatly between bacteria/archae and eukaryotes, recruitment of initiator-Met-tRNAs to the P-site of the SSU is the central feature of translation initiation in all organisms.", [["Met", "CHEMICAL", 126, 129], ["archae", "GENE_OR_GENE_PRODUCT", 78, 84], ["Met", "GENE_OR_GENE_PRODUCT", 126, 129], ["SSU", "CELLULAR_COMPONENT", 157, 160], ["initiator-Met-tRNAs", "PROTEIN", 116, 135], ["P-site", "DNA", 143, 149], ["SSU", "DNA", 157, 160], ["translation initiation", "TREATMENT", 23, 45], ["bacteria/archae and eukaryotes", "PROBLEM", 69, 99], ["initiator", "TREATMENT", 116, 125], ["translation initiation", "PROBLEM", 187, 209], ["translation", "OBSERVATION", 187, 198]]], ["In sum, translational reading frame is generally established by bringing a special species of tRNA to an AUG codon positioned at the ribosomal P-site.Maintenance of Translational Reading FrameHaving established translational reading frame on an mRNA, the ribosome must maintain it throughout the remaining course of translation, the bulk of which is termed the elongation phase.", [["ribosomal", "ANATOMY", 133, 142], ["ribosome", "ANATOMY", 255, 263], ["ribosomal", "CELLULAR_COMPONENT", 133, 142], ["ribosome", "CELLULAR_COMPONENT", 255, 263], ["translational reading frame", "DNA", 8, 35], ["AUG codon", "DNA", 105, 114], ["ribosomal P-site", "DNA", 133, 149], ["translational reading frame", "DNA", 211, 238], ["mRNA", "RNA", 245, 249], ["tRNA", "TREATMENT", 94, 98], ["an AUG codon", "TREATMENT", 102, 114], ["the ribosome", "TREATMENT", 251, 263], ["elongation", "OBSERVATION_MODIFIER", 361, 371], ["phase", "OBSERVATION_MODIFIER", 372, 377]]], ["The first step of elongation occurs when elongator tRNAs are brought to the ribosome in association with a trans-acting factor, called EF-Tu in bacteria/archae, and eEF1A in eukaryotes, and GTP, forming the ternary complex (TC).", [["ribosome", "ANATOMY", 76, 84], ["GTP", "CHEMICAL", 190, 193], ["GTP", "CHEMICAL", 190, 193], ["ribosome", "CELLULAR_COMPONENT", 76, 84], ["EF-Tu", "GENE_OR_GENE_PRODUCT", 135, 140], ["archae", "GENE_OR_GENE_PRODUCT", 153, 159], ["eEF1A", "GENE_OR_GENE_PRODUCT", 165, 170], ["GTP", "SIMPLE_CHEMICAL", 190, 193], ["elongator tRNAs", "RNA", 41, 56], ["trans-acting factor", "PROTEIN", 107, 126], ["EF", "PROTEIN", 135, 137], ["Tu", "PROTEIN", 138, 140], ["archae", "PROTEIN", 153, 159], ["eEF1A", "PROTEIN", 165, 170], ["ternary complex", "PROTEIN", 207, 222], ["TC", "PROTEIN", 224, 226], ["elongator tRNAs", "PROBLEM", 41, 56], ["EF", "TEST", 135, 137], ["Tu in bacteria", "TEST", 138, 152], ["archae", "PROBLEM", 153, 159], ["GTP", "TEST", 190, 193], ["elongation", "OBSERVATION_MODIFIER", 18, 28]]], ["The anticodon loop of elongator aa-tRNA is delivered to the decoding center in the A-site of the SSU, where a correct match between the mRNA codon and aa-tRNA anticodon results in formation of a mini-helix that is recognized and stabilized by additional interactions between both SSU rRNA bases and proteins.", [["SSU", "CELLULAR_COMPONENT", 97, 100], ["elongator aa-tRNA", "PROTEIN", 22, 39], ["A-site", "DNA", 83, 89], ["SSU", "DNA", 97, 100], ["mRNA codon", "RNA", 136, 146], ["aa-tRNA anticodon", "DNA", 151, 168], ["mini-helix", "PROTEIN", 195, 205], ["SSU rRNA bases", "DNA", 280, 294], ["The anticodon loop of elongator aa-tRNA", "TREATMENT", 0, 39], ["the mRNA codon", "TREATMENT", 132, 146], ["aa-tRNA anticodon", "TREATMENT", 151, 168], ["a mini-helix", "PROBLEM", 193, 205], ["anticodon loop", "OBSERVATION", 4, 18], ["elongator", "OBSERVATION_MODIFIER", 22, 31], ["aa-tRNA", "OBSERVATION", 32, 39], ["bases", "ANATOMY_MODIFIER", 289, 294]]], ["14 This in turn results in a structural rearrangement of the SSU and aa-tRNA, which transduces information that causes EF-Tu/eEF1A to hydrolyze GTP, releasing the tRNA from the elongation factor (reviewed in Ref 13) .", [["GTP", "CHEMICAL", 144, 147], ["GTP", "CHEMICAL", 144, 147], ["SSU", "CELLULAR_COMPONENT", 61, 64], ["EF-Tu", "GENE_OR_GENE_PRODUCT", 119, 124], ["eEF1A", "GENE_OR_GENE_PRODUCT", 125, 130], ["GTP", "SIMPLE_CHEMICAL", 144, 147], ["SSU", "DNA", 61, 64], ["aa-tRNA", "PROTEIN", 69, 76], ["EF", "PROTEIN", 119, 121], ["Tu", "PROTEIN", 122, 124], ["eEF1A", "PROTEIN", 125, 130], ["elongation factor", "PROTEIN", 177, 194], ["Ref 13", "PROTEIN", 208, 214], ["EF", "TEST", 119, 121], ["Tu/eEF1A", "TREATMENT", 122, 130], ["hydrolyze GTP", "TREATMENT", 134, 147], ["the tRNA", "TREATMENT", 159, 167]]], ["The aminoacylated 3 end of the aa-tRNA then moves in a process called accommodation, from outside of the LSU through a structural element (the accommodation corridor), and into the A-site side of the PTC.", [["PTC", "ANATOMY", 200, 203], ["PTC", "CANCER", 200, 203], ["aminoacylated 3 end", "DNA", 4, 23], ["aa-tRNA", "PROTEIN", 31, 38], ["LSU", "DNA", 105, 108], ["The aminoacylated", "TREATMENT", 0, 17], ["the aa-tRNA", "TREATMENT", 27, 38], ["structural element", "OBSERVATION", 119, 137], ["PTC", "OBSERVATION", 200, 203]]], ["Simultaneously, EF-Tu/eEF1A + GDP is released from the ribosome to be recharged with GTP and aa-tRNAs.", [["ribosome", "ANATOMY", 55, 63], ["GDP", "CHEMICAL", 30, 33], ["GTP", "CHEMICAL", 85, 88], ["GDP", "CHEMICAL", 30, 33], ["GTP", "CHEMICAL", 85, 88], ["EF-Tu", "GENE_OR_GENE_PRODUCT", 16, 21], ["eEF1A", "GENE_OR_GENE_PRODUCT", 22, 27], ["GDP", "SIMPLE_CHEMICAL", 30, 33], ["ribosome", "CELLULAR_COMPONENT", 55, 63], ["GTP", "SIMPLE_CHEMICAL", 85, 88], ["aa-tRNAs", "SIMPLE_CHEMICAL", 93, 101], ["EF", "PROTEIN", 16, 18], ["Tu", "PROTEIN", 19, 21], ["eEF1A", "PROTEIN", 22, 27], ["GDP", "PROTEIN", 30, 33], ["aa-tRNAs", "PROTEIN", 93, 101], ["EF", "TEST", 16, 18], ["Tu/eEF1A", "TEST", 19, 27], ["GDP", "PROBLEM", 30, 33], ["GTP and aa-tRNAs", "TREATMENT", 85, 101]]], ["15 Catalysis, i.e., peptidyltransfer, occurs in the PTC, where the methionine is transferred from the initiator-tRNA to the elongator tRNA in a process that involves both steric positioning and active catalysis through a transesterification reaction by the ribosome.", [["methionine", "CHEMICAL", 67, 77], ["methionine", "CHEMICAL", 67, 77], ["PTC", "CANCER", 52, 55], ["methionine", "SIMPLE_CHEMICAL", 67, 77], ["ribosome", "CELLULAR_COMPONENT", 257, 265], ["initiator-tRNA", "DNA", 102, 116], ["elongator tRNA", "DNA", 124, 138], ["peptidyltransfer", "TREATMENT", 20, 36], ["the elongator tRNA", "TREATMENT", 120, 138], ["active catalysis", "TREATMENT", 194, 210], ["a transesterification reaction", "TREATMENT", 219, 249], ["PTC", "OBSERVATION", 52, 55], ["elongator tRNA", "OBSERVATION", 124, 138], ["steric positioning", "OBSERVATION", 171, 189], ["active catalysis", "OBSERVATION", 194, 210]]], ["After this process, the 3 end of the deacylated tRNA moves to the E-site on the LSU, the 3 end of the dipeptidyl-tRNA moves to the P-site of the LSU, while the anticodon loops of both tRNAs remain bound to the P-and A-sites of the SSU respectively.", [["dipeptidyl-tRNA", "CHEMICAL", 102, 117], ["tRNA", "CELLULAR_COMPONENT", 48, 52], ["LSU", "CELLULAR_COMPONENT", 80, 83], ["LSU", "GENE_OR_GENE_PRODUCT", 145, 148], ["SSU", "CELLULAR_COMPONENT", 231, 234], ["E-site", "DNA", 66, 72], ["LSU", "DNA", 80, 83], ["dipeptidyl-tRNA", "DNA", 102, 117], ["P-site", "DNA", 131, 137], ["LSU", "DNA", 145, 148], ["anticodon loops", "DNA", 160, 175], ["P-and A-sites", "DNA", 210, 223], ["SSU", "DNA", 231, 234], ["the deacylated tRNA", "TREATMENT", 33, 52], ["the dipeptidyl-tRNA", "TREATMENT", 98, 117], ["the anticodon loops of both tRNAs", "TREATMENT", 156, 189], ["deacylated tRNA", "OBSERVATION", 37, 52], ["anticodon loops", "OBSERVATION", 160, 175], ["both tRNAs", "OBSERVATION", 179, 189]]], ["This conformation is called the 'hybrid state' because the tRNAs occupy one site on the LSU and another on the SSU.", [["SSU", "CELLULAR_COMPONENT", 111, 114], ["LSU", "DNA", 88, 91], ["SSU", "DNA", 111, 114], ["the tRNAs", "TREATMENT", 55, 64]]], ["16 It is also at this step that the ribosome reorients itself from the 'classical' or 'unrotated' state to the 'ratcheted' or 'rotated' state, a process that involves a complex spatial repositioning of the two subunits relative to one another (reviewed in Refs 17 and 18) .", [["ribosome", "ANATOMY", 36, 44], ["ribosome", "CELLULAR_COMPONENT", 36, 44]]], ["Here, a second trans-acting factor, EF-G/eEF2, is recruited to the ribosome.", [["ribosome", "ANATOMY", 67, 75], ["EF-G", "GENE_OR_GENE_PRODUCT", 36, 40], ["eEF2", "GENE_OR_GENE_PRODUCT", 41, 45], ["ribosome", "CELLULAR_COMPONENT", 67, 75], ["trans-acting factor", "PROTEIN", 15, 34], ["EF", "PROTEIN", 36, 38], ["G", "PROTEIN", 39, 40], ["eEF2", "PROTEIN", 41, 45], ["EF", "TEST", 36, 38]]], ["Hydrolysis of GTP by this protein leads to a transition state for translocation where the ribosome disengages from the tRNA-mRNA complexes to allow movement of the anticodons of the P and A-site tRNAs.", [["ribosome", "ANATOMY", 90, 98], ["GTP", "CHEMICAL", 14, 17], ["GTP", "CHEMICAL", 14, 17], ["GTP", "SIMPLE_CHEMICAL", 14, 17], ["ribosome", "CELLULAR_COMPONENT", 90, 98], ["tRNA-mRNA complexes", "PROTEIN", 119, 138], ["P and A-site tRNAs", "RNA", 182, 200], ["Hydrolysis of GTP", "PROBLEM", 0, 17], ["the ribosome disengages", "PROBLEM", 86, 109], ["the tRNA-mRNA complexes", "TREATMENT", 115, 138], ["A-site tRNAs", "TREATMENT", 188, 200]]], ["This movement, coupled with release of the elongation factor, results in full tRNA occupation of the E and P-sites by the deacylated tRNA and dipeptidyl-tRNA, respectively, leaving an empty A-site ready for the next aa-tRNA to decode the next codon.", [["dipeptidyl-tRNA", "CHEMICAL", 142, 157], ["dipeptidyl-tRNA", "GENE_OR_GENE_PRODUCT", 142, 157], ["elongation factor", "PROTEIN", 43, 60], ["E and P-sites", "DNA", 101, 114], ["deacylated tRNA and dipeptidyl-tRNA", "RNA", 122, 157], ["empty A-site", "DNA", 184, 196], ["next aa-tRNA", "RNA", 211, 223], ["the elongation factor", "PROBLEM", 39, 60], ["the E and P-sites", "TREATMENT", 97, 114], ["the deacylated tRNA", "TREATMENT", 118, 137], ["dipeptidyl-tRNA", "TREATMENT", 142, 157], ["the next aa-tRNA", "TREATMENT", 207, 223], ["empty", "OBSERVATION", 184, 189]]], ["15 It is thought that the two subunit nature of the ribosome separates movement of the body of the tRNA on the LSU from that of the mRNA/tRNA complexes on the SSU, enabling it to faithfully maintain translational reading frame (reviewed in Ref 17) .", [["body", "ANATOMY", 87, 91], ["ribosome", "CELLULAR_COMPONENT", 52, 60], ["tRNA", "CELLULAR_COMPONENT", 99, 103], ["LSU", "CELLULAR_COMPONENT", 111, 114], ["SSU", "CELLULAR_COMPONENT", 159, 162], ["LSU", "DNA", 111, 114], ["mRNA", "RNA", 132, 136], ["tRNA complexes", "PROTEIN", 137, 151], ["SSU", "DNA", 159, 162], ["translational reading frame", "DNA", 199, 226], ["the mRNA/tRNA complexes", "TREATMENT", 128, 151], ["ribosome separates", "OBSERVATION", 52, 70], ["movement", "OBSERVATION_MODIFIER", 71, 79], ["tRNA complexes", "OBSERVATION", 137, 151]]], ["More recently, high resolution methods have revealed numerous structural features that are thought to work in concert to assure that tRNAs remain correctly positioned in the ribosome, and that translocation is precisely limited to three nucleotides.", [["ribosome", "ANATOMY", 174, 182], ["nucleotides", "CHEMICAL", 237, 248], ["ribosome", "CELLULAR_COMPONENT", 174, 182], ["numerous structural features", "PROBLEM", 53, 81], ["tRNAs", "TREATMENT", 133, 138], ["numerous", "OBSERVATION_MODIFIER", 53, 61], ["structural features", "OBSERVATION", 62, 81]]], ["18 Subsequent rounds of elongation reiterate this cycle until the ribosome encounters a termination codon (UUA, UGA, or UAG).", [["ribosome", "ANATOMY", 66, 74], ["ribosome", "CELLULAR_COMPONENT", 66, 74], ["termination codon", "DNA", 88, 105], ["UUA", "DNA", 107, 110], ["UGA", "DNA", 112, 115], ["UAG", "DNA", 120, 123], ["UGA", "TEST", 112, 115], ["UAG", "TEST", 120, 123]]], ["Termination codons are specifically recognized by release factors (RF1 and RF2 in bacteria/archae, eF1-eRF3 complex in eukaryotes) that are structural mimics of the TC, which specifically recognize termination codons.", [["RF1", "GENE_OR_GENE_PRODUCT", 67, 70], ["RF2", "GENE_OR_GENE_PRODUCT", 75, 78], ["archae", "GENE_OR_GENE_PRODUCT", 91, 97], ["eF1-eRF3 complex", "GENE_OR_GENE_PRODUCT", 99, 115], ["TC", "GENE_OR_GENE_PRODUCT", 165, 167], ["release factors", "PROTEIN", 50, 65], ["RF1", "PROTEIN", 67, 70], ["RF2", "PROTEIN", 75, 78], ["archae", "PROTEIN", 91, 97], ["eF1", "PROTEIN", 99, 102], ["RF3 complex", "PROTEIN", 104, 115], ["TC", "PROTEIN", 165, 167], ["Termination codons", "TREATMENT", 0, 18], ["RF1", "TEST", 67, 70], ["RF2 in bacteria", "TEST", 75, 90], ["archae", "TEST", 91, 97], ["eF1", "TEST", 99, 102]]], ["19 The lack of an amino donor site by the RFs enables a water molecule to enter the PTC, promoting hydrolysis of the C-terminus of the nascent polypeptide chain from the peptidyl-tRNA, resulting in peptide release.", [["peptidyl-tRNA", "CHEMICAL", 170, 183], ["amino", "CHEMICAL", 18, 23], ["C", "CHEMICAL", 117, 118], ["amino", "AMINO_ACID", 18, 23], ["RFs", "PROTEIN", 42, 45], ["C-terminus", "PROTEIN", 117, 127], ["nascent polypeptide chain", "PROTEIN", 135, 160], ["peptidyl-tRNA", "PROTEIN", 170, 183], ["an amino donor site", "TREATMENT", 15, 34], ["a water molecule", "TREATMENT", 54, 70], ["the PTC", "TREATMENT", 80, 87], ["the C-terminus", "TREATMENT", 113, 127], ["the peptidyl-tRNA", "TREATMENT", 166, 183], ["peptide release", "TREATMENT", 198, 213], ["PTC", "OBSERVATION", 84, 87]]], ["20MECHANISMS OF PROGRAMMED TRANSLATIONAL FRAMESHIFTINGWhile it is obvious that the translational apparatus needs to faithfully maintain reading frame, altering translational fidelity could be advantageous in special circumstances.", [["the translational apparatus", "PROBLEM", 79, 106]]], ["Indeed, many viruses employ numerous molecular mechanisms, generically termed translational recoding.", [["many", "OBSERVATION_MODIFIER", 8, 12], ["viruses", "OBSERVATION", 13, 20]]], ["21 These include but are not limited to directing elongating ribosomes to shift into an alternate reading frame, directing ribosomes to utilize alternative start sites, and bypassing or recoding termination codons.", [["ribosomes", "ANATOMY", 61, 70], ["ribosomes", "ANATOMY", 123, 132], ["ribosomes", "CELLULAR_COMPONENT", 61, 70], ["ribosomes", "CELLULAR_COMPONENT", 123, 132], ["alternate reading frame", "DNA", 88, 111], ["alternative start sites", "DNA", 144, 167], ["elongating ribosomes", "PROBLEM", 50, 70], ["alternative start sites", "TREATMENT", 144, 167]]], ["5 This is particularly relevant when genomic space is physically constrained, e.g., in viruses, where genome size is limited by the volume of the viral particle.", [["size", "OBSERVATION_MODIFIER", 109, 113], ["viral particle", "OBSERVATION", 146, 160]]], ["Here, expanding the information content of a viral mRNA by enabling it to encode multiple proteins may confer a selective advantage.", [["viral mRNA", "RNA", 45, 55], ["a viral mRNA", "PROBLEM", 43, 55], ["a selective advantage", "TREATMENT", 110, 131]]], ["Another idea is that the ability for a single RNA to encode multiple proteins without having to alter its sequence (e.g., through splicing), may have conferred a selective advantage in the prebiotic RNA world.", [["a single RNA", "PROBLEM", 37, 49], ["multiple proteins", "PROBLEM", 60, 77]]], ["22 Additionally, the ability to recode mRNAs provides yet another level at which gene expression can be controlled.", [["mRNAs", "RNA", 39, 44]]], ["Notably, these mechanisms are all 'programmed' to occur at specific sequences by cis-acting elements present on mRNAs, and at rates that are two or more orders of magnitude more frequent than nonprogrammed events.MECHANISMS OF PROGRAMMED TRANSLATIONAL FRAMESHIFTINGHaving identified the players and defined the contexts during which PRF events occur, we will focus on molecular mechanisms that program elongating ribosomes to shift translational reading frame at specific sites along mRNAs, and discuss their physiological relevance.\u22121 Programmed Ribosomal FrameshiftingOur understanding of \u22121 PRF originates from studies of RNA viruses, many of which use this molecular mechanism to expand the information content of their mRNAs.", [["ribosomes", "ANATOMY", 413, 422], ["ribosomes", "CELLULAR_COMPONENT", 413, 422], ["\u22121", "GENE_OR_GENE_PRODUCT", 591, 593], ["cis-acting elements", "DNA", 81, 100], ["mRNAs", "RNA", 112, 117], ["translational reading frame", "DNA", 432, 459], ["mRNAs", "RNA", 484, 489], ["\u22121 PRF", "DNA", 591, 597], ["mRNAs", "RNA", 724, 729], ["\u22121 PRF", "PROBLEM", 591, 597], ["RNA viruses", "PROBLEM", 625, 636], ["Ribosomal Frameshifting", "OBSERVATION", 547, 570]]], ["The relatively large number of viral \u22121 PRF signals has enabled definition of some of the parameters constituting a \u22121 PRF signal.", [["viral \u22121 PRF signals", "PROBLEM", 31, 51], ["the parameters", "TEST", 86, 100], ["a \u22121 PRF signal", "PROBLEM", 114, 129], ["relatively", "OBSERVATION_MODIFIER", 4, 14], ["large", "OBSERVATION_MODIFIER", 15, 20], ["number", "OBSERVATION_MODIFIER", 21, 27], ["viral \u22121", "OBSERVATION", 31, 39]]], ["The most welldefined \u22121 PRF phenomena are directed by an mRNA sequence motif composed of three important elements: a 'slippery site' composed of seven nucleotides where the translational shift in reading frame actually takes place; a short spacer sequence of usually less than 12 nucleotides; and a downstream stimulatory structure (usually an mRNA pseudoknot).", [["nucleotides", "CHEMICAL", 151, 162], ["nucleotides", "CHEMICAL", 280, 291], ["mRNA sequence motif", "DNA", 57, 76], ["slippery site", "DNA", 118, 131], ["reading frame", "DNA", 196, 209], ["short spacer sequence", "DNA", 234, 255], ["downstream stimulatory structure", "DNA", 299, 331], ["mRNA pseudoknot", "RNA", 344, 359], ["The most welldefined \u22121 PRF phenomena", "PROBLEM", 0, 37], ["an mRNA sequence motif", "TREATMENT", 54, 76], ["a 'slippery site", "TREATMENT", 115, 131], ["seven nucleotides", "TREATMENT", 145, 162], ["a short spacer sequence", "TEST", 232, 255], ["a downstream stimulatory structure", "PROBLEM", 297, 331]]], ["In eukaryotic viruses, the slippery site has the heptameric motif N NNW WWH (IUPAC notation), where the incoming reading frame is indicated by spaces.", [["N", "CHEMICAL", 66, 67], ["slippery site", "DNA", 27, 40], ["incoming reading frame", "DNA", 104, 126], ["eukaryotic viruses", "OBSERVATION", 3, 21]]], ["23 In general, it has been accepted that the downstream structure causes elongating ribosomes to pause with tRNAs positioned at the slippery site.", [["ribosomes", "ANATOMY", 84, 93], ["ribosomes", "CELLULAR_COMPONENT", 84, 93], ["slippery site", "DNA", 132, 145], ["elongating ribosomes", "PROBLEM", 73, 93], ["tRNAs", "TREATMENT", 108, 113], ["elongating ribosomes", "OBSERVATION", 73, 93], ["slippery site", "OBSERVATION", 132, 145]]], ["The nature of the slippery sequence enables repairing of the nonwobble bases of both the aa and peptidyl-tRNAs with the \u22121 frame codons.", [["slippery sequence", "DNA", 18, 35], ["aa and peptidyl-tRNAs", "RNA", 89, 110], ["\u22121 frame codons", "DNA", 120, 135], ["the slippery sequence", "TREATMENT", 14, 35], ["the aa and peptidyl-tRNAs", "TREATMENT", 85, 110], ["bases", "ANATOMY_MODIFIER", 71, 76]]], ["24 While it is generally accepted that mRNA pseudoknots are the most common type of downstream stimulatory elements, other mRNA structures are capable of filling this role as well.", [["mRNA pseudoknots", "RNA", 39, 55], ["downstream stimulatory elements", "DNA", 84, 115], ["mRNA pseudoknots", "PROBLEM", 39, 55], ["mRNA pseudoknots", "OBSERVATION", 39, 55], ["most common", "OBSERVATION_MODIFIER", 64, 75], ["stimulatory elements", "OBSERVATION", 95, 115], ["filling", "OBSERVATION", 154, 161]]], ["[25] [26] [27] Generally, it is thought that the essential function of the stimulatory structure short spacer, and a complex tertiary mRNA structure, typically an H-type pseudoknot.", [["stimulatory structure short spacer", "RNA", 75, 109], ["complex tertiary mRNA structure", "RNA", 117, 148], ["the stimulatory structure short spacer", "PROBLEM", 71, 109], ["a complex tertiary mRNA structure", "PROBLEM", 115, 148], ["complex", "OBSERVATION_MODIFIER", 117, 124], ["tertiary mRNA", "OBSERVATION", 125, 138], ["type pseudoknot", "OBSERVATION", 165, 180]]], ["The original translational reading frame at the slippery site is indicated by spaces.", [["translational reading frame", "DNA", 13, 40], ["slippery site", "DNA", 48, 61]]], ["The 22 functional slippery sites are shown. (b) The many paths to \u22121 PRF.", [["22 functional slippery sites", "DNA", 4, 32], ["PRF", "DNA", 69, 72], ["The 22 functional slippery sites", "TREATMENT", 0, 32], ["22 functional", "OBSERVATION_MODIFIER", 4, 17], ["slippery sites", "OBSERVATION", 18, 32]]], ["As described in the text, \u22121 PRF can occur at three different times during translation at the frameshift signal.", [["\u22121 PRF", "DNA", 26, 32]]], ["The pseudoknot can direct a two nucleotide translocation event either as the ribosome enters (left, boxed 1) or exits (right, boxed 3) the slippery site.", [["ribosome", "ANATOMY", 77, 85], ["nucleotide", "CHEMICAL", 32, 42], ["nucleotide", "CHEMICAL", 32, 42], ["right, boxed 3) the slippery site", "DNA", 119, 152], ["a two nucleotide translocation event", "PROBLEM", 26, 62], ["exits (right, boxed 3) the slippery site", "PROBLEM", 112, 152], ["pseudoknot", "OBSERVATION", 4, 14], ["left", "ANATOMY_MODIFIER", 94, 98], ["right", "ANATOMY_MODIFIER", 119, 124], ["slippery site", "OBSERVATION", 139, 152]]], ["Alternatively, accommodation of the aminoacyl tRNA (aa-tRNA) into the slippery site pulls the downstream mRNA into the ribosome by 9\u00c5, creating tension between the slippery site and pseudoknot (center, boxed 2).", [["ribosome", "ANATOMY", 119, 127], ["aminoacyl tRNA", "CHEMICAL", 36, 50], ["aminoacyl", "CHEMICAL", 36, 45], ["ribosome", "CELLULAR_COMPONENT", 119, 127], ["aminoacyl tRNA", "PROTEIN", 36, 50], ["aa-tRNA", "PROTEIN", 52, 59], ["slippery site", "DNA", 70, 83], ["downstream mRNA", "RNA", 94, 109], ["slippery site", "DNA", 164, 177], ["the aminoacyl tRNA (aa-tRNA)", "TREATMENT", 32, 60], ["the slippery site", "PROBLEM", 66, 83], ["creating tension between the slippery site", "PROBLEM", 135, 177], ["aminoacyl tRNA", "OBSERVATION", 36, 50], ["slippery site", "OBSERVATION", 70, 83], ["ribosome", "ANATOMY", 119, 127], ["tension", "OBSERVATION", 144, 151], ["slippery site", "OBSERVATION", 164, 177], ["pseudoknot", "OBSERVATION", 182, 192]]], ["The tension is relieved by decoupling tRNAs from the mRNA, with the mRNA slipping backward by one base.\u22121 Programmed Ribosomal Frameshiftingis to provide an energetic barrier to an elongating ribosome, and to position it over the slippery site.", [["ribosome", "ANATOMY", 192, 200], ["ribosome", "CELLULAR_COMPONENT", 192, 200], ["tRNAs", "RNA", 38, 43], ["mRNA", "RNA", 53, 57], ["mRNA", "RNA", 68, 72], ["slippery site", "DNA", 230, 243], ["The tension", "PROBLEM", 0, 11], ["decoupling tRNAs", "PROBLEM", 27, 43], ["Programmed Ribosomal Frameshiftingis", "TREATMENT", 106, 142], ["an energetic barrier", "TREATMENT", 154, 174], ["an elongating ribosome", "TREATMENT", 178, 200], ["tension", "OBSERVATION", 4, 11], ["relieved", "OBSERVATION_MODIFIER", 15, 23], ["decoupling tRNAs", "OBSERVATION", 27, 43], ["base", "ANATOMY_MODIFIER", 98, 102], ["Ribosomal Frameshiftingis", "OBSERVATION", 117, 142], ["elongating ribosome", "OBSERVATION", 181, 200], ["slippery site", "OBSERVATION", 230, 243]]], ["However, the thermodynamic stability of the downstream barrier is not the sole determinant of frameshift efficiency: additional parameters, both known and unknown influence this parameter.", [["frameshift efficiency", "PROBLEM", 94, 115], ["thermodynamic stability", "OBSERVATION", 13, 36], ["downstream barrier", "OBSERVATION", 44, 62], ["frameshift efficiency", "OBSERVATION", 94, 115]]], ["28 The original simultaneous-slippage model 24 of \u22121 PRF suggested that peptidyl and aa-tRNAs simultaneously slip by one base in the 5 direction to base pair with the \u22121 frame codons in the slippery site.", [["peptidyl", "SIMPLE_CHEMICAL", 72, 80], ["\u22121 PRF", "DNA", 50, 56], ["peptidyl and aa-tRNAs", "PROTEIN", 72, 93], ["\u22121 frame codons", "DNA", 167, 182], ["slippery site", "DNA", 190, 203], ["\u22121 PRF", "TREATMENT", 50, 56], ["peptidyl and aa-tRNAs simultaneously slip", "TREATMENT", 72, 113], ["slippery site", "OBSERVATION", 190, 203]]], ["From this general conceptual framework, the precise mechanistic details of \u22121 PRF have been debated, and three apparently competing models were proposed for the mechanism of \u22121 PRF.", [["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 75, 81], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 174, 180], ["\u22121 PRF", "PROTEIN", 75, 81], ["\u22121 PRF", "PROBLEM", 174, 180]]], ["In each of these, physical slippage of the ribosome is coupled to the energetic input of GTP hydrolysis.", [["ribosome", "ANATOMY", 43, 51], ["GTP", "CHEMICAL", 89, 92], ["GTP", "CHEMICAL", 89, 92], ["ribosome", "CELLULAR_COMPONENT", 43, 51], ["GTP", "SIMPLE_CHEMICAL", 89, 92], ["GTP hydrolysis", "PROBLEM", 89, 103], ["slippage", "OBSERVATION", 27, 35], ["GTP hydrolysis", "OBSERVATION", 89, 103]]], ["The 'integrated model' model of \u22121 PRF posited that the shift occurs after delivery of the aa-tRNA to the A-site, but before peptidyltransfer.", [["\u22121 PRF", "DNA", 32, 38], ["aa-tRNA", "RNA", 91, 98], ["A-site", "DNA", 106, 112], ["The 'integrated model' model of \u22121 PRF", "TREATMENT", 0, 38], ["delivery", "TREATMENT", 75, 83], ["the aa-tRNA", "TREATMENT", 87, 98]]], ["23 This corresponds to Box 2 in Figure 1 (b).", [["Box 2", "DNA", 23, 28]]], ["A refinement of this model, called the '9\u00c5 solution' proposed that the downstream stimulatory element plays an active role in \u22121 PRF by resisting 5 movement of the mRNA subsequent to aa-tRNA accommodation (enabled by eEF1A hydrolysis of GTP).", [["GTP", "CHEMICAL", 237, 240], ["GTP", "CHEMICAL", 237, 240], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 126, 132], ["aa-tRNA", "SIMPLE_CHEMICAL", 183, 190], ["eEF1A", "GENE_OR_GENE_PRODUCT", 217, 222], ["GTP", "SIMPLE_CHEMICAL", 237, 240], ["downstream stimulatory element", "DNA", 71, 101], ["\u22121 PRF", "DNA", 126, 132], ["mRNA", "RNA", 164, 168], ["eEF1A", "PROTEIN", 217, 222], ["the '9\u00c5 solution'", "TREATMENT", 35, 52], ["the downstream stimulatory element", "TREATMENT", 67, 101], ["\u22121 PRF", "TREATMENT", 126, 132], ["eEF1A hydrolysis of GTP", "TREATMENT", 217, 240], ["active", "OBSERVATION_MODIFIER", 111, 117]]], ["This creates tension along the mRNA that can be relieved by disengaging the tRNAs from the mRNA, thus allowing the mRNA to shift forward by one base relative to the tRNA/ribosome complex.", [["ribosome", "CELLULAR_COMPONENT", 170, 178], ["mRNA", "RNA", 31, 35], ["tRNAs", "RNA", 76, 81], ["mRNA", "RNA", 91, 95], ["mRNA", "RNA", 115, 119], ["tRNA/ribosome complex", "PROTEIN", 165, 186], ["tension along the mRNA", "PROBLEM", 13, 35], ["the tRNAs", "PROBLEM", 72, 81], ["the tRNA/ribosome complex", "TREATMENT", 161, 186], ["tension", "OBSERVATION", 13, 20], ["ribosome complex", "OBSERVATION", 170, 186]]], ["29 A second model proposed that \u22121 PRF occurs during translocation, where the energy driving slippage is supplied by eEF2 hydrolysis of GTP, and the downstream stimulatory element resists forward movement of the ribosome, resulting in translocation by only two nucleotides.", [["ribosome", "ANATOMY", 212, 220], ["GTP", "CHEMICAL", 136, 139], ["GTP", "CHEMICAL", 136, 139], ["nucleotides", "CHEMICAL", 261, 272], ["\u22121", "GENE_OR_GENE_PRODUCT", 32, 34], ["eEF2", "GENE_OR_GENE_PRODUCT", 117, 121], ["GTP", "SIMPLE_CHEMICAL", 136, 139], ["ribosome", "CELLULAR_COMPONENT", 212, 220], ["\u22121 PRF", "PROTEIN", 32, 38], ["eEF2", "PROTEIN", 117, 121], ["downstream stimulatory element", "DNA", 149, 179], ["the energy driving slippage", "PROBLEM", 74, 101], ["eEF2 hydrolysis of GTP", "PROBLEM", 117, 139], ["the downstream stimulatory element", "PROBLEM", 145, 179], ["driving slippage", "OBSERVATION", 85, 101], ["eEF2 hydrolysis", "OBSERVATION", 117, 132], ["stimulatory element", "OBSERVATION", 160, 179], ["resists", "OBSERVATION_MODIFIER", 180, 187], ["forward movement", "OBSERVATION", 188, 204], ["ribosome", "ANATOMY", 212, 220]]], ["Importantly, this cotranslocation model can occur through two discrete kinetic pathways.", [["discrete", "OBSERVATION_MODIFIER", 62, 70], ["kinetic pathways", "OBSERVATION", 71, 87]]], ["One of these pathways occurs after peptidyltransfer, with the two tRNAs moving to P/E and A/P states, followed by an incomplete, two-base translocation event.", [["P", "DNA", 82, 83], ["E", "DNA", 84, 85], ["P states", "DNA", 92, 100], ["peptidyltransfer", "TREATMENT", 35, 51], ["the two tRNAs", "TREATMENT", 58, 71], ["an incomplete, two-base translocation event", "PROBLEM", 114, 157], ["translocation event", "OBSERVATION", 138, 157]]], ["30, 31 This is denoted by Box 3 in Figure 1(b) .", [["Box 3", "PROTEIN", 26, 31]]], ["The second cotranslocational model proposed that incomplete translocation stimulated by the downstream element occurs one elongation cycle earlier: here, the E and P-site tRNAs slip so that the new A-site codon is in the \u22121 frame 32 as indicated by Box 1 in Figure 1(b) .\u22121 Programmed Ribosomal FrameshiftingImportantly, there is strong experimental evidence supporting all three models, suggesting that rather than explaining \u22121 PRF through a single molecular mechanism, \u22121 PRF should be conceived as a problem of kinetic partitioning occurring within the context of the translation elongation cycle.", [["Box 1", "GENE_OR_GENE_PRODUCT", 249, 254], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 427, 433], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 472, 478], ["downstream element", "DNA", 92, 110], ["E and P-site", "DNA", 158, 170], ["A-site codon", "DNA", 198, 210], ["\u22121 frame 32", "DNA", 221, 232], ["Box 1", "DNA", 249, 254], ["\u22121 PRF", "DNA", 427, 433], ["incomplete translocation", "PROBLEM", 49, 73], ["the E and P-site tRNAs slip", "TREATMENT", 154, 181], ["the new A-site codon", "PROBLEM", 190, 210], ["\u22121 PRF", "PROBLEM", 427, 433], ["\u22121 PRF", "TREATMENT", 472, 478], ["kinetic partitioning", "PROBLEM", 515, 535], ["elongation", "OBSERVATION_MODIFIER", 122, 132], ["tRNAs slip", "OBSERVATION", 171, 181], ["new", "OBSERVATION_MODIFIER", 194, 197], ["strong", "OBSERVATION_MODIFIER", 330, 336], ["experimental", "OBSERVATION", 337, 349], ["kinetic partitioning", "OBSERVATION", 515, 535], ["translation elongation", "OBSERVATION", 572, 594]]], ["With this in mind, the 'many pathways model' of \u22121 PRF unified all three models and revealed the major steps in the translation elongation cycle that affect \u22121 PRF.", [["\u22121 PRF", "DNA", 48, 54], ["\u22121 PRF", "PROTEIN", 157, 163], ["elongation", "OBSERVATION_MODIFIER", 128, 138]]], ["Importantly, this model provides a mathematical framework within which estimates can be calculated regarding the relative contributions of each of the elements to rates of \u22121 PRF, how often ribosomes will partition between the 0 and \u22121 frames, and how this partitioning will distribute at each of the three possible stages of the elongation cycle.", [["ribosomes", "ANATOMY", 190, 199], ["ribosomes", "CELLULAR_COMPONENT", 190, 199], ["0 and \u22121 frames", "DNA", 227, 242], ["\u22121 PRF", "TREATMENT", 172, 178], ["elongation cycle", "OBSERVATION", 330, 346]]], ["In sum, the 'many pathways model' of \u22121 PRF presents a unified theory of \u22121 PRF that also provides a toolbox for quantitative prediction of \u22121 PRF rates.+1 Programmed Ribosomal FrameshiftingIn contrast to \u22121 PRF where the translational reading frame is recoded by one nucleotide toward the 5 direction of the mRNA, the elongating ribosome is induced to bypass one nucleotide toward 3 direction in +1 PRF. +1 PRF has been observed in Escherichia coli in the translation of prfB to produce RF2.", [["ribosome", "ANATOMY", 330, 338], ["nucleotide", "CHEMICAL", 268, 278], ["nucleotide", "CHEMICAL", 364, 374], ["ribosome", "CELLULAR_COMPONENT", 330, 338], ["Escherichia coli", "ORGANISM", 433, 449], ["prfB", "GENE_OR_GENE_PRODUCT", 472, 476], ["RF2", "GENE_OR_GENE_PRODUCT", 488, 491], ["\u22121 PRF", "DNA", 37, 43], ["\u22121 PRF", "DNA", 205, 211], ["translational reading frame", "DNA", 222, 249], ["mRNA", "RNA", 309, 313], ["+1 PRF", "DNA", 397, 403], ["+1 PRF", "DNA", 405, 411], ["prfB", "PROTEIN", 472, 476], ["RF2", "PROTEIN", 488, 491], ["Escherichia coli", "SPECIES", 433, 449], ["Escherichia coli", "SPECIES", 433, 449], ["\u22121 PRF", "PROBLEM", 73, 79], ["a toolbox", "TEST", 99, 108], ["\u22121 PRF rates", "TREATMENT", 140, 152], ["Programmed Ribosomal Frameshifting", "TREATMENT", 156, 190], ["the elongating ribosome", "PROBLEM", 315, 338], ["+1 PRF", "PROBLEM", 405, 411], ["Escherichia coli", "PROBLEM", 433, 449], ["prfB", "TREATMENT", 472, 476], ["1 Programmed", "OBSERVATION_MODIFIER", 154, 166], ["Ribosomal Frameshifting", "OBSERVATION", 167, 190], ["elongating ribosome", "OBSERVATION", 319, 338], ["Escherichia coli", "OBSERVATION", 433, 449]]], ["34 In the yeast Saccharomyces cerevisiae two retrotransposable elements, Ty1 and Ty3, 35, 36 and three genes, ABP140, 37 EST3, 38 and OAZ1 39 use +1 PRF.", [["yeast Saccharomyces cerevisiae", "ORGANISM", 10, 40], ["Ty1", "GENE_OR_GENE_PRODUCT", 73, 76], ["Ty3", "GENE_OR_GENE_PRODUCT", 81, 84], ["yeast Saccharomyces cerevisiae two retrotransposable elements", "DNA", 10, 71], ["Ty1", "DNA", 73, 76], ["Ty3", "DNA", 81, 84], ["35, 36 and three genes", "DNA", 86, 108], ["ABP140", "DNA", 110, 116], ["EST3", "DNA", 121, 125], ["OAZ1 39", "DNA", 134, 141], ["+1 PRF", "DNA", 146, 152], ["yeast", "SPECIES", 10, 15], ["Saccharomyces cerevisiae", "SPECIES", 16, 40], ["yeast", "SPECIES", 10, 15], ["Saccharomyces cerevisiae", "SPECIES", 16, 40], ["Ty1", "TEST", 73, 76], ["Ty3", "TEST", 81, 84], ["ABP140", "TEST", 110, 116], ["EST3", "TEST", 121, 125], ["OAZ1", "TEST", 134, 138]]], ["The expression of the mammalian equivalent of yeast OAZ1, ornithine decarboxylase antizyme (i.e., OAZ), has also been shown to involve +1 PRF.", [["ornithine", "CHEMICAL", 58, 67], ["ornithine", "CHEMICAL", 58, 67], ["OAZ1", "GENE_OR_GENE_PRODUCT", 52, 56], ["ornithine decarboxylase antizyme", "GENE_OR_GENE_PRODUCT", 58, 90], ["+1 PRF", "GENE_OR_GENE_PRODUCT", 135, 141], ["yeast OAZ1", "PROTEIN", 46, 56], ["ornithine decarboxylase antizyme", "PROTEIN", 58, 90], ["OAZ", "PROTEIN", 98, 101], ["+1 PRF", "PROTEIN", 135, 141], ["yeast", "SPECIES", 46, 51], ["yeast", "SPECIES", 46, 51], ["yeast OAZ1", "TREATMENT", 46, 56], ["ornithine decarboxylase antizyme", "TREATMENT", 58, 90], ["yeast OAZ1", "OBSERVATION", 46, 56]]], ["40 Unlike \u22121 PRF, where there is only one generally well-understood type of frameshift signal, +1 PRF signals appear case specific.", [["frameshift signal", "PROBLEM", 76, 93]]], ["However, it is clear that +1 PRF is also driven by cis-acting elements that cause elongating ribosomes to kinetically partition into the +1 frame, and that slippage of P-site tRNA appear to be the most important parameter.", [["ribosomes", "ANATOMY", 93, 102], ["PRF", "GENE_OR_GENE_PRODUCT", 29, 32], ["ribosomes", "CELLULAR_COMPONENT", 93, 102], ["+1 PRF", "DNA", 26, 32], ["cis-acting elements", "DNA", 51, 70], ["+1 frame", "DNA", 137, 145], ["P-site tRNA", "DNA", 168, 179], ["+1 PRF", "PROBLEM", 26, 32], ["elongating ribosomes", "PROBLEM", 82, 102], ["slippage of P-site tRNA", "TREATMENT", 156, 179], ["clear", "OBSERVATION", 15, 20], ["slippage", "OBSERVATION_MODIFIER", 156, 164]]], ["In the bacterial cases such as the E. coli prfB mRNA, the U CUU UGA slippery site contains the in frame UGA termination codon which is recognized by RF2.", [["E. coli", "ORGANISM", 35, 42], ["prfB", "GENE_OR_GENE_PRODUCT", 43, 47], ["U CUU", "GENE_OR_GENE_PRODUCT", 58, 63], ["RF2", "GENE_OR_GENE_PRODUCT", 149, 152], ["E. coli prfB mRNA", "RNA", 35, 52], ["U CUU UGA slippery site", "DNA", 58, 81], ["UGA termination codon", "DNA", 104, 125], ["RF2", "PROTEIN", 149, 152], ["E. coli", "SPECIES", 35, 42], ["E. coli", "SPECIES", 35, 42], ["the E. coli prfB mRNA", "TREATMENT", 31, 52], ["the U CUU UGA slippery site", "TREATMENT", 54, 81], ["UGA termination codon", "TREATMENT", 104, 125], ["bacterial cases", "OBSERVATION", 7, 22], ["UGA slippery", "OBSERVATION", 64, 76], ["termination codon", "OBSERVATION", 108, 125]]], ["41 While translation termination is efficient when RF2 levels are high, low RF2 levels result in inefficient recognition of the UGA codon.", [["RF2", "GENE_OR_GENE_PRODUCT", 51, 54], ["RF2", "GENE_OR_GENE_PRODUCT", 76, 79], ["RF2", "PROTEIN", 51, 54], ["RF2", "PROTEIN", 76, 79], ["UGA codon", "DNA", 128, 137], ["RF2 levels", "TEST", 51, 61], ["low RF2 levels", "PROBLEM", 72, 86], ["the UGA codon", "PROBLEM", 124, 137], ["UGA codon", "OBSERVATION", 128, 137]]], ["This causes the ribosome to pause.", [["ribosome", "CELLULAR_COMPONENT", 16, 24], ["ribosome to pause", "OBSERVATION", 16, 33]]], ["An SD-like sequence located in the prfB mRNA immediately 5 of the slippery site interacts with the anti-SD sequence on the 16S rRNA so as to reposition the ribosome in the +1 frame.", [["ribosome", "ANATOMY", 156, 164], ["prfB", "GENE_OR_GENE_PRODUCT", 35, 39], ["rRNA", "CELLULAR_COMPONENT", 127, 131], ["ribosome", "CELLULAR_COMPONENT", 156, 164], ["SD-like sequence", "DNA", 3, 19], ["prfB mRNA", "RNA", 35, 44], ["slippery site", "DNA", 66, 79], ["anti-SD sequence", "DNA", 99, 115], ["16S rRNA", "DNA", 123, 131], ["+1 frame", "DNA", 172, 180], ["An SD-like sequence", "PROBLEM", 0, 19], ["the anti-SD sequence", "TEST", 95, 115], ["SD", "OBSERVATION", 3, 5], ["slippery site", "OBSERVATION", 66, 79], ["+1 frame", "OBSERVATION", 172, 180]]], ["Thus, RF2 production is autoregulated through +1 PRF.", [["RF2", "GENE_OR_GENE_PRODUCT", 6, 9], ["+1 PRF", "GENE_OR_GENE_PRODUCT", 46, 52], ["RF2", "PROTEIN", 6, 9], ["+1 PRF", "DNA", 46, 52]]], ["42 More recently, mathematical modeling of the prfB +1 PRF signal revealed that this mechanism is influenced by three distinct kinetic parameters: (1) destabilization of deacylated tRNA in the E-site, (2) rearrangement of peptidyl-tRNA in the P-site, and (3) the availability of cognate aa-tRNA corresponding to the A-site.", [["prfB", "GENE_OR_GENE_PRODUCT", 47, 51], ["peptidyl-tRNA", "GENE_OR_GENE_PRODUCT", 222, 235], ["prfB", "PROTEIN", 47, 51], ["deacylated tRNA", "RNA", 170, 185], ["E-site", "DNA", 193, 199], ["peptidyl-tRNA", "PROTEIN", 222, 235], ["P-site", "DNA", 243, 249], ["cognate aa-tRNA", "PROTEIN", 279, 294], ["the prfB +1 PRF signal", "TEST", 43, 65], ["deacylated tRNA", "TREATMENT", 170, 185], ["peptidyl-tRNA", "TREATMENT", 222, 235], ["cognate aa-tRNA", "TREATMENT", 279, 294], ["kinetic parameters", "OBSERVATION", 127, 145], ["deacylated tRNA", "OBSERVATION", 170, 185]]], ["43 While all three function synergistically to promote efficient +1 PRF, a rate constant of \u22481.9 s \u22121 for slippage of the P-site tRNA from CUU to UUU is the driving force behind this mechanism.", [["CUU", "CHEMICAL", 139, 142], ["CUU", "SIMPLE_CHEMICAL", 139, 142], ["+1 PRF", "DNA", 65, 71], ["P-site tRNA", "DNA", 122, 133], ["a rate", "TEST", 73, 79], ["slippage", "PROBLEM", 106, 114], ["the P-site tRNA", "TREATMENT", 118, 133]]], ["The +1 PRF is also enhanced by the presence of a 'hungry codon' in the A-site (i.e., low abundance of RF2), and destabilization of tRNA-mRNA interactions in the E-site.+1 Programmed Ribosomal FrameshiftingEukaryotic translation does not utilize mechanisms analogous to the SD/anti-SD interactions that direct prokaryotic initiation and +1 PRF.", [["RF2", "GENE_OR_GENE_PRODUCT", 102, 105], ["+1 PRF", "GENE_OR_GENE_PRODUCT", 336, 342], ["+1 PRF", "DNA", 4, 10], ["A-site", "DNA", 71, 77], ["RF2", "PROTEIN", 102, 105], ["E-site", "DNA", 161, 167], ["prokaryotic initiation and +1 PRF", "DNA", 309, 342], ["a 'hungry codon'", "PROBLEM", 47, 63], ["tRNA", "TREATMENT", 131, 135], ["mRNA interactions", "PROBLEM", 136, 153], ["Programmed Ribosomal Frameshifting", "TREATMENT", 171, 205], ["+1 PRF", "OBSERVATION_MODIFIER", 4, 10], ["hungry codon", "OBSERVATION", 50, 62], ["Ribosomal Frameshifting", "OBSERVATION", 182, 205], ["Eukaryotic translation", "OBSERVATION", 205, 227]]], ["Thus, the +1 PRF kinetic partitioning must be driven by other mechanisms.", [["the +1 PRF kinetic partitioning", "TREATMENT", 6, 37]]], ["In OAZ mRNA +1 PRF, the primary kinetic trap appears to be the presence of a strong secondary mRNA structure 3 of the slippery site.", [["+1 PRF", "GENE_OR_GENE_PRODUCT", 12, 18], ["OAZ mRNA", "RNA", 3, 11], ["slippery site", "DNA", 118, 131], ["the primary kinetic trap", "TEST", 20, 44], ["a strong secondary mRNA structure", "PROBLEM", 75, 108], ["strong", "OBSERVATION_MODIFIER", 77, 83], ["secondary mRNA structure", "OBSERVATION", 84, 108], ["slippery site", "OBSERVATION", 118, 131]]], ["However, the element that stimulates OAZ +1 PRF has undergone a significant amount of evolutionary divergence.", [["OAZ +1 PRF", "GENE_OR_GENE_PRODUCT", 37, 47], ["OAZ +1 PRF", "DNA", 37, 47], ["evolutionary divergence", "PROBLEM", 86, 109], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["amount", "OBSERVATION_MODIFIER", 76, 82], ["evolutionary divergence", "OBSERVATION", 86, 109]]], ["For example, while almost all vertebrate OAZ +1 PRF signals involve mRNA pseudoknots, fewer protostome OAZ sequences contain predicted pseudoknots, most nematodes lack the ability to form this type of structure, and no pseudoknots can be calculated in any yeast/fungi or insect OAZ +1 PRF signals.", [["OAZ", "GENE_OR_GENE_PRODUCT", 41, 44], ["PRF", "GENE_OR_GENE_PRODUCT", 48, 51], ["OAZ", "DNA", 41, 44], ["mRNA pseudoknots", "RNA", 68, 84], ["protostome OAZ sequences", "DNA", 92, 116], ["yeast", "SPECIES", 256, 261], ["yeast", "SPECIES", 256, 261], ["mRNA pseudoknots", "PROBLEM", 68, 84], ["fewer protostome OAZ sequences", "TEST", 86, 116], ["predicted pseudoknots", "PROBLEM", 125, 146], ["pseudoknots", "PROBLEM", 219, 230], ["any yeast/fungi", "PROBLEM", 252, 267], ["mRNA pseudoknots", "OBSERVATION", 68, 84], ["predicted pseudoknots", "OBSERVATION", 125, 146], ["no", "UNCERTAINTY", 216, 218], ["pseudoknots", "OBSERVATION", 219, 230]]], ["39 Similarly, the slippery sites of OAZ have diverged.", [["OAZ", "CANCER", 36, 39], ["slippery sites", "DNA", 18, 32], ["slippery", "OBSERVATION_MODIFIER", 18, 26], ["diverged", "OBSERVATION_MODIFIER", 45, 53]]], ["The metazoan OAZ slippery site is UCC UGA U, 44 but has degenerated in fungi and arthropods.", [["UGA U", "CHEMICAL", 38, 43], ["metazoan OAZ slippery site", "DNA", 4, 30], ["The metazoan OAZ slippery", "TREATMENT", 0, 25], ["OAZ slippery", "OBSERVATION", 13, 25], ["UCC UGA", "OBSERVATION", 34, 41], ["degenerated", "OBSERVATION", 56, 67], ["fungi", "OBSERVATION", 71, 76]]], ["45 Importantly, similar to prfB, the OAZ +1 frameshift is stimulated by a 0-frame A-site UGA codon, and is also primarily dependent on tRNA-mRNA interactions in the ribosomal P-site.", [["ribosomal", "ANATOMY", 165, 174], ["prfB", "GENE_OR_GENE_PRODUCT", 27, 31], ["OAZ", "GENE_OR_GENE_PRODUCT", 37, 40], ["-mRNA", "GENE_OR_GENE_PRODUCT", 139, 144], ["ribosomal", "CELLULAR_COMPONENT", 165, 174], ["prfB", "DNA", 27, 31], ["OAZ +1 frameshift", "DNA", 37, 54], ["0-frame A-site UGA codon", "DNA", 74, 98], ["ribosomal P-site", "DNA", 165, 181], ["the OAZ +1 frameshift", "PROBLEM", 33, 54], ["a 0-frame A-site UGA codon", "TREATMENT", 72, 98], ["tRNA-mRNA interactions", "TREATMENT", 135, 157], ["+1 frameshift", "OBSERVATION", 41, 54], ["UGA codon", "OBSERVATION", 89, 98], ["dependent", "OBSERVATION_MODIFIER", 122, 131], ["tRNA-mRNA", "OBSERVATION", 135, 144], ["ribosomal", "ANATOMY", 165, 174]]], ["For example, mutation of the rat OAZ P-site sequence from UCC to CCC inhibited frameshifting in S. cerevisiae.", [["CCC", "CHEMICAL", 65, 68], ["rat", "ORGANISM", 29, 32], ["OAZ", "GENE_OR_GENE_PRODUCT", 33, 36], ["S. cerevisiae", "ORGANISM", 96, 109], ["rat OAZ P-site sequence", "DNA", 29, 52], ["CCC", "DNA", 65, 68], ["rat", "SPECIES", 29, 32], ["S. cerevisiae", "SPECIES", 96, 109], ["S. cerevisiae", "SPECIES", 96, 109], ["mutation of the rat OAZ", "PROBLEM", 13, 36]]], ["39 Also similar to pfrB, the E-site of the OAZ +1 PRF signal also modulates frameshifting efficiency, although this is less well understood.", [["pfrB", "GENE_OR_GENE_PRODUCT", 19, 23], ["OAZ +1 PRF", "GENE_OR_GENE_PRODUCT", 43, 53], ["pfrB", "DNA", 19, 23], ["E-site", "DNA", 29, 35], ["OAZ +1 PRF signal", "DNA", 43, 60], ["modulates frameshifting efficiency", "PROBLEM", 66, 100], ["modulates", "OBSERVATION_MODIFIER", 66, 75], ["frameshifting efficiency", "OBSERVATION", 76, 100]]], ["39 OAZ +1 PRF is also autoregulated: it is stimulated by polyamines.", [["polyamines", "CHEMICAL", 57, 67], ["polyamines", "CHEMICAL", 57, 67], ["polyamines", "SIMPLE_CHEMICAL", 57, 67], ["OAZ +1 PRF", "DNA", 3, 13]]], ["46 Neutralization of negative charge repulsion by positively charged polyamines may facilitate the formation of mRNA-r-RNA interactions that enhance tRNA slippage in the P-site while the ribosome is paused at the 0-frame UGA termination codon.", [["polyamines", "CHEMICAL", 69, 79], ["polyamines", "CHEMICAL", 69, 79], ["polyamines", "SIMPLE_CHEMICAL", 69, 79], ["ribosome", "CELLULAR_COMPONENT", 187, 195], ["mRNA", "RNA", 112, 116], ["P-site", "DNA", 170, 176], ["0-frame UGA termination codon", "DNA", 213, 242], ["charged polyamines", "TREATMENT", 61, 79], ["mRNA-r-RNA interactions", "TREATMENT", 112, 135], ["tRNA slippage", "TREATMENT", 149, 162], ["tRNA slippage", "OBSERVATION", 149, 162]]], ["Importantly, OAZ +1 PRF is autoregulated.", [["OAZ +1 PRF", "GENE_OR_GENE_PRODUCT", 13, 23], ["OAZ", "PROTEIN", 13, 16], ["PRF", "PROTEIN", 20, 23]]], ["Ornithine decarboxylase (ODC) catalyzes the first step in polyamine biosynthesis, while OAZ downregulates polyamine synthesis by stimulating ubiquitin-independent degradation of ODC by the proteasome.", [["Ornithine", "CHEMICAL", 0, 9], ["polyamine", "CHEMICAL", 58, 67], ["OAZ", "CHEMICAL", 88, 91], ["polyamine", "CHEMICAL", 106, 115], ["Ornithine", "CHEMICAL", 0, 9], ["polyamine", "CHEMICAL", 58, 67], ["polyamine", "CHEMICAL", 106, 115], ["Ornithine decarboxylase", "GENE_OR_GENE_PRODUCT", 0, 23], ["ODC", "GENE_OR_GENE_PRODUCT", 25, 28], ["polyamine", "SIMPLE_CHEMICAL", 58, 67], ["OAZ", "SIMPLE_CHEMICAL", 88, 91], ["polyamine", "SIMPLE_CHEMICAL", 106, 115], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 141, 150], ["ODC", "GENE_OR_GENE_PRODUCT", 178, 181], ["Ornithine decarboxylase", "PROTEIN", 0, 23], ["ODC", "PROTEIN", 25, 28], ["OAZ", "PROTEIN", 88, 91], ["ubiquitin", "PROTEIN", 141, 150], ["ODC", "PROTEIN", 178, 181], ["proteasome", "PROTEIN", 189, 199], ["Ornithine decarboxylase (ODC)", "TREATMENT", 0, 29], ["polyamine biosynthesis", "TREATMENT", 58, 80], ["polyamine synthesis", "TREATMENT", 106, 125], ["stimulating ubiquitin", "TREATMENT", 129, 150], ["the proteasome", "TREATMENT", 185, 199], ["polyamine biosynthesis", "OBSERVATION", 58, 80]]], ["Thus, increased levels of polyamines negatively feedback on polyamine synthesis by stimulating +1 PRF, and hence the synthesis of OAZ.+1 Programmed Ribosomal FrameshiftingThe yeast Ty retrotransposable elements utilize +1 PRF to direct synthesis of Gag-pol fusion proteins.", [["polyamines", "CHEMICAL", 26, 36], ["polyamine", "CHEMICAL", 60, 69], ["OAZ", "CHEMICAL", 130, 133], ["polyamines", "CHEMICAL", 26, 36], ["polyamine", "CHEMICAL", 60, 69], ["polyamines", "SIMPLE_CHEMICAL", 26, 36], ["polyamine", "SIMPLE_CHEMICAL", 60, 69], ["+1 PRF", "GENE_OR_GENE_PRODUCT", 95, 101], ["OAZ", "SIMPLE_CHEMICAL", 130, 133], ["+1 PRF", "GENE_OR_GENE_PRODUCT", 219, 225], ["Gag-pol", "GENE_OR_GENE_PRODUCT", 249, 256], ["+1 PRF", "PROTEIN", 95, 101], ["OAZ", "PROTEIN", 130, 133], ["yeast Ty retrotransposable elements", "DNA", 175, 210], ["+1 PRF", "DNA", 219, 225], ["Gag", "PROTEIN", 249, 252], ["pol fusion proteins", "PROTEIN", 253, 272], ["yeast", "SPECIES", 175, 180], ["yeast", "SPECIES", 175, 180], ["increased levels of polyamines", "PROBLEM", 6, 36], ["polyamine synthesis", "TREATMENT", 60, 79], ["the synthesis of OAZ", "TREATMENT", 113, 133], ["1 Programmed Ribosomal Frameshifting", "PROBLEM", 135, 171], ["The yeast Ty retrotransposable elements", "TREATMENT", 171, 210], ["+1 PRF", "TREATMENT", 219, 225], ["direct synthesis of Gag-pol fusion proteins", "TREATMENT", 229, 272], ["increased", "OBSERVATION_MODIFIER", 6, 15], ["polyamines negatively", "OBSERVATION", 26, 47], ["1 Programmed", "OBSERVATION_MODIFIER", 135, 147], ["Ribosomal Frameshifting", "OBSERVATION", 148, 171], ["yeast Ty", "OBSERVATION", 175, 183]]], ["47 The Ty1 slippery site is CUU AGG C. 35 Like prfB and OAZ, the frameshift is primarily driven by slippage of the P-site tRNA from CUU to UUA.", [["Ty1", "GENE_OR_GENE_PRODUCT", 7, 10], ["prfB", "GENE_OR_GENE_PRODUCT", 47, 51], ["Ty1 slippery site", "DNA", 7, 24], ["CUU AGG C. 35 Like prfB and OAZ, the frameshift", "DNA", 28, 75], ["P-site tRNA", "DNA", 115, 126], ["UUA", "DNA", 139, 142], ["OAZ", "TREATMENT", 56, 59], ["the frameshift", "PROBLEM", 61, 75], ["Ty1 slippery", "OBSERVATION", 7, 19], ["frameshift", "OBSERVATION", 65, 75], ["slippage", "OBSERVATION", 99, 107]]], ["Unlike the prior two examples however, this slippery site does not contain a 0-frame termination codon.", [["slippery site", "DNA", 44, 57], ["0-frame termination codon", "DNA", 77, 102], ["this slippery site", "PROBLEM", 39, 57]]], ["Rather, the kinetic trap is supplied by the rare A-site AGG codon, which is decoded by the low abundance Arg-tRNA CCU tRNA.", [["Arg", "CHEMICAL", 105, 108], ["A-site", "DNA", 49, 55], ["tRNA CCU tRNA", "RNA", 109, 122], ["the kinetic trap", "TEST", 8, 24], ["tRNA CCU tRNA", "TREATMENT", 109, 122], ["kinetic trap", "OBSERVATION", 12, 24]]], ["Overexpression of this tRNA caused a 50-fold decrease in +1 PRF, while deleting it caused +1 PRF efficiency to approach 100%.", [["+1 PRF", "DNA", 57, 63], ["this tRNA", "TREATMENT", 18, 27], ["a 50-fold decrease in +1 PRF", "PROBLEM", 35, 63], ["+1 PRF efficiency", "PROBLEM", 90, 107], ["+1 PRF", "OBSERVATION_MODIFIER", 57, 63]]], ["48 The +1 frameshifts of Ty2 and Ty4, and other members of the copia family of retrotransposable elements are thought to utilize this mechanism of tRNA slippage, as well as the yeast ABP140 frameshift signal.", [["Ty2", "GENE_OR_GENE_PRODUCT", 25, 28], ["Ty4", "GENE_OR_GENE_PRODUCT", 33, 36], ["copia", "GENE_OR_GENE_PRODUCT", 63, 68], ["ABP140", "GENE_OR_GENE_PRODUCT", 183, 189], ["+1 frameshifts", "DNA", 7, 21], ["Ty2", "DNA", 25, 28], ["Ty4", "DNA", 33, 36], ["copia family", "DNA", 63, 75], ["retrotransposable elements", "DNA", 79, 105], ["yeast ABP140 frameshift", "DNA", 177, 200], ["yeast", "SPECIES", 177, 182], ["yeast", "SPECIES", 177, 182], ["Ty2", "TEST", 25, 28], ["Ty4", "TEST", 33, 36], ["tRNA slippage", "TREATMENT", 147, 160], ["+1 frameshifts", "OBSERVATION", 7, 21], ["tRNA slippage", "OBSERVATION", 147, 160], ["ABP140 frameshift", "OBSERVATION", 183, 200]]], ["37, 49 While, the genome organization of the Ty3 gypsy-like yeast retrotransposon is similar to Ty1, 50 its +1 PRF signal is different.", [["genome", "CELLULAR_COMPONENT", 18, 24], ["Ty3", "GENE_OR_GENE_PRODUCT", 45, 48], ["Ty1", "CELLULAR_COMPONENT", 96, 99], ["Ty3 gypsy-like yeast retrotransposon", "DNA", 45, 81], ["Ty1", "DNA", 96, 99], ["yeast", "SPECIES", 60, 65], ["yeast", "SPECIES", 60, 65], ["the Ty3 gypsy", "PROBLEM", 41, 54], ["yeast retrotransposon", "PROBLEM", 60, 81], ["Ty1", "TEST", 96, 99], ["yeast retrotransposon", "OBSERVATION", 60, 81], ["different", "OBSERVATION_MODIFIER", 125, 134]]], ["The GCG AGU U slippery site disallows the possibility of the 0-frame tRNA in the P-site to base pair with the +1 frame.", [["GCG AGU U slippery site", "DNA", 4, 27], ["0-frame tRNA", "DNA", 61, 73], ["P-site", "DNA", 81, 87], ["+1 frame", "DNA", 110, 118], ["The GCG AGU U slippery site", "PROBLEM", 0, 27], ["the 0-frame tRNA", "TREATMENT", 57, 73], ["+1 frame", "OBSERVATION", 110, 118]]], ["36 It is thought that Ty3directed +1 PRF involves skipping the first A of the 0-frame P-site codon followed by recognition of the +1 frame GUU codon.", [["Ty3directed +1 PRF", "GENE_OR_GENE_PRODUCT", 22, 40], ["Ty3directed +1 PRF", "DNA", 22, 40], ["0-frame P-site codon", "DNA", 78, 98], ["+1 frame GUU codon", "DNA", 130, 148], ["Ty3directed +1 PRF", "PROBLEM", 22, 40], ["GUU codon", "OBSERVATION", 139, 148]]], ["Further analysis demonstrated that +1 PRF depended on some special characteristic of the Ala-tRNA UGC , and that this was also shared by four more tRNAs.", [["Ala-tRNA", "GENE_OR_GENE_PRODUCT", 89, 97], ["+1 PRF", "DNA", 35, 41], ["Ala-tRNA UGC", "DNA", 89, 101], ["Further analysis", "TEST", 0, 16], ["+1 PRF", "PROBLEM", 35, 41], ["the Ala-tRNA UGC", "TEST", 85, 101]]], ["A downstream stimulatory element is also been proposed to constitute the kinetic trap utilized in Ty3 +1 PRF.", [["Ty3 +1 PRF", "GENE_OR_GENE_PRODUCT", 98, 108], ["downstream stimulatory element", "DNA", 2, 32], ["Ty3 +1 PRF", "DNA", 98, 108], ["A downstream stimulatory element", "TREATMENT", 0, 32], ["the kinetic trap", "TREATMENT", 69, 85], ["stimulatory element", "OBSERVATION", 13, 32], ["kinetic trap", "OBSERVATION", 73, 85]]], ["While the original hypothesis involving direct base pairing between this sequence and the 18S rRNA helix 18 51 has been ruled out, a very stringent set of mutagenesis experiments suggest that the Ty3 stimulatory element may interact with rRNA and ribosomal proteins in the ribosomal entry tunnel, as well as unknown constituents of the solvent face of the 40S subunit.", [["ribosomal", "ANATOMY", 247, 256], ["ribosomal", "ANATOMY", 273, 282], ["Ty3", "GENE_OR_GENE_PRODUCT", 196, 199], ["rRNA", "CELLULAR_COMPONENT", 238, 242], ["ribosomal", "CELLULAR_COMPONENT", 247, 256], ["ribosomal", "CELLULAR_COMPONENT", 273, 282], ["18S rRNA helix 18 51", "DNA", 90, 110], ["Ty3 stimulatory element", "DNA", 196, 219], ["ribosomal proteins", "PROTEIN", 247, 265], ["40S subunit", "PROTEIN", 356, 367], ["this sequence", "TEST", 68, 81], ["the 18S rRNA helix", "TEST", 86, 104], ["a very stringent set of mutagenesis experiments", "PROBLEM", 131, 178], ["the Ty3 stimulatory element", "TREATMENT", 192, 219], ["rRNA", "PROBLEM", 238, 242], ["ribosomal proteins in the ribosomal entry tunnel", "PROBLEM", 247, 295], ["ribosomal proteins", "OBSERVATION", 247, 265], ["ribosomal", "OBSERVATION", 273, 282], ["entry tunnel", "OBSERVATION", 283, 295]]], ["52 Interestingly, while the EST3 slippery site is identical to that of Ty1 and frameshifting is dependent on limiting quantities of cognate A-site tRNA, its +1 PRF signal also contains a downstream stimulatory element.", [["EST3", "GENE_OR_GENE_PRODUCT", 28, 32], ["Ty1", "GENE_OR_GENE_PRODUCT", 71, 74], ["EST3 slippery site", "DNA", 28, 46], ["Ty1", "DNA", 71, 74], ["cognate A-site tRNA", "DNA", 132, 151], ["+1 PRF signal", "DNA", 157, 170], ["downstream stimulatory element", "DNA", 187, 217], ["the EST3 slippery site", "PROBLEM", 24, 46], ["A-site tRNA", "TREATMENT", 140, 151], ["a downstream stimulatory element", "TREATMENT", 185, 217], ["frameshifting", "OBSERVATION", 79, 92], ["dependent", "OBSERVATION_MODIFIER", 96, 105], ["downstream", "OBSERVATION_MODIFIER", 187, 197], ["stimulatory element", "OBSERVATION", 198, 217]]], ["53 It has been speculated that interaction of this element with specific targets of the paused ribosome may limit A-site access by tRNAs.IMPLICATIONS OF PROGRAMMED FRAMESHIFTING IN VIROLOGYMany RNA viruses utilize PRF to posttranscriptionally regulate expression of multiple genes encoded by their monocistronic mRNAs.", [["ribosome", "ANATOMY", 95, 103], ["ribosome", "CELLULAR_COMPONENT", 95, 103], ["PRF", "GENE_OR_GENE_PRODUCT", 214, 217], ["tRNAs", "RNA", 131, 136], ["PRF", "PROTEIN", 214, 217], ["monocistronic mRNAs", "RNA", 298, 317], ["the paused ribosome", "PROBLEM", 84, 103], ["A-site access", "TREATMENT", 114, 127], ["PROGRAMMED FRAMESHIFTING", "PROBLEM", 153, 177], ["VIROLOGYMany RNA viruses", "TREATMENT", 181, 205], ["PRF", "TREATMENT", 214, 217], ["PROGRAMMED FRAMESHIFTING", "OBSERVATION", 153, 177]]], ["The mRNAs of many such viruses, e.g., totiviruses, Ty elements, and most retroviruses, contain two or more overlapping ORFs in which the major viral nucleocapsid proteins (e.g., Gag) are encoded by a 5 ORF, while sequences encoding proteins with enzymatic functions (typically Pro and Pol) are located 3 of, and out-of-frame with, the Gag ORF.", [["totiviruses", "GENE_OR_GENE_PRODUCT", 38, 49], ["Ty", "GENE_OR_GENE_PRODUCT", 51, 53], ["retroviruses", "ORGANISM", 73, 85], ["Gag", "GENE_OR_GENE_PRODUCT", 178, 181], ["Pol", "GENE_OR_GENE_PRODUCT", 285, 288], ["Gag", "GENE_OR_GENE_PRODUCT", 335, 338], ["mRNAs", "RNA", 4, 9], ["Ty elements", "DNA", 51, 62], ["ORFs", "DNA", 119, 123], ["major viral nucleocapsid proteins", "PROTEIN", 137, 170], ["Gag", "PROTEIN", 178, 181], ["5 ORF", "DNA", 200, 205], ["Pol", "PROTEIN", 285, 288], ["Gag ORF", "DNA", 335, 342], ["many such viruses", "PROBLEM", 13, 30], ["most retroviruses", "PROBLEM", 68, 85], ["more overlapping ORFs", "PROBLEM", 102, 123], ["the major viral nucleocapsid proteins", "PROBLEM", 133, 170], ["a 5 ORF", "PROBLEM", 198, 205], ["the Gag ORF", "PROBLEM", 331, 342], ["many", "OBSERVATION_MODIFIER", 13, 17], ["such viruses", "OBSERVATION", 18, 30], ["viral nucleocapsid proteins", "OBSERVATION", 143, 170], ["Gag ORF", "OBSERVATION", 335, 342]]], ["The enzymatic proteins are only translated as a result of PRF events that occur at frequencies of 1-40% depending on the specific virus and assay system employed.", [["enzymatic proteins", "PROTEIN", 4, 22], ["The enzymatic proteins", "TEST", 0, 22], ["PRF events", "PROBLEM", 58, 68], ["the specific virus", "PROBLEM", 117, 135], ["enzymatic proteins", "OBSERVATION", 4, 22]]], ["54 This ensures production of a greater ratio of structural nucleocapsid proteins to products having enzymatic/replicative activities.", [["structural nucleocapsid proteins", "PROTEIN", 49, 81], ["structural nucleocapsid proteins", "PROBLEM", 49, 81], ["production", "OBSERVATION_MODIFIER", 16, 26], ["nucleocapsid proteins", "OBSERVATION", 60, 81], ["replicative activities", "OBSERVATION", 111, 133]]], ["The importance of maintaining precise ratios of structural to enzymatic proteins on viral propagation has been demonstrated using two endogenous viruses of the yeast S. cerevisiae and two retroviruses.", [["yeast S. cerevisiae", "ORGANISM", 160, 179], ["retroviruses", "ORGANISM", 188, 200], ["enzymatic proteins", "PROTEIN", 62, 80], ["yeast", "SPECIES", 160, 165], ["S. cerevisiae", "SPECIES", 166, 179], ["yeast", "SPECIES", 160, 165], ["S. cerevisiae", "SPECIES", 166, 179], ["viral propagation", "PROBLEM", 84, 101], ["viral propagation", "OBSERVATION", 84, 101], ["endogenous viruses", "OBSERVATION", 134, 152], ["retroviruses", "OBSERVATION", 188, 200]]], ["In the yeast dsRNA L-A 'killer' virus, Gag-pol dimerization nucleates formation of the viral particle.", [["L-A", "GENE_OR_GENE_PRODUCT", 19, 22], ["'killer' virus", "ORGANISM", 23, 37], ["Gag-pol", "GENE_OR_GENE_PRODUCT", 39, 46], ["Gag", "PROTEIN", 39, 42], ["yeast", "SPECIES", 7, 12], ["yeast", "SPECIES", 7, 12], ["A 'killer' virus", "TREATMENT", 21, 37], ["Gag-pol dimerization", "TREATMENT", 39, 59], ["the viral particle", "PROBLEM", 83, 101], ["yeast dsRNA", "ANATOMY", 7, 18], ["viral particle", "OBSERVATION", 87, 101]]], ["55 Small alterations in programmed frameshifting efficiencies promote rapid loss of the virus, and it is thought that increasing the amount of Gag-pol protein synthesized may cause too many particles to initiate nonproductively while producing too little may prevent efficient dimerization.", [["Gag", "GENE_OR_GENE_PRODUCT", 143, 146], ["Gag", "PROTEIN", 143, 146], ["pol protein", "PROTEIN", 147, 158], ["Small alterations", "PROBLEM", 3, 20], ["programmed frameshifting efficiencies", "TREATMENT", 24, 61], ["rapid loss of the virus", "PROBLEM", 70, 93], ["Gag-pol protein synthesized", "TREATMENT", 143, 170], ["Small", "OBSERVATION_MODIFIER", 3, 8], ["alterations", "OBSERVATION", 9, 20], ["programmed frameshifting efficiencies", "OBSERVATION", 24, 61], ["rapid", "OBSERVATION_MODIFIER", 70, 75], ["loss", "OBSERVATION_MODIFIER", 76, 80], ["amount", "OBSERVATION_MODIFIER", 133, 139], ["Gag", "OBSERVATION", 143, 146], ["dimerization", "OBSERVATION", 277, 289]]], ["56 Similarly, increasing or decreasing the efficiency of the +1 ribosomal frameshift in the Ty1 retrotransposable element of yeast results in reduced retrotranspostion frequencies by inhibiting proteolytic processing of the TyA-TyB polyprotein (Gag-pol equivalent), thus blocking formation of the mature forms of RNase H, integrase and reverse transcriptase.", [["ribosomal", "ANATOMY", 64, 73], ["ribosomal", "CELLULAR_COMPONENT", 64, 73], ["TyA", "GENE_OR_GENE_PRODUCT", 224, 227], ["Gag-pol", "GENE_OR_GENE_PRODUCT", 245, 252], ["RNase H", "GENE_OR_GENE_PRODUCT", 313, 320], ["+1 ribosomal frameshift", "DNA", 61, 84], ["Ty1 retrotransposable element", "DNA", 92, 121], ["TyA", "PROTEIN", 224, 227], ["TyB polyprotein", "PROTEIN", 228, 243], ["Gag", "PROTEIN", 245, 248], ["pol equivalent", "PROTEIN", 249, 263], ["RNase H", "PROTEIN", 313, 320], ["integrase and reverse transcriptase", "PROTEIN", 322, 357], ["yeast", "SPECIES", 125, 130], ["yeast", "SPECIES", 125, 130], ["the +1 ribosomal frameshift", "PROBLEM", 57, 84], ["reduced retrotranspostion frequencies", "PROBLEM", 142, 179], ["the TyA", "TEST", 220, 227], ["RNase H", "TREATMENT", 313, 320], ["integrase", "TREATMENT", 322, 331], ["reverse transcriptase", "TREATMENT", 336, 357], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["decreasing", "OBSERVATION_MODIFIER", 28, 38], ["efficiency", "OBSERVATION_MODIFIER", 43, 53], ["ribosomal frameshift", "OBSERVATION", 64, 84], ["yeast results", "OBSERVATION", 125, 138], ["reduced", "OBSERVATION_MODIFIER", 142, 149], ["retrotranspostion frequencies", "OBSERVATION", 150, 179]]], ["48 Similarly, changing the ratio of Gag to Gag-pol proteins in retroviruses like HIV or Moloney Murine Leukemia Virus interferes with virus-particle formation.", [["Gag", "GENE_OR_GENE_PRODUCT", 36, 39], ["Gag-pol", "GENE_OR_GENE_PRODUCT", 43, 50], ["retroviruses", "ORGANISM", 63, 75], ["HIV", "ORGANISM", 81, 84], ["Moloney Murine Leukemia Virus", "ORGANISM", 88, 117], ["Gag", "PROTEIN", 36, 39], ["Gag", "PROTEIN", 43, 46], ["pol proteins", "PROTEIN", 47, 59], ["HIV", "SPECIES", 81, 84], ["Murine", "SPECIES", 96, 102], ["HIV", "SPECIES", 81, 84], ["pol proteins in retroviruses", "PROBLEM", 47, 75], ["HIV", "PROBLEM", 81, 84], ["Moloney Murine Leukemia Virus", "PROBLEM", 88, 117], ["retroviruses", "ANATOMY", 63, 75], ["Moloney Murine Leukemia Virus", "OBSERVATION", 88, 117]]], ["[57] [58] [59] [60] [61] In these viruses, overexpression of the Gag-pol protein also resulted in inefficient processing of the polyprotein and inhibition of virus production.IMPLICATIONS OF PROGRAMMED FRAMESHIFTING IN VIROLOGYCoronaviruses also utilize \u22121 PRF to synthesize C-terminally extended fusion proteins that are subsequently proteolytically processed.", [["C", "CHEMICAL", 275, 276], ["[57] [58] [59] [60] [61]", "SIMPLE_CHEMICAL", 0, 24], ["Gag-pol", "GENE_OR_GENE_PRODUCT", 65, 72], ["Gag", "PROTEIN", 65, 68], ["pol protein", "PROTEIN", 69, 80], ["PRF", "PROTEIN", 257, 260], ["C-terminally extended fusion proteins", "PROTEIN", 275, 312], ["the Gag-pol protein", "TEST", 61, 80], ["the polyprotein", "PROBLEM", 124, 139], ["virus production", "PROBLEM", 158, 174], ["PROGRAMMED FRAMESHIFTING IN VIROLOGYCoronaviruses", "TREATMENT", 191, 240], ["\u22121 PRF", "TREATMENT", 254, 260], ["synthesize C-terminally extended fusion proteins", "TREATMENT", 264, 312], ["PROGRAMMED FRAMESHIFTING", "OBSERVATION", 191, 215]]], ["62 The genomic organization of coronaviruses is different in that the structural proteins are encoded in subgenomic mRNAs while the genes regulated by \u22121 PRF are involved in replicase/transcriptase function.", [["coronaviruses", "ORGANISM", 31, 44], ["\u22121", "GENE_OR_GENE_PRODUCT", 151, 153], ["PRF", "GENE_OR_GENE_PRODUCT", 154, 157], ["structural proteins", "PROTEIN", 70, 89], ["subgenomic mRNAs", "RNA", 105, 121], ["\u22121 PRF", "PROTEIN", 151, 157], ["replicase/transcriptase", "PROTEIN", 174, 197], ["coronaviruses", "PROBLEM", 31, 44], ["genomic", "OBSERVATION_MODIFIER", 7, 14], ["organization", "OBSERVATION_MODIFIER", 15, 27], ["coronaviruses", "OBSERVATION", 31, 44], ["different", "OBSERVATION_MODIFIER", 48, 57], ["subgenomic mRNAs", "OBSERVATION", 105, 121]]], ["A study examining the consequences of altering \u22121 PRF efficiencies in the SARS-associated coronavirus (SARS-CoV) demonstrated that, although the functional genesets involved are very different, they supported the general hypothesis that viral PRF efficiencies have been finely tuned to deliver a 'golden mean' of proteins required for optimal virus replication and viability 63 (Figure 2 ).IMPLICATIONS OF PROGRAMMED FRAMESHIFTING IN VIROLOGYThe requirement of many RNA viruses for precise rates of \u22121 PRF suggested a target for antiviral therapeutics.", [["SARS", "DISEASE", 74, 78], ["SARS-associated coronavirus", "ORGANISM", 74, 101], ["SARS-CoV", "ORGANISM", 103, 111], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 499, 505], ["\u22121 PRF", "PROTEIN", 499, 505], ["SARS-associated coronavirus", "SPECIES", 74, 101], ["SARS-CoV", "SPECIES", 103, 111], ["A study", "TEST", 0, 7], ["altering \u22121 PRF efficiencies", "PROBLEM", 38, 66], ["the SARS", "PROBLEM", 70, 78], ["coronavirus", "PROBLEM", 90, 101], ["viral PRF efficiencies", "PROBLEM", 237, 259], ["a 'golden mean' of proteins", "TREATMENT", 294, 321], ["optimal virus replication", "TREATMENT", 335, 360], ["PROGRAMMED FRAMESHIFTING", "PROBLEM", 406, 430], ["many RNA viruses", "TREATMENT", 461, 477], ["\u22121 PRF", "TREATMENT", 499, 505], ["antiviral therapeutics", "TREATMENT", 529, 551], ["PROGRAMMED FRAMESHIFTING", "OBSERVATION", 406, 430]]], ["64 The peptidyltransferase inhibitors anisomycin, sparsomycin, and preussin all affect \u22121 PRF efficiency and inhibit virus propagation in yeast, 65, 66 and the eEF-2 inhibitor sordarin alters +1 PRF and Ty1 retrotranspositon.", [["anisomycin", "CHEMICAL", 38, 48], ["sparsomycin", "CHEMICAL", 50, 61], ["preussin", "CHEMICAL", 67, 75], ["anisomycin", "CHEMICAL", 38, 48], ["sparsomycin", "CHEMICAL", 50, 61], ["preussin", "CHEMICAL", 67, 75], ["sordarin", "CHEMICAL", 176, 184], ["peptidyltransferase", "GENE_OR_GENE_PRODUCT", 7, 26], ["anisomycin", "SIMPLE_CHEMICAL", 38, 48], ["sparsomycin", "SIMPLE_CHEMICAL", 50, 61], ["preussin", "SIMPLE_CHEMICAL", 67, 75], ["\u22121", "GENE_OR_GENE_PRODUCT", 87, 89], ["eEF-2", "GENE_OR_GENE_PRODUCT", 160, 165], ["sordarin", "SIMPLE_CHEMICAL", 176, 184], ["+1 PRF", "GENE_OR_GENE_PRODUCT", 192, 198], ["Ty1 retrotranspositon", "SIMPLE_CHEMICAL", 203, 224], ["+1 PRF and Ty1 retrotranspositon", "DNA", 192, 224], ["yeast", "SPECIES", 138, 143], ["yeast", "SPECIES", 138, 143], ["The peptidyltransferase inhibitors anisomycin", "TREATMENT", 3, 48], ["sparsomycin", "TREATMENT", 50, 61], ["preussin", "TREATMENT", 67, 75], ["PRF efficiency", "PROBLEM", 90, 104], ["inhibit virus propagation in yeast", "PROBLEM", 109, 143], ["the eEF", "TEST", 156, 163], ["Ty1 retrotranspositon", "TREATMENT", 203, 224]]], ["66 Biochemical and computational screens have identified small compounds capable of binding the \u22121 PRF signals of HIV-1 59,67,68 and SARS-CoV.", [["HIV-1 59,67,68", "CHEMICAL", 114, 128], ["HIV-1 59,67,68", "ORGANISM", 114, 128], ["SARS-CoV", "ORGANISM", 133, 141], ["HIV-1", "SPECIES", 114, 119], ["HIV-1 59,67,68", "SPECIES", 114, 128], ["SARS-CoV", "SPECIES", 133, 141], ["Biochemical and computational screens", "TEST", 3, 40], ["small compounds", "PROBLEM", 57, 72], ["HIV", "TEST", 114, 117], ["SARS", "TEST", 133, 137], ["small", "OBSERVATION_MODIFIER", 57, 62]]], ["69 Synthetic oligonucleotide-based compounds have also been shown to alter rates of \u22121 PRF.", [["\u22121 PRF", "PROTEIN", 84, 90], ["Synthetic oligonucleotide", "TREATMENT", 3, 28], ["\u22121 PRF", "PROBLEM", 84, 90]]], ["[70] [71] [72] [73] [74] [75] The recent development of cell-based dual-fluorescence reporter systems provide inexpensive platforms for high throughput screens directed at viral PRF signals.", [["cell", "ANATOMY", 56, 60], ["[70] [71] [72] [73] [74] [75]", "CHEMICAL", 0, 29], ["[70] [71] [72] [73] [74] [75]", "SIMPLE_CHEMICAL", 0, 29], ["cell", "CELL", 56, 60], ["inexpensive platforms", "TEST", 110, 131], ["high throughput screens", "PROBLEM", 136, 159], ["viral PRF signals", "PROBLEM", 172, 189]]], ["76, 77 Genetic methods have been employed to identify numerous cellular gene products that affect both \u22121 and +1 PRF (reviewed in Ref 78) .", [["cellular", "ANATOMY", 63, 71], ["cellular", "CELL", 63, 71], ["cellular gene products", "PROTEIN", 63, 85], ["\u22121 and +1 PRF", "DNA", 103, 116]]], ["Importantly however, all of the mutants generated by the genetics approaches promote deleterious cellular phenotypes, suggesting that global dysregulation of PRF may interfere with expression of cellular genes (see next section).", [["cellular", "ANATOMY", 97, 105], ["cellular", "ANATOMY", 195, 203], ["cellular", "CELL", 97, 105], ["PRF", "GENE_OR_GENE_PRODUCT", 158, 161], ["cellular", "CELL", 195, 203], ["PRF", "PROTEIN", 158, 161], ["cellular genes", "DNA", 195, 209], ["deleterious cellular phenotypes", "PROBLEM", 85, 116], ["global dysregulation of PRF", "PROBLEM", 134, 161], ["cellular genes", "PROBLEM", 195, 209], ["deleterious cellular phenotypes", "OBSERVATION", 85, 116], ["cellular genes", "OBSERVATION", 195, 209]]], ["Indeed, the recent demonstration that defects in rRNA pseudouridylation promote increased rates of \u22121 PRF support this, and suggest that such defects may contribute to the pathologies associated with the human diseases X-linked Dyskeratosis Congenita and Hoyeraal-Hreidarsson syndrome.", [["Dyskeratosis Congenita", "DISEASE", 228, 250], ["Hoyeraal-Hreidarsson syndrome", "DISEASE", 255, 284], ["rRNA", "CELLULAR_COMPONENT", 49, 53], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 99, 105], ["human", "ORGANISM", 204, 209], ["\u22121 PRF", "PROTEIN", 99, 105], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 204, 209], ["defects in rRNA pseudouridylation", "PROBLEM", 38, 71], ["\u22121 PRF", "TREATMENT", 99, 105], ["such defects", "PROBLEM", 137, 149], ["the pathologies", "PROBLEM", 168, 183], ["the human diseases", "PROBLEM", 200, 218], ["Dyskeratosis Congenita", "PROBLEM", 228, 250], ["Hoyeraal-Hreidarsson syndrome", "PROBLEM", 255, 284], ["defects", "OBSERVATION", 38, 45], ["rRNA pseudouridylation", "OBSERVATION", 49, 71], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["rates", "OBSERVATION_MODIFIER", 90, 95], ["defects", "OBSERVATION", 142, 149], ["Dyskeratosis Congenita", "OBSERVATION", 228, 250], ["Hreidarsson syndrome", "OBSERVATION", 264, 284]]], ["79IMPLICATIONS OF PROGRAMMED FRAMESHIFTING IN CONTROL OF CELLULAR GENE EXPRESSIONAs with most basic molecular mechanisms, although first described in viruses, it is now clear that PRF is much more widespread and is likely employed by organisms representing every branch in the tree of life (for reviews see Refs 21 and 80, 81) .", [["PRF", "PROTEIN", 180, 183], ["PROGRAMMED FRAMESHIFTING", "PROBLEM", 18, 42], ["PROGRAMMED FRAMESHIFTING", "OBSERVATION", 18, 42], ["viruses", "OBSERVATION", 150, 157], ["branch", "ANATOMY_MODIFIER", 263, 269], ["tree", "ANATOMY_MODIFIER", 277, 281]]], ["While functional PRF signals in expressed eukaryotic genes have been identified, until recently these discoveries have been serendipitous.", [["PRF", "GENE_OR_GENE_PRODUCT", 17, 20], ["PRF", "PROTEIN", 17, 20], ["eukaryotic genes", "DNA", 42, 58], ["eukaryotic genes", "OBSERVATION", 42, 58]]], ["[85] [86] [87] [88] [89] [90] [91] While the methodologies of each study covered a broad range of bioinformatics techniques, the general goal of most was to try to first identify overlapping reading frames, and then to test sequences in the overlap regions for their ability to promote PRF.", [["[85] [86] [87] [88] [89]", "CHEMICAL", 0, 24], ["[85] [86] [87] [88] [89] [90", "SIMPLE_CHEMICAL", 0, 28], ["overlapping reading frames", "DNA", 179, 205], ["PRF", "PROTEIN", 286, 289], ["each study", "TEST", 62, 72], ["bioinformatics techniques", "TREATMENT", 98, 123], ["test sequences", "TEST", 219, 233], ["PRF", "PROBLEM", 286, 289]]], ["The strength of this approach is that it can identify new classes of PRF-promoting elements.", [["PRF-promoting elements", "DNA", 69, 91]]], ["However, this strategy is based on the assumption that PRF outcomes should mimic those observed in viral genomes: thus, it cannot identify new functional outcomes of frameshifting.", [["viral genomes", "DNA", 99, 112], ["frameshifting", "PROBLEM", 166, 179], ["viral genomes", "OBSERVATION", 99, 112], ["frameshifting", "OBSERVATION", 166, 179]]], ["In contrast, while 'outcome-neutral' approaches using mRNA motifs known to promote efficient PRF cannot identify new classes of frameshift signals, they can enable an expansion of our understanding of functional uses for PRF.", [["PRF", "GENE_OR_GENE_PRODUCT", 221, 224], ["mRNA motifs", "DNA", 54, 65], ["PRF", "DNA", 93, 96], ["PRF", "PROTEIN", 221, 224], ["mRNA motifs", "TREATMENT", 54, 65], ["frameshift signals", "PROBLEM", 128, 146], ["PRF", "PROBLEM", 221, 224], ["frameshift", "OBSERVATION", 128, 138]]], ["With this in mind, rather than focusing on identifying two overlapping out-of-frame ORFs, our first computational search for eukaryotic \u22121 PRF signals aimed to identify \u22121 PRF promoting motifs that resembled well-characterized examples of viral \u22121 PRF signals.", [["viral \u22121", "GENE_OR_GENE_PRODUCT", 239, 247], ["overlapping out-of-frame ORFs", "DNA", 59, 88], ["\u22121 PRF promoting motifs", "DNA", 169, 192], ["eukaryotic \u22121 PRF signals", "TREATMENT", 125, 150], ["viral \u22121 PRF signals", "PROBLEM", 239, 259], ["viral", "OBSERVATION", 239, 244]]], ["87 This first study identified \u223c260 putative \u22121 PRF signals in the annotated portion of the S. cerevisiae genome.", [["\u22121", "GENE_OR_GENE_PRODUCT", 45, 47], ["S. cerevisiae", "ORGANISM", 92, 105], ["S. cerevisiae genome", "DNA", 92, 112], ["S. cerevisiae", "SPECIES", 92, 105], ["S. cerevisiae", "SPECIES", 92, 105], ["This first study", "TEST", 3, 19], ["cerevisiae genome", "OBSERVATION", 95, 112]]], ["However, it was limited by incomplete annotation of the yeast genome and relatively insufficient computational resources available at the time (ca.", [["yeast genome", "DNA", 56, 68], ["yeast", "SPECIES", 56, 61], ["yeast", "SPECIES", 56, 61], ["the yeast genome", "PROBLEM", 52, 68], ["yeast genome", "OBSERVATION", 56, 68]]], ["Each new iteration of this approach has been more comprehensive and powerful, utilizing new informatics tools applied to faster and more robust computational platforms.", [["new informatics tools", "TEST", 88, 109]]], ["The 'second generation' analysis utilizing pattern matching approaches coupled with a statistical feature based on RNA folding algorithms using the S. cerevisiae genome as the testbed demonstrated that (1) \u223c10% of yeast genes contain at least one high probability \u22121 PRF signal and (2) >95% of all \u22121 PRF events would direct elongating ribosomes to encounter premature termination codons (PTCs).", [["ribosomes", "ANATOMY", 336, 345], ["S. cerevisiae", "ORGANISM", 148, 161], ["ribosomes", "CELLULAR_COMPONENT", 336, 345], ["S. cerevisiae genome", "DNA", 148, 168], ["yeast genes", "DNA", 214, 225], ["elongating ribosomes", "RNA", 325, 345], ["premature termination codons", "DNA", 359, 387], ["S. cerevisiae", "SPECIES", 148, 161], ["yeast", "SPECIES", 214, 219], ["S. cerevisiae", "SPECIES", 148, 161], ["yeast", "SPECIES", 214, 219], ["The 'second generation' analysis", "TREATMENT", 0, 32], ["RNA folding algorithms", "TREATMENT", 115, 137], ["the testbed", "TEST", 172, 183], ["yeast genes", "PROBLEM", 214, 225], ["all \u22121 PRF events", "PROBLEM", 294, 311], ["premature termination codons", "PROBLEM", 359, 387]]], ["85 Expansion of this analysis to >20 genomes suggests that these two important findings may be a universal feature of eukaryotic transcriptomes 92 .", [["this analysis", "TEST", 16, 29], ["eukaryotic transcriptomes", "PROBLEM", 118, 143]]], ["The predicted ribosomal frameshift database (PRFdB, http://prfdb.umd. edu) contains a searchable catalog putative eukaryotic \u22121 PRF signals.IMPLICATIONS OF PROGRAMMED FRAMESHIFTING IN CONTROL OF CELLULAR GENE EXPRESSIONAs noted above, while viral \u22121 PRF events result in synthesis of fusion proteins with N-terminal domains encoded by the original reading frame and C-terminal extensions encoded by the -1 frame ORF, genomic frameshifting directs elongating ribosomes to PTCs.", [["ribosomal", "ANATOMY", 14, 23], ["ribosomes", "ANATOMY", 458, 467], ["PTCs", "ANATOMY", 471, 475], ["N", "CHEMICAL", 305, 306], ["C", "CHEMICAL", 366, 367], ["ribosomal", "CELLULAR_COMPONENT", 14, 23], ["ribosomes", "CELLULAR_COMPONENT", 458, 467], ["ribosomal frameshift database", "DNA", 14, 43], ["PRFdB", "DNA", 45, 50], ["PRF", "PROTEIN", 128, 131], ["fusion proteins", "PROTEIN", 284, 299], ["N-terminal domains", "PROTEIN", 305, 323], ["original reading frame", "DNA", 339, 361], ["C-terminal extensions", "DNA", 366, 387], ["1 frame ORF", "DNA", 404, 415], ["The predicted ribosomal frameshift database", "PROBLEM", 0, 43], ["CELLULAR GENE EXPRESSIONAs", "TEST", 195, 221], ["viral \u22121 PRF events", "PROBLEM", 241, 260], ["synthesis of fusion proteins", "TREATMENT", 271, 299], ["terminal domains", "PROBLEM", 307, 323], ["C-terminal extensions", "PROBLEM", 366, 387], ["genomic frameshifting", "PROBLEM", 417, 438], ["ribosomal frameshift", "OBSERVATION", 14, 34], ["PROGRAMMED FRAMESHIFTING", "OBSERVATION", 156, 180], ["genomic frameshifting", "OBSERVATION", 417, 438]]], ["This engendered the hypothesis that \u22121 PRF is used by cells to control mRNA abundance and stability through the nonsense-mediated mRNA decay (NMD) pathway.", [["cells", "ANATOMY", 54, 59], ["\u22121", "GENE_OR_GENE_PRODUCT", 36, 38], ["cells", "CELL", 54, 59], ["\u22121 PRF", "PROTEIN", 36, 42], ["\u22121 PRF", "TREATMENT", 36, 42], ["mRNA abundance", "PROBLEM", 71, 85], ["the nonsense", "PROBLEM", 108, 120]]], ["A proof-of-principle study demonstrated that (1) a well-characterized viral \u22121 PRF signal can act as an mRNA destabilizing element in cis, (2) mRNA destabilization required an intact NMD pathway, and (3) the extent of mRNA destabilization was inversely proportional to \u22121 PRF efficiency.", [["mRNA destabilizing element", "DNA", 104, 130], ["NMD", "DNA", 183, 186], ["mRNA", "RNA", 218, 222], ["principle study", "TEST", 11, 26], ["an mRNA destabilizing element in cis", "PROBLEM", 101, 137], ["mRNA destabilization", "PROBLEM", 143, 163], ["mRNA destabilization", "PROBLEM", 218, 238], ["inversely proportional", "PROBLEM", 243, 265], ["PRF efficiency", "PROBLEM", 272, 286]]], ["93 A follow-up study using a series of \u22121 PRF signals isolated from four endogenous cellular mRNAs from S. cerevisiae showed that a subset of these also promoted mRNA degradation through the no-go decay (NGD) pathway, presumably because frameshift-promoting mRNA secondary structures also promote sufficiently long ribosome pausing to activate this pathway.", [["cellular", "ANATOMY", 84, 92], ["ribosome", "ANATOMY", 315, 323], ["cellular", "CELL", 84, 92], ["S. cerevisiae", "ORGANISM", 104, 117], ["NGD", "GENE_OR_GENE_PRODUCT", 204, 207], ["endogenous cellular mRNAs", "RNA", 73, 98], ["S. cerevisiae", "SPECIES", 104, 117], ["S. cerevisiae", "SPECIES", 104, 117], ["A follow-up study", "TEST", 3, 20], ["\u22121 PRF signals", "TEST", 39, 53], ["S. cerevisiae", "TEST", 104, 117], ["mRNA degradation", "PROBLEM", 162, 178], ["frameshift", "PROBLEM", 237, 247], ["mRNA secondary structures", "PROBLEM", 258, 283]]], ["In that study, more detailed investigations revealed that the EST2 mRNA, encoding the catalytic subunit of telomerase, was destabilized by \u22121 PRF, and that ablation of \u22121 PRF signals in this mRNA promoted its stabilization.", [["EST2", "GENE_OR_GENE_PRODUCT", 62, 66], ["telomerase", "GENE_OR_GENE_PRODUCT", 107, 117], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 139, 145], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 168, 174], ["EST2 mRNA", "RNA", 62, 71], ["catalytic subunit", "PROTEIN", 86, 103], ["telomerase", "PROTEIN", 107, 117], ["\u22121 PRF", "PROTEIN", 139, 145], ["\u22121 PRF", "PROTEIN", 168, 174], ["mRNA", "RNA", 191, 195], ["that study", "TEST", 3, 13], ["detailed investigations", "TEST", 20, 43], ["the EST2 mRNA", "PROBLEM", 58, 71], ["ablation of \u22121 PRF signals", "TREATMENT", 156, 182], ["stabilization", "OBSERVATION_MODIFIER", 209, 222]]], ["Unpublished work in our laboratory has identified functional \u22121 PRF signals in mRNAs encoding additional subunits in yeast telomerase, suggesting that PRF may play a role in telomere length homeostasis by controlling the abundance and relative ratios of telomerase-associated factors.", [["telomere", "ANATOMY", 174, 182], ["\u22121", "GENE_OR_GENE_PRODUCT", 61, 63], ["telomerase", "GENE_OR_GENE_PRODUCT", 123, 133], ["PRF", "GENE_OR_GENE_PRODUCT", 151, 154], ["telomere", "CELLULAR_COMPONENT", 174, 182], ["telomerase", "GENE_OR_GENE_PRODUCT", 254, 264], ["mRNAs", "RNA", 79, 84], ["yeast telomerase", "PROTEIN", 117, 133], ["PRF", "PROTEIN", 151, 154], ["telomerase", "PROTEIN", 254, 264], ["associated factors", "PROTEIN", 265, 283], ["yeast", "SPECIES", 117, 122], ["yeast", "SPECIES", 117, 122], ["yeast telomerase", "PROBLEM", 117, 133], ["telomere length homeostasis", "TREATMENT", 174, 201], ["yeast telomerase", "OBSERVATION", 117, 133]]], ["If PRF is used to control cellular gene expression, then it is reasonable to hypothesize that it is regulated.", [["cellular", "ANATOMY", 26, 34], ["cellular", "CELL", 26, 34], ["PRF", "PROTEIN", 3, 6], ["PRF", "PROBLEM", 3, 6]]], ["As described above, regulation would have to involve mechanisms that would target specific signals rather than promoting global changes in PRF.", [["PRF", "GENE_OR_GENE_PRODUCT", 139, 142], ["PRF", "PROTEIN", 139, 142], ["PRF", "PROBLEM", 139, 142]]], ["Autoregulation as described for OAZ and prfB +1 PRF provide one such PRF signal-specific mechanism.", [["OAZ", "GENE_OR_GENE_PRODUCT", 32, 35], ["prfB +1 PRF", "GENE_OR_GENE_PRODUCT", 40, 51], ["OAZ", "PROTEIN", 32, 35], ["prfB", "PROTEIN", 40, 44], ["PRF", "PROTEIN", 48, 51], ["PRF", "PROTEIN", 69, 72], ["Autoregulation", "TEST", 0, 14], ["OAZ", "PROBLEM", 32, 35]]], ["However, in these cases the products encoded by frameshift events directly feedback on the PRF signals.", [["PRF", "DNA", 91, 94], ["frameshift events", "PROBLEM", 48, 65]]], ["This would not apply to most other cellular \u22121 PRF signals because they do not encode any new protein products.", [["cellular", "ANATOMY", 35, 43], ["cellular \u22121", "GENE_OR_GENE_PRODUCT", 35, 46], ["protein products", "PROTEIN", 94, 110]]], ["Thus, regulation should involve the use of sequence-specific trans-acting factors.", [["trans-acting factors", "PROTEIN", 61, 81]]], ["In addition, the ability of \u22121 PRF signals to direct mRNA destabilization in a manner that is inversely proportional to \u22121 PRF rates 93, 97 would suggest that, rather than turning \u22121 PRF completely on or off, trans-acting regulatory factors may function to increase or decrease rates of \u22121 PRF, thus providing for nuanced effects on gene expression that could be fine-tuned to specific circumstances.", [["\u22121", "GENE_OR_GENE_PRODUCT", 28, 30], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 287, 293], ["\u22121 PRF", "PROTEIN", 28, 34], ["trans-acting regulatory factors", "PROTEIN", 209, 240], ["\u22121 PRF", "PROTEIN", 287, 293], ["direct mRNA destabilization", "TREATMENT", 46, 73], ["PRF rates", "TEST", 123, 132], ["\u22121 PRF", "TREATMENT", 287, 293]]], ["As discussed above, the ability of synthetic oligonucleotide-based compounds to alter rates of \u22121 PRF suggests that naturally occurring oligonucleotides, e.g., small noncoding RNAs, may hold the key to regulation of \u22121 PRF.", [["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 95, 101], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 216, 222], ["\u22121 PRF", "PROTEIN", 95, 101], ["small noncoding RNAs", "RNA", 160, 180], ["\u22121 PRF", "PROTEIN", 216, 222], ["synthetic oligonucleotide", "TREATMENT", 35, 60], ["\u22121 PRF", "TREATMENT", 95, 101], ["naturally occurring oligonucleotides", "PROBLEM", 116, 152], ["small noncoding RNAs", "PROBLEM", 160, 180], ["\u22121 PRF", "TREATMENT", 216, 222], ["small", "OBSERVATION_MODIFIER", 160, 165], ["noncoding RNAs", "OBSERVATION", 166, 180]]], ["Base pairing interactions would provide the requisite sequence specificity, and their potential ability to either disrupt or stabilize \u22121 PRF promoting mRNA tertiary structures would provide them with the capacity to promote increased or decreased rates of \u22121 PRF.", [["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 135, 141], ["PRF", "PROTEIN", 260, 263], ["decreased rates of \u22121 PRF", "PROBLEM", 238, 263], ["increased", "OBSERVATION_MODIFIER", 225, 234]]], ["Indeed, preliminary studies from our laboratory have identified at least two endogenous micro-RNAs (miRNAs) capable of stimulating -1 PRF in a human mRNA.", [["-1 PRF", "GENE_OR_GENE_PRODUCT", 131, 137], ["human", "ORGANISM", 143, 148], ["endogenous micro-RNAs", "RNA", 77, 98], ["miRNAs", "RNA", 100, 106], ["1 PRF", "RNA", 132, 137], ["human mRNA", "RNA", 143, 153], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148], ["preliminary studies", "TEST", 8, 27], ["our laboratory", "TEST", 33, 47], ["a human mRNA", "TREATMENT", 141, 153], ["endogenous micro", "OBSERVATION", 77, 93]]], ["As a final thought, if PRF is an important regulator of cellular gene expression, then mutations in \u22121 PRF signals might impact PRF rates, and hence mRNA stability and protein abundance.", [["cellular", "ANATOMY", 56, 64], ["cellular", "CELL", 56, 64], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 100, 106], ["PRF", "GENE_OR_GENE_PRODUCT", 128, 131], ["PRF", "PROTEIN", 23, 26], ["PRF", "PROTEIN", 103, 106], ["PRF", "PROTEIN", 128, 131], ["PRF", "PROBLEM", 23, 26], ["PRF rates", "TREATMENT", 128, 137], ["mRNA stability", "TEST", 149, 163]]], ["We suggest that this may explain why some single nucleotide polymorphisms have been shown to promote discernable phenotypes, e.g., inherited diseases, despite the fact that they are silent with regard to the amino acids that they encode.CONCLUSIONThe history of modern molecular biology is replete with examples in which basic biological regulatory mechanisms were first discovered in viruses.", [["inherited diseases", "DISEASE", 131, 149], ["amino acids", "CHEMICAL", 208, 219], ["amino acids", "CHEMICAL", 208, 219], ["amino acids", "AMINO_ACID", 208, 219], ["some single nucleotide polymorphisms", "PROBLEM", 37, 73], ["discernable phenotypes", "PROBLEM", 101, 123], ["inherited diseases", "PROBLEM", 131, 149], ["the amino acids", "TREATMENT", 204, 219]]], ["This is not because viruses are special, but rather because their small genomes help to increase signal-to-noise ratios, thus facilitating the scientific discovery process.", [["viruses", "PROBLEM", 20, 27], ["not because", "UNCERTAINTY", 8, 19], ["viruses", "OBSERVATION", 20, 27]]], ["Indeed, as obligate intracellular parasites, viruses are subject to the same rules and regulations that govern their host cells.", [["intracellular", "ANATOMY", 20, 33], ["cells", "ANATOMY", 122, 127], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 20, 33], ["host cells", "CELL", 117, 127], ["host cells", "CELL_TYPE", 117, 127], ["obligate intracellular parasites", "PROBLEM", 11, 43], ["viruses", "PROBLEM", 45, 52], ["intracellular", "OBSERVATION_MODIFIER", 20, 33], ["parasites", "OBSERVATION", 34, 43], ["viruses", "OBSERVATION", 45, 52], ["host cells", "OBSERVATION", 117, 127]]], ["Thus, while PRF was first thought to be a virus-specific mechanism, it is becoming clear that cellular mRNAs employ this mechanism as well.", [["cellular", "ANATOMY", 94, 102], ["PRF", "GENE_OR_GENE_PRODUCT", 12, 15], ["cellular", "CELL", 94, 102], ["PRF", "PROTEIN", 12, 15], ["cellular mRNAs", "RNA", 94, 108], ["a virus", "PROBLEM", 40, 47], ["virus", "OBSERVATION", 42, 47], ["cellular mRNAs", "OBSERVATION", 94, 108]]], ["The study of PRF continues to illuminate our understanding of how ribosomes normally maintain reading frame.", [["ribosomes", "ANATOMY", 66, 75], ["ribosomes", "CELLULAR_COMPONENT", 66, 75], ["PRF", "PROTEIN", 13, 16], ["reading frame", "DNA", 94, 107], ["The study", "TEST", 0, 9]]], ["In particular, viewed from a kinetic standpoint, we have come to understand that \u22121 PRF represents an endpoint resulting from changes in kinetic partitioning at different steps along a reaction pathway rather than a single mechanism.", [["\u22121 PRF", "PROTEIN", 81, 87], ["changes in kinetic partitioning", "PROBLEM", 126, 157], ["a reaction pathway", "TREATMENT", 183, 201], ["kinetic partitioning", "OBSERVATION", 137, 157]]], ["We hope that this kinetic view of \u22121 PRF will be useful in identifying specific targets for antiviral therapeutics.", [["this kinetic view", "TEST", 13, 30], ["\u22121 PRF", "TREATMENT", 34, 40], ["antiviral therapeutics", "TREATMENT", 92, 114]]], ["Another recurring motif in virology is that viruses tend to repurpose molecular mechanisms that were originally taken from host cells.", [["cells", "ANATOMY", 128, 133], ["host cells", "CELL", 123, 133], ["host cells", "CELL_TYPE", 123, 133], ["Another recurring motif in virology", "PROBLEM", 0, 35], ["viruses", "PROBLEM", 44, 51], ["molecular mechanisms", "PROBLEM", 70, 90]]], ["The finding that viruses use PRF to make C-terminally extended fusion proteins differs from most of their cellular counterparts, which appear to use \u22121 PRF to regulate gene expression through mRNA stability.", [["cellular", "ANATOMY", 106, 114], ["C", "CHEMICAL", 41, 42], ["cellular counterparts", "CELL", 106, 127], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 149, 155], ["PRF", "PROTEIN", 29, 32], ["C-terminally extended fusion proteins", "PROTEIN", 41, 78], ["\u22121 PRF", "PROTEIN", 149, 155], ["PRF", "TREATMENT", 29, 32], ["C-terminally extended fusion proteins", "TREATMENT", 41, 78], ["\u22121 PRF", "TREATMENT", 149, 155], ["viruses", "OBSERVATION", 17, 24]]], ["Indeed, this observation may help to explain why global changes in \u22121 PRF efficiency are detrimental to cell viability, and may even help to elucidate one of the underlying causes of human ribosomopathies.", [["cell", "ANATOMY", 104, 108], ["ribosomopathies", "DISEASE", 189, 204], ["\u22121", "GENE_OR_GENE_PRODUCT", 67, 69], ["cell", "CELL", 104, 108], ["human", "ORGANISM", 183, 188], ["ribosomopathies", "CANCER", 189, 204], ["PRF", "PROTEIN", 70, 73], ["human", "SPECIES", 183, 188], ["human", "SPECIES", 183, 188], ["global changes in \u22121 PRF efficiency", "PROBLEM", 49, 84], ["human ribosomopathies", "PROBLEM", 183, 204], ["cell viability", "OBSERVATION", 104, 118], ["human ribosomopathies", "OBSERVATION", 183, 204]]], ["This would also explain why \u22121 PRF should be regulated by sequence-specific mechanisms, e.g., by ncRNAs as proposed here.", [["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 28, 34], ["PRF", "PROTEIN", 31, 34], ["ncRNAs", "DNA", 97, 103]]], ["Corollary to this may be the explanation for why viruses that utilize \u22121 PRF are able to successfully replicate in their host cells because permissive cells would presumably not express ncRNAs capable of interacting with the viral \u22121 PRF signals.", [["cells", "ANATOMY", 126, 131], ["cells", "ANATOMY", 151, 156], ["\u22121 PRF", "GENE_OR_GENE_PRODUCT", 70, 76], ["host cells", "CELL", 121, 131], ["cells", "CELL", 151, 156], ["PRF", "GENE_OR_GENE_PRODUCT", 234, 237], ["\u22121 PRF", "PROTEIN", 70, 76], ["host cells", "CELL_TYPE", 121, 131], ["permissive cells", "CELL_TYPE", 140, 156], ["why viruses", "PROBLEM", 45, 56], ["\u22121 PRF", "TREATMENT", 70, 76], ["permissive cells", "PROBLEM", 140, 156]]], ["In particular, I thank a few critical people.", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44]]], ["I have had the good fortune and pleasure of working with Dr. Arturas Meskauskas over the past decade: he has been my second brain.", [["brain", "ANATOMY", 124, 129], ["brain", "ORGAN", 124, 129], ["brain", "ANATOMY", 124, 129]]], ["Dr. Ewan Plant provided critical insight and expertise that both solidified our view of PRF and virology, as well as uncovering mechanism through which \u22121 PRF may be regulated.", [["\u22121", "GENE_OR_GENE_PRODUCT", 152, 154], ["PRF", "PROTEIN", 155, 158], ["PRF", "TREATMENT", 88, 91]]], ["Dr. Jonathan Jacobs was the first computer wizard who cracked the problem of cellular \u22121 PRF: the PRFdB is built on his original source code.", [["cellular", "ANATOMY", 77, 85], ["cellular", "CELL", 77, 85], ["cellular \u22121 PRF", "DNA", 77, 92], ["PRFdB", "DNA", 98, 103]]], ["Most recently, Ashton Trey Belew has expanded and improved upon this project, making the PRFdB a much more powerful and user friendly tool, and providing heroic service to the quest to understand how cellular gene expression is regulated by \u22121 PRF.", [["cellular", "ANATOMY", 200, 208], ["cellular", "CELL", 200, 208], ["PRF", "PROTEIN", 244, 247], ["expanded", "OBSERVATION_MODIFIER", 37, 45], ["improved", "OBSERVATION_MODIFIER", 50, 58]]]], "PMC7347264": [], "27faec4085a3862934f98c2e8d2c765e6efe6a6b": [["INTRODUCTION 25Successful airway management is a critical skill in emergency medicine.", [["airway", "ANATOMY", 26, 32], ["airway", "MULTI-TISSUE_STRUCTURE", 26, 32], ["Successful airway management", "TREATMENT", 15, 43], ["airway", "ANATOMY", 26, 32]]], ["1, 2 The majority of 26 emergent and unplanned intubations in emergency departments (ED) are managed by emergency 27 physicians using rapid-sequence intubation, with success rates as high as 99%.", [["rapid-sequence intubation", "TREATMENT", 134, 159], ["success rates", "TEST", 166, 179]]], ["2-4 However, 28 emergency physicians must be able to prepare for and manage critically ill patients with a wide 29 range of physiologic challenges in the peri-intubation setting.", [["critically ill", "DISEASE", 76, 90], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["physiologic challenges", "TREATMENT", 124, 146]]], ["30 31 First pass success is a priority in any attempt at endotracheal intubation, but especially in 32 physiologically challenging airways, as multiple attempts are associated with an increase in 33 adverse events.", [["endotracheal", "ANATOMY", 57, 69], ["airways", "ANATOMY", 131, 138], ["airways", "MULTI-TISSUE_STRUCTURE", 131, 138], ["endotracheal intubation", "TREATMENT", 57, 80], ["an increase in 33 adverse events", "PROBLEM", 181, 213], ["airways", "ANATOMY", 131, 138], ["increase", "OBSERVATION_MODIFIER", 184, 192]]], ["5,6 Difficult visualization and intubation, generally defined as 3 or more attempts, 34 occur as often as 6.6-12% in critically ill patients.", [["critically ill", "DISEASE", 117, 131], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["intubation", "TREATMENT", 32, 42], ["intubation", "OBSERVATION", 32, 42]]], ["[6] [7] [8] [9] This rate may be decreasing in the ED 35 population, potentially because of video laryngoscopy or improved techniques, as shown by a 36 decreased rate of multiple attempts of 1.5% in a more recent study of ED intubations.", [["[6] [7] [8] [9]", "SIMPLE_CHEMICAL", 0, 15], ["This rate", "TEST", 16, 25], ["video laryngoscopy", "TEST", 92, 110], ["ED intubations", "TREATMENT", 222, 236], ["may be", "UNCERTAINTY", 26, 32], ["decreasing", "OBSERVATION_MODIFIER", 33, 43]]], ["4 Severe 37 complications occur as frequently as 24-28% of endotracheal intubation in critically ill patients, 38 most commonly hypoxemia and hypotension.", [["endotracheal", "ANATOMY", 59, 71], ["critically ill", "DISEASE", 86, 100], ["hypoxemia", "DISEASE", 128, 137], ["hypotension", "DISEASE", 142, 153], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["Severe 37 complications", "PROBLEM", 2, 25], ["endotracheal intubation", "TREATMENT", 59, 82], ["hypoxemia", "PROBLEM", 128, 137], ["hypotension", "PROBLEM", 142, 153], ["Severe", "OBSERVATION_MODIFIER", 2, 8], ["37 complications", "OBSERVATION_MODIFIER", 9, 25], ["hypoxemia", "OBSERVATION", 128, 137], ["hypotension", "OBSERVATION", 142, 153]]], ["6, 8 Patients with high risk comorbid disease and 39INTRODUCTION 25pre-intubation factors such as hypoxemia, hypotension, and severe acidosis are at high risk for 40 peri-intubation hemodynamic collapse and resultant worse outcomes.", [["comorbid disease", "DISEASE", 29, 45], ["hypoxemia", "DISEASE", 98, 107], ["hypotension", "DISEASE", 109, 120], ["acidosis", "DISEASE", 133, 141], ["Patients", "ORGANISM", 5, 13], ["Patients", "SPECIES", 5, 13], ["high risk comorbid disease", "PROBLEM", 19, 45], ["intubation factors", "TREATMENT", 71, 89], ["hypoxemia", "PROBLEM", 98, 107], ["hypotension", "PROBLEM", 109, 120], ["severe acidosis", "PROBLEM", 126, 141], ["40 peri-intubation hemodynamic collapse", "PROBLEM", 163, 202], ["resultant worse outcomes", "PROBLEM", 207, 231], ["hypoxemia", "OBSERVATION", 98, 107], ["hypotension", "OBSERVATION", 109, 120], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["acidosis", "OBSERVATION", 133, 141], ["collapse", "OBSERVATION", 194, 202], ["resultant", "OBSERVATION_MODIFIER", 207, 216], ["worse", "OBSERVATION_MODIFIER", 217, 222]]], ["8,10-13 The incidence of 41 peri-intubation cardiac arrest is as high as 1 in 25 emergency airways in one series.", [["cardiac", "ANATOMY", 44, 51], ["airways", "ANATOMY", 91, 98], ["8,10-13", "CHEMICAL", 0, 7], ["cardiac arrest", "DISEASE", 44, 58], ["8,10-13", "CHEMICAL", 0, 7], ["cardiac", "ORGAN", 44, 51], ["airways", "MULTI-TISSUE_STRUCTURE", 91, 98], ["41 peri-intubation cardiac arrest", "PROBLEM", 25, 58], ["cardiac", "ANATOMY", 44, 51], ["arrest", "OBSERVATION", 52, 58], ["airways", "ANATOMY", 91, 98]]], ["10 Post-42 intubation hypotension is more common, occurring as frequently as 25% of emergency 43 intubations and is associated with increased mortality.", [["hypotension", "DISEASE", 22, 33], ["intubation hypotension", "PROBLEM", 11, 33], ["intubations", "TREATMENT", 97, 108], ["increased mortality", "PROBLEM", 132, 151], ["hypotension", "OBSERVATION", 22, 33], ["more common", "OBSERVATION_MODIFIER", 37, 48], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["mortality", "OBSERVATION", 142, 151]]], ["11 Many of the pre-intubation risks for 44 decompensation can be recognized and prevented with proper preparation and evaluation.", [["decompensation", "DISEASE", 43, 57], ["44 decompensation", "PROBLEM", 40, 57], ["evaluation", "TEST", 118, 128]]], ["8,10,14-18 45 46 This first part of a two-part series will focus on the latest literature, recommendations, and 47 tidal volume of 8 mL/kg predicted body weight (PBW) or higher may be needed.", [["body", "ANATOMY", 149, 153], ["8,10,14-18 45 46", "CHEMICAL", 0, 16], ["body", "ORGANISM_SUBDIVISION", 149, 153]]], ["A blood gas 120 should be assessed within 15 minutes of intubation to make sure the pH has not significantly 121 worsened.", [["blood", "ANATOMY", 2, 7], ["blood", "ORGANISM_SUBSTANCE", 2, 7], ["A blood gas", "TEST", 0, 11], ["intubation", "TREATMENT", 56, 66], ["the pH", "TEST", 80, 86], ["worsened", "OBSERVATION_MODIFIER", 113, 121]]], ["Continuous ETCO 2 may be used to follow PaCO 2 once intubated; in the patient with 122 normal lung function the ETCO 2 value is 2-5 mm Hg lower than PaCO 2 .", [["lung", "ANATOMY", 94, 98], ["PaCO 2", "CHEMICAL", 40, 46], ["Hg", "CHEMICAL", 135, 137], ["PaCO 2", "CHEMICAL", 149, 155], ["PaCO 2", "GENE_OR_GENE_PRODUCT", 40, 46], ["patient", "ORGANISM", 70, 77], ["lung", "ORGAN", 94, 98], ["patient", "SPECIES", 70, 77], ["Continuous ETCO 2", "TREATMENT", 0, 17], ["PaCO", "TEST", 40, 44], ["intubated", "TREATMENT", 52, 61], ["the ETCO", "TEST", 108, 116], ["PaCO", "TEST", 149, 153], ["lung", "ANATOMY", 94, 98]]], ["20,31 123 124 There are many different mechanical ventilator strategies post intubation.", [["different mechanical ventilator strategies", "TREATMENT", 29, 71], ["intubation", "TREATMENT", 77, 87], ["many", "OBSERVATION_MODIFIER", 24, 28], ["different", "OBSERVATION_MODIFIER", 29, 38], ["mechanical", "OBSERVATION_MODIFIER", 39, 49], ["ventilator strategies", "OBSERVATION", 50, 71]]], ["12,24 When the sedation 125 and neuromuscular blockade medications are metabolized some advocate for spontaneous 126 ventilatory modes such as pressure support ventilation so the patient can set the respiratory rate, 127 tidal volume, and inspiratory time.", [["neuromuscular", "ANATOMY", 32, 45], ["respiratory", "ANATOMY", 199, 210], ["12,24", "CHEMICAL", 0, 5], ["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 179, 186], ["the sedation", "TREATMENT", 11, 23], ["neuromuscular blockade medications", "TREATMENT", 32, 66], ["spontaneous 126 ventilatory modes", "TREATMENT", 101, 134], ["pressure support ventilation", "TREATMENT", 143, 171], ["the respiratory rate", "TEST", 195, 215], ["tidal volume", "TEST", 221, 233], ["tidal volume", "OBSERVATION", 221, 233]]], ["12 Alternatively, adequate sedation and assist control modes of 128 ventilation with a prescribed tidal volume (e.g. VC-AC) or pressure (PC-AC) and respiratory rate 129 may be used, but the patient should be monitored for patient-ventilator dyssynchrony with the 130 increased respiratory drive stimulated by the acidosis.", [["respiratory", "ANATOMY", 277, 288], ["acidosis", "DISEASE", 313, 321], ["patient", "ORGANISM", 190, 197], ["patient", "ORGANISM", 222, 229], ["patient", "SPECIES", 190, 197], ["patient", "SPECIES", 222, 229], ["adequate sedation", "TREATMENT", 18, 35], ["assist control modes", "TREATMENT", 40, 60], ["ventilation", "TREATMENT", 68, 79], ["a prescribed tidal volume", "TEST", 85, 110], ["VC", "TEST", 117, 119], ["pressure (PC-AC", "TREATMENT", 127, 142], ["respiratory rate", "TEST", 148, 164], ["ventilator dyssynchrony", "PROBLEM", 230, 253], ["the acidosis", "PROBLEM", 309, 321], ["respiratory drive", "OBSERVATION", 277, 294], ["acidosis", "OBSERVATION", 313, 321]]], ["12,24 The recommended approach is to 131 deliver a guaranteed minute ventilation by setting the respiratory rate and a starting tidal volume 132 of 8 mL/kg PBW in an assist control type mode.hypotension.", [["respiratory", "ANATOMY", 96, 107], ["12,24", "CHEMICAL", 0, 5], ["hypotension", "DISEASE", 191, 202], ["a guaranteed minute ventilation", "TREATMENT", 49, 80], ["the respiratory rate", "TEST", 92, 112], ["a starting tidal volume", "TREATMENT", 117, 140], ["an assist control type mode", "TREATMENT", 163, 190], ["hypotension", "PROBLEM", 191, 202]]], ["143Patients with shock and hypotension requiring intubation and mechanical ventilation are at high 144 risk for peri-intubation cardiovascular collapse.", [["cardiovascular", "ANATOMY", 128, 142], ["shock", "DISEASE", 17, 22], ["hypotension", "DISEASE", 27, 38], ["cardiovascular collapse", "DISEASE", 128, 151], ["cardiovascular", "ANATOMICAL_SYSTEM", 128, 142], ["shock", "PROBLEM", 17, 22], ["hypotension", "PROBLEM", 27, 38], ["intubation", "TREATMENT", 49, 59], ["mechanical ventilation", "TREATMENT", 64, 86], ["peri-intubation cardiovascular collapse", "PROBLEM", 112, 151], ["shock", "OBSERVATION", 17, 22], ["hypotension", "OBSERVATION", 27, 38], ["mechanical ventilation", "OBSERVATION", 64, 86], ["cardiovascular", "ANATOMY", 128, 142], ["collapse", "OBSERVATION", 143, 151]]], ["7,8,10,17,32 Post intubation hypotension (PIH) is 145 common and occurs in up to 25% of emergently intubated patients, is associated with adverse 146 outcomes, and should be aggressively avoided and treated.", [["intubation hypotension", "DISEASE", 18, 40], ["PIH", "DISEASE", 42, 45], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["Post intubation hypotension", "PROBLEM", 13, 40], ["PIH", "PROBLEM", 42, 45], ["adverse 146 outcomes", "PROBLEM", 138, 158], ["hypotension", "OBSERVATION", 29, 40], ["145 common", "OBSERVATION_MODIFIER", 50, 60]]], ["8,11,12,33 Studies suggest pre-intubation 147 hypotension and shock index >0.8-0.9 (heart rate/systolic blood pressure [BP] ) are the best 148 predictors of post-intubation cardiac arrest and PIH.", [["heart", "ANATOMY", 84, 89], ["blood", "ANATOMY", 104, 109], ["cardiac", "ANATOMY", 173, 180], ["hypotension", "DISEASE", 46, 57], ["shock", "DISEASE", 62, 67], ["cardiac arrest", "DISEASE", 173, 187], ["PIH", "DISEASE", 192, 195], ["heart", "ORGAN", 84, 89], ["blood", "ORGANISM_SUBSTANCE", 104, 109], ["cardiac", "ORGAN", 173, 180], ["Studies", "TEST", 11, 18], ["pre-intubation", "TEST", 27, 41], ["hypotension", "PROBLEM", 46, 57], ["shock index", "TEST", 62, 73], ["heart rate", "TEST", 84, 94], ["systolic blood pressure", "TEST", 95, 118], ["BP", "TEST", 120, 122], ["post-intubation cardiac arrest", "PROBLEM", 157, 187], ["PIH", "PROBLEM", 192, 195], ["cardiac", "ANATOMY", 173, 180], ["arrest", "OBSERVATION", 181, 187], ["PIH", "OBSERVATION", 192, 195]]], ["7,10,12,17,32 The shock index is associated with 149 severity of illness and suggests impending instability.", [["7,10,12,17,32", "CHEMICAL", 0, 13], ["shock", "DISEASE", 18, 23], ["illness", "DISEASE", 65, 72], ["The shock index", "TEST", 14, 29], ["illness", "PROBLEM", 65, 72], ["impending instability", "PROBLEM", 86, 107], ["shock index", "OBSERVATION", 18, 29], ["149 severity", "OBSERVATION_MODIFIER", 49, 61], ["impending", "OBSERVATION_MODIFIER", 86, 95], ["instability", "OBSERVATION", 96, 107]]], ["17 Post-intubation cardiac arrest occurs in 150 approximately 2%, though one series reported a higher rate of 4.2% in emergency intubations.", [["cardiac", "ANATOMY", 19, 26], ["cardiac arrest", "DISEASE", 19, 33], ["Post-intubation cardiac arrest", "TREATMENT", 3, 33], ["emergency intubations", "TREATMENT", 118, 139], ["cardiac", "ANATOMY", 19, 26], ["arrest", "OBSERVATION", 27, 33]]], ["10 151hypotension.", [["hypotension", "DISEASE", 6, 17], ["hypotension", "PROBLEM", 6, 17], ["hypotension", "OBSERVATION", 6, 17]]], ["143The reported incidence of cardiac arrest in those with pre-intubation hypotension is even higher 152 at 12-15% of emergency intubations.", [["cardiac", "ANATOMY", 29, 36], ["cardiac arrest", "DISEASE", 29, 43], ["hypotension", "DISEASE", 73, 84], ["cardiac", "ORGAN", 29, 36], ["cardiac arrest", "PROBLEM", 29, 43], ["pre-intubation hypotension", "PROBLEM", 58, 84], ["emergency intubations", "TREATMENT", 117, 138], ["cardiac", "ANATOMY", 29, 36], ["arrest", "OBSERVATION", 37, 43], ["hypotension", "OBSERVATION", 73, 84]]], ["7,10 Post intubation cardiac arrest is unsurprisingly 153 associated with increased mortality.", [["cardiac", "ANATOMY", 21, 28], ["cardiac arrest", "DISEASE", 21, 35], ["Post intubation cardiac arrest", "PROBLEM", 5, 35], ["increased mortality", "PROBLEM", 74, 93], ["cardiac", "ANATOMY", 21, 28], ["arrest", "OBSERVATION", 29, 35], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["mortality", "OBSERVATION", 84, 93]]], ["8Pitfall: Using induction agents or inappropriate doses that worsen or precipitate hypotension.", [["hypotension", "DISEASE", 83, 94], ["induction agents", "TREATMENT", 16, 32], ["inappropriate doses", "TREATMENT", 36, 55], ["hypotension", "PROBLEM", 83, 94], ["hypotension", "OBSERVATION", 83, 94]]], ["190In those with anticipated hemodynamic instability, the dosing and familiarity of the inductionPitfall: Failure to aggressively treat with NIPPV prior to intubation.", [["hemodynamic instability", "DISEASE", 29, 52], ["anticipated hemodynamic instability", "PROBLEM", 17, 52], ["the dosing", "TREATMENT", 54, 64], ["NIPPV", "TREATMENT", 141, 146], ["intubation", "TREATMENT", 156, 166], ["hemodynamic instability", "OBSERVATION", 29, 52]]], ["213Respiratory failure from obstructive lung disease, such as asthma and chronic obstructive 214 and a respiratory acidosis with a pH of > 7.20 can be tolerated in most patients aside from those 264 with a potential contraindication to a respiratory acidosis such as those with pulmonary 265 hypertension, brain injuries at risk for increased intracranial pressure (ICP), severe right sided 266 heart failure, pregnancy, and certain toxic ingestions.", [["lung", "ANATOMY", 40, 44], ["respiratory", "ANATOMY", 103, 114], ["respiratory", "ANATOMY", 238, 249], ["pulmonary", "ANATOMY", 278, 287], ["brain", "ANATOMY", 306, 311], ["intracranial", "ANATOMY", 343, 355], ["heart", "ANATOMY", 395, 400], ["213Respiratory failure", "DISEASE", 0, 22], ["obstructive lung disease", "DISEASE", 28, 52], ["asthma", "DISEASE", 62, 68], ["respiratory acidosis", "DISEASE", 103, 123], ["respiratory acidosis", "DISEASE", 238, 258], ["hypertension", "DISEASE", 292, 304], ["brain injuries", "DISEASE", 306, 320], ["heart failure", "DISEASE", 395, 408], ["lung", "ORGAN", 40, 44], ["patients", "ORGANISM", 169, 177], ["pulmonary", "ORGAN", 278, 287], ["brain", "ORGAN", 306, 311], ["heart", "ORGAN", 395, 400], ["patients", "SPECIES", 169, 177], ["213Respiratory failure", "PROBLEM", 0, 22], ["obstructive lung disease", "PROBLEM", 28, 52], ["asthma", "PROBLEM", 62, 68], ["chronic obstructive 214", "PROBLEM", 73, 96], ["a respiratory acidosis", "PROBLEM", 101, 123], ["a pH", "TEST", 129, 133], ["a respiratory acidosis", "PROBLEM", 236, 258], ["pulmonary 265 hypertension", "PROBLEM", 278, 304], ["brain injuries", "PROBLEM", 306, 320], ["increased intracranial pressure", "PROBLEM", 333, 364], ["severe right sided 266 heart failure", "PROBLEM", 372, 408], ["pregnancy", "PROBLEM", 410, 419], ["certain toxic ingestions", "PROBLEM", 425, 449], ["failure", "OBSERVATION", 15, 22], ["obstructive", "OBSERVATION_MODIFIER", 28, 39], ["lung", "ANATOMY", 40, 44], ["disease", "OBSERVATION", 45, 52], ["asthma", "OBSERVATION", 62, 68], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["obstructive", "OBSERVATION_MODIFIER", 81, 92], ["respiratory", "ANATOMY", 103, 114], ["acidosis", "OBSERVATION", 115, 123], ["respiratory acidosis", "OBSERVATION", 238, 258], ["pulmonary", "ANATOMY", 278, 287], ["hypertension", "OBSERVATION", 292, 304], ["brain", "ANATOMY", 306, 311], ["injuries", "OBSERVATION", 312, 320], ["increased", "OBSERVATION_MODIFIER", 333, 342], ["intracranial pressure", "OBSERVATION", 343, 364], ["severe", "OBSERVATION_MODIFIER", 372, 378], ["right", "ANATOMY_MODIFIER", 379, 384], ["sided", "ANATOMY_MODIFIER", 385, 390], ["heart", "ANATOMY", 395, 400], ["failure", "OBSERVATION", 401, 408]]], ["49 267 Table 3 obstructive lung disease likely indicates hyperinflation from auto-PEEP.", [["lung", "ANATOMY", 27, 31], ["obstructive lung disease", "DISEASE", 15, 39], ["lung", "ORGAN", 27, 31], ["Table 3 obstructive lung disease", "PROBLEM", 7, 39], ["hyperinflation", "PROBLEM", 57, 71], ["auto-PEEP", "TREATMENT", 77, 86], ["obstructive", "OBSERVATION_MODIFIER", 15, 26], ["lung", "ANATOMY", 27, 31], ["disease", "OBSERVATION", 32, 39], ["hyperinflation", "OBSERVATION", 57, 71]]], ["53 The peak pressure will be elevated due to airway resistance, but this pressure is less important, and can be tolerated, if 282 the plateau pressure remains < 30 cm H 2 O, since the peak pressure is not transmitted to the 283 alveoli of lung parenchyma.", [["airway", "ANATOMY", 45, 51], ["alveoli", "ANATOMY", 228, 235], ["lung parenchyma", "ANATOMY", 239, 254], ["H 2 O", "CHEMICAL", 167, 172], ["airway", "MULTI-TISSUE_STRUCTURE", 45, 51], ["alveoli", "MULTI-TISSUE_STRUCTURE", 228, 235], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 239, 254], ["The peak pressure", "TEST", 3, 20], ["elevated", "PROBLEM", 29, 37], ["airway resistance", "PROBLEM", 45, 62], ["this pressure", "TEST", 68, 81], ["the plateau pressure", "TEST", 130, 150], ["the peak pressure", "TEST", 180, 197], ["peak pressure", "OBSERVATION", 7, 20], ["airway resistance", "OBSERVATION", 45, 62], ["lung", "ANATOMY", 239, 243], ["parenchyma", "ANATOMY_MODIFIER", 244, 254]]], ["24,28,53 An example of a pressure waveform in a mechanically 284 ventilated patient with high airway resistance is demonstrated in Figure 2 . requiring emergent intubation in the ICU, preoxygenation with NIPPV compared to non-408 rebreather mask resulted in an increased SpO 2 after preoxygenation as well as during and after 409 intubation.", [["airway", "ANATOMY", 94, 100], ["24,28,53", "CHEMICAL", 0, 8], ["SpO 2", "CHEMICAL", 271, 276], ["patient", "ORGANISM", 76, 83], ["airway", "MULTI-TISSUE_STRUCTURE", 94, 100], ["patient", "SPECIES", 76, 83], ["a pressure waveform", "TEST", 23, 42], ["high airway resistance", "PROBLEM", 89, 111], ["emergent intubation", "TREATMENT", 152, 171], ["preoxygenation", "TREATMENT", 184, 198], ["NIPPV", "TREATMENT", 204, 209], ["non-408 rebreather mask", "TREATMENT", 222, 245], ["an increased SpO", "PROBLEM", 258, 274], ["preoxygenation", "TREATMENT", 283, 297], ["intubation", "TREATMENT", 330, 340], ["pressure", "OBSERVATION_MODIFIER", 25, 33], ["waveform", "OBSERVATION_MODIFIER", 34, 42], ["high airway resistance", "OBSERVATION", 89, 111], ["intubation", "OBSERVATION", 161, 171], ["increased", "OBSERVATION_MODIFIER", 261, 270]]], ["67 Episodes of severe desaturation to SpO 2 < 80% were significantly less common in 410 the NIPPV group than the control group (2/27 compared to 12/26).", [["desaturation", "DISEASE", 22, 34], ["severe desaturation", "PROBLEM", 15, 34], ["SpO", "TEST", 38, 41], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["desaturation", "OBSERVATION", 22, 34]]], ["67 The FLORALI-2 trial 411 compared preoxygenation with HFNC to NIPPV in 322 ICU patients with acute hypoxemic 412 respiratory failure.", [["respiratory", "ANATOMY", 115, 126], ["respiratory failure", "DISEASE", 115, 134], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["The FLORALI", "TEST", 3, 14], ["HFNC", "TREATMENT", 56, 60], ["NIPPV", "TREATMENT", 64, 69], ["acute hypoxemic", "PROBLEM", 95, 110], ["respiratory failure", "PROBLEM", 115, 134], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["hypoxemic", "OBSERVATION", 101, 110], ["respiratory failure", "OBSERVATION", 115, 134]]], ["68 It found no significant difference in the incidence of severe hypoxemia or 413 serious adverse events between groups.", [["hypoxemia", "DISEASE", 65, 74], ["severe hypoxemia", "PROBLEM", 58, 74], ["serious adverse events between groups", "PROBLEM", 82, 119], ["no", "UNCERTAINTY", 12, 14], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["difference", "OBSERVATION_MODIFIER", 27, 37], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["hypoxemia", "OBSERVATION", 65, 74]]], ["However, in the subgroup of patients with pre-intubation 414 moderate-to-severe hypoxemia (Pa0 2 /FiO 2 < 200), NIPPV resulted in a statistically significant 415 decrease in incidence of severe hypoxemia.", [["hypoxemia", "DISEASE", 80, 89], ["hypoxemia", "DISEASE", 194, 203], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["pre-intubation", "TEST", 42, 56], ["moderate-to-severe hypoxemia", "PROBLEM", 61, 89], ["Pa0", "TEST", 91, 94], ["FiO", "TEST", 98, 101], ["NIPPV", "TREATMENT", 112, 117], ["severe hypoxemia", "PROBLEM", 187, 203], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["hypoxemia", "OBSERVATION", 80, 89], ["decrease", "OBSERVATION_MODIFIER", 162, 170], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["hypoxemia", "OBSERVATION", 194, 203]]], ["68 Of note, the lack of difference may be confounded 416 by the fact that NIPPV ventilation group received no apneic oxygenation while the HFNC group 417 continued to receive apneic oxygenation via HFNC.", [["NIPPV ventilation group", "TREATMENT", 74, 97], ["apneic oxygenation", "TREATMENT", 110, 128], ["the HFNC group", "TEST", 135, 149], ["apneic oxygenation", "TREATMENT", 175, 193], ["HFNC", "TREATMENT", 198, 202]]], ["NIPPV may be beneficial in those with 418 severe hypoxemia for preoxygenation, as this group had equivalent overall outcomes and 419 reduced hypoxemia despite not receiving apneic oxygenation.", [["hypoxemia", "DISEASE", 49, 58], ["hypoxemia", "DISEASE", 141, 150], ["NIPPV", "TREATMENT", 0, 5], ["severe hypoxemia", "PROBLEM", 42, 58], ["preoxygenation", "TREATMENT", 63, 77], ["reduced hypoxemia", "PROBLEM", 133, 150], ["apneic oxygenation", "TREATMENT", 173, 191], ["hypoxemia", "OBSERVATION", 49, 58], ["hypoxemia", "OBSERVATION", 141, 150]]], ["68 The benefit of HFNC for preoxygenation and apneic oxygenation compared to conventional 428 oxygen therapy is unclear.", [["HFNC", "CHEMICAL", 18, 22], ["oxygen", "CHEMICAL", 94, 100], ["oxygen", "CHEMICAL", 94, 100], ["HFNC", "SIMPLE_CHEMICAL", 18, 22], ["oxygen", "SIMPLE_CHEMICAL", 94, 100], ["HFNC", "TREATMENT", 18, 22], ["preoxygenation", "TREATMENT", 27, 41], ["apneic oxygenation", "TREATMENT", 46, 64], ["conventional 428 oxygen therapy", "TREATMENT", 77, 108], ["oxygen therapy", "OBSERVATION", 94, 108]]], ["Several small randomized controlled trials comparing HFNC to BVM 429 or face mask in hypoxemic patients found no statistically significant difference in mean lowest 430Pearl: Use an initial ventilator strategy as shown inSpO 2 between groups.", [["BVM 429", "CHEMICAL", 61, 68], ["patients", "ORGANISM", 95, 103], ["inSpO 2", "GENE_OR_GENE_PRODUCT", 219, 226], ["patients", "SPECIES", 95, 103], ["Several small randomized controlled trials", "TREATMENT", 0, 42], ["HFNC", "TREATMENT", 53, 57], ["BVM", "TREATMENT", 61, 64], ["face mask", "TREATMENT", 72, 81], ["hypoxemic", "PROBLEM", 85, 94], ["an initial ventilator strategy", "TREATMENT", 179, 209], ["small", "OBSERVATION_MODIFIER", 8, 13], ["no", "UNCERTAINTY", 110, 112]]], ["[70] [71] [72] Recently, the OPTINIV trial compared the combination of HFNC 431 and NIPPV to NIPPV alone for preoxygenation in ICU patients requiring intubation for 432 hypoxemic respiratory failure.", [["respiratory", "ANATOMY", 179, 190], ["HFNC 431", "CHEMICAL", 71, 79], ["hypoxemic respiratory failure", "DISEASE", 169, 198], ["HFNC 431", "CHEMICAL", 71, 79], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["HFNC", "TREATMENT", 71, 75], ["NIPPV", "TREATMENT", 84, 89], ["NIPPV", "TREATMENT", 93, 98], ["preoxygenation", "TREATMENT", 109, 123], ["intubation", "TREATMENT", 150, 160], ["hypoxemic respiratory failure", "PROBLEM", 169, 198], ["respiratory failure", "OBSERVATION", 179, 198]]], ["73 The intervention group (HFNC + NIPPV) continued to receive 433 apneic oxygenation via HFNC while the NIPPV group alone received no further oxygenation 434 after the standardized 4-minute preoxygenation period.", [["The intervention group (HFNC", "TREATMENT", 3, 31], ["NIPPV", "TREATMENT", 34, 39], ["apneic oxygenation", "TREATMENT", 66, 84], ["HFNC", "TREATMENT", 89, 93], ["the NIPPV group", "TREATMENT", 100, 115], ["further oxygenation", "TREATMENT", 134, 153]]], ["Authors found that the intervention 435 groups had higher minimum SpO 2 during intubation (100% vs 96%) and fewer episodes of 436 desaturation SpO 2 <80% (0% vs 21%) than the control group.", [["intubation", "TEST", 79, 89], ["desaturation SpO", "TEST", 130, 146]]], ["73 It is important to note that these preoxygenation strategies are effective in those requiring 443 intubation due to respiratory infections.", [["respiratory", "ANATOMY", 119, 130], ["respiratory infections", "DISEASE", 119, 141], ["these preoxygenation strategies", "TREATMENT", 32, 63], ["intubation", "TREATMENT", 101, 111], ["respiratory infections", "PROBLEM", 119, 141], ["respiratory", "ANATOMY", 119, 130], ["infections", "OBSERVATION", 131, 141]]], ["In the study by Baillard et al, 65-70% of included 444 patients had a diagnosis of pneumonia.", [["pneumonia", "DISEASE", 83, 92], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["the study", "TEST", 3, 12], ["pneumonia", "PROBLEM", 83, 92], ["pneumonia", "OBSERVATION", 83, 92]]], ["67 Additionally, 35% of study participants in the 445 FLORALI-2 trial had primary respiratory failure due to infection.", [["respiratory", "ANATOMY", 82, 93], ["primary respiratory failure", "DISEASE", 74, 101], ["infection", "DISEASE", 109, 118], ["participants", "ORGANISM", 30, 42], ["participants", "SPECIES", 30, 42], ["study", "TEST", 24, 29], ["primary respiratory failure", "PROBLEM", 74, 101], ["infection", "PROBLEM", 109, 118], ["respiratory failure", "OBSERVATION", 82, 101], ["infection", "OBSERVATION", 109, 118]]], ["68 Though discussion of airway 446 management for patients with novel COVID-19 is beyond the scope of this paper, in the midst of 447 a respiratory illness pandemic appropriate personal protective equipment (PPE) with airborne 448 precautions, careful donning and doffing of PPE, and use of negative pressure rooms should be 449 employed to reduce the risk of disease transmission.", [["airway", "ANATOMY", 24, 30], ["respiratory illness", "DISEASE", 136, 155], ["airway", "MULTI-TISSUE_STRUCTURE", 24, 30], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["airway 446 management", "TREATMENT", 24, 45], ["novel COVID", "TREATMENT", 64, 75], ["airborne 448 precautions", "TREATMENT", 218, 242], ["PPE", "TREATMENT", 275, 278], ["negative pressure rooms", "TREATMENT", 291, 314], ["disease transmission", "PROBLEM", 360, 380], ["airway", "ANATOMY", 24, 30], ["disease", "OBSERVATION", 360, 367]]], ["If COVID-19 is suspected, video 451 laryngoscopy is recommended.", [["COVID-19", "DNA", 3, 11], ["COVID", "TEST", 3, 8], ["video 451 laryngoscopy", "TEST", 26, 48]]], ["Viral filters must also be appropriately utilized.", [["Viral filters", "TREATMENT", 0, 13], ["filters", "OBSERVATION", 6, 13]]], ["Emergency clinicians are experts in airway management and routinely encounter critically ill 457 patients with pre-and post-intubation physiologic challenges associated with adverse events.Pearl: Preoxygenate using NIPPV in a head-elevated position if the patient's clinicalThose with a severe metabolic acidosis require maintenance of the minute ventilation to prevent 459 a sudden deterioration in pH.", [["airway", "ANATOMY", 36, 42], ["head", "ANATOMY", 226, 230], ["critically ill", "DISEASE", 78, 92], ["metabolic acidosis", "DISEASE", 294, 312], ["airway", "MULTI-TISSUE_STRUCTURE", 36, 42], ["patients", "ORGANISM", 97, 105], ["head", "ORGANISM_SUBDIVISION", 226, 230], ["patient", "ORGANISM", 256, 263], ["patients", "SPECIES", 97, 105], ["patient", "SPECIES", 256, 263], ["airway management", "TREATMENT", 36, 53], ["pre-and post-intubation physiologic challenges", "TREATMENT", 111, 157], ["adverse events", "PROBLEM", 174, 188], ["NIPPV", "TREATMENT", 215, 220], ["a head-elevated position", "TREATMENT", 224, 248], ["a severe metabolic acidosis", "PROBLEM", 285, 312], ["the minute ventilation", "TREATMENT", 336, 358], ["a sudden deterioration in pH", "PROBLEM", 374, 402], ["airway", "ANATOMY", 36, 42], ["severe", "OBSERVATION_MODIFIER", 287, 293], ["metabolic acidosis", "OBSERVATION", 294, 312]]], ["In the case of shock and hypotension, resuscitation prior to 460 induction is the goal, and a shock index of >0.8-0.9 predicts post intubation hypotension.", [["shock", "DISEASE", 15, 20], ["hypotension", "DISEASE", 25, 36], ["shock", "DISEASE", 94, 99], ["hypotension", "DISEASE", 143, 154], ["shock", "PROBLEM", 15, 20], ["hypotension", "PROBLEM", 25, 36], ["resuscitation", "TREATMENT", 38, 51], ["a shock index", "TEST", 92, 105], ["hypotension", "PROBLEM", 143, 154], ["shock", "OBSERVATION", 15, 20], ["hypotension", "OBSERVATION", 25, 36]]], ["461Pearl: Preoxygenate using NIPPV in a head-elevated position if the patient's clinicalPreceding hypoxemia should be aggressively preoxygenated using NIPPV.", [["head", "ANATOMY", 40, 44], ["hypoxemia", "DISEASE", 98, 107], ["head", "ORGANISM_SUBDIVISION", 40, 44], ["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["NIPPV", "TREATMENT", 29, 34], ["a head-elevated position", "TREATMENT", 38, 62], ["Preceding hypoxemia", "PROBLEM", 88, 107], ["NIPPV", "TREATMENT", 151, 156], ["hypoxemia", "OBSERVATION", 98, 107]]], ["Pulmonary 462 hypertension and right ventricle failure present complex physiologic challenges; the major goal 463 is to avoid systemic hypotension or a sudden increase in PVR from hypercapnia or hypoxemia.", [["Pulmonary", "ANATOMY", 0, 9], ["right ventricle", "ANATOMY", 31, 46], ["hypertension", "DISEASE", 14, 26], ["right ventricle failure", "DISEASE", 31, 54], ["hypotension", "DISEASE", 135, 146], ["hypercapnia", "DISEASE", 180, 191], ["hypoxemia", "DISEASE", 195, 204], ["ventricle", "MULTI-TISSUE_STRUCTURE", 37, 46], ["hypertension", "PROBLEM", 14, 26], ["right ventricle failure", "PROBLEM", 31, 54], ["systemic hypotension", "PROBLEM", 126, 146], ["a sudden increase in PVR", "PROBLEM", 150, 174], ["hypercapnia", "PROBLEM", 180, 191], ["hypoxemia", "PROBLEM", 195, 204], ["hypertension", "OBSERVATION", 14, 26], ["right ventricle", "ANATOMY", 31, 46], ["failure", "OBSERVATION", 47, 54], ["complex", "OBSERVATION_MODIFIER", 63, 70], ["physiologic", "OBSERVATION_MODIFIER", 71, 82], ["hypotension", "OBSERVATION", 135, 146], ["sudden", "OBSERVATION_MODIFIER", 152, 158], ["increase", "OBSERVATION_MODIFIER", 159, 167], ["PVR", "OBSERVATION", 171, 174], ["hypercapnia", "OBSERVATION", 180, 191], ["hypoxemia", "OBSERVATION", 195, 204]]], ["464Pearl: Preoxygenate using NIPPV in a head-elevated position if the patient's clinicalObstructive lung disease presents a risk of hemodynamic collapse from high intrathoracic 465 pressure caused by air-trapping, and patients require prolonged expiratory times with slow 466 respiratory rate while mechanically ventilated.", [["head", "ANATOMY", 40, 44], ["lung", "ANATOMY", 100, 104], ["respiratory", "ANATOMY", 276, 287], ["Obstructive lung disease", "DISEASE", 88, 112], ["head", "ORGANISM_SUBDIVISION", 40, 44], ["patient", "ORGANISM", 70, 77], ["lung", "ORGAN", 100, 104], ["patients", "ORGANISM", 218, 226], ["patient", "SPECIES", 70, 77], ["patients", "SPECIES", 218, 226], ["NIPPV", "TREATMENT", 29, 34], ["a head-elevated position", "TREATMENT", 38, 62], ["Obstructive lung disease", "PROBLEM", 88, 112], ["hemodynamic collapse", "PROBLEM", 132, 152], ["high intrathoracic 465 pressure", "PROBLEM", 158, 189], ["prolonged expiratory times", "TREATMENT", 235, 261], ["slow 466 respiratory rate", "PROBLEM", 267, 292], ["mechanically ventilated", "TREATMENT", 299, 322], ["lung", "ANATOMY", 100, 104], ["disease", "OBSERVATION", 105, 112], ["hemodynamic", "OBSERVATION_MODIFIER", 132, 143], ["collapse", "OBSERVATION", 144, 152], ["high", "OBSERVATION_MODIFIER", 158, 162], ["intrathoracic", "ANATOMY", 163, 176], ["465 pressure", "OBSERVATION", 177, 189], ["mechanically ventilated", "OBSERVATION", 299, 322]]], ["These considerations can assist emergency 467 clinicians in optimizing the patient during and after intubation attempts.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["intubation attempts", "TREATMENT", 100, 119]]], ["Pearls and pitfalls in the management of high-risk airways.Pearl: Preoxygenate using NIPPV in a head-elevated position if the patient's clinicalHigh-Risk Airway", [["airways", "ANATOMY", 51, 58], ["head", "ANATOMY", 96, 100], ["airways", "MULTI-TISSUE_STRUCTURE", 51, 58], ["head", "ORGANISM_SUBDIVISION", 96, 100], ["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 126, 133], ["the management", "TREATMENT", 23, 37], ["NIPPV", "TREATMENT", 85, 90], ["a head-elevated position", "TREATMENT", 94, 118], ["pitfalls", "OBSERVATION", 11, 19], ["airways", "ANATOMY", 51, 58], ["Airway", "ANATOMY", 154, 160]]]], "PMC7111078": [["Focusing on innovation excellence prevents evolution stagnation.", [["stagnation", "OBSERVATION_MODIFIER", 53, 63]]], ["Regardless of the individual\u2019s role on the perioperative team (eg, RN circulator, scrub person, anesthesia personnel, surgeon, or personnel from materials management, laboratory, radiology, housekeeping, administration), each person assumes a lead role at various times and contributes to the success of the team for the patient.Philosophy of LeadershipSports analogies illustrate similar team approaches to understanding leadership.", [["patient", "ORGANISM", 321, 328], ["person", "SPECIES", 88, 94], ["person", "SPECIES", 226, 232], ["patient", "SPECIES", 321, 328]]], ["For example, if my role in a baseball organization is to collect the bat immediately after the player's at-bats, I am contributing to the health of the team by preventing injury from tripping over a bat left in the running path.", [["injury", "PROBLEM", 171, 177], ["injury", "OBSERVATION", 171, 177]]], ["If my role is right fielder and it is the bottom of the ninth inning with two outs and my team is in the lead, one out will win the game: the pitcher throws the ball, the batter hits a fly ball to right field, and as right fielder, the burden of responsibility is mine.", [["right", "ANATOMY_MODIFIER", 14, 19], ["right", "ANATOMY_MODIFIER", 197, 202], ["right", "ANATOMY_MODIFIER", 217, 222]]], ["The fans (ie, family members or designated support person[s]) hold their breath, and my teammates (ie, OR team members) move in to support my personal action.", [["person", "SPECIES", 51, 57]]], ["After I catch the ball, there is a collective sigh of relief from the fans, high fives all around, and joy for the win.", [["relief", "OBSERVATION_MODIFIER", 54, 60]]], ["Although dejected, the fans are hopeful because the game is not over, the opposing player (ie, the disease) made it on base but has not scored.", [["the disease)", "PROBLEM", 95, 107], ["disease", "OBSERVATION", 99, 106]]], ["Challenges can cause action and occasionally adaptation,2 and becoming overwhelmed by the challenge creates immobility and results in the stagnation2 of progress.Philosophy of LeadershipPerioperative nurses are adaptive leaders who respond to the changing environment unique to each patient encountered.", [["patient", "ORGANISM", 283, 290], ["patient", "SPECIES", 283, 290], ["immobility", "PROBLEM", 108, 118]]], ["The preceding baseball analogy is similar to that of the perioperative nurse caring for the patient in the OR setting.", [["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99]]], ["In some situations, the responsibility for care outcome actions rests solely with the RN circulator (ie, the right fielder); in other situations, the contributions of each member of the health care team are the foundation for continuing to offer hope to the patient and family (ie, the fans).", [["patient", "ORGANISM", 258, 265], ["patient", "SPECIES", 258, 265], ["right", "ANATOMY_MODIFIER", 109, 114]]], ["When the team helps an individual member who has made a mistake to refocus his or her attention on the end goal (ie, re-establishing the optimal health of the patient) instead of on the error, that helps brings the team member \u201cback in the game\u201d with a desire to contribute even more for the patient.\u201cBy looking at potential future accomplishments as if we have already achieved them, we set goals by envisioning the outcomes clearly.\u201d", [["patient", "ORGANISM", 159, 166], ["patient", "ORGANISM", 292, 299], ["patient", "SPECIES", 159, 166], ["patient", "SPECIES", 292, 299]]]], "PMC7276810": [["ELECTRONIC HEALTH RECORDS FOR COVID\u201019 DRUG REPURPOSINGAt time of writing this commentary (late April 2020), humanity is struggling with the SARS\u2010Cov\u20102 pandemic which has already infected more than 3.7 million people and caused over 250,000 fatalities globally, mostly among older individuals.", [["SARS", "DISEASE", 141, 145], ["fatalities", "DISEASE", 241, 251], ["people", "ORGANISM", 210, 216], ["people", "SPECIES", 210, 216]]], ["Even the most optimistic scenarios estimate that it may take until mid\u20102021 to develop, receive approval, and start population\u2010wide distribution of an effective SARS\u2010Cov\u20102 vaccine (Callaway, 2020; Gewin, 2020).", [["SARS", "DISEASE", 161, 165], ["an effective SARS", "PROBLEM", 148, 165]]], ["Meanwhile, many million further individuals will likely be infected, some with fatal outcome.", [["individuals", "ORGANISM", 32, 43], ["infected", "PROBLEM", 59, 67], ["infected", "OBSERVATION", 59, 67]]], ["Drug repurposing, also termed drug repositioning, attempts to apply drugs already approved for certain indications for a new indication; this approach is by far less costly and more efficient compared with developing a new drug (Koromina, Pandi, & Patrinos, 2019; Xu et al., 2015; Xu, Li, Jiang, & Chen, 2020).", [["drug repositioning", "TREATMENT", 30, 48], ["drugs", "TREATMENT", 68, 73]]], ["A notable example is the demonstration, based on prescription records data mining, that the diabetes drug metformin is protective against many solid cancers: decreased mortality following a cancer diagnosis was observed in patients prescribed metformin (Xu et al., 2015).", [["solid cancers", "ANATOMY", 143, 156], ["cancer", "ANATOMY", 190, 196], ["diabetes", "DISEASE", 92, 100], ["metformin", "CHEMICAL", 106, 115], ["cancers", "DISEASE", 149, 156], ["cancer", "DISEASE", 190, 196], ["metformin", "CHEMICAL", 243, 252], ["metformin", "CHEMICAL", 106, 115], ["metformin", "CHEMICAL", 243, 252], ["metformin", "SIMPLE_CHEMICAL", 106, 115], ["solid cancers", "CANCER", 143, 156], ["cancer", "CANCER", 190, 196], ["patients", "ORGANISM", 223, 231], ["metformin", "SIMPLE_CHEMICAL", 243, 252], ["patients", "SPECIES", 223, 231], ["the diabetes drug metformin", "TREATMENT", 88, 115], ["many solid cancers", "PROBLEM", 138, 156], ["a cancer", "PROBLEM", 188, 196], ["metformin", "TREATMENT", 243, 252], ["cancers", "OBSERVATION", 149, 156], ["decreased", "OBSERVATION_MODIFIER", 158, 167], ["cancer", "OBSERVATION", 190, 196]]], ["The number of new drugs approved per billion US dollars spent for drug research and development was halved every 9 years since 1950, decreasing about 80\u2010fold from 1950 to 2012 after adjustment for inflation (Scannell, Blanckley, Boldon, & Warrington, 2012).", [["new drugs", "TREATMENT", 14, 23], ["inflation", "TREATMENT", 197, 206], ["new", "OBSERVATION_MODIFIER", 14, 17], ["drugs", "OBSERVATION", 18, 23]]], ["These numbers illustrate the need for considering drug repurposing for drastically reducing development costs, improving success rates, and reducing toxicity risks, as the latter are, for most drugs, already established.ELECTRONIC HEALTH RECORDS FOR COVID\u201019 DRUG REPURPOSINGAs of late April 2020, the National Institutes of Health (NIH) website for clinical trials (ClinicalTrials.gov) lists over thousand registered trials in COVID\u201019 patients.", [["toxicity", "DISEASE", 149, 157], ["patients", "ORGANISM", 437, 445], ["patients", "SPECIES", 437, 445], ["drug repurposing", "TREATMENT", 50, 66], ["drastically reducing development costs", "PROBLEM", 71, 109], ["reducing toxicity risks", "PROBLEM", 140, 163]]], ["Some of these trials examine the potential to repurpose (reposition) therapeutics approved for other conditions for COVID\u201019 patients; notable examples are listed in Table 1.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["repurpose (reposition) therapeutics", "TREATMENT", 46, 81]]], ["However, clinical trials typically take many months to complete, require high level of funding, and are usually done with small cohorts (fewer than 100 patients in each study arm) and at a single site.", [["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160]]], ["A by far faster and more efficient method for rapidly identifying approved therapeutics and repurpose them for COVID\u201019 patients is data mining of electronic health and prescription records of COVID\u201019 patients.", [["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 202, 210]]], ["Electronic health records (EHRs) of COVID\u201019 patients were already useful for identifying and assessing hypertension and diabetes as its major fatality risks (T. Chen, Wu et al., 2020; Li et al., 2020).", [["hypertension", "DISEASE", 104, 116], ["diabetes", "DISEASE", 121, 129], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["hypertension", "PROBLEM", 104, 116], ["diabetes", "PROBLEM", 121, 129], ["hypertension", "OBSERVATION", 104, 116]]], ["Health records were also useful for studying infectivity among children (Qiu et al., 2020) and in embryos of infected pregnant women (H. Chen, Guo et al., 2020; Li et al., 2020), and COVID\u201019 neurological manifestations (Mao et al., 2020).ELECTRONIC HEALTH RECORDS FOR COVID\u201019 DRUG REPURPOSINGMany health providers maintain EHRs which include, in addition to detailed longitudinal clinical phenotypes, prescription records of their customers.", [["embryos", "ANATOMY", 98, 105], ["neurological", "ANATOMY", 192, 204], ["neurological manifestations", "DISEASE", 192, 219], ["children", "ORGANISM", 63, 71], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 98, 105], ["women", "ORGANISM", 127, 132], ["children", "SPECIES", 63, 71], ["women", "SPECIES", 127, 132], ["neurological manifestations", "PROBLEM", 192, 219]]], ["For example, Maccabi Healthcare, the second largest Israeli healthcare provider, maintains such records and has utilized them for epidemiologic studies (Levkovitch\u2010Verbin, Goldshtein, Chodick, Zigman, & Shalev, 2014).", [["epidemiologic studies", "TEST", 130, 151], ["Levkovitch", "TREATMENT", 153, 163]]], ["Drug prescription records data mining is also useful for identifying adverse events due to drug interactions (Hansen et al., 2016; Zhan, Roughead, Liu, Pratt, & Li, 2018).", [["adverse events", "PROBLEM", 69, 83]]], ["Making such prescription record datasets valuable for clinical and epidemiological research requires a common data collection and encryption modes that enable rapid, comparable, and systematic analyses across unrelated observational data sources for identifying and evaluating the safety and efficacy of therapeutics and their combinations for various clinical morbidities (Reisinger et al., 2010; Shabo, 2010: Shabo, 2014).", [["a common data collection", "TEST", 101, 125], ["encryption modes", "TEST", 130, 146], ["systematic analyses", "TEST", 182, 201], ["therapeutics", "TREATMENT", 304, 316]]], ["This remains an unmet need for improved international collaboration of prescription records data mining.ELECTRONIC HEALTH RECORDS FOR COVID\u201019 DRUG REPURPOSINGApplying data mining of prescription records for COVID\u201019 patients for whom rich phenotypic information is available on the course of their disease, starting with early phase prior to hospital admission, seems a promising method for identification of drug candidates that can be repurposed for COVID\u201019 patients.", [["patients", "ORGANISM", 217, 225], ["patients", "ORGANISM", 462, 470], ["patients", "SPECIES", 217, 225], ["patients", "SPECIES", 462, 470], ["their disease", "PROBLEM", 293, 306], ["drug candidates", "TREATMENT", 410, 425]]], ["Such combined data mining may assist in identifying the most suitable existing therapeutics, possibly including drug combinations, that may protect SARS\u2010CoV\u20102 infected individuals from life\u2010threatening symptoms.PRESCRIPTION RECORDS DATA MINING AND DRUG REPURPOSING FOR COVID\u201019Table 1 lists examples for clinical trials registered with ClinicalTrials.gov and aimed at assessing the potential of drug repurposing for COVID\u201019.", [["SARS\u2010CoV\u20102 infected", "DISEASE", 148, 167], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 153, 158], ["drug combinations", "TREATMENT", 112, 129], ["SARS", "PROBLEM", 148, 152], ["life\u2010threatening symptoms", "PROBLEM", 185, 210], ["ClinicalTrials", "TREATMENT", 336, 350], ["COVID\u2010", "TREATMENT", 416, 422]]], ["Some of such clinical trials may benefit from data mining prescription records: plans for such clinical trials may be modified to prescribe a different dosage, another approved therapeutic from the same drug family, or to change the inclusion and exclusion criteria, such as excluding patients with certain comorbidities or taking certain co\u2010medications.", [["patients", "ORGANISM", 285, 293], ["patients", "SPECIES", 285, 293], ["a different dosage", "TREATMENT", 140, 158], ["certain comorbidities", "PROBLEM", 299, 320]]], ["Below, I discuss three examples among the repurposing trials listed in Table 1 for which data mining of prescription records seems in particular beneficial.", [["the repurposing trials", "TREATMENT", 38, 60]]], ["The use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for COVID\u201019 patients has been debated, with some suggesting that it may offer protection from serious COVID\u201019 (e.g., Gurwitz, 2020; Rothlin et al., 2020) while others warning that ACE inhibitors and ARBs need to be carefully considered for COVID\u201019 patients due to potential risks (Zheng, Ma, Zhang, & Xie, 2020).", [["angiotensin converting enzyme (ACE) inhibitors", "CHEMICAL", 11, 57], ["angiotensin receptor blockers", "CHEMICAL", 62, 91], ["ACE inhibitors", "CHEMICAL", 281, 295], ["angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 11, 40], ["ACE", "GENE_OR_GENE_PRODUCT", 42, 45], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 62, 91], ["patients", "ORGANISM", 112, 120], ["ACE", "GENE_OR_GENE_PRODUCT", 281, 284], ["ARBs", "SIMPLE_CHEMICAL", 300, 304], ["patients", "ORGANISM", 350, 358], ["angiotensin converting enzyme", "PROTEIN", 11, 40], ["ACE", "PROTEIN", 42, 45], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 350, 358], ["angiotensin converting enzyme (ACE) inhibitors", "TREATMENT", 11, 57], ["angiotensin receptor blockers", "TREATMENT", 62, 91], ["ARBs", "TEST", 93, 97], ["COVID\u2010", "TREATMENT", 103, 109], ["ACE inhibitors", "TREATMENT", 281, 295], ["ARBs", "TREATMENT", 300, 304]]], ["The current consensus is to continue using ACE inhibitors and ARBs as prescribed for hypertensive patients, but not apply them as a COVID\u201019 therapeutic until their value and risks are clarified (Danser, Epstein, & Batlle, 2020; Patel & Verma, 2020; Vaduganathan et al., 2020).", [["ARBs", "CHEMICAL", 62, 66], ["hypertensive", "DISEASE", 85, 97], ["ACE", "GENE_OR_GENE_PRODUCT", 43, 46], ["ARBs", "SIMPLE_CHEMICAL", 62, 66], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["ACE inhibitors", "TREATMENT", 43, 57], ["ARBs", "TREATMENT", 62, 66], ["hypertensive patients", "TREATMENT", 85, 106], ["a COVID\u2010", "TREATMENT", 130, 138]]], ["Indeed, several clinical trials registered with ClinicalTrials.gov will be assessing the value of ACE inhibitors and ARBs in COVID\u201019 (Table 1).", [["ACE", "GENE_OR_GENE_PRODUCT", 98, 101], ["ClinicalTrials", "TREATMENT", 48, 62], ["ACE inhibitors", "TREATMENT", 98, 112], ["ARBs", "TREATMENT", 117, 121]]], ["Clearly, data mining of prescription records for COVID\u201019 patients taking ACE inhibitors or ARBs would be highly valuable for assessing their utility, as well as for optimal design of ongoing and planned clinical trials.", [["ACE inhibitors", "CHEMICAL", 74, 88], ["patients", "ORGANISM", 58, 66], ["ACE", "GENE_OR_GENE_PRODUCT", 74, 77], ["ARBs", "SIMPLE_CHEMICAL", 92, 96], ["patients", "SPECIES", 58, 66], ["COVID\u2010", "TREATMENT", 49, 55], ["ACE inhibitors", "TREATMENT", 74, 88], ["ARBs", "TREATMENT", 92, 96]]], ["Another example concerns transdermal estradiol patches, commonly used as hormone replacement therapy for postmenopausal women or other indications (La Vignera et al., 2020).", [["estradiol", "CHEMICAL", 37, 46], ["estradiol", "CHEMICAL", 37, 46], ["estradiol", "SIMPLE_CHEMICAL", 37, 46], ["women", "ORGANISM", 120, 125], ["women", "SPECIES", 120, 125], ["transdermal estradiol patches", "TREATMENT", 25, 54], ["hormone replacement therapy", "TREATMENT", 73, 100], ["postmenopausal women", "PROBLEM", 105, 125]]], ["Transdermal or oral estradiol are prescription drugs, thus health providers should have such records.", [["oral", "ANATOMY", 15, 19], ["estradiol", "CHEMICAL", 20, 29], ["estradiol", "CHEMICAL", 20, 29], ["oral", "ORGANISM_SUBDIVISION", 15, 19], ["estradiol", "SIMPLE_CHEMICAL", 20, 29], ["Transdermal", "TREATMENT", 0, 11], ["oral estradiol", "TREATMENT", 15, 29], ["prescription drugs", "TREATMENT", 34, 52]]], ["Hence, trials such as NCT04359329 (Table 1) may benefit from data mining estradiol's prescription records for assessing the value of transdermal or oral estradiol.", [["oral", "ANATOMY", 148, 152], ["estradiol", "CHEMICAL", 73, 82], ["estradiol", "CHEMICAL", 153, 162], ["estradiol", "CHEMICAL", 73, 82], ["estradiol", "CHEMICAL", 153, 162], ["estradiol", "SIMPLE_CHEMICAL", 73, 82], ["transdermal", "SIMPLE_CHEMICAL", 133, 144], ["oral", "ORGANISM_SUBDIVISION", 148, 152], ["estradiol", "SIMPLE_CHEMICAL", 153, 162], ["transdermal", "TREATMENT", 133, 144], ["oral estradiol", "TREATMENT", 148, 162]]], ["Lastly, antiandrogens, commonly used for treating acne or alopecia and sometimes applied for treating prostate cancer patients, were suggested as beneficial for reducing COVID\u201019 severity (Wambier & Goren, 2020).", [["prostate cancer", "ANATOMY", 102, 117], ["antiandrogens", "CHEMICAL", 8, 21], ["acne", "DISEASE", 50, 54], ["alopecia", "DISEASE", 58, 66], ["prostate cancer", "DISEASE", 102, 117], ["antiandrogens", "CHEMICAL", 8, 21], ["antiandrogens", "SIMPLE_CHEMICAL", 8, 21], ["prostate cancer", "CANCER", 102, 117], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["antiandrogens", "TREATMENT", 8, 21], ["acne", "PROBLEM", 50, 54], ["alopecia", "PROBLEM", 58, 66], ["prostate cancer", "PROBLEM", 102, 117], ["prostate", "ANATOMY", 102, 110], ["cancer", "OBSERVATION", 111, 117]]], ["This suggestion is based on the well\u2010established androgen\u2010mediated upregulation of TMPRSS2, coding for a protease which is essential for ARS\u2010CoV\u20102 cell entry subsequent to the binding of its spike protein to the ACE2 receptor (Clinckemalie et al., 2013).", [["cell", "ANATOMY", 147, 151], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 83, 90], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 212, 225], ["TMPRSS2", "PROTEIN", 83, 90], ["protease", "PROTEIN", 105, 113], ["spike protein", "PROTEIN", 191, 204], ["ACE2 receptor", "PROTEIN", 212, 225], ["the well\u2010established androgen\u2010mediated upregulation of TMPRSS2", "TREATMENT", 28, 90], ["a protease", "TREATMENT", 103, 113], ["ARS", "PROBLEM", 137, 140]]], ["This suggestion is supported by the comparatively low rates of COVID\u201019 fatalities among children, whose androgen levels remain low until puberty.HUMAN LIVES MATTERAccess of health informatics researchers to EHRs, including to individual prescription records, is key for efficient and time\u2010saving drug repurposing studies.", [["fatalities", "DISEASE", 72, 82], ["androgen", "CHEMICAL", 105, 113], ["children", "ORGANISM", 89, 97], ["androgen", "GENE_OR_GENE_PRODUCT", 105, 113], ["children", "SPECIES", 89, 97], ["whose androgen levels", "TEST", 99, 120]]], ["An effective and fast response for reducing COVID\u201019 morbidity and fatalities requires novel expedited ways of applying information technologies for supporting clinical needs (Grange et al., 2020).", [["fatalities", "DISEASE", 67, 77], ["reducing COVID\u2010", "TREATMENT", 35, 50]]], ["As discussed above, applying health informatics is in particular valuable for drug repurposing (drug repositioning).", [["drug repurposing (drug repositioning", "TREATMENT", 78, 114]]], ["During the ongoing pandemic, and as long as a safe and effective vaccines are not available, applying medical and prescription records data mining for drug repurposing requires a reasonable degree of easing current data access regulations, as summarized in Table 2.", [["a safe and effective vaccines", "TREATMENT", 44, 73], ["drug repurposing", "TREATMENT", 151, 167]]], ["Some of these suggestions, in particular relaxing rules for institutional review board (IRB) approval for access to individual prescription records, may seem a risk of patients' privacy.", [["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176]]], ["However, relaxing IRB rules, including waivers for consent, are justified during emergencies (Dix, Esposito, Spinosa, Olson, & Chapman, 2004; McRae, Ackroyd\u2010Stolarz, & Weijer, 2005); undeniably the current SARS\u2010CoV\u20102 pandemic falls into this category.", [["SARS", "DISEASE", 206, 210], ["Spinosa", "ANATOMY", 109, 116]]], ["A policy that only allows the publication of finding as aggregated patient data should minimize such privacy risks.", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74]]], ["Withholding these health records from the research community would be an unforgivable breach of their commitment to human health.", [["human", "ORGANISM", 116, 121], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121]]], ["Health records sharing is possible along with careful anonymization of identifiers for assuring patient privacy.", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103]]], ["As long as the SARS\u2010CoV\u20102 pandemic is ongoing, saving lives matters the most, and drug repurposing could save lives by far faster and more efficiently than new clinical trials.HUMAN LIVES MATTER", [["SARS", "DISEASE", 15, 19], ["SARS\u2010CoV", "SPECIES", 15, 23]]]], "PMC7472675": []}